Intracellular signaling molecules

ABSTRACT

The invention provides human intracellular signaling molecules (INTSIG) and polynucleotides which identify and encode INTSIG. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of INSTSIG.

TECHNICAL FIELD

[0001] This invention relates to nucleic acid and amino acid sequences of intracellular signaling molecules and to the use of these sequences in the diagnosis, treatment, and prevention of cell proliferative, autoimmune/inflammatory, neurological, gastrointestinal, reproductive, developmental, vesicle trafficking disorders, and viral infections, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of intracellular signaling molecules.

BACKGROUND OF THE INVENTION

[0002] Cell-cell communication is essential for the growth, development, and survival of multicellular organisms. Cells communicate by sending and receiving molecular signals. An example of a molecular signal is a growth factor, which binds and activates a specific transmembrane receptor on the surface of a target cell. The activated receptor transduces the signal intracellularly, thus initiating a cascade of biochemical reactions that ultimately affect gene transcription and cell cycle progression in the target cell.

[0003] Intracellular signaling is the process by which cells respond to extracellular signals (hormones, neurotransmitters, growth and differentiation factors, etc.) through a cascade of biochemical reactions that begins with the binding of a signaling molecule to a cell membrane receptor and ends with the activation of an intracellular target molecule. Intermediate steps in the process involve the activation of various cytoplasmic proteins by phosphorylation via protein kinases, and their deactivation by protein phosphatases, and the eventual translocation of some of these activated proteins to the cell nucleus where the transcription of specific genes is triggered. The intracellular signaling process regulates all types of cell functions including cell proliferation, cell differentiation, and gene transcription, and involves a diversity of molecules including protein kinases and phosphatases, and second messenger molecules such as cyclic nucleotides, calcium-calmodulin, inositol, and various mitogens that regulate protein phosphorylation.

[0004] A distinctive class of signal transduction molecules are involved in odorant detection. The process of odorant detection involves specific recognition by odorant receptors. The olfactory mucosa also appears to possess an additional group of odorant-binding proteins which recognize and bind separate classes of odorants. For example, cDNA clones from rat have been isolated which correspond to mRNAs highly expressed in olfactory mucosa but not detected in other tissues. The proteins encoded by these clones are homologous to proteins that bind lipopolysaccharides or polychlorinated biphenyls, and the different proteins appear to be expressed in specific areas of the mucosal tissue. These proteins are believed to interact with odorants before or after specific recognition by odorant receptors, perhaps acting as selective signal filters (Dear, T. N. et al. (1991) EMBO J. 10:2813-2819; Vogt, R. G. et al. (1991) J. Neurobiol. 22:74-84).

[0005] Cells also respond to changing conditions by switching off signals. Many signal transduction proteins are short-lived and rapidly targeted for degradation by covalent ligation to ubiquitin, a highly conserved small protein. Cells also maintain mechanisms to monitor changes in the concentration of denatured or unfolded proteins in membrane-bound extracytoplasmic compartments, including a transmembrane receptor that monitors the concentration of available chaperone molecules in the endoplasmic reticulum and transmits a signal to the cytosol to activate the transcription of nuclear genes encoding chaperones in the endoplasmic reticulum.

[0006] Certain proteins in intracellular signaling pathways serve to link or cluster other proteins involved in the signaling cascade. These proteins are referred to as scaffold, anchoring, or adaptor proteins. (For review, see Pawson, T. and J. D. Scott (1997) Science 278:2075-2080.) As many intracellular signaling proteins such as protein kinases and phosphatases have relatively broad substrate specificities, the adaptors help to organize the component signaling proteins into specific biochemical pathways. Many of the above signaling molecules are characterized by the presence of particular domains that promote protein-protein interactions. A sampling of these domains is discussed below, along with other important intracellular messengers.

[0007] Intracellar Signaling Second Messenger Molecules

[0008] Protein Phosphorylation

[0009] Protein kinases and phosphatases play a key role in the intracellular signaling process by controlling the phosphorylation and activation of various signaling proteins. The high energy phosphate for this reaction is generally transferred from the adenosine triphosphate molecule (ATP) to a particular protein by a protein kinase and removed from that protein by a protein phosphatase. Protein kinases are roughly divided into two groups: those that phosphorylate serine or threonine residues (serine/threonine kinases, STK) and those that phosphorylate tyrosine residues (protein tyrosine kinases, PTK). A few protein kinases have dual specificity for serine/threonine and tyrosine residues. Almost all kinases contain a conserved 250-300 amino acid catalytic domain containing specific residues and sequence motifs characteristic of the kinase family (Hardie, G. and S. Hanks (1995) The Protein Kinase Facts Books, Vol I:7-20, Academic Press, San Diego, Calif.).

[0010] STKs include the second messenger dependent protein kinases such as the cyclic-AMP dependent protein kinases (PKA), involved in mediating hormone-induced cellular responses; calcium-calmodulin (CaM) dependent protein kinases, involved in regulation of smooth muscle contraction, glycogen breakdown, and neurotransmission; and the mitogen-activated protein kinases (MAP kinases) which mediate signal transduction from the cell surface to the nucleus via phosphorylation cascades. Altered PKA expression is implicated in a variety of disorders and diseases including cancer, thyroid disorders, diabetes, atherosclerosis, and cardiovascular disease (Isselbacher, K. J. et al. (1994) Harrison's Principles of Internal Medicine, McGraw-Hill, New York, N.Y., pp. 416-431, 1887).

[0011] PTKs are divided into transmembrane, receptor PTKs and nontransmembrane, non-receptor PTKs. Transmembrane PTKs are receptors for most growth factors. Non-receptor PTKs lack transmembrane regions and, instead, form complexes with the intracellular regions of cell surface receptors. Receptors that function through non-receptor PTKs include those for cytokines and hormones (growth hormone and prolactin) and antigen-specific receptors on T and B lymphocytes. Many of these PTKs were first identified as the products of mutant oncogenes in cancer cells in which their activation was no longer subject to normal cellular controls. In fact, about one third of the known oncogenes encode PTKs, and it is well known that cellular transformation (oncogenesis) is often accompanied by increased tyrosine phosphorylation activity (Charbonneau H. and N. K. Tonks (1992) Annu. Rev. Cell Biol. 8:463-493).

[0012] An additional family of protein kinases previously thought to exist only in prokaryotes is the histidine protein kinase family (HPK). HPKs bear little homology with mammalian STKs or PTKs but have distinctive sequence motifs of their own (Davie, J. R. et al. (1995) J. Biol. Chem. 270:19861-19867). A histidine residue in the N-terminal half of the molecule (region I) is an autophosphorylation site. Three additional motifs located in the C-terminal half of the molecule include an invariant asparagine residue in region II and two glycine-rich loops characteristic of nucleotide binding domains in regions m and IV. Recently a branched chain alpha-ketoacid dehydrogenase kinase has been found with characteristics of HPK in rat (Davie et al., supra.

[0013] Protein phosphatases regulate the effects of protein kinases by removing phosphate groups from molecules previously activated by kinases. The two principal categories of protein phosphatases are the protein (serine/threonine) phosphatases (PPs) and the protein tyrosine phosphatases (PTPs). PPs dephosphorylate phosphoserine/threonine residues and are important regulators of many cAMP-mediated hormone responses (Cohen, P. (1989) Annu. Rev. Biochem. 58:453-508). PTPs reverse the effects of protein tyrosine kinases and play a significant role in cell cycle and cell signaling processes (Charbonneau and Tonks, supra). As previously noted, many PTKs are encoded by oncogenes, and oncogenesis is often accompanied by increased tyrosine phosphorylation activity. It is therefore possible that PTPs may prevent or reverse cell transformation and the growth of various cancers by controlling the levels of tyrosine phosphorylation in cells. This hypothesis is supported by studies showing that overexpression of PTPs can suppress transformation in cells, and that specific inhibition of PTPs can enhance cell transformation (Charbonneau and Tonks, supra).

[0014] Phospholipid and Inositol-Phosphate Signaling

[0015] Inositol phospholipids (phosphoinositides) are involved in an intracellular signaling pathway that begins with binding of a signaling molecule to a G-protein linked receptor in the plasma membrane. This leads to the phosphorylation of phosphatidylinositol (PI) residues on the inner side of the plasma membrane to the biphosphate state β2) by inositol kinases. Simultaneously, the G-protein linked receptor binding stimulates a trimeric G-protein which in turn activates a phosphoinositide-specific phospholipase C-β. Phospholipase C-β then cleaves PIP₂ into two products, inositol triphosphate (IP₃) and diacylglycerol. These two products act as mediators for separate signaling events. IP₃ diffuses through the plasma membrane to induce calcium release from the endoplasmic reticulum (ER), while diacylglycerol remains in the membrane and helps activate protein kinase C, a serine-threonine kinase that phosphorylates selected proteins in the target cell. The calcium response initiated by IP₃ is terminated by the dephosphorylation of IP₃ by specific inositol phosphatases. Cellular responses that are mediated by this pathway are glycogen breakdown in the liver in response to vasopressin, smooth muscle contraction in response to acetylcholine, and thrombin-induced platelet aggregation.

[0016] Inositol-phosphate signaling controls tubby, a membrane bound transcriptional regulator that serves as an intracellular messenger of Gα_(q)-coupled receptors (Santagata et al. (2001) Science 292:2041-2050). Members of the tubby family contain a C-terminal tubby domain of about 260 amino acids that binds to double-stranded DNA and an N-terminal transcriptional activation domain. Tubby binds to phosphatidylinositol 4,5-bisphosphate, which localizes tubby to the plasma membrane. Activation of the G-protein α_(q) leads to activation of phospholipase C-β and hydrolysis of phosphoinositide. Loss of phosphatidylinositol 4,5-bisphosphate causes tubby to dissociate from the plasma membrane and to translocate to the nucleus where tubby regulates transcription of its target genes. Defects in the tubby gene are associated with obesity, retinal degeneration, and hearing loss (Boggon, T. J. et al. (1999) Science 286:2119-2125).

[0017] Cyclic Nucleotide Signaling

[0018] Cyclic nucleotides (cAMP and cGMP) function as intracellular second messengers to transduce a variety of extracellular signals including hormones, light, and neurotransmitters. In particular, cyclic-AMP dependent protein kinases (PKA) are thought to account for all of the effects of cAMP in most mammalian cells, including various hormone-induced cellular responses. Visual excitation and the phototransmission of light signals in the eye is controlled by cyclic-GMP regulated, Ca²⁺-specific channels. Because of the importance of cellular levels of cyclic nucleotides in mediating these various responses, regulating the synthesis and breakdown of cyclic nucleotides is an important matter. Thus adenylyl cyclase, which synthesizes cAMP from AMP, is activated to increase cAMP levels in muscle by binding of adrenaline to β-adrenergic receptors, while activation of guanylate cyclase and increased cGMP levels in photoreceptors leads to reopening of the Ca²⁺-specific channels and recovery of the dark state in the eye. There are nine known transmembrane isoforms of mammalian adenylyl cyclase, as well as a soluble form preferentially expressed in testis. Soluble adenylyl cyclase contains a P-loop, or nucleotide binding domain, and may be involved in male fertility (Buck, J. et al. (1999) Proc. Natl. Acad. Sci. USA 96:79-84).

[0019] In contrast, hydrolysis of cyclic nucleotides by cAMP and cGMP-specific phosphodiesterases (PDEs) produces the opposite of these and other effects mediated by increased cyclic nucleotide levels. PDEs appear to be particularly important in the regulation of cyclic nucleotides, considering the diversity found in this family of proteins. At least seven families of mammalian PDEs (PDE1-7) have been identified based on substrate specificity and affinity, sensitivity to cofactors, and sensitivity to inhibitory drugs (Beavo, J. A. (1995) Physiol. Rev. 75:725-748). PDE inhibitors have been found to be particularly useful in treating various clinical disorders. Rolipram, a specific inhibitor of PDE4, has been used in the treatment of depression, and similar inhibitors are undergoing evaluation as anti-inflammatory agents. Theophylline is a nonspecific PDE inhibitor used in the treatment of bronchial asthma and other respiratory diseases (Banner, K. H. and C. P. Page (1995) Eur. Respir. J. 8:996-1000).

[0020] Calcium Sigaling Molecules

[0021] Ca²⁺ is another second messenger molecule that is even more widely used as an intracellular mediator than cAMP. Ca²⁺ can enter the cytosol by two pathways, in response to extracellular signals. One pathway acts primarily in nerve signal transduction where Ca²⁺ enters a nerve terminal through a voltage-gated Ca²⁺ channel. The second is a more ubiquitous pathway in which Ca²⁺ is released from the ER into the cytosol in response to binding of an extracellular signaling molecule to a receptor. Ca²⁺ directly activates regulatory enzymes, such as protein kinase C, which trigger signal transduction pathways. Ca²⁺ also binds to specific Ca²⁺-binding proteins (CBPs) such as calmodulin (CaM) which then activate multiple target proteins in the cell including enzymes, membrane transport pumps, and ion channels. CaM interactions are involved in a multitude of cellular processes including, but not limited to, gene regulation, DNA synthesis, cell cycle progression, mitosis, cytokinesis, cytoskeletal organization, muscle contraction, signal transduction, ion homeostasis, exocytosis, and metabolic regulation (Celio, M. R. et al. (1996) Guidebook to Calcium-binding Proteins, Oxford University Press, Oxford, UK, pp. 15-20). Some Ca²⁺ binding proteins are characterized by the presence of one or more EF-hand Ca²⁺ binding motifs, which are comprised of 12 amino acids flanked by α-helices (Celio, supra). The regulation of CBPs has implications for the control of a variety of disorders. Calcineurin, a CaM-regulated protein phosphatase, is a target for inhibition by the immunosuppressive agents cyclosporin and FK506. This indicates the importance of calcineurin and CaM in the immune response and immune disorders (Schwaninger M. et al. (1993) J. Biol. Chem. 268:23111-23115). The level of CaM is increased several-fold in tumors and tumor-derived cell lines for various types of cancer (Rasmussen, C. D. and A. R. Means (1989) Trends Neurosci. 12:433-438).

[0022] The annexins are a family of calcium-binding proteins that associate with the cell membrane (Towle, C. A. and B. V. Treadwell (1992) J. Biol. Chem. 267:5416-5423). Annexins reversibly bind to negatively charged phospholipids (phosphatidylcholine and phosphatidylserine) in a calcium dependent manner. Annexins participate in various processes pertaining to signal transduction at the plasma membrane, including membrane-cytoskeleton interactions, phospholipase inhibition, anticoagulation, and membrane fusion. Annexins contain four to eight repeated segments of about 60 residues. Each repeat folds into five alpha helices wound into a right-handed superhelix.

[0023] G-Protein Signaling

[0024] Guanine nucleotide binding proteins (G-proteins) are critical mediators of signal transduction between a particular class of extracellular receptors, the G-protein coupled receptors (GPCRs), and intracellular second messengers such as cAMP and Ca²⁺. G-proteins are linked to the cytosolic side of a GPCR such that activation of the GPCR by ligand binding stimulates binding of the G-protein to GTP, inducing an “active” state in the G-protein. In the active state, the G-protein acts as a signal to trigger other events in the cell such as the increase of cAMP levels or the release of Ca²⁺ into the cytosol from the ER, which, in turn, regulate phosphorylation and activation of other intracellular proteins. Recycling of the G-protein to the inactive state involves hydrolysis of the bound GTP to GDP by a GTPase activity in the G-protein. (See Alberts, B. et al. (1994) Molecular Biology of the Cell Garland Publishing, Inc. New York, N.Y., pp.734-759.) The superfamily of G-proteins consists of several families which may be grouped as translational factors, heterotrimeric G-proteins involved in transmembrane signaling processes, and low molecular weight (LMW) G-proteins including the proto-oncogene Ras proteins and products of rab, rap, rho, rac, smg21, smg25, YPT, SEC4, and ARF genes, and tubulins (Kaziro, Y. et al. (1991) Annu. Rev. Biochem. 60:349-400). In all cases, the GTPase activity is regulated through interactions with other proteins.

[0025] Heterotrimeric G-proteins are composed of 3 subunits, α, β, and γ, which in their inactive conformation associate as a trimer at the inner face of the plasma membrane. Gα binds GDP or GTP and contains the GTPase activity. The βγ complex enhances binding of Gα to a receptor. Gγ is necessary for the folding and activity of Gβ (Neer, E. J. et al. (1994) Nature 371:297-300). Multiple homologs of each subunit have been identified in mammalian tissues, and different combinations of subunits have specific functions and tissue specificities (Spiegel, A. M. (1997) J. Inher. Metab. Dis. 20:113-121).

[0026] The alpha subunits of heterotrimeric G-proteins can be divided into four distinct classes. The α-s class is sensitive to ADP-ribosylation by pertussis toxin which uncouples the receptor:G-protein interaction. This uncoupling blocks signal transduction to receptors that decrease cAMP levels which normally regulate ion channels and activate phospholipases. The inhibitory α-I class is also susceptible to modification by pertussis toxin which prevents α-I from lowering cAMP levels. Two novel classes of α subunits refractory to pertussis toxin modification are α-q, which activates phospholipase C, and α-12, which has sequence homology with the Drosophila gene concertina and may contribute to the regulation of embryonic development (Simon, M. L (1991) Science 252:802-808).

[0027] The mammalian Gβ and Gγ subunits, each about 340 amino acids long, share more than 80% homology. The Gβ subunit (also called transducin) contains seven repeating units, each about 43 amino acids long. The activity of both subunits may be regulated by other proteins such as calmodulin and phosducin or the neural protein GAP 43 (Clapham, D. and E. Neer (1993) Nature 365:403-406). The β and γ subunits are tightly associated. The β subunit sequences are highly conserved between species, implying that they perform a fundamentally important role in the organization and function of G-protein linked systems (Van der Voorn, L. (1992) FEBS Lett. 307:131-134). They contain seven tandem repeats of the WD-repeat sequence motif, a motif found in many proteins with regulatory functions. WD-repeat proteins contain from four to eight copies of a loosely conserved repeat of approximately 40 amino acids which participates in protein-protein interactions. Mutations and variant expression of β transducin proteins are linked with various disorders. Mutations in LIS1, a subunit of the human platelet activating factor acetylhydrolase, cause Miller-Dieker lissencephaly. RACK1 binds activated protein kinase C, and RbAp48 binds retinoblastoma protein. CstF is required for polyadenylation of mammalian pre-mRNA in vitro and associates with subunits of cleavage-stimulating factor. Defects in the regulation of β-catenin contribute to the neoplastic transformation of human cells. The WD40 repeats of the human F-box protein bTrCP mediate binding to β-catenin, thus regulating the targeted degradation of β-catenin by ubiquitin ligase (Neer, supra; Hart, M. et al. (1999) Curr. Biol. 9:207-210). The y subunit primary structures are more variable than those of the β subunits. They are often post-translationally modified by isoprenylation and carboxyl-methylation of a cysteine residue four amino acids from the C-terminus; this appears to be necessary for the interaction of the βγ subunit with the membrane and with other G-proteins. The βγ subunit has been shown to modulate the activity of isoforms of adenylyl cyclase, phospholipase C, and some ion channels. It is involved in receptor phosphorylation via specific kinases, and has been implicated in the p21ras-dependent activation of the MAP kinase cascade and the recognition of specific receptors by G-proteins (Clapham and Neer, supra).

[0028] G-proteins interact with a variety of effectors including adenylyl cyclase (Clapham and Neer, supra). The signaling pathway mediated by cAMP is mitogenic in hormone-dependent endocrine tissues such as adrenal cortex, thyroid, ovary, pituitary, and testes. Cancers in these tissues have been related to a mutationally activated form of a Gα_(s) known as the gsp (Gs protein) oncogene (Dhanasekaran, supra). Another effector is phosducin, a retinal phosphoprotein, which forms a specific complex with retinal Gβ and Gγ (Gβγ) and modulates the ability of Gβγ to interact with retinal Gα (Clapham and Neer, supra).

[0029] Irregularities in the G-protein signaling cascade may result in abnormal activation of leukocytes and lymphocytes, leading to the tissue damage and destruction seen in many inflammatory and autoimmune diseases such as rheumatoid arthritis, biliary cirrhosis, hemolytic anemia, lupus erythematosus, and thyroiditis. Abnormal cell proliferation, including cyclic AMP stimulation of brain, thyroid, adrenal, and gonadal tissue proliferation is regulated by G proteins. Mutations in Gα subunits have been found in growth-hormone-secreting pituitary somatotroph tumors, hyperfunctioning thyroid adenomas, and ovarian and adrenal neoplasms (Meij, J. T. A. (1996) Mol. Cell Biochem 157:31-38; Aussel, C. et al. (1988) J. Immunol. 140:215-220).

[0030] LMW G-proteins are GTPases which regulate cell growth, cell cycle control, protein secretion, and intracellular vesicle interaction. They consist of single polypeptides which, like the alpha subunit of the heterotrimeric G-proteins, are able to bind to and hydrolyze GTP, thus cycling between an inactive and an active state. LMW G-proteins respond to extracellular signals from receptors and activating proteins by transducing mitogenic signals involved in various cell functions. The binding and hydrolysis of GTP regulates the response of LMW G-proteins and acts as an energy source during this process (Bokoch, G. M. and C. J. Der (1993) FASEB J. 7:750-759).

[0031] At least sixty members of the LMW G-protein superfamily have been identified and are currently grouped into the ras, rho, arf, sar1, ran, and rab subfamilies. Activated ras genes were initially found in human cancers, and subsequent studies confirmed that ras function is critical in determining whether cells continue to grow or become differentiated. Ras1 and Ras2 proteins stimulate adenylate cyclase (Kaziro, supra), affecting a broad array of cellular processes. Stimulation of cell surface receptors activates Ras which, in turn, activates cytoplasmic kinases. These kinases translocate to the nucleus and activate key transcription factors that control gene expression and protein synthesis (Barbacid, M. (1987) Annu. Rev. Biochem. 56:779-827, Treisman, R. (1994) Curr. Opin. Genet Dev. 4:96-98). Other members of the LMW G-protein superfamily have roles in signal transduction that vary with the function of the activated genes and the locations of the G-proteins that initiate the activity. Rho G-proteins control signal transduction pathways that link growth factor receptors to actin polymerization, which is necessary for normal cellular growth and division. The rab, arf, and sar1 families of proteins control the translocation of vesicles to and from membranes for protein processing, localization, and secretion. Vesicle- and target-specific identifiers (v-SNAREs and t-SNAREs) bind to each other and dock the vesicle to the acceptor membrane. The budding process is regulated by the closely related ADP ribosylation factors (ARFs) and SAR proteins, while rab proteins allow assembly of SNARE complexes and may play a role in removal of defective complexes (Rothman, J. and F. Wieland (1996) Science 272:227-234). Ran G-proteins are located in the nucleus of cells and have a key role in nuclear protein import, the control of DNA synthesis, and cell-cycle progression (Hall, A. (1990) Science 249:635-640; Barbacid, M. (1987) Annu. Rev. Biochem. 56:779-827; Ktistakis, N. (1998) BioEssays 20:495-504; and Sasaki, T. and Y. Takai (1998) Biochem. Biophys. Res. Commun. 245:641-645).

[0032] Rab proteins have a highly variable amino terminus containing membrane-specific signal information and a prenylated carboxy terminus which determines the target membrane to which the Rab proteins anchor. More than 30 Rab proteins have been identified in a variety of species, and each has a characteristic intracellular location and distinct transport function. In particular, Rab1 and Rab2 are important in ER-to-Golgi transport; Rab3 transports secretory vesicles to the extracellular membrane; Rab5 is localized to endosomes and regulates the fusion of early endosomes into late endosomes; Rab6 is specific to the Golgi apparatus and regulates intra-Golgi transport events; Rab7 and Rab9 stimulate the fusion of late endosomes and Golgi vesicles with lysosomes, respectively; and Rab10 mediates vesicle fusion from the medial Golgi to the trans Golgi. Mutant forms of Rab proteins are able to block protein transport along a given pathway or alter the sizes of entire organelles. Therefore, Rabs play key regulatory roles in membrane trafficking (Schimmöller, I. S. and S. R. Pfeffer (1998) J. Biol. Chem 243:22161-22164).

[0033] The function of Rab proteins in vesicular transport requires the cooperation of many other proteins. Specifically, the membrane-targeting process is assisted by a series of escort proteins (Khosravi-Far, R. et al. (1991) Proc. Natl. Acad. Sci. USA 88:6264-6268). In the medial Golgi, it has been shown that GTP-bound Rab proteins initiate the binding of VAMP-like proteins of the transport vesicle to syntaxin-like proteins on the acceptor membrane, which subsequently triggers a cascade of protein-binding and membrane-fusion events. After transport, GTPase-activating proteins (GAPs) in the target membrane are responsible for converting the GTP-bound Rab proteins to their GDP-bound state. And finally, guanine-nucleotide dissociation inhibitor (GDI) recruits the GDP-bound proteins to their membrane of origin.

[0034] The cycling of LMW G-proteins between the GTP-bound active form and the GDP-bound inactive form is regulated by a variety of proteins. Guanosine nucleotide exchange factors (GEFs) increase the rate of nucleotide dissociation by several orders of magnitude, thus facilitating release of GDP and loading with GTP. The best characterized is the mammalian homolog of the Drosophila Son-of-Sevenless protein. Certain Ras-family proteins are also regulated by guanine nucleotide dissociation inhibitors (GDIs), which inhibit GDP dissociation. The intrinsic rate of GTP hydrolysis of the LMW G-proteins is typically very slow, but it can be stimulated by several orders of magnitude by GAPs (Geyer, M. and A. Wittinghofer (1997) Curr. Opin. Struct. Biol. 7:786-792). Both GEF and GAP activity may be controlled in response to extracellular stimuli and modulated by accessory proteins such as RalBP1 and POB1. Mutant Ras-family proteins, which bind but cannot hydrolyze GTP, are permanently activated, and cause cell proliferation or cancer, as do GEFs that inappropriately activate LMW G-proteins, such as the human oncogene NET1, a Rho-GEF (Drivas, G. T. et al. (1990) Mol. Cell Biol. 10: 1793-1798; Alberts, A. S. and R. Treisman (1998) EMBO J. 14:4075-4085).

[0035] A member of the ARF family of G-proteins is centaurin beta 2, a regulator of membrane traffic and the actin cytoskeleton. The centaurin β family of GTPase-activating proteins (GAPs) and Arf guanine nucleotide exchange factors contain pleckstrin homology (PH) domains, which are activated by phosphoinositides, as well as ankyrin repeats and a conserved zinc-binding motif. These proteins are targets for the receptor-stimulated phospohinositide 3-kinase cascade (Jackson, T. R. et al. (2000) Trends Biochem. Sci. 25:489-495). PH domains bind phosphoinositides, implicating PH domains in signaling processes. Phosphoinositides have a role in converting Arf-GTP to Arf-GDP via the centaurin β family and a role in Arf activation (Kam, J. L. et al. (2000) J. Biol. Chem. 275:9653-9663). The rho GAP family is also implicated in the regulation of actin polymerization at the plasma membrane and in several cellular processes. The gene ARHGAP6 encodes GTPase-activating protein 6 isoform 4. Mutations in ARHGAP6, seen as a deletion of a 500 kb critical region in Xp22.3, causes the syndrome microphthalmia with linear skin defects (MLS). MLS is an X-linked dominant, male-lethal syndrome (Prakash, S. K. et al. (2000) Hum Mol. Genet. 9:477-488).

[0036] The signal-induced proliferation-associated protein (Sipa1) is a mitogen induced GAP. Sipa1 contains a C-terminal leucine zipper and an N-terminal GAP domain homologous to the human RAP1GAP protein. The human SIPA1 gene is widely expressed, in fetal as well as adult tissues, but is most highly expressed in lymphoid organs. (OMIM (Online Mendelian Inheritance in Man) Entry 602180; Ebrahimi, S. (1998) Gene 214:215-221.)

[0037] A member of the Rho family of G-proteins is CDC42, a regulator of cytoskeletal rearrangements required for cell division. CDC42 is inactivated by a specific GAP (CDC42GAP) that strongly stimulates the GTPase activity of CDC42 while having a much lesser effect on other Rho family members. CDC42GAP also contains an SH3-binding domain that interacts with the SH3 domains of cell signaling proteins such as p85 alpha and c-Src, suggesting that CDC42GAP may serve as a link between CDC42 and other cell signaling pathways (Barfod, E. T. et al. (1993) J. Biol. Chem 268:26059-26062).

[0038] GTP-binding proteins are involved in protein biosynthesis and include initiation factor 2 (IF-2), elongation factor 2 (EF-Tu), and elongation factor G (EF-G), observed in prokaryotes; and initiation factor 2 (EF-2), elongation factor Iα (EF-Iα), elongation factor 2 (EF-2), and release factor 3 (eRF3) observed in eukaryotes (Kaziro, Y. et al. (1991) Ann. Rev. Biochem 60:349-400). IF-2 promotes the GTP-dependent binding of the tRNA to the small subunit of the ribosome, the step that initiates protein translation. Elongation factors promote the binding of tRNA and GTP and the displacement of GDP after hydrolysis as protein biosynthesis proceeds. eRF3 participates in the recognition of stop codons and the release of nascent proteins from ribosomes.

[0039] The bacterial mutt protein is involved in the GO system (Koonin E. V. (1993) Nucleic Acids Res. 21:4847-4847) responsible for removing an oxidatively damaged form of guanine (8-hydroxyguanine or 7,8-dihydro-8-oxoguanine) from DNA and the nucleotide pool. 8-oxo-dGTP is inserted opposite to dA and dC residues of template DNA with almost equal efficiency thus leading to A.T to G.C transversions. MutT specifically degrades 8-oxo-dGTP to the monophosphate with the concomitant release of pyrophosphate. MutT is a small protein of about 12 to 15 Kd. (PROSITE PDOC00695).

[0040] The Dbl proteins are a family of GEFs for the Rho and Ras G-proteins (Whitehead, LP. et al. (1997) Biochim. Biophys. Acta 1332:F1-F23). All Dbl family members contain a Dbl homology (DH) domain of approximately 180 amino acids, as well as a pleckstrin homology (PH) domain located immediately C-terminal to the DH domain. Most Dbl proteins have oncogenic activity, as demonstrated by the ability to transform various cell lines, consistent with roles as regulators of Rho-mediated oncogenic signaling pathways. The kalirin proteins are neuron-specific members of the Dbl family, which are located to distinct subcellular regions of cultured neurons (Johnson, R. C. (2000) J. Cell Biol. 275:19324-19333).

[0041] Other regulators of G-protein signaling (RGS) also exist that act primarily by negatively regulating the G-protein pathway by an unknown mechanism (Druey, K. M. et al. (1996) Nature 379:742-746). Some 15 members of the RGS family have been identified. RGS family members are related structurally through similarities in an approximately 120 amino acid region termed the RGS domain and functionally by their ability to inhibit the interleukin (cytokine) induction of MAP kinase in cultured mammalian 293T cells (Druey et al., supra).

[0042] The Immuno-associated nucleotide (IAN) family of proteins has GTP-binding activity as indicated by the conserved ATP/GTP-binding site P-loop motif. The IAN family includes IAN-1, IAN4, IAP38, and IAG-1. IAN-1 is expressed in the immune system, specifically in T cells and thymocytes. Its expression is induced during thymic events (Poirier, G. M. C. et al. (1999) J. Immunol. 163:4960-4969). IAP38 is expressed in B cells and macrophages and its expression is induced in splenocytes by pathogens. IAG-1, which is a plant molecule, is induced upon bacterial infection (Krucken, J. et al. (1997) Biochem. Biophys. Res. Commun. 230:167-170). IAN-4 is a mitochondrial membrane protein which is preferentially expressed in hematopoietic precursor 32D cells transfected with wild-type versus mutant forms of the bcr/abl oncogene. The bcr/abl oncogene is known to be associated with chronic myelogenous leukemia, a clonal myelo-proliferative disorder, which is due to the translocation between the bcr gene on chromosome 22 and the abl gene on chromosome 9. Bcr is the breakpoint cluster region gene and abl is the cellular homolog of the transforming gene of the Abelson murine leukemia virus. Therefore, the LAN family of proteins appears to play a role in cell survival in immune responses and cellular transformation (Daheron, L. et al. (2001) Nucleic Acids Res. 29:1308-1316).

[0043] The large GTP-binding proteins having a high-turnover, concentration-dependent GTPase activity and an antiviral effect include the Mx proteins, the dynamin family, and the guanylate-binding proteins (GBPs) such as GBP1 and GBP2. The GBPs are characterized by their ability to bind GMP, GDP, and GTP, but not any other nucleotides. Most of these proteins have a relative molecular mass in the range of 50-100 kD. GBP expression is induced by interferons, cytokines that have antiviral effects and inhibit tumor cell proliferation. GBPs are the most abundant class of proteins induced by interferon-gamma Human GBP1 has recently been shown to mediate an antiviral effect against vesicular stomatitis virus and encephalomyocarditis virus. (OMIM (Online Mendelian Inheritance in Man) Entry 600411; Prakash, B. et al. (2000) EMBO J. 19:4555-4564.) The antiviral GTP-binding Mx proteins are induced by α- and β-interferon whereas GBP1 and GBP2 are induced by γ-interferon (Prakash, B. et al. (2000) Nature 403:567-571; Richter, M. F. et al. (1995) J. Biol. Chem. 270:13512-13517; van der Bliek, A. M. (1999) Trends in Cell Biology 9:96-102). GBP1 and GBP2 are distinguished from the other GTP-binding proteins by the presence of 2 binding motifs rather than 3 (OMIM #600411). The enzymatic properties of GTP hydrolysis by these proteins are well documented (Warnock, D. E. et al. (1996) J. Biol. Chem. 271:22310-22314). Although the full range of functions of this group of proteins has yet to be elucidated, the current state of understanding in this area indicates a role in, among other things, vesicle trafficking, cell cycle progression, and antiviral defense (van der Bliek, A. M. supra; Prakash, B. supra).

[0044] Formin-related genes (FRL) comprise a large family of morphoregulatory genes and have been shown to play important roles in morphogenesis, embryogenesis, cell polarity, cell migration, and cytokinesis through their interaction with Rho family small GTPases. Formin was first identified in mouse limb deformity (Id) mutants where the distal bones and digits of all limbs are fused and reduced in size. FRL contains formin homology domains FH1, FH2, and FH3. The FH1 domain has been shown to bind the Src homology 3 (SH3) domain, WWP/WW domains, and profilin. The FH2 domain is conserved and was shown to be essential for formin function as disruption at the FH2 domain results in the characteristic Id phenotype. The FH3 domain is located at the N-terminus of FRL, and is required for associating with Rac, a Rho family GTPase (Yayoshi-Yamamoto, S. et al. (2000) Mol. Cell. Biol. 20:6872-6881).

[0045] Signaling Complex Protein Domains

[0046] PDZ domains were named for three proteins in which this domain was initially discovered. These proteins include PSD-95 (postsynaptic density 95), Dlg (Drosophila lethal (1) discs large-1), and ZO-1 (zonula occludens-1). These proteins play important roles in neuronal synaptic transmission, tumor suppression, and cell junction formation, respectively. Since the discovery of these proteins, over sixty additional PDZ-containing proteins have been identified in diverse prokaryotic and eukaryotic organisms. This domain has been implicated in receptor and ion channel clustering and in the targeting of multiprotein signaling complexes to specialized functional regions of the cytosolic face of the plasma membrane. (For a review of PDZ domain-containing proteins, see Ponting, C. P. et al. (1997) Bioessays 19:469-479.) A large proportion of PDZ domains are found in the eukaryotic MAGUK (membrane-associated guanylate kinase) protein family, members of which bind to the intracellular domains of receptors and channels. However, PDZ domains are also found in diverse membrane-localized proteins such as protein tyrosine phosphatases, serine/threonine kinases, G-protein cofactors, and synapse-associated proteins such as syntrophins and neuronal nitric oxide synthase (nNOS). Generally, about one to three PDZ domains are found in a given protein, although up to nine PDZ domains have been identified in a single protein. The glutamate receptor interacting protein (GRIP) contains seven PDZ domains. GRIP is an adaptor that links certain glutamate receptors to other proteins and may be responsible for the clustering of these receptors at excitatory synapses in the brain (Dong, H. et al. (1997) Nature 386:279-284). The Drosophila scribble (SCRIB) protein contains both multiple PDZ domains and leucine-rich repeats. SCRIB is located at the epithelial septate junction, which is analogous to the vertebrate tight junction, at the boundary of the apical and basolateral cell surface. SCRIB is involved in the distribution of apical proteins and correct placement of adherens junctions to the basolateral cell surface (Bilder, D. and N. Perrimon (2000) Nature 403:676-680).

[0047] The PX domain is an example of a domain specialized for promoting protein-protein interactions. The PX domain is found in sorting nexins and in a variety of other proteins, including the PhoX components of NADPH oxidase and the Cpk class of phosphatidylinositol 3-kinase. Most PX domains contain a polyproline motif which is characteristic of SH3 domain-binding proteins (Ponting, C. P. (1996) Protein Sci. 5:2353-2357). Two SH3 domain-containing cytosolic components of the NADPH oxidase, p47phox and p40phox, are shown by analyses of their sequences to contain single copies of the PX (phox) domain. Homologous domains are demonstrated to be present in the Cpk class of phosphatidylinositol 3-kinase, S. cerevisiae Bemlp, and S. pombe Scd2, and a large family of human sorting nexin 1 (SNX1) homologues. The majority of these domains contains a polyproline motif, typical of SH3 domain-binding proteins. Two further findings are reported. A third NADPH oxidase subunit, p67phox, is shown to contain four tetratricopeptide repeats (TPRS) within its N-terminal Rac1GTP-binding region, and a 28 residue motif in p40phox is demonstrated to be present in protein kinase C isoforms iota/lambda and zeta, and in three ZZ domain-containing proteins. SH3 domain-mediated interactions involving the PhoX components of NADPH oxidase play a role in the formation of the NADPH oxidase multi-protein complex (Leto, T. L. et al. (1994) Proc. Natl. Acad. Sci. USA 91:10650-10654; Wilson, L. et al. (1997) Inflamm. Res. 46:265-271).

[0048] The SH3 domain is defined by homology to a region of the proto-oncogene c-Src, a cytoplasmic protein tyrosine kinase. SH3 is a small domain of 50 to 60 amino acids that interacts with proline-rich ligands. SH3 domains are found in a variety of eukaryotic proteins involved in signal transduction, cell polarization, and membrane-cytoskeleton interactions. In some cases, SH3 domain-containing proteins interact directly with receptor tyrosine kinases. For example, the SLAP-130 protein is a substrate of the T-cell receptor (TCR) stimulated protein kinase. SLAP-130 interacts via its SH3 domain with the protein SLP-76 to affect the TCR-induced expression of interleukin-2 (Musci, M. A. et al. (1997) J. Biol. Chem. 272:11674-11677). Another recently identified SH3 domain protein is macrophage actin-associated tyrosine-phosphorylated protein (MAYP) which is phosphorylated during the response of macrophages to colony stimulating factor-1 (CSF-1) and is likely to play a role in regulating the CSF-1-induced reorganization of the actin cytoskeleton (Yeung, Y.-G. et al. (1998) J. Biol. Chem. 273:30638-30642). The structure of the SH3 domain is characterized by two antiparallel beta sheets packed against each other at right angles. This packing forms a hydrophobic pocket lined with residues that are highly conserved between different SH3 domains. This pocket makes critical hydrophobic contacts with proline residues in the ligand (Feng, S. et al. (1994) Science 266:1241-1247).

[0049] A novel domain, called the WW domain, resembles the SH3 domain in its ability to bind proline-rich ligands. This domain was originally discovered in dystrophin, a cytoskeletal protein with direct involvement in Duchenne muscular dystrophy (Bork, P. and M. Sudol (1994) Trends Biochem. Sci. 19:531-533). WW domains have since been discovered in a variety of intracellular signaling molecules involved in development, cell differentiation, and cell proliferation. The structure of the WW domain is composed of beta strands grouped around four conserved aromatic residues, generally tryptophan.

[0050] Like SH3, the SH2 domain is defined by homology to a region of c-Src. SH2 domains interact directly with phospho-tyrosine residues, thus providing an immediate mechanism for the regulation and transduction of receptor tyrosine kinase-mediated signaling pathways. For example, as many as ten distinct SH2 domains are capable of binding to phosphorylated tyrosine residues in the activated PDGF receptor, thereby providing a highly coordinated and finely tuned response to ligand-mediated receptor activation. (Reviewed in Schaffhausen, B. (1995) Biochim. Biophys. Acta. 1242:61-75.) The BLNK protein is a linker protein involved in B cell activation, that bridges B cell receptor-associated kinases with SH2 domain effectors that link to various signaling pathways (Fu, C. et al. (1998) Immunity 9:93-103).

[0051] The pleckstrin homology (PH) domain was originally identified in pleckstrin, the predominant substrate for protein kinase C in platelets. Since its discovery, this domain has been identified in over 90 proteins involved in intracellular signaling or cytoskeletal organization. Proteins containing the pleckstrin homology domain include a variety of kinases, phospholipase-C isoforms, guanine nucleotide release factors, and GTPase activating proteins. For example, members of the FGD1 family contain both Rho-guanine nucleotide exchange factor (GEF) and PH domains, as well as a FYVE zinc finger domain. FGD1 is the gene responsible for faciogenital dysplasia, an inherited skeletal dysplasia (Pasteris, N. G. and J. L. Gorski (1999) Genomics 60:57-66). Many PH domain proteins function in association with the plasma membrane, and this association appears to be mediated by the PH domain itself. PH domains share a common structure composed of two antiparallel beta sheets flanked by an amphipathic alpha helix. Variable loops connecting the component beta strands generally occur within a positively charged environment and may function as ligand binding sites (Lemmon, M. A. et al. (1996) Cell 85:621-624).

[0052] Ankyrin (ANK) repeats mediate protein-protein interactions associated with diverse intracellular signaling functions. For example, ANK repeats are found in proteins involved in cell proliferation such as kinases, kinase inhibitors, tumor suppressors, and cell cycle control proteins. (See, for example, Kalus, W. et al. (1997) FEBS Lett. 401:127-132; Ferrante, A. W. et al. (1995) Proc. Natl. Acad. Sci. USA 92:1911-1915.) These proteins generally contain multiple ANK repeats, each composed of about 33 amino acids. Myotrophin is an ANK repeat protein that plays a key role in the development of cardiac hypertrophy, a contributing factor to many heart diseases. Structural studies show that the myotrophin ANK repeats, like other ANK repeats, each form a helix-turn-helix core preceded by a protruding “tip.” These tips are of variable sequence and may play a role in protein-protein interactions. The helix-turn-helix region of the ANK repeats stack on top of one another and are stabilized by hydrophobic interactions (Yang, Y. et al. (1998) Structure 6:619-626). Members of the ASB protein family contain a suppressor of cytokine signaling (SOCS) domain as well as multiple ankyrin repeats (Hilton, D. J. et al. (1998) Proc. Natl. Acad. Sci. USA 95:114-119).

[0053] The tetratricopeptide repeat (TPR) is a 34 amino acid repeated motif found in organisms from bacteria to humans. TPRs are predicted to form ampipathic helices, and appear to mediate protein-protein interactions. TPR domains are found in CDC16, CDC23, and CDC27, members of the anaphase promoting complex which targets proteins for degradation at the onset of anaphase. Other processes involving TPR proteins include cell cycle control, transcription repression, stress response, and protein kinase inhibition (Lamb, J. R. et al. (1995) Trends Biochem. Sci. 20:257-259).

[0054] The armadillo/beta-catenin repeat is a 42 amino acid motif which forms a superhelix of alpha helices when tandemly repeated. The structure of the armadillo repeat region from beta-catenin revealed a shallow groove of positive charge on one face of the superhelix, which is a potential binding surface. The armadillo repeats of beta-catenin, plakoglobin, and p120^(cas) bind the cytoplasmic domains of cadherins. Beta-catenin/cadherin complexes are targets of regulatory signals that govern cell adhesion and mobility (Huber, A. H. et al. (1997) Cell 90:871-882).

[0055] Eight tandem repeats of about 40 residues (WD40 repeats), each containing a central Trp-Asp motif, make up beta-transducin (G-beta), which is one of the three subunits (alpha, beta, and gamma) of the guanine nucleotide-binding proteins (G proteins). In higher eukaryotes G-beta exists as a small multigene family of highly conserved proteins of about 340 amino acid residues. WD repeats are also found in other protein families. For example, betaTRCP is a component of the ubiquitin ligase complex, which recruits specific proteins, including beta-catenin, to the ubiquitin-proteasome degradation pathway. BetaTRCP and its isoforms all contain seven WD repeats, as well as a characteristic “F-box” motif. (Koike, J. et al. (2000) Biochem. Biophys. Res. Commun. 269:103-109.)

[0056] The discovery of new intracellular signaling molecules, and the polynucleotides encoding them, satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of cell proliferative, autoimmune/inflammatory, neurological, gastrointestinal, reproductive, developmental, vesicle trafficking disorders, and viral infections, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of intracellular signaling molecules.

SUMMARY OF THE INVENTION

[0057] The invention features purified polypeptides, intracellular signaling molecules, referred to collectively as “INTSIG” and individually as “INTSIG-1,” “INTSIG-2,” “INTSIG-3,” “INTSIG4,” “INTSIG-5,” “INTSIG-6,” “INTSIG-7,” “INTSIG-8,” “INTSIG-9,” “INTSIG-10,” “INTSIG-11,” “INTSIG-12,” “INTSIG-13,” “INTSIG-14,” “INTSIG-15,” “INTSIG-16,” “INTSIG-17,” and “INTSIG-18.” In one aspect, the invention provides an isolated polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18. In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1-18.

[0058] The invention further provides an isolated polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18. In one alternative, the polynucleotide encodes a polypeptide selected from the group consisting of SEQ ID NO:1-18. In another alternative, the polynucleotide is selected from the group consisting of SEQ ID NO:19-36.

[0059] Additionally, the invention provides a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ D NO:1-18, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18. In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.

[0060] The invention also provides a method for producing a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18. The method comprises a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.

[0061] Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18.

[0062] The invention further provides an isolated polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:19-36, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:19-36, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). In one alternative, the polynucleotide comprises at least 60 contiguous nucleotides.

[0063] Additionally, the invention provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:19-36, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:19-36, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and optionally, if present, the amount thereof. In one alternative, the probe comprises at least 60 contiguous nucleotides.

[0064] The invention further provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:19-36, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:19-36, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

[0065] The invention further provides a composition comprising an effective amount of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, and a pharmaceutically acceptable excipient. In one embodiment, the composition comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-18. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional INTSIG, comprising administering to a patient in need of such treatment the composition.

[0066] The invention also provides a method for screening a compound for effectiveness as an agonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with decreased expression of functional INTSIG, comprising administering to a patient in need of such treatment the composition.

[0067] Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. In one alternative, the invention provides a composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional INTSIG, comprising administering to a patient in need of such treatment the composition.

[0068] The invention further provides a method of screening for a compound that specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18. The method comprises a) combining the polypeptide with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide to the test compound, thereby identifying a compound that specifically binds to the polypeptide.

[0069] The invention further provides a method of screening for a compound that modulates the activity of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide.

[0070] The invention further provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a polynucleotide sequence selected from the group consisting of SEQ ID NO:19-36, the method comprising a) exposing a sample comprising the target polynucleotide to a compound, b) detecting altered expression of the target polynucleotide, and c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.

[0071] The invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:19-36, ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:19-36, iii) a polynucleotide having a sequence complementary to i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:19-36, ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:19-36, iii) a polynucleotide complementary to the polynucleotide of i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Alternatively, the target polynucleotide comprises a fragment of a polynucleotide sequence selected from the group consisting of i)-v) above; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

BRIEF DESCRIPTION OF THE TABLES

[0072] Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the present invention.

[0073] Table 2 shows the GenBank identification number and annotation of the nearest GenBank homolog for polypeptides of the invention. The probability scores for the matches between each polypeptide and its homolog(s) are also shown.

[0074] Table 3 shows structural features of polypeptide sequences of the invention, including predicted motifs and domains, along with the methods, algorithms, and searchable databases used for analysis of the polypeptides.

[0075] Table 4 lists the cDNA and/or genomic DNA fragments which were used to assemble polynucleotide sequences of the invention, along with selected fragments of the polynucleotide sequences.

[0076] Table 5 shows the representative cDNA library for polynucleotides of the invention.

[0077] Table 6 provides an appendix which describes the tissues and vectors used for construction of the cDNA libraries shown in Table 5.

[0078] Table 7 shows the tools, programs, and algorithms used to analyze the polynucleotides and polypeptides of the invention, along with applicable descriptions, references, and threshold parameters.

DESCRIPTION OF THE INVENTION

[0079] Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

[0080] It must be noted that as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to “a host cell” includes a plurality of such host cells, and a reference to “an antibody” is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

[0081] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

[0082] Definitions

[0083] “INTSIG” refers to the amino acid sequences of substantially purified INTSIG obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

[0084] The term “agonist” refers to a molecule which intensifies or mimics the biological activity of INTSIG. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of INTSIG either by directly interacting with INTSIG or by acting on components of the biological pathway in which INTSIG participates.

[0085] An “allelic variant” is an alternative form of the gene encoding INTSIG. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

[0086] “Altered” nucleic acid sequences encoding INTSIG include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as INTSIG or a polypeptide with at least one functional characteristic of INTSIG. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding INTSIG, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding INTSIG. The encoded protein may also be “altered,” and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent INTSIG. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of INTSIG is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

[0087] The terms “amino acid” and “amino acid sequence” refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. Where “amino acid sequence” is recited to refer to a sequence of a naturally occurring protein molecule, “amino acid sequence” and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

[0088] “Amplification” relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

[0089] The term “antagonist” refers to a molecule which inhibits or attenuates the biological activity of INTSIG. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of INTSIG either by directly interacting with INTSIG or by acting on components of the biological pathway in which INTSIG participates.

[0090] The term “antibody” refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, F(ab′)₂, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind INTSIG polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

[0091] The term “antigenic determinant” refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

[0092] The term “aptamer” refers to a nucleic acid or oligonucleotide molecule that binds to a specific molecular target. Aptamers are derived from an in vitro evolutionary process (e.g., SELEX (Systematic Evolution of Ligands by EXponential Enrichment), described in U.S. Pat. No. 5,270,163), which selects for target-specific aptamer sequences from large combinatorial libraries. Aptamer compositions may be double-stranded or single-stranded, and may include deoxyribonucleotides, ribonucleotides, nucleotide derivatives, or other nucleotide-like molecules. The nucleotide components of an aptamer may have modified sugar groups (e.g., the 2′-OH group of a ribonucleotide may be replaced by 2′-F or 2′-NH2), which may improve a desired property, e.g., resistance to nucleases or longer lifetime in blood. Aptamers may be conjugated to other molecules, e.g., a high molecular weight carrier to slow clearance of the aptamer from the circulatory system. Aptamers may be specifically cross-linked to their cognate ligands, e.g., by photo-activation of a cross-linker. (See, e.g., Brody, E. N. and L. Gold (2000) J. Biotechnol. 74:5-13.) The term “intramer” refers to an aptamer which is expressed in vivo. For example, a vaccinia virus-based RNA expression system has been used to express specific RNA aptamers at high levels in the cytoplasm of leukocytes (Blind, M. et al. (1999) Proc. Natl. Acad. Sci. USA 96:3606-3610).

[0093] The term “spiegelmer” refers to an aptamer which includes L-DNA, L-RNA, or other left-handed nucleotide derivatives or nucleotide-like molecules. Aptamers containing left-handed nucleotides are resistant to degradation by naturally occurring enzymes, which normally act on substrates containing right-handed nucleotides.

[0094] The term “antisense” refers to any composition capable of base-pairing with the “sense” (coding) strand of a specific nucleic acid sequence. Antisense compositions may include DNA; RNA; peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2′-methoxyethyl sugars or 2′-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2′-deoxyuracil, or 7-deaza-2′-deoxyguanosine. Antisense molecules may be produced by any method including chemical synthesis or transcription. Once introduced into a cell, the complementary antisense molecule base-pairs with a naturally occurring nucleic acid sequence produced by the cell to form duplexes which block either transcription or translation. The designation “negative” or “minus” can refer to the antisense strand, and the designation “positive” or “plus” can refer to the sense strand of a reference DNA molecule.

[0095] The term “biologically active” refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, “immunologically active” or “immunogenic” refers to the capability of the natural, recombinant, or synthetic INTSIG, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

[0096] “Complementary” describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing. For example, 5′-AGT-3′ pairs with its complement, 3′-TCA-5′.

[0097] A “composition comprising a given polynucleotide sequence” and a “composition comprising a given amino acid sequence” refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding INTSIG or fragments of INTSIG may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

[0098] “Consensus sequence” refers to a nucleic acid sequence which has been subjected to repeated DNA sequence analysis to resolve uncalled bases, extended using the XL-PCR kit (Applied Biosystems, Foster City Calif.) in the 5′ and/or the 3′ direction, and resequenced, or which has been assembled from one or more overlapping cDNA, EST, or genomic DNA fragments using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison Wis.) or Phrap (University of Washington, Seattle Wash.). Some sequences have been both extended and assembled to produce the consensus sequence.

[0099] “Conservative amino acid substitutions” are those substitutions that are predicted to least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions. Original Residue Conservative Substitution Ala Gly, Ser Arg His, Lys Asn Asp, Gln, His Asp Asn, Glu Cys Ala, Ser Gln Asn, Glu, His Glu Asp, Gln, His Gly Ala His Asn, Arg, Gln, Glu Ile Leu, Val Leu Ile, Val Lys Arg, Gln, Glu Met Leu, Ile Phe His, Met, Leu, Trp, Tyr Ser Cys, Thr Thr Ser, Val Trp Phe, Tyr Tyr His, Phe, Trp Val Ile, Leu, Thr

[0100] Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.

[0101] A “deletion” refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

[0102] The term “derivative” refers to a chemically modified polynucleotide or polypeptide. Chemical modifications of a polynucleotide can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

[0103] A “detectable label” refers to a reporter molecule or enzyme that is capable of generating a measurable signal and is covalently or noncovalently joined to a polynucleotide or polypeptide.

[0104] “Differential expression” refers to increased or upregulated; or decreased, downregulated, or absent gene or protein expression, determined by comparing at least two different samples. Such comparisons may be carried out between, for example, a treated and an untreated sample, or a diseased and a normal sample.

[0105] “Exon shuffling” refers to the recombination of different coding regions (exons). Since an exon may represent a structural or functional domain of the encoded protein, new proteins may be assembled through the novel reassortment of stable substructures, thus allowing acceleration of the evolution of new protein functions,

[0106] A “fragment” is a unique portion of INTSIG or the polynucleotide encoding INTSIG which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.

[0107] A fragment of SEQ ID NO:19-36 comprises a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:19-36, for example, as distinct from any other sequence in the genome from which the fragment was obtained. A fragment of SEQ ID NO:19-36 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:19-36 from related polynucleotide sequences. The precise length of a fragment of SEQ ID NO:19-36 and the region of SEQ ID NO:19-36 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

[0108] A fragment of SEQ ID NO:1-18 is encoded by a fragment of SEQ ID NO:19-36. A fragment of SEQ ID NO:1-18 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-18. For example, a fragment of SEQ ID NO:1-18 is useful as an immunogenic peptide for the development of antibodies that specifically recognize SEQ ID NO:1-18. The precise length of a fragment of SEQ ID NO:1-18 and the region of SEQ ID NO:1-18 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

[0109] A “full length” polynucleotide sequence is one containing at least a translation initiation codon (e.g., methionine) followed by an open reading frame and a translation termination codon. A “full length” polynucleotide sequence encodes a “full length” polypeptide sequence.

[0110] “Homology” refers to sequence similarity or, interchangeably, sequence identity, between two or more polynucleotide sequences or two or more polypeptide sequences.

[0111] The terms “percent identity” and “% identity,” as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

[0112] Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison Wis.). CLUSTAL V is described in Higgins, D. G. and P. M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D. G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and “diagonals saved”=4. The “weighted” residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the “percent similarity” between aligned polynucleotide sequences.

[0113] Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S. F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBL Bethesda, Md., and on the Internet at http://www.ncbi.nlm.nih.gov/BLAST/. The BLAST software suite includes various sequence analysis programs including “blastn,” that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called “BLAST 2 Sequences” that is used for direct pairwise comparison of two nucleotide sequences. “BLAST 2 Sequences” can be accessed and used interactively at http://www.ncbi.nlm.nih.gov/gov/bl2.html. The “BLAST 2 Sequences” tool can be used for both blastn and blastp (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the “BLAST 2 Sequences” tool Version 2.0.12 (Apr. 21, 2000) set at default parameters. Such default parameters may be, for example:

[0114] Matrix: BLOSUM62

[0115] Reward for match: 1

[0116] Penalty for mismatch: −2

[0117] Open Gap: 5 and Extension Gap: 2 penalties

[0118] Gap x drop-off: 50

[0119] Expect: 10

[0120] Word Size: 11

[0121] Filter: on

[0122] Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

[0123] Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

[0124] The phrases “percent identity” and “% identity,” as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the charge and hydrophobicity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

[0125] Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and “diagonals saved”=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the “percent similarity” between aligned polypeptide sequence pairs.

[0126] Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the “BLAST 2 Sequences” tool Version 2.0.12 (Apr. 21, 2000) with blastp set at default parameters. Such default parameters may be, for example:

[0127] Matrix: BLOSUM62

[0128] Open Gap: 11 and Extension Gap: 1 penalties

[0129] Gap x drop-off. 50

[0130] Expect: 10

[0131] Word Size: 3

[0132] Filter: on

[0133] Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

[0134] “Human artificial chromosomes” (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size and which contain all of the elements required for chromosome replication, segregation and maintenance.

[0135] The term “humanized antibody” refers to an antibody molecule in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

[0136] “Hybridization” refers to the process by which a polynucleotide strand anneals with a complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of complementarity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the “washing” step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68° C. in the presence of about 6×SSC, about 1% (w/v) SDS, and about 100 μg/ml sheared, denatured salmon sperm DNA.

[0137] Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Such wash temperatures are typically selected to be about 5° C. to 20° C. lower than the thermal melting point (T_(m)) for the specific sequence at a defined ionic strength and pH. The T_(m) is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating T_(m) and conditions for nucleic acid hybridization are well known and can be found in Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2^(nd) ed., vol. 1-3, Cold Spring Harbor Press, Plainview N.Y.; specifically see volume 2, chapter 9.

[0138] High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68° C. in the presence of about 0.2×SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65° C., 60° C., 55° C., or 42° C. may be used. SSC concentration may be varied from about 0.1 to 2×SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, sheared and denatured salmon sperm DNA at about 100-200 μg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

[0139] The term “hybridization complex” refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C₀t or R₀t analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

[0140] The words “insertion” and “addition” refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

[0141] “Immune response” can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytolines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

[0142] An “immunogenic fragment” is a polypeptide or oligopeptide fragment of INTSIG which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term “immunogenic fragment” also includes any polypeptide or oligopeptide fragment of INTSIG which is useful in any of the antibody production methods disclosed herein or known in the art.

[0143] The term “microarray” refers to an arrangement of a plurality of polynucleotides, polypeptides, or other chemical compounds on a substrate.

[0144] The terms “element” and “array element” refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microarray.

[0145] The term “modulate” refers to a change in the activity of INTSIG. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of INTSIG.

[0146] The phrases “nucleic acid” and “nucleic acid sequence” refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

[0147] “Operably linked” refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with a second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

[0148] “Peptide nucleic acid” (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

[0149] “Post-translational modification” of an INTSIG may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu of INTSIG.

[0150] “Probe” refers to nucleic acid sequences encoding INTSIG, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes.

[0151] “Primers” are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

[0152] Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

[0153] Methods for preparing and using probes and primers are described in the references, for example Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2^(nd) ed., vol. 1-3, Cold Spring Harbor Press, Plainview N.Y.; Ausubel, F. M. et al. (1987) Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York N.Y.; Innis, M. et al. (1990) PCR Protocols, A Guide to Methods and Applications, Academic Press, San Diego Calif. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge Mass.).

[0154] Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas Tex.) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge Mass.) allows the user to input a “mispriming library,” in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

[0155] A “recombinant nucleic acid” is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

[0156] Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be use to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

[0157] A “regulatory element” refers to a nucleic acid sequence usually derived from untranslated regions of a gene and includes enhancers, promoters, introns, and 5′ and 3′ untranslated regions (UTRs). Regulatory elements interact with host or viral proteins which control transcription, translation, or RNA stability.

[0158] “Reporter molecules” are chemical or biochemical moieties used for labeling a nucleic acid, amino acid, or antibody. Reporter molecules include radionuclides; enzymes; fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and other moieties known in the art.

[0159] An “RNA equivalent,” in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

[0160] The term “sample” is used in its broadest sense. A sample suspected of containing INTSIG, nucleic acids encoding INTSIG, or fragments thereof may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

[0161] The terms “specific binding” and “specifically binding” refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope “A,” the presence of a polypeptide comprising the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

[0162] The term “substantially purified” refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other components with which they are naturally associated.

[0163] A “substitution” refers to the replacement of one or more amino acid residues or nucleotides by different amino acid residues or nucleotides, respectively.

[0164] “Substrate” refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

[0165] A “Vscript image” or “expression profile” refers to the collective pattern of gene expression by a particular cell type or tissue under given conditions at a given time.

[0166] “Transformation” describes a process by which exogenous DNA is introduced into a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, bacteriophage or viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term “transformed cells” includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

[0167] A “transgenic organism,” as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or in vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, plants and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook et al. (1989), supra.

[0168] A “variant” of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the “BLAST 2 Sequences” tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length. A variant may be described as, for example, an “allelic” (as defined above), “splice,” “species,” or “polymorphic” variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides will generally have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass “single nucleotide polymorphisms” (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

[0169] A “variant” of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the “BLAST 2 Sequences” tool Version 2.0.9 (May 7, 1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length of one of the polypeptides.

[0170] The Invention

[0171] The invention is based on the discovery of new human intracellular signaling molecules (INTSIG), the polynucleotides encoding INTSIG, and the use of these compositions for the diagnosis, treatment, or prevention of cell proliferative, autoimmune/inflammatory, neurological, gastrointestinal, reproductive, developmental, vesicle trafficking disorders, and viral infections.

[0172] Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the invention. Each polynucleotide and its corresponding polypeptide are correlated to a single Incyte project identification number (Incyte Project ID). Each polypeptide sequence is denoted by both a polypeptide sequence identification number (Polypeptide SEQ ID NO:) and an Incyte polypeptide sequence number (Incyte Polypeptide ID) as shown. Each polynucleotide sequence is denoted by both a polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and an Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) as shown.

[0173] Table 2 shows sequences with homology to the polypeptides of the invention as identified by BLAST analysis against the GenBank protein (genpept) database. Columns 1 and 2 show the polypeptide sequence identification number (Polypeptide SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for polypeptides of the invention. Column 3 shows the GenBank identification number (GenBank ID NO:) of the nearest GenBank homolog. Column 4 shows the probability scores for the matches between each polypeptide and its homolog(s). Column 5 shows the annotation of the GenBank homolog(s) along with relevant citations where applicable, all of which are expressly incorporated by reference herein.

[0174] Table 3 shows various structural features of the polypeptides of the invention. Columns 1 and 2 show the polypeptide sequence identification number (SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for each polypeptide of the invention. Column 3 shows the number of amino acid residues in each polypeptide. Column 4 shows potential phosphorylation sites, and column 5 shows potential glycosylation sites, as determined by the MOTIFS program of the GCG sequence analysis software package (Genetics Computer Group, Madison Wis.). Column 6 shows amino acid residues comprising signature sequences, domains, and motifs. Column 7 shows analytical methods for protein structure/function analysis and in some cases, searchable databases to which the analytical methods were applied.

[0175] Together, Tables 2 and 3 summarize the properties of polypeptides of the invention, and these properties establish that the claimed polypeptides are intracellular signaling molecules. For example, SEQ ID NO:1 is 26% identical, from residue R221 to residue A458, to human F-box and WD-repeats protein beta-TRCP isoform B (GenBank ID g28577) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 6.1e-11, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:1 also contains an F-box domain and six WD repeats as determined by searching for statistically significant matches in the hidden Markov model (HMM-based PFAM database of conserved protein family domains. (See Table 3.) Data from BUMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:1 is a WD-repeat protein. SEQ ID NO:2 is 91% identical, from residue R146 to residue S613, to rat potential ligand-binding protein from olfactory mucosa (GenBank ID g57732) with a BLAST probability score of 2.5e-222. (See Table 2.) SEQ ID NO:2 also appears to be expressed exclusively in nasal tissues. In an alternative example, SEQ ID NO:4 is 65% identical, from residue M1 to residue K520, to human centaurin beta2 (GenBank ID g4688902) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 5.5e-240, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:4 also contains a GTPase activating protein for Arf domain, as well as a PH domain and ankyrin repeats as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS analysis provides further corroborative evidence that SEQ ID NO:4 is a centaurin beta family ArfGAP. In an alternative example, SEQ ID NO:6 is 70% identical, from residue M22 to residue S638, to mouse purine nucleotide binding protein (GenBank ID g1174187), 64% identical from residue M22 to K627, to mouse guanylate binding protein (GenBank ID g193444), and 55% identical from residue S18 to K601, to human guanylate binding protein 1, interferon-inducible (GenBank ID g12803663) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The respective BLAST probability scores are 4.5e-234, 1.9e-205, and 5.1e-171, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:6 also contains a guanylate-binding protein domain as determined by searching for statistically significant matches in the hidden Markov model (HMM-based PFAM database of conserved protein family domains. (See Table 3.) Data from MOTIFS, and additional BLAST analyses provide further corroborative evidence that SEQ ID NO:6 is an interferon-induced guanylate-binding protein. In an alternative example, SEQ ID NO:7 is 76% identical, from residue M1 to residue Q386, to Mus musculus HS1 binding protein 3 (GenBank ID g4160304) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 1.2e-148, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:7 also contains a PX domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) These data provide corroborative evidence that SEQ ID NO:7 is an HS1 binding protein. In an alternative example, SEQ ID NO:9 is 36% identical, from residue P1110 to residue L1437, to rat kalirin-9a (GenBank ID g7650388), a neuronal Dbl family member, as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 6.0e-59, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:9 also contains a RhoGEF domain and a PH domain as determined by searching for statistically significant matches in the hidden Markov model (HMM-based PFAM database of conserved protein family domains. (See Table 3.) Data from additional BLAST analyses provide further corroborative evidence that SEQ ID NO:9 is a member of the Dbl family of guanosine nucleotide exchange factors. In an alternative example, SEQ ID NO:11 is 99% identical, from residue M649 to residue S1725, to the human T-cell lymphoma invasion and metastasis 2 polypeptide (GenBank ID g6224676) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 0.0, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:11 also contains a PDZ domain, a RhoGEF domain, and two PH domains as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS and MOTIFS analyses provide further corroborative evidence that SEQ ID NO:11 is a member of the Dbl family of guanosine nucleotide exchange factors. In an alternative example, SEQ ID NO:14 is 95% identical, from residue M1 to residue L979, to rat PSD-95/SAP90-associated protein-3, a membrane-associated guanylate kinase (GenBank ID g1864091) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 0.0, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. Data from further BLAST analyses provide corroborative evidence that SEQ ID NO:14 is a guanylate kinase. In an alternative example, SEQ ID NO:15 is 56% identical, from residue M1 to residue Q162, to rat ras-related protein (GenBank ID g498257) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 1.8e46, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:15 also contains a ras family domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS, MOTIFS, and further BLAST analyses provide corroborative evidence that SEQ ID NO:15 is a ras-related protein. SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:16-18 were analyzed and annotated in a similar manner. The algorithms and parameters for the analysis of SEQ ID NO:1-18 are described in Table 7.

[0176] As shown in Table 4, the full length polynucleotide sequences of the present invention were assembled using cDNA sequences or coding (exon) sequences derived from genomic DNA, or any combination of these two types of sequences. Column 1 lists the polynucleotide sequence identification number (Polynucleotide SEQ ID NO:), the corresponding Incyte polynucleotide consensus sequence number (Incyte ID) for each polynucleotide of the invention, and the length of each polynucleotide sequence in basepairs. Column 2 shows the nucleotide start (5′) and stop (3′) positions of the cDNA and/or genomic sequences used to assemble the full length polynucleotide sequences of the invention, and of fragments of the polynucleotide sequences which are useful, for example, in hybridization or amplification technologies that identify SEQ ID NO:19-36 or that distinguish between SEQ ID NO:19-36 and related polynucleotide sequences.

[0177] The polynucleotide fragments described in Column 2 of Table 4 may refer specifically, for example, to Incyte cDNAs derived from tissue-specific cDNA libraries or from pooled cDNA libraries. Alternatively, the polynucleotide fragments described in column 2 may refer to GenBank cDNAs or ESTs which contributed to the assembly of the full length polynucleotide sequences. In addition, the polynucleotide fragments described in column 2 may identify sequences derived from the ENSEMBL (The Sanger Centre, Cambridge, UK) database (i.e., those sequences including the designation “ENST”). Alternatively, the polynucleotide fragments described in column 2 may be derived from the NCBI RefSeq Nucleotide Sequence Records Database (i.e., those sequences including the designation ‘NM’ or “NT”) or the NCBI RefSeq Protein Sequence Records (i.e., those sequences including the designation “NP”). Alternatively, the polynucleotide fragments described in column 2 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an “exon stitching” algorithm For example, a polynucleotide sequence identified as FL_XXXXXX_N₁_N₂_YYYYY_N_(3—)N₄ represents a “stitched” sequence in which X is the identification number of the cluster of sequences to which the algorithm was applied, and YYYYY is the number of the prediction generated by the algorithm, and N_(1,2,3) . . . , if present, represent specific exons that may have been manually edited during analysis (See Example V). Alternatively, the polynucleotide fragments in column 2 may refer to assemblages of exons brought together by an “exon-stretching” algorithm. For example, a polynucleotide sequence identified as FLXXXXXX_gAAAAA_gBBBBB_(—)1_N is a “stretched” sequence, with XXXXXX being the Incyte project identification number, gAAAAA being the GenBank identification number of the human genomic sequence to which the “exon-stretching” algorithm was applied, gBBBBB being the GenBank identification number or NCBI RefSeq identification number of the nearest GenBank protein homolog, and N referring to specific exons (See Example V). In instances where a RefSeq sequence was used as a protein homolog for the “exon-stretching” algorithm, a RefSeq identifier (denoted by “NM,” “NP,” or “NT”) may be used in place of the GenBank identifier (i.e., gBBBBB).)

[0178] Alternatively, a prefix identifies component sequences that were hand-edited, predicted from genomic DNA sequences, or derived from a combination of sequence analysis methods. The following Table lists examples of component sequence prefixes and corresponding sequence analysis methods associated with the prefixes (see Example IV and Example V). Prefix Type of analysis and/or examples of programs GNN, Exon prediction from genomic sequences using, for example, GFG, GENSCAN (Stanford University, CA, USA) or FGENES ENST (Computer Genomics Group, The Sanger Centre, Cambridge, UK). GBI Hand-edited analysis of genomic sequences. FL Stitched or stretched genomic sequences (see Example V). INCY Full length transcript and exon prediction from mapping of EST sequences to the genome. Genomic location and EST composition data are combined to predict the exons and resulting transcript.

[0179] In some cases, Incyte cDNA coverage redundant with the sequence coverage shown in Table 4 was obtained to confirm the final consensus polynucleotide sequence, but the relevant Incyte cDNA identification numbers are not shown.

[0180] Table 5 shows the representative cDNA libraries for those full length polynucleotide sequences which were assembled using Incyte cDNA sequences. The representative cDNA library is the Incyte cDNA library which is most frequently represented by the Incyte cDNA sequences which were used to assemble and confirm the above polynucleotide sequences. The tissues and vectors which were used to construct the cDNA libraries shown in Table 5 are described in Table 6.

[0181] The invention also encompasses INTSIG variants. A preferred INTSIG variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the INTSIG amino acid sequence, and which contains at least one functional or structural characteristic of INTSIG.

[0182] The invention also encompasses polynucleotides which encode INTSIG. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:19-36, which encodes INTSIG. The polynucleotide sequences of SEQ ID NO:19-36, as presented in the Sequence Listing, embrace the equivalent RNA sequences, wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

[0183] The invention also encompasses a variant of a polynucleotide sequence encoding INTSIG. In particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding INTSIG. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:19-36 which has at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:19-36. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of INTSIG.

[0184] In addition, or in the alternative, a polynucleotide variant of the invention is a splice variant of a polynucleotide sequence encoding INTSIG. A splice variant may have portions which have significant sequence identity to the polynucleotide sequence encoding INTSIG, but will generally have a greater or lesser number of polynucleotides due to additions or deletions of blocks of sequence arising from alternate splicing of exons during mRNA processing. A splice variant may have less than about 70%, or alternatively less than about 60%, or alternatively less than about 50% polynucleotide sequence identity to the polynucleotide sequence encoding INTSIG over its entire length; however, portions of the splice variant will have at least about 70%, or alternatively at least about 85%, or alternatively at least about 95%, or alternatively 100% polynucleotide sequence identity to portions of the polynucleotide sequence encoding INTSIG. Any one of the splice variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of INTSIG.

[0185] It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding INTSIG, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring INTSIG, and all such variations are to be considered as being specifically disclosed.

[0186] Although nucleotide sequences which encode INTSIG and its variants are generally capable of hybridizing to the nucleotide sequence of the naturally occurring INTSIG under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding INTSIG or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding INTSIG and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

[0187] The invention also encompasses production of DNA sequences which encode INTSIG and INTSIG derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding INTSIG or any fragment thereof.

[0188] Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:19-36 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G. M. and S. L. Berger (1987) Methods Enzymol. 152:399-407; Kimmel, A. R. (1987) Methods Enzymol. 152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in “Definitions.”

[0189] Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase L SEQUENASE (US Biochemical, Cleveland Oreg.), Taq polymerase (Applied Biosystems), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway N.J.), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg Md.). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno Nev.), PTC200 thermal cycler (MJ Research, Watertown Mass.) and ABI CATALYST 800 thermal cycler (Applied Biosystems). Sequencing is then carried out using either the ABI 373 or 377 DNA sequencing system (Applied Biosystems), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale Calif.), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art (See, e.g., Ausubel, F. M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York N.Y., unit 7.7; Meyers, R. A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York N.Y., pp. 85&853.)

[0190] The nucleic acid sequences encoding INTSIG may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic. 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J. D. et al. (1991) Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto Calif.) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 primer analysis software (National Biosciences, Plymouth Minn.) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68° C. to 72° C.

[0191] When screening for full length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5′ regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5′ non-transcribed regulatory regions.

[0192] Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Applied Biosystems), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

[0193] In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode INTSIG may be cloned in recombinant DNA molecules that direct expression of INTSIG, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express INTSIG.

[0194] The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter INTSIG-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

[0195] The nucleotides of the present invention may be subjected to DNA shuffling techniques such as MOLECULARBREEDING (Maxygen Inc., Santa Clara Calif.; described in U.S. Pat. No. 5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F. C. et al. (1999) Nat. Biotechnol. 17:259-264; and Crameri, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or improve the biological properties of INTSIG, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through “artificial” breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.

[0196] In another embodiment, sequences encoding INTSIG may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M. H. et al. (1980) Nucleic Acids Symp. Ser. 7:215-223; and Horn, T. et al. (1980) Nucleic Acids Symp. Ser. 7:225-232.) Alternatively, INTSIG itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solution-phase or solid-phase techniques. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, W H Freeman, New York N.Y., pp. 55-60; and Roberge, J. Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Applied Biosystems). Additionally, the amino acid sequence of INTSIG, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide or a polypeptide having a sequence of a naturally occurring polypeptide.

[0197] The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R. M. and F. Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, supra, pp. 28-53.)

[0198] In order to express a biologically active INTSIG, the nucleotide sequences encoding INTSIG or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5′ and 3′ untranslated regions in the vector and in polynucleotide sequences encoding INTSIG. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding INTSIG. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding INTSIG and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162.)

[0199] Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding INTSIG and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview N.Y., ch. 4, 8, and 16-17; Ausubel, F. M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York N.Y., ch. 9, 13, and 16.)

[0200] A variety of expression vector/host systems may be utilized to contain and express sequences encoding INTSIG. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. (See, e.g., Sambrook, supra; Ausubel, supra; Van Heeke, G. and S. M. Schuster (1989) J. Biol. Chem. 264:5503-5509; Engelhard, E. K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945; Takamatsu, N. (1987) EMBO J. 6:307-311; The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York N.Y., pp. 191-196; Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659; and Harrington, J. J. et al. (1997) Nat. Genet. 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di Nicola, M. et al. (1998) Cancer Gen. Ther. 5(6):350-356; Yu, M. et al. (1993) Proc. Natl. Acad. Sci. USA 90(13):6340-6344; Buller, R. M. et al. (1985) Nature 317(6040):813-815; McGregor, D. P. et al. (1994) Mol. Immunol. 31(3):219-226; and Verma, I. M. and N. Somia (1997) Nature 389:239-242.) The invention is not limited by the host cell employed.

[0201] In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding INTSIG. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding INTSIG can be achieved using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla Calif.) or PSPORT1 plasmid (Life Technologies). Ligation of sequences encoding INTSIG into the vector's multiple cloning site disrupts the lacZ gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S. M. Schuster (1989) J. Biol. Chem. 264:5503-5509.) When large quantities of INTSIG are needed, e.g. for the production of antibodies, vectors which direct high level expression of INTSIG may be used. For example, vectors containing the strong, inducible SP6 or T7 bacteriophage promoter may be used.

[0202] Yeast expression systems may be used for production of INTSIG. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, supra; Bitter, G. A. et al. (1987) Methods Enzymol. 153:516-544; and Scorer, C. A. et al. (1994) BioTechnology 12:181-184.)

[0203] Plant systems may also be used for expression of INTSIG. Transcription of sequences encoding INTSIG may be driven by viral promoters, e.g., the ³⁵S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York N.Y., pp. 191-196.)

[0204] In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding INTSIG may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses INTSIG in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

[0205] Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J. J. et al. (1997) Nat. Genet. 15:345-355.)

[0206] For long term production of recombinant proteins in mammalian systems, stable expression of INTSIG in cell lines is preferred. For example, sequences encoding INTSIG can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

[0207] Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in tk- and apr cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, dhfr confers resistance to methotrexate; neo confers resistance to the aminoglycosides neomycin and G-418; and als and pat confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., trpB and hisD, which alter cellular requirements for metabolites. (See, e.g., Hartman, S. C. and R. C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), B glucuronidase and its substrate B-glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C. A. (1995) Methods Mol. Biol. 55:121-131.)

[0208] Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding INTSIG is inserted within a marker gene sequence, transformed cells containing sequences encoding INTSIG can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding INTSIG under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

[0209] In general, host cells that contain the nucleic acid sequence encoding INTSIG and that express INTSIG may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

[0210] Immunological methods for detecting and measuring the expression of INTSIG using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on INTSIG is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul Minn., Sect. IV; Coligan, J. E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York N.Y.; and Pound, J. D. (1998) Immunochemical Protocols, Humana Press, Totowa N.J.)

[0211] A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding INTSIG include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding INTSIG, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison Wis.), and US Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

[0212] Host cells transformed with nucleotide sequences encoding INTSIG may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode INTSIG may be designed to contain signal sequences which direct secretion of INTSIG through a prokaryotic or eukaryotic cell membrane.

[0213] In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a “prepro” or “pro” form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, EK293, and W138) are available from the American Type Culture Collection (ATCC, Manassas Va.) and may be chosen to ensure the correct modification and processing of the foreign protein.

[0214] In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding INTSIG may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric INTSIG protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of INTSIG activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, c-myc, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, c-c-myc, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the INTSIG encoding sequence and the heterologous protein sequence, so that INTSIG may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, cb. 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

[0215] In a further embodiment of the invention, synthesis of radiolabeled INTSIG may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the 17, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, ³⁵S-methionine.

[0216] INTSIG of the present invention or fragments thereof may be used to screen for compounds that specifically bind to INTSIG. At least one and up to a plurality of test compounds may be screened for specific binding to INTSIG. Examples of test compounds include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

[0217] In one embodiment, the compound thus identified is closely related to the natural ligand of INTSIG, e.g., a ligand or fragment thereof, a natural substrate, a structural or functional mimetic, or a natural binding partner. (See, e.g., Coligan, J. E. et al. (1991) Current Protocols in Immunology (2): Chapter 5.) Similarly, the compound can be closely related to the natural receptor to which INTSIG binds, or to at least a fragment of the receptor, e.g., the ligand binding site. In either case, the compound can be rationally designed using known techniques. In one embodiment, screening for these compounds involves producing appropriate cells which express INTSIG, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or E. coli. Cells expressing INTSIG or cell membrane fractions which contain INTSIG are then contacted with a test compound and binding, stimulation, or inhibition of activity of either INTSIG or the compound is analyzed.

[0218] An assay may simply test binding of a test compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. For example, the assay may comprise the steps of combining at least one test compound with INTSIG, either in solution or affixed to a solid support, and detecting the binding of INTSIG to the compound. Alternatively, the assay may detect or measure binding of a test compound in the presence of a labeled competitor. Additionally, the assay may be carried out using cell-free preparations, chemical libraries, or natural product mixtures, and the test compound(s) may be free in solution or affixed to a solid support.

[0219] INTSIG of the present invention or fragments thereof may be used to screen for compounds that modulate the activity of INTSIG. Such compounds may include agonists, antagonists, or partial or inverse agonists. In one embodiment, an assay is performed under conditions permissive for INTSIG activity, wherein INTSIG is combined with at least one test compound, and the activity of INTSIG in the presence of a test compound is compared with the activity of INTSIG in the absence of the test compound. A change in the activity of INTSIG in the presence of the test compound is indicative of a compound that modulates the activity of INTSIG. Alternatively, a test compound is combined with an in vitro or cell-free system comprising INTSIG under conditions suitable for INTSIG activity, and the assay is performed. In either of these assays, a test compound which modulates the activity of INTSIG may do so indirectly and need not come in direct contact with the test compound. At least one and up to a plurality of test compounds may be screened.

[0220] In another embodiment, polynucleotides encoding INTSIG or their mammalian homologs may be “knocked out” in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e.g., U.S. Pat. No. 5,175,383 and U.S. Pat. No. 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo; Capecchi, M. R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J. D. (1996) Clin. Invest. 97:1999-2002; Wagner, K. U. et al. (1997) Nucleic Acids Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BUL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.

[0221] Polynucleotides encoding INTSIG may also be manipulated in vitro in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J. A. et al. (1998) Science 282:1145-1147).

[0222] Polynucleotides encoding INTSIG can also be used to create “knockin” humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of a polynucleotide encoding INTSIG is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease. Alternatively, a mammal inbred to overexpress INTSIG, e.g., by secreting INTSIG in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) Biotechnol. Annu. Rev. 4:55-74).

[0223] Therapeutics

[0224] Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of INTSIG and intracellular signaling molecules. In addition, examples of tissues expressing INTSIG are ovarian tissue and brain tissue and can be found in Table 6. Therefore, INTSIG appears to play a role in cell proliferative, autoimmune/inflammatory, neurological, gastrointestinal, reproductive, developmental, vesicle trafficking disorders, and viral infections. In the treatment of disorders associated with increased INTSIG expression or activity, it is desirable to decrease the expression or activity of INTSIG. In the treatment of disorders associated with decreased INTSIG expression or activity, it is desirable to increase the expression or activity of INTSIG.

[0225] Therefore, in one embodiment, INTSIG or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of INTSIG. Examples of such disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysnal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an autoimmune/inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracanial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system including Down syndrome, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; a gastrointestinal disorder such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis, pancreatitis, pancreatic carcinoma, biliary tract disease, hepatitis, hyperbilirubinemia, cirrhosis, passive congestion of the liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, acquired immunodeficiency syndrome (AIDS) enteropathy, jaundice, hepatic encephalopathy, hepatorenal syndrome, hepatic steatosis, hemochromatosis, Wilson's disease, alpha₁-antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein obstruction and thrombosis, centrilobular necrosis, peliosis hepatis, hepatic vein thrombosis, veno-occlusive disease, preeclampsia, eclampsia, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, and hepatic tumors including nodular hyperplasias, adenomas, and carcinomas; a reproductive disorder such as a disorder of prolactin production, infertility, including tubal disease, ovulatory defects, endometriosis, a disruption of the estrous cycle, a disruption of the menstrual cycle, polycystic ovary syndrome, ovarian hyperstimulation syndrome, an endometrial or ovarian tumor, a uterine fibroid, autoimmune disorders, ectopic pregnancy, teratogenesis, cancer of the breast, fibrocystic breast disease, galactorrhea, a disruption of spermatogenesis, abnormal sperm physiology, cancer of the testis, cancer of the prostate, benign prostatic hyperplasia, prostatitis, Peyronie's disease, impotence, carcinoma of the male breast, gynecomastia, hypergonadotropic and hypogonadotropic hypogonadism, pseudohermaphroditism, azoospermia, premature ovarian failure, acrosin deficiency, delayed puperty, retrograde ejaculation and anejaculation, haemangioblastomas, cystsphaeochromocytomas, paraganglioma, cystadenomas of the epididymis, and endolymphatic sac tumours; a developmental disorder such as renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Syndenham's chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss; a vesicle trafficking disorder such as cystic fibrosis, glucose-galactose malabsorption syndrome, hypercholesterolemia, diabetes mellitus, diabetes insipidus, hyper- and hypoglycemia, Grave's disease, goiter, Cushing's disease, and Addison's disease, gastrointestinal disorders including ulcerative colitis, gastric and duodenal ulcers, other conditions associated with abnormal vesicle trafficking, including acquired immunodeficiency syndrome (AIDS), allergies including hay fever, asthma, and urticaria (hives), autoimmune hemolytic anemia, proliferative glomerulonephritis, inflammatory bowel disease, multiple sclerosis, myasthenia gravis, rheumatoid and osteoarthritis, scleroderma, Chediak-Higashi and Sjogren's syndromes, systemic lupus erythematosus, toxic shock syndrome, and traumatic tissue damage; and an infection by a viral agent classified as adenovirus, arenavirus, bunyavirus, calicivirus, coronavirus, filovirus, hepadnavirus, herpesvirus, flavivirus, orthomyxovirus, parvovirus, papovavirus, paramyxovirus, picomavirus, poxvirus, reovirus, retrovirus, rhabdovirus, and togavirus.

[0226] In another embodiment, a vector capable of expressing INTSIG or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of INTSIG including, but not limited to, those described above.

[0227] In a further embodiment, a composition comprising a substantially purified INTSIG in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of INTSIG including, but not limited to, those provided above.

[0228] In still another embodiment, an agonist which modulates the activity of INTSIG may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of INTSIG including, but not limited to, those listed above.

[0229] In a further embodiment, an antagonist of INTSIG may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of INTSIG. Examples of such disorders include, but are not limited to, those cell proliferative, autoimmune/inflammatory, neurological, gastrointestinal, reproductive, developmental, vesicle trafficking disorders, and viral infections described above. In one aspect, an antibody which specifically binds INTSIG may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express INTSIG.

[0230] In an additional embodiment, a vector expressing the complement of the polynucleotide encoding INTSIG may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of INTSIG including, but not limited to, those described above.

[0231] In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

[0232] An antagonist of INTSIG may be produced using methods which are generally known in the art. In particular, purified INTSIG may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind INTSIG. Antibodies to INTSIG may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use. Single chain antibodies (e.g., from camels or llamas) may be potent enzyme inhibitors and may have advantages in the design of peptide mimetics, and in the development of immuno-adsorbents and biosensors (Muyldermans, S. (2001) J. Biotechnol. 74:277-302).

[0233] For the production of antibodies, various hosts including goats, rabbits, rats, mice, camels, dromedaries, llamas, humans, and others may be immunized by injection with INTSIG or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KUI, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

[0234] It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to INTSIG have an amino acid sequence consisting of at least about 5 amino acids, and generally win consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of INTSIG amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

[0235] Monoclonal antibodies to INTSIG may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R. J. et al. (1983) Proc. Natl. Acad. Sci. USA 80:2026-2030; and Cole, S. P. et al. (1984) Mol. Cell Biol. 62:109-120.)

[0236] In addition, techniques developed for the production of “chimeric antibodies,” such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S. L. et al. (1984) Proc. Natl. Acad. Sci. USA 81:6851-6855; Neuberger, M. S. et al. (1984) Nature 312:604-608; and Takeda, S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce INTSIG-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D. R. (1991) Proc. Natl. Acad. Sci. USA 88:10134-10137.)

[0237] Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. USA 86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299.)

[0238] Antibody fragments which contain specific binding sites for INTSIG may also be generated. For example, such fragments include, but are not limited to, F(ab)₂ fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab)₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W. D. et al. (1989) Science 246:1275-1281.)

[0239] Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between INTSIG and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering INTSIG epitopes is generally used, but a competitive binding assay may also be employed (Pound, supra).

[0240] Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for INTSIG. Affinity is expressed as an association constant, K_(a), which is defined as the molar concentration of INTSIG-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The K_(a) determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple INTSIG epitopes, represents the average affinity, or avidity, of the antibodies for INTSIG. The K_(a) determined for a preparation of monoclonal antibodies, which are monospecific for a particular INTSIG epitope, represents a true measure of affinity. High-affinity antibody preparations with K_(a) ranging from about 10⁹ to 10¹² L/mole are preferred for use in immunoassays in which the INTSIG-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K_(a) ranging from about 10⁶ to 10¹² L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of INTSIG, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington D.C.; Liddell, J. E. and A. Cryer (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York N.Y.).

[0241] The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of INTSIG-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al. supra.)

[0242] In another embodiment of the invention, the polynucleotides encoding INTSIG, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, modifications of gene expression can be achieved by designing complementary sequences or antisense molecules (DNA, RNA, PNA, or modified oligonucleotides) to the coding or regulatory regions of the gene encoding INTSIG. Such technology is well known in the art, and antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding INTSIG. (See, e.g., Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Totawa N.J.)

[0243] In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g., Slater, J. E. et al. (1998) J. Allergy Clin. Immunol. 102(3):469-475; and Scanlon, K. J. et al. (1995) 9(13):1288-1296.) Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retroviris and adeno-associated virus vectors. (See, e.g., Miller, A. D. (1990) Blood 76:271; Ausubel, supra; Uckert, W. and W. Walther (1994) Pharmacol. Ther. 63(3):323-347.) Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the art. (See, e.g., Rossi, J. J. (1995) Br. Med. Bull. 51(1):217-225; Boado, R. J. et al. (1998) J. Pharm. Sci. 87(11):1308-1315; and Morris, M. C. et al. (1997) Nucleic Acids Res. 25(14):2730-2736.)

[0244] In another embodiment of the invention, polynucleotides encoding INTSIG may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) Science 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R. M. et al. (1995) Science 270:475-480; Bordignon, C. et al. (1995) Science 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) Cell 75:207-216; Crystal, R. G. et al. (1995) Hum. Gene Therapy 6:643-666; Crystal, R. G. et al. (1995) Hum. Gene Therapy 6:667-703), thalassamias, familial hypercholesteroleinia, and hemophilia resulting from Factor VIII or Factor IX deficiencies (Crystal, R. G. (1995) Science 270:404-410; Verma, I. M. and N. Somia (1997) Nature 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) Nature 335:395-396; Poeschla, E. et al. (1996) Proc. Natl. Acad. Sci. USA 93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparum and Trypanosoma cruzi). In the case where a genetic deficiency in INTSIG expression or regulation causes disease, the expression of INTSIG from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.

[0245] In a further embodiment of the invention, diseases or disorders caused by deficiencies in INTSIG are treated by constructing mammalian expression vectors encoding INTSIG and introducing these vectors by mechanical means into INTSIG-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, RA and W. F. Anderson (1993) Annu. Rev. Biochem. 62:191-217; Ivics, Z. (1997) Cell 91:501-510; Boulay, J-L. and H. Récipon (1998) Curr. Opin. Biotechnol. 9:445-450).

[0246] Expression vectors that may be effective for the expression of INTSIG include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX, PCR2-TOPOTA vectors (Invitrogen, Carlsbad Calif.), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla Calif.), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto Calif.). INTSIG may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (IX), or β-actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and H. Bujard (1992) Proc. Natl. Acad. Sci. USA 89:5547-5551; Gossen, M. et al. (1995) Science 268:1766-1769; Rossi, F. M. V. and H. M. Blau (1998) Curr. Opin. Biotechnol. 9:451-456), commercially available in the T-REX plasmid (Invitrogen)); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND; Invitrogen); the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F. M. V. and H. M. Blau, supra)), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding INTSIG from a normal individual.

[0247] Commercially available liposome transformation kits (e.g., the PERFECT LIPID TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F. L. and A. J. Eb (1973) Virology 52:456-467), or by electroporation (Neumann, E. et al. (1982) EMBO J. 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.

[0248] In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to INTSIG expression are treated by constructing a retrovirus vector consisting of (i) the polynucleotide encoding INTSIG under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus cis-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, L et al. (1995) Proc. Natl. Acad. Sci. USA 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al. (1987) J. Virol. 61:1647-1650; Bender, M. A. et al. (1987) J. Virol. 61:1639-1646; Adam, M. A. and A. D. Miller (1988) J. Virol. 62:3802-3806; Dull, T. et al. (1998) J. Virol. 72:8463-8471; Zufferey, R. et al. (1998) J. Virol. 72:9873-9880). U.S. Pat. No. 5,910,434 to Rigg (“Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant”) discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4⁺ T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) J. Virol. 71:7020-7029; Bauer, G. et al. (1997) Blood 89:2259-2267; Bonyhadi, M. L. (1997) J. Virol. 71:4707-4716; Ranga, U. et al. (1998) Proc. Natl. Acad. Sci. USA 95:1201-1206; Su, L. (1997) Blood 89:2283-2290).

[0249] In the alternative, an adenovirus-based gene therapy delivery system is used to deliver polynucleotides encoding INTSIG to cells which have one or more genetic abnormalities with respect to the expression of INTSIG. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csete, M. E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are described in U.S. Pat. No. 5,707,618 to Armentano (“Adenovirus vectors for gene therapy”), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P. A. et al. (1999) Annu. Rev. Nutr. 19:511-544 and Verma, I. M. and N. Somia (1997) Nature 18:389:239-242, both incorporated by reference herein.

[0250] In another alternative, a herpes-based, gene therapy delivery system is used to deliver polynucleotides encoding INTSIG to target cells which have one or more genetic abnormalities with respect to the expression of INTSIG. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing INTSIG to cells of the central nervous system, for which HSV has a tropism. The construction and packaging of herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) Exp. Eye Res. 169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S. Pat. No. 5,804,413 to DeLuca (“Herpes simplex virus strains for gene transfer”), which is hereby incorporated by reference. U.S. Pat. No. 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strins deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W. F. et al. (1999) J. Virol. 73:519-532 and Xu, H. et al. (1994) Dev. Biol. 163:152-161, hereby incorporated by reference. The manipulation of cloned herpesvirus sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.

[0251] In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to deliver polynucleotides encoding INTSIG to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and K.-J. Li (1998) Curr. Opin. Biotechnol. 9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting the coding sequence for INTSIG into the alphavirus genome in place of the capsid-coding region results in the production of a large number of INTSIG-coding RNAs and the synthesis of high levels of INTSIG in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S. A. et al. (1997) Virology 228:7483). The wide host range of alphaviruses will allow the introduction of INTSIG into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.

[0252] Oligonucleotides derived from the transcription initiation site, e.g., between about positions −10 and +10 from the start site, may also be employed to inhibit gene expression. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J. E. et al. (1994) in Huber, B. E. and B. I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco N.Y., pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

[0253] Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding INTSIG.

[0254] Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

[0255] Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding INTSIG. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as 17 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

[0256] RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanldng sequences at the 5′ and/or 3′ ends of the molecule, or the use of phosphorothioate or 2′ O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

[0257] An additional embodiment of the invention encompasses a method for screening for a compound which is effective in altering expression of a polynucleotide encoding INTSIG. Compounds which may be effective in altering expression of a specific polynucleotide may include, but are not limited to, oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, transcription factors and other polypeptide transcriptional regulators, and non-macromolecular chemical entities which are capable of interacting with specific polynucleotide sequences. Effective compounds may alter polynucleotide expression by acting as either inhibitors or promoters of polynucleotide expression. Thus, in the treatment of disorders associated with increased INTSIG expression or activity, a compound which specifically inhibits expression of the polynucleotide encoding INTSIG may be therapeutically useful, and in the treatment of disorders associated with decreased INTSIG expression or activity, a compound which specifically promotes expression of the polynucleotide encoding INTSIG may be therapeutically useful.

[0258] At least one, and up to a plurality, of test compounds may be screened for effectiveness in altering expression of a specific polynucleotide. A test compound may be obtained by any method commonly known in the art, including chemical modification of a compound known to be effective in altering polynucleotide expression; selection from an existing, commercially-available or proprietary library of naturally-occurring or non-natural chemical compounds; rational design of a compound based on chemical and/or structural properties of the target polynucleotide; and selection from a library of chemical compounds created combinatorially or randomly. A sample comprising a polynucleotide encoding INTSIG is exposed to at least one test compound thus obtained. The sample may comprise, for example, an intact or permeabilized cell, or an in vitro cell-free or reconstituted biochemical system Alterations in the expression of a polynucleotide encoding INTSIG are assayed by any method commonly known in the art. Typically, the expression of a specific nucleotide is detected by hybridization with a probe having a nucleotide sequence complementary to the sequence of the polynucleotide encoding INTSIG. The amount of hybridization may be quantified, thus forming the basis for a comparison of the expression of the polynucleotide both with and without exposure to one or more test compounds. Detection of a change in the expression of a polynucleotide exposed to a test compound indicates that the test compound is effective in altering the expression of the polynucleotide. A screen for a compound effective in altering expression of a specific polynucleotide can be carried out, for example, using a Schizosaccharomyces pombe gene expression system (Atkins, D. et al. (1999) U.S. Pat. No. 5,932,435; Arndt, G. M. et al. (2000) Nucleic Acids Res. 28:E15) or a human cell line such as HeLa cell (Clarke, M. L. et al. (2000) Biochem. Biophys. Res. Commun. 268:8-13). A particular embodiment of the present invention involves screening a combinatorial library of oligonucleotides (such as deoxyribonucleotides, ribonucleotides, peptide nucleic acids, and modified oligonucleotides) for antisense activity against a specific polynucleotide sequence (Bruice, T. W. et al. (1997) U.S. Pat. No. 5,686,242; Bruice, T. W. et al. (2000) U.S. Pat. No. 6,022,691).

[0259] Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C. K. et al. (1997) Nat. Biotechnol. 15:462-466.)

[0260] Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

[0261] An additional embodiment of the invention relates to the administration of a composition which generally comprises an active ingredient formulated with a pharmaceutically acceptable excipient Excipients may include, for example, sugars, starches, celluloses, gums, and proteins. Various formulations are commonly known and are thoroughly discussed in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton Pa.). Such compositions may consist of INTSIG, antibodies to INTSIG, and mimetics, agonists, antagonists, or inhibitors of INTSIG.

[0262] The compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

[0263] Compositions for pulmonary administration may be prepared in liquid or dry powder form. These compositions are generally aerosolized immediately prior to inhalation by the patient. In the case of small molecules (e.g. traditional low molecular weight organic drugs), aerosol delivery of fast-acting formulations is well-known in the art. In the case of macromolecules (e.g. larger peptides and proteins), recent developments in the field of pulmonary delivery via the alveolar region of the lung have enabled the practical delivery of drugs such as insulin to blood circulation (see, e.g., Patton, J. S. et al., U.S. Pat. No. 5,997,848). Pulmonary delivery has the advantage of administration without needle injection, and obviates the need for potentially toxic penetration enhancers.

[0264] Compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

[0265] Specialized forms of compositions may be prepared for direct intracellular delivery of macromolecules comprising INTSIG or fragments thereof. For example, liposome preparations containing a cell-impermeable macromolecule may promote cell fusion and intracellular delivery of the macromolecule. Alternatively, INTSIG or a fragment thereof may be joined to a short cationic N-terminal portion from the HIV Tat-1 protein. Fusion proteins thus generated have been found to transduce into the cells of all tissues, including the brain, in a mouse model system (Schwarze, S. R. et al. (1999) Science 285:1569-1572).

[0266] For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, monkeys, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

[0267] A therapeutically effective dose refers to that amount of active ingredient, for example INTSIG or fragments thereof, antibodies of INTSIG, and agonists, antagonists or inhibitors of INTSIG, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED₅₀ (the dose therapeutically effective in 50% of the population) or LD₅₀ (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD₅₀/ED₅₀ ratio. Compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED₅₀ with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

[0268] The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

[0269] Normal dosage amounts may vary from about 0.1 μg to 100,000 μg, up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

[0270] Diagnostics

[0271] In another embodiment, antibodies which specifically bind INTSIG may be used for the diagnosis of disorders characterized by expression of INTSIG, or in assays to monitor patients being treated with INTSIG or agonists, antagonists, or inhibitors of INTSIG. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for INTSIG include methods which utilize the antibody and a label to detect INTSIG in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

[0272] A variety of protocols for measuring INTSIG, including BLISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of INTSIG expression. Normal or standard values for INTSIG expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibodies to INTSIG under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of INTSIG expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

[0273] In another embodiment of the invention, the polynucleotides encoding INTSIG may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of INTSIG may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of INTSIG, and to monitor regulation of INTSIG levels during therapeutic intervention.

[0274] In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding INTSIG or closely related molecules may be used to identify nucleic acid sequences which encode INTSIG. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5′ regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding INTSIG, allelic variants, or related sequences.

[0275] Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the INTSIG encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:19-36 or from genomic sequences including promoters, enhancers, and introns of the INTSIG gene.

[0276] Means for producing specific hybridization probes for DNAs encoding INTSIG include the cloning of polynucleotide sequences encoding INTSIG or INTSIG derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as ³²P or ³⁵S, or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

[0277] Polynucleotide sequences encoding INTSIG may be used for the diagnosis of disorders associated with expression of INTSIG. Examples of such disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an autoimmune/inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes meritus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helninthic infections, and trauma; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system including Down syndrome, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; a gastrointestinal disorder such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis, pancreatitis, pancreatic carcinoma, biliary tract disease, hepatitis, hyperbilirubinemia, cirrhosis, passive congestion of the liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, acquired immunodeficiency syndrome (AIDS) enteropathy, jaundice, hepatic encephalopathy, hepatorenal syndrome, hepatic steatosis, hemochromatosis, Wilson's disease, alpha₁-antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein obstruction and thrombosis, centrilobular necrosis, peliosis hepatis, hepatic vein thrombosis, veno-occlusive disease, preeclampsia, eclampsia, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, and hepatic tumors including nodular hyperplasias, adenomas, and carcinomas; a reproductive disorder such as a disorder of prolactin production, infertility, including tubal disease, ovulatory defects, endometriosis, a disruption of the estrous cycle, a disruption of the menstrual cycle, polycystic ovary syndrome, ovarian hyperstimulation syndrome, an endometrial or ovarian tumor, a uterine fibroid, autoimmune disorders, ectopic pregnancy, teratogenesis, cancer of the breast, fibrocystic breast disease, galactorrhea, a disruption of spermatogenesis, abnormal sperm physiology, cancer of the testis, cancer of the prostate, benign prostatic hyperplasia, prostatitis, Peyronie's disease, impotence, carcinoma of the male breast, gynecomastia, hypergonadotropic and hypogonadotropic hypogonadism, pseudohermaphroditism, azoospermia, premature ovarian failure, acrosin deficiency, delayed puperty, retrograde ejaculation and anejaculation, haemangioblastomas, cystsphaeochromocytomas, paraganglioma, cystadenomas of the epididymis, and endolymphatic sac tumours; a developmental disorder such as renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Syndenham's chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss; a vesicle trafficking disorder such as cystic fibrosis, glucose-galactose malabsorption syndrome, hypercholesterolemia, diabetes mellitus, diabetes insipidus, hyper- and hypoglycemia, Grave's disease, goiter, Cushing's disease, and Addison's disease, gastrointestinal disorders including ulcerative colitis, gastric and duodenal ulcers, other conditions associated with abnormal vesicle trafficking, including acquired immunodeficiency syndrome (AIDS), allergies including hay fever, asthma, and urticaria (hives), autoimmune hemolytic anemia, proliferative glomerulonephritis, inflammatory bowel disease, multiple sclerosis, myasthenia gravis, rheumatoid and osteoarthritis, scleroderma, Chediak-Higashi and Sjogren's syndromes, systemic lupus erythematosus, toxic shock syndrome, and traumatic tissue damage; and an infection by a viral agent classified as adenovirus, arenavirus, bunyavirus, calicivirus, coronavirus, filovirus, hepadnavirus, herpesvirus, flavivirus, orthomyxovirus, parvovirus, papovavirus, paramyxovirus, picomavirus, poxvirus, reovirus, retrovirus, rhabdovirus, and togavirus. The polynucleotide sequences encoding INTSIG may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered INTSIG expression. Such qualitative or quantitative methods are well known in the art.

[0278] In a particular aspect, the nucleotide sequences encoding INTSIG may be usefull in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding INTSIG may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding INTSIG in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

[0279] In order to provide a basis for the diagnosis of a disorder associated with expression of INTSIG, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding INTSIG, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

[0280] Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

[0281] With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

[0282] Additional diagnostic uses for oligonucleotides designed from the sequences encoding INTSIG may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding INTSIG, or a fragment of a polynucleotide complementary to the polynucleotide encoding INTSIG, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.

[0283] In a particular aspect, oligonucleotide primers derived from the polynucleotide sequences encoding INTSIG may be used to detect single nucleotide polymorphisms (SNPs). SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from the polynucleotide sequences encoding INTSIG are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSCCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high-throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed in silico SNP (is SNP), are capable of identifying polymorphisms by comparing the sequence of individual overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego Calif.).

[0284] SNPs may be used to study the genetic basis of human disease. For example, at least 16 common SNPs have been associated with non-insulin-dependent diabetes mellitus. SNPs are also useful for examining differences in disease outcomes in monogenic disorders, such as cystic fibrosis, sickle cell anemia, or chronic granulomatous disease. For example, variants in the mannose-binding lectin, MBL2, have been shown to be correlated with deleterious pulmonary outcomes in cystic fibrosis. SNPs also have utility in pharmacogenomics, the identification of genetic variants that influence a patient's response to a drug, such as life-threatening toxicity. For example, a variation in N-acetyl transferase is associated with a high incidence of peripheral neuropathy in response to the anti-tuberculosis drug isoniazid, while a variation in the core promoter of the ALOX5 gene results in diminished clinical response to treatment with an anti-asthma drug that targets the 5-lipoxygenase pathway. Analysis of the distribution of SNPs in different populations is useful for investigating genetic drift, mutation, recombination, and selection, as well as for tracing the origins of populations and their migrations. (Taylor, J. G. et al. (2001) Trends Mol. Med. 7:507-512; Kwok, P.-Y. and Z. Gu (1999) Mol. Med. Today 5:538-543; Nowotny, P. et al. (2001) Curr. Opin. Neurobiol. 11:637-641.)

[0285] Methods which may also be used to quantify the expression of INTSIG include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P. C. et al. (1993) J. Immunol. Methods 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer or polynucleotide of interest is presented in various dilutions and a spectrophotometric or calorimetric response gives rapid quantitation.

[0286] In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as elements on a microarray. The microarray can be used in transcript imaging techniques which monitor the relative expression levels of large numbers of genes simultaneously as described below. The microarray may also be used to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, to monitor progression/regression of disease as a function of gene expression, and to develop and monitor the activities of therapeutic agents in the treatment of disease. In particular, this information may be used to develop a pharmacogenomic profile of a patient in order to select the most appropriate and effective treatment regimen for that patient. For example, therapeutic agents which are highly effective and display the fewest side effects may be selected for a patient based on his/her pharmacogenomic profile.

[0287] In another embodiment, INTSIG, fragments of INTSIG, or antibodies specific for INTSIG may be used as elements on a microarray. The microarray may be used to monitor or measure protein-protein interactions, drug-target interactions, and gene expression profiles, as described above.

[0288] A particular embodiment relates to the use of the polynucleotides of the present invention to generate a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., “Comparative Gene Transcript Analysis,” U.S. Pat. No. 5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant transcript image would provide a profile of gene activity.

[0289] Transcript images may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect gene expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.

[0290] Transcript images which profile the expression of the polynucleotides of the present invention may also be used in conjunction with in vitro model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E. F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S. and N. L. Anderson (2000) Toxicol. Lett. 112-113:467-471, expressly incorporated by reference herein). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families. Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released Feb. 29, 2000, available at http://www.niehs.nih.gov/oc/news/toxchip.htm.) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.

[0291] In one embodiment, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.

[0292] Another particular embodiment relates to the use of the polypeptide sequences of the present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and analyzing the polypeptides of a particular tissue or cell type. In one embodiment, the separation is achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, supra. The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment. The proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification.

[0293] A proteomic profile may also be generated using antibodies specific for INTSIG to quantify the levels of INTSIG expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) Anal. Biochem. 270:103-111; Mendoze, L. G. et al. (1999) Biotechniques 27:778-788). Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol- or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array element

[0294] Toxicant signatures at the proteome level are also useful for toxicological screening, and should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N. L. and J. Seilhamer (1997) Electrophoresis 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.

[0295] In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the polypeptides of the present invention.

[0296] In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the polypeptides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.

[0297] Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T. M. et al. (1995) U.S. Pat. No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, RA. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2150-2155; and Heller, M. J. et al. (1997) U.S. Pat. No. 5,605,662.) Various types of microarrays are well known and thoroughly described in DNA Microarrays: A Practical Approach, M. Schena, ed. (1999) Oxford University Press, London, hereby expressly incorporated by reference.

[0298] In another embodiment of the invention, nucleic acid sequences encoding INTSIG may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. Either coding or noncoding sequences may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of a coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J. J. et al. (1997) Nat. Genet. 15:345-355; Price, C. M. (1993) Blood Rev. 7:127-134; and Trask, B. J. (1991) Trends Genet. 7:149-154.) Once mapped, the nucleic acid sequences of the invention may be used to develop genetic linkage maps, for example, which correlate the inheritance of a disease state with the inheritance of a particular chromosome region or restriction fragment length polymorphism (RFLP). (See, for example, Lander, E. S. and D. Botstein (1986) Proc. Natl. Acad. Sci. USA 83:7353-7357.)

[0299] Fluorescent in situ hybridization (FISH) may be correlated with other physical and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding INTSIG on a physical map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder and thus may further positional cloning efforts.

[0300] In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the exact chromosomal locus is not known. This information is valuable to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the gene or genes responsible for a disease or syndrome have been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R. A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the instant invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

[0301] In another embodiment of the invention, INTSIG, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between INTSIG and the agent being tested may be measured.

[0302] Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with INTSIG, or fragments thereof, and washed. Bound INTSIG is then detected by methods well known in the art Purified INTSIG can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

[0303] In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding INTSIG specifically compete with a test compound for binding INTSIG. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with INTSIG.

[0304] In additional embodiments, the nucleotide sequences which encode INTSIG may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

[0305] Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

[0306] The disclosures of all patents, applications, and publications mentioned above and below, including U.S. Ser. No. 60/267,925, U.S., Ser. No. 60/274,435, U.S. Ser. No. 60/281,326, U.S. Ser. No. 60/277,819, U.S. Ser. No. 60/291,195, U.S. Ser. No. 60/291,550, U.S. Ser. No. 60/293,591, and U.S. Ser. No. 60/295,348, are hereby expressly incorporated by reference.

EXAMPLES

[0307] I. Construction of cDNA Libraries

[0308] Incyte cDNAs were derived from cDNA libraries described in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto Calif.). Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

[0309] Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A)+ RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth Calif.), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin Tex.).

[0310] In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the ZAP vector system (Stratagene) or SUPERSCRIPT plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), PCDNA2.1 plasmid (Invitrogen, Carlsbad Calif.), PBK-CMV plasmid (Stratagene), PCR2-TOPOTA plasmid (Invitrogen), PCMV-ICIS plasmid (Stratagene), pIGEN (Incyte Genomics, Palo Alto Calif.), pRARE (Incyte Genomics), or pINCY (Incyte Genomics), or derivatives thereof. Recombinant plasmids were transformed into competent E. coli cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5α, DH10B, or ElectroMAX DH10B from Life Technologies.

[0311] II. Isolation of cDNA Clones

[0312] Plasmids obtained as described in Example I were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg Md.); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4° C.

[0313] Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V. B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene Oreg.) and a FLUOROSKAN I[fluorescence scanner (Labsystems Oy, Helsinki, Finland).

[0314] III. Sequencing and Analysis

[0315] Incyte cDNA recovered in plasmids as described in Example II were sequenced as follows. Sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Applied Biosystems) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, supra, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VIII.

[0316] The polynucleotide sequences derived from Incyte cDNAs were validated by removing vector, linker, and poly(A) sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The Incyte cDNA sequences or translations thereof were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM; PROTEOME databases with sequences from Homo sapiens, Rattus norvegicus, Mus musculus, Caenorhabditis elegans, Saccharomyces cerevisiae, Schizosaccharomyces pombe, and Candida albicans (Incyte Genomics, Palo Alto Calif.); hidden Markov model (HMM)-based protein family databases such as PFAM; and HMM-based protein domain databases such as SMART (Schultz et al. (1998) Proc. Natl. Acad. Sci. USA 95:5857-5864; Letunic, I. et al. (2002) Nucleic Acids Res. 30:242-244). (HMM is a probabilistic approach which analyzes consensus primary structures of gene families. See, for example, Eddy, S. R. (1996) Curr. Opin. Struct. Biol. 6:361-365.) The queries were performed using programs based on BLAST, FASTA, BLIMPS, and HMMER. The Incyte cDNA sequences were assembled to produce full length polynucleotide sequences. Alternatively, GenBank cDNAs, GenBank ESTs, stitched sequences, stretched sequences, or Genscan-predicted coding sequences (see Examples IV and V) were used to extend Incyte cDNA assemblages to full length. Assembly was performed using programs based on Phred, Phrap, and Consed, and cDNA assemblages were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length polypeptide sequences. Alternatively, a polypeptide of the invention may begin at any of the methionine residues of the full length translated polypeptide. Full length polypeptide sequences were subsequently analyzed by querying against databases such as the GenBank protein databases (genpept), SwissProt, the PROTEOME databases, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, hidden Markov model (HM-based protein family databases such as PFAM; and HMM-based protein domain databases such as SMART. Full length polynucleotide sequences are also analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco Calif.) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments are generated using default parameters specified by the CLUSTAL algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.

[0317] Table 7 summarizes the tools, programs, and algorithms used for the analysis and assembly of Incyte cDNA and full length sequences and provides applicable descriptions, references, and threshold parameters. The first column of Table 7 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score or the lower the probability value, the greater the identity between two sequences).

[0318] The programs described above for the assembly and analysis of full length polynucleotide and polypeptide sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:19-36. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies are described in Table 4, column 2.

[0319] IV. Identification and Editing of Coding Sequences from Genomic DNA

[0320] Putative intracellular signaling molecules were initially identified by running the Genscan gene identification program against public genomic sequence databases (e.g., gbpri and gbhtg). Genscan is a general-purpose gene identification program which analyzes genomic DNA sequences from a variety of organisms (See Burge, C. and S. Karlin (1997) J. Mol. Biol. 268:78-94, and Burge, C. and S. Karlin (1998) Curr. Opin. Struct. Biol. 8:346-354). The program concatenates predicted exons to form an assembled cDNA sequence extending from a methionine to a stop codon. The output of Genscan is a PASTA database of polynucleotide and polypeptide sequences. The maximum range of sequence for Genscan to analyze at once was set to 30 kb. To determine which of these Genscan predicted cDNA sequences encode intracellular signaling molecules, the encoded polypeptides were analyzed by querying against PFAM models for intracellular signaling molecules. Potential intracellular signaling molecules were also identified by homology to Incyte cDNA sequences that had been annotated as intracellular signaling molecules. These selected Genscan-predicted sequences were then compared by BLAST analysis to the genpept and gbpri public databases. Where necessary, the Genscan-predicted sequences were then edited by comparison to the top BLAST hit from genpept to correct errors in the sequence predicted by Genscan, such as extra or omitted exons. BLAST analysis was also used to find any Incyte cDNA or public cDNA coverage of the Genscan-predicted sequences, thus providing evidence for transcription. When Incyte cDNA coverage was available, this information was used to correct or confirm the Genscan predicted sequence. Full length polynucleotide sequences were obtained by assembling Genscan-predicted coding sequences with Incyte cDNA sequences and/or public cDNA sequences using the assembly process described in Example m. Alternatively, full length polynucleotide sequences were derived entirely from edited or unedited Genscan-predicted coding sequences.

[0321] V. Assembly of Genomic Sequence Data with cDNA Sequence Data

[0322] “Stitched” Sequences

[0323] Partial cDNA sequences were extended with exons predicted by the Genscan gene identification program described in Example IV. Partial cDNAs assembled as described in Example m were mapped to genomic DNA and parsed into clusters containing related cDNAs and Genscan exon predictions from one or more genomic sequences. Each cluster was analyzed using an algorithm based on graph theory and dynamic programming to integrate cDNA and genomic information, generating possible splice variants that were subsequently confirmed, edited, or extended to create a full length sequence. Sequence intervals in which the entire length of the interval was present on more than one sequence in the cluster were identified, and intervals thus identified were considered to be equivalent by transitivity. For example, if an interval was present on a cDNA and two genomic sequences, then all three intervals were considered to be equivalent. This process allows unrelated but consecutive genomic sequences to be brought together, bridged by cDNA sequence. Intervals thus identified were then “stitched” together by the stitching algorithm in the order that they appear along their parent sequences to generate the longest possible sequence, as well as sequence variants. Linkages between intervals which proceed along one type of parent sequence (cDNA to cDNA or genomic sequence to genomic sequence) were given preference over linkages which change parent type (cDNA to genomic sequence). The resultant stitched sequences were translated and compared by BLAST analysis to the genpept and gbpri public databases. Incorrect exons predicted by Genscan were corrected by comparison to the top BLAST hit from genpept. Sequences were further extended with additional cDNA sequences, or by inspection of genomic DNA, when necessary.

[0324] “Stretched” Sequences

[0325] Partial DNA sequences were extended to full length with an algorithm based on BLAST analysis. First, partial cDNAs assembled as described in Example m were queried against public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases using the BLAST program The nearest GenBank protein homolog was then compared by BLAST analysis to either Incyte cDNA sequences or GenScan exon predicted sequences described in Example IV. A chimeric protein was generated by using the resultant high-scoring segment pairs (HSPs) to map the translated sequences onto the GenBank protein homolog. Insertions or deletions may occur in the chimeric protein with respect to the original GenBank protein homolog. The GenBank protein homolog, the chimeric protein, or both were used as probes to search for homologous genomic sequences from the public human genome databases. Partial DNA sequences were therefore “stretched” or extended by the addition of homologous genomic sequences. The resultant stretched sequences were examined to determine whether it contained a complete gene.

[0326] VI. Chromosomal Mapping of INTSIG Encoding Polynucleotides

[0327] The sequences which were used to assemble SEQ ID NO:19-36 were compared with sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm Sequences from these databases that matched SEQ ID NO:19-36 were assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as Phrap (Table 7). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Genethon were used to determine if any of the clustered sequences had been previously mapped. Inclusion of a mapped sequence in a cluster resulted in the assignment of all sequences of that cluster, including its particular SEQ ID NO:, to that map location.

[0328] Map locations are represented by ranges, or intervals, of human chromosomes. The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM distances are based on genetic markers mapped by Généthon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters. Human genome maps and other resources available to the public, such as the NCBI “GeneMap'99” World Wide Web site (http://www.ncbi.nlm.nih.gov/genemap/), can be employed to determine if previously identified disease genes map within or in proximity to the intervals indicated above.

[0329] In this manner, SEQ ID NO:23 was mapped to chromosome 16 within the interval from 81.80 to 84.40 centiMorgans.

[0330] VII. Analysis of Polynucleotide Expression

[0331] Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel (1995) supra, ch 4 and 16.) Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as: $\frac{{BLAST}\quad {Score} \times {Percent}\quad {Identity}}{5 \times {minimum}\quad \left\{ {{{length}\quad \left( {{Seq}.\quad 1} \right)},{{length}\quad \left( {{Seq}.\quad 2} \right)}} \right\}}$

[0332] The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 tines the length of the shorter of the two sequences). The BLAST score is calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and 4 for every mismatch. Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.

[0333] Alternatively, polynucleotide sequences encoding INTSIG are analyzed with respect to the tissue sources from which they were derived. For example, some full length sequences are assembled, at least in part, with overlapping Incyte cDNA sequences (see Example III). Each cDNA sequence is derived from a cDNA library constructed from a human tissue. Each human tissue is classified into one of the following organ/tissue categories: cardiovascular system; connective tissue; digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female; genitalia, male; germ cells; hemic and immune system; liver; musculoskeletal system; nervous system; pancreas; respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed; or urinary tract. The number of libraries in each category is counted and divided by the total number of libraries across all categories. Similarly, each human tissue is classified into one of the following disease/condition categories: cancer, cell line, developmental, inflammation, neurological, trauma, cardiovascular, pooled, and other, and the number of libraries in each category is counted and divided by the total number of libraries across all categories. The resulting percentages reflect the tissue- and disease-specific expression of cDNA encoding INTSIG. cDNA sequences and cDNA library/tissue information are found in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto Calif.).

[0334] VIII. Extension of INTSIG Encoding Polynucleotides

[0335] Full length polynucleotide sequences were also produced by extension of an appropriate fragment of the fill length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5′ extension of the known fragment, and the other primer was synthesized to initiate 3′ extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68° C. to about 72° C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

[0336] Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

[0337] High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg²⁺, (NH₄)₂SO₄, and 2-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94° C., 3 min; Step 2: 94° C., 15 sec; Step 3: 60° C., 1 min; Step 4: 68° C., 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68° C., 5 min; Step 7: storage at 4° C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94° C., 3 min; Step 2: 94° C., 15 sec; Step 3: 57° C., 1 min; Step 4: 68° C., 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68° C., 5 min; Step 7: storage at 4° C.

[0338] The concentration of DNA in each well was determined by dispensing 100 μl PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene Oreg.) dissolved in 1×TE and 0.5 μl of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton Mass.), allowing the DNA to bind to the reagent The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 μl to 10 μl aliquot of the reaction mixture was analyzed by electrophoresis on a 1% agarose gel to determine which reactions were successful in extending the sequence.

[0339] The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison Wis.), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly Mass.) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent E. coli cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37° C. in 384-well plates in LB/2× carb liquid media.

[0340] The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94° C., 3 min; Step 2: 94° C., 15 sec; Step 3: 60° C., 1 min; Step 4: 72° C., 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72° C., 5 min; Step 7: storage at 4° C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethysulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).

[0341] In like manner, full length polynucleotide sequences are verified using the above procedure or are used to obtain 5′ regulatory sequences using the above procedure along with oligonucleotides designed for such extension, and an appropriate genomic library.

[0342] IX. Identification of Single Nucleotide Polymorphisms in INTSIG Encoding Polynucleotides

[0343] Common DNA sequence variants known as single nucleotide polymorphisms (SNPs) were identified in SEQ ID NO:19-36 using the LIFESEQ database (Incyte Genomics). Sequences from the same gene were clustered together and assembled as described in Example m, allowing the identification of all sequence variants in the gene. An algorithm consisting of a series of filters was used to distinguish SNPs from other sequence variants. Preliminary filters removed the majority of basecall errors by requiring a minimum Phred quality score of 15, and removed sequence alignment errors and errors resulting from improper trimming of vector sequences, chimeras, and splice variants. An automated procedure of advanced chromosome analysis analysed the original chromatogram files in the vicinity of the putative SNP. Clone error filters used statistically generated algorithms to identify errors introduced during laboratory processing, such as those caused by reverse transcriptase, polymerase, or somatic mutation. Clustering error filters used statistically generated algorithms to identify errors resulting from clustering of close homologs or pseudogenes, or due to contamination by non-human sequences. A final set of filters removed duplicates and SNPs found in immunoglobulins or T-cell receptors.

[0344] Certain SNPs were selected for further characterization by mass spectrometry using the high throughput MASSARRAY system (Sequenom, Inc.) to analyze allele frequencies at the SNP sites in four different human populations. The Caucasian population comprised 92 individuals (46 male, 46 female), including 83 from Utah, four French, three Venezualan, and two Amish individuals. The African population comprised 194 individuals (97 male, 97 female), all African Americans. The Hispanic population comprised 324 individuals (162 male, 162 female), all Mexican Hispanic. The Asian population comprised 126 individuals (64 male, 62 female) with a reported parental breakdown of 43% Chinese, 31% Japanese, 13% Korean, 5% Vietnamese, and 8% other Asian. Allele frequencies were first analyzed in the Caucasian population; in some cases those SNPs which showed no allelic variance in this population were not further tested in the other three populations.

[0345] X. Labeling and Use of Individual Hybridization Probes

[0346] Hybridization probes derived from SEQ ID NO:19-36 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state of the art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 μCi of [γ-³²P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston Mass.). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10⁷ counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

[0347] The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40° C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1× saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and compared.

[0348] XI. Microarrays

[0349] The linkage or synthesis of array elements upon a microarray can be achieved utilizing photolithography, piezoelectric printing (ink-jet printing, See, e.g., Baldeschweiler, supra.), mechanical microspotting technologies, and derivatives thereof. The substrate in each of the aforementioned technologies should be uniform and solid with a non-porous surface (Schena (1999), supra). Suggested substrates include silicon, silica, glass slides, glass chips, and silicon wafers. Alternatively, a procedure analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced using available methods and machines well known to those of ordinary skill in the art and may contain any appropriate number of elements. (See, e.g., Schena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645; Marshall, A. and J. Hodgson (1998) Nat. Biotechnol. 16:27-31.)

[0350] Full length cDNAs, Expressed Sequence Tags (ESTs), or fragments or oligomers thereof may comprise the elements of the microarray. Fragments or oligomers suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). The array elements are hybridized with polynucleotides in a biological sample. The polynucleotides in the biological sample are conjugated to a fluorescent label or other molecular tag for ease of detection. After hybridization, nonhybridized nucleotides from the biological sample are removed, and a fluorescence scanner is used to detect hybridization at each array element. Alternatively, laser desorbtion and mass spectrometry may be used for detection of hybridization. The degree of complementarity and the relative abundance of each polynucleotide which hybridizes to an element on the microarray may be assessed. In one embodiment, microarray preparation and usage is described in detail below.

[0351] Tissue or Cell Sample Preparation

[0352] Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and poly(A)⁺ RNA is purified using the oligo-(dT) cellulose method. Each poly(A)⁺ RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/μl oligo-(dT) primer (21mer), 1× first strand buffer, 0.03 units/μl RNase inhibitor, 500 μM dATP, 500 μM dGTP, 500 μM dTTP, 40 μM dCTP, 40 μM dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse transcription reaction is performed in a 25 ml volume containing 200 ng poly(A)⁺ RNA with GEMBRIGHT kits Incyte). Specific control poly(A)⁺ RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA. After incubation at 37° C. for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85° C. to the stop the reaction and degrade the RNA. Samples are purified using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc. (CLONTECH), Palo Alto Calif.) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The sample is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook N.Y.) and resuspended in 14 μL 5×SSC/0.2% SDS.

[0353] Microarray Preparation

[0354] Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 μg. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech).

[0355] Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4% hydrofluoric acid (VWR Scientific Products Corporation (VWR), West Chester Pa.), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110° C. oven.

[0356] Array elements are applied to the coated glass substrate using a procedure described in U.S. Pat. No. 5,807,522, incorporated herein by reference. 1 μl of the array element DNA, at an average concentration of 100 ng/μl, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 nl of array element sample per slide.

[0357] Microarrays are UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene). Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford Mass.) for 30 minutes at 60° C. followed by washes in 0.2% SDS and distilled water as before.

[0358] Hybridization

[0359] Hybridization reactions contain 9 μl of sample mixture consisting of 0.2 μg each of Cy3 and Cy5 labeled cDNA synthesis products in 5×SSC, 0.2% SDS hybridization buffer. The sample mixture is heated to 65° C. for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cm² coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 μl of 5×SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 60° C. The arrays are washed for 10 min at 45° C. in a first wash buffer (1×SSC, 0.1% SDS), three times for 10 minutes each at 45° C. in a second wash buffer (O. 1×SSC), and dried.

[0360] Detection

[0361] Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara Calif.) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light is focused on the array using a 20× microscope objective (Nikon, Inc., Melville N.Y.). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm×1.8 cm array used in the present example is scanned with a resolution of 20 micrometers.

[0362] In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially. Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477, Hamamatsu Photonics Systems, Bridgewater N.J.) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.

[0363] The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the sample mixture at a known concentration. A specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two samples from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.

[0364] The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital (A/D) conversion board (Analog Devices, Inc., Norwood Mass.) installed in an IBM-compatible PC computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.

[0365] A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).

[0366] For example, SEQ ID NO:28 showed differential expression in non-malignant mammary epithelial cells versus various breast carcinoma lines as determined by microarray analysis. The expression of SEQ ID NO:28 was decreased by at least two fold in the breast carcinoma lines relative to non-malignant mammary epithelial cells. Therefore, SEQ ID NO:28 is useful in diagnostic assays for detection of breast cancer.

[0367] In addition, SEQ ID NO:28 showed differential expression in primary prostate epithelial cells versus various prostate carcinoma lines as determined by microarray analysis. The expression of SEQ ID NO:28 was decreased by at least two fold in the prostate carcinoma lines relative to primary prostate epithelial cells. Therefore, SEQ ID NO:28 is useful in diagnostic assays for detection of prostate cancer.

[0368] XII. Complementary Polynucleotides

[0369] Sequences complementary to the INTSIG-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring INTSIG. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of INTSIG. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5′ sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the INTSIG-encoding transcript.

[0370] XIII. Expression of INTSIG

[0371] Expression and purification of INTSIG is achieved using bacterial or virus-based expression systems. For expression of INTSIG in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the trp-lac (tac) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the lac operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21 (DE3). Antibiotic resistant bacteria express INTSIG upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of INTSIG in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding INTSIG by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E. K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

[0372] In most expression systems, INTSIG is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from INTSIG at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch. 10 and 16). Purified INTSIG obtained by these methods can be used directly in the assays shown in Examples XVII and XVIII where applicable.

[0373] XIV. Functional Assays

[0374] INTSIG function is assessed by expressing the sequences encoding INTSIG at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include PCMV SPORT (Life Technologies) and PCR3.1 (Invitrogen, Carlsbad Calif.), both of which contain the cytomegalovirus promoter. 5-10 μg of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2 μg of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M. G. (1994) Flow Cytometry, Oxford, New York N.Y.

[0375] The influence of INTSIG on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding INTSIG and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success N.Y.). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding INTSIG and other genes of interest can be analyzed by northern analysis or microarray techniques.

[0376] XV. Production of INTSIG Specific Antibodies

[0377] INTSIG substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M. G. (1990) Methods Enzymol. 182:488-495), or other purification techniques, is used to immunize animals (e.g., rabbits, mice, etc.) and to produce antibodies using standard protocols.

[0378] Alternatively, the INTSIG amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra, ch 11.) Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Applied Biosystems) using FMOC chemistry and coupled to KLH (Sigma-Aldrich, St. Louis Mo.) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, supra) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-INTSIG activity by, for example, binding the peptide or INTSIG to a substrate, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

[0379] XVI. Purification of Naturally Occurring INTSIG Using Specific Antibodies

[0380] Naturally occurring or recombinant INTSIG is substantially purified by immunoaffinity chromatography using antibodies specific for INTSIG. An immunoaffinity column is constructed by covalently coupling anti-INTSIG antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

[0381] Media containing INTSIG are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of INTSIG (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/INTSIG binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and INTSIG is collected.

[0382] XVII. Identification of Molecules Which Interact with INTSIG

[0383] INTSIG, or biologically active fragments thereof, are labeled with ¹²⁵I Bolton-Hunter reagent. (See, e.g., Bolton, A. E. and W. M. Hunter (1973) Biochem. J. 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled INTSIG, washed, and any wells with labeled INTSIG complex are assayed. Data obtained using different concentrations of INTSIG are used to calculate values for the number, affinity, and association of INTSIG with the candidate molecules.

[0384] Alternatively, molecules interacting with INTSIG are analyzed using the yeast two-hybrid system as described in Fields, S. and 0. Song (1989) Nature 340:245-246, or using commercially available kits based on the two-hybrid system, such as the MATCHMA system (Clontech).

[0385] INTSIG may also be used in the PATHCALLING process (CuraGen Corp., New Haven Conn.) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) U.S. Pat. No. 6,057,101).

[0386] XVIII. Demonstration of INTSIG Activity

[0387] INTSIG activity is associated with its ability to form protein-protein complexes and is measured by its ability to regulate growth characteristics of NIH3T3 mouse fibroblast cells. A cDNA encoding INTSIG is subcloned into an appropriate eukaryotic expression vector. This vector is transfected into NIH3T3 cells using methods known in the art Transfected cells are compared with non-transfected cells for the following quantifiable properties: growth in culture to high density, reduced attachment of cells to the substrate, altered cell morphology, and ability to induce tumors when injected into immunodeficient mice. The activity of INTSIG is proportional to the extent of increased growth or frequency of altered cell morphology in NIH3T3 cells transfected with INTSIG.

[0388] Alternatively, INTSIG activity is measured by binding of INTSIG to radiolabeled formin polypeptides containing the proline-rich region that specifically binds to SH3 containing proteins (Chan, D. C. et al. (1996) EMBO J. 15:1045-1054). Samples of INTSIG are run on SDS-PAGE gels, and transferred onto nitrocellulose by electroblotting. The blots are blocked for 1 hr at room temperature in TBST (137 mM NaCl, 2.7 mM KCl, 25 mM Tris (pH 8.0) and 0.1% Tween-20) containing non-fat dry milk. Blots are then incubated with TBST containing the radioactive formin polypeptide for 4 hrs to overnight. After washing the blots four times with TBST, the blots are exposed to autoradiographic film Radioactivity is quantitated by cutting out the radioactive spots and counting them in a radioisotope counter. The amount of radioactivity recovered is proportional to the activity of INTSIG in the assay.

[0389] Alternatively, INTSIG protein kinase activity is measured by quantifying the phosphorylation of an appropriate substrate in the presence of gamma-labeled ³²P-ATP. INTSIG is incubated with the substrate, ³²P-ATP, and an appropriate kinase buffer. The ³²P incorporated into the product is separated from free ³²P-ATP by electrophoresis, and the incorporated ³²P is quantified using a beta radioisotope counter. The amount of incorporated ³²P is proportional to the protein kinase activity of INTSIG in the assay. A determination of the specific amino acid residue phosphorylated by protein kinase activity is made by phosphoamino acid analysis of the hydrolyzed protein.

[0390] Alternatively, an assay for INTSIG protein phosphatase activity measures the hydrolysis of para-nitrophenyl phosphate (PNPP). INTSIG is incubated together with PNPP in HEPES buffer pH 7.5, in the presence of 0.1% β-mercaptoethanol at 37° C. for 60 min. The reaction is stopped by the addition of 6 ml of 10 N NaOH, and the increase in light absorbance of the reaction mixture at 410 nm resulting from the hydrolysis of PNPP is measured using a spectrophotometer. The increase in light absorbance is proportional to the activity of INTSIG in the assay (Diamond, R. H. et al. (1994) Mol. Cell Biol. 14:3752-3762).

[0391] Alternatively, adenylyl cylcase activity of INTSIG is demonstrated by the ability to convert ATP to cAMP (Mittal, C. K. (1986) Meth. Enzymol. 132:422-428). In this assay INTSIG is incubated with the substrate [α-³²P]ATP, following which the excess substrate is separated from the product cyclic [³²P] AMP. INTSIG activity is determined in 12×75 mm disposable culture tubes containing 5 μl of 0.6 M Tris-HCl, pH 7.5, 5 μl of 0.2 M MgCl₂, 5 μl of 150 mM creatine phosphate containing 3 units of creatine phospholinase, 5 μl of 4.0 mM 1-methyl-3-isobutylxanthine, 5 μl of 20 mM cAMP, 5 μl 20 mM dithiothreitol, 5 μl of 10 mM ATP, 10 μl [α-³²P]]ATP (24×10⁶ cpm), and water in a total volume of 100 μl. The reaction mixture is prewarmed to 30° C. The reaction is initiated by adding INTSIG to the prewarmed reaction mixture. After 10-15 minutes of incubation at 30° C., the reaction is terminated by adding 25 μl of 30% ice-cold trichloroacetic acid (TCA). Zero-time incubations and reactions incubated in the absence of INTSIG are used as negative controls. Products are separated by ion exchange chromatography, and cyclic [³²P] AMP is quantified using a β-radioisotope counter. The INTSIG activity is proportional to the amount of cyclic [³²P] AMP formed in the reaction.

[0392] An alternative assay measures INTSIG-mediated G-protein signaling activity by monitoring the mobilization of Ca²⁺ as an indicator of the signal transduction pathway stimulation. (See, e.g., Grynkiewicz, G. et al. (1985) J. Biol. Chem. 260:3440; McColl, S. et al. (1993) J. Immunol. 150:4550-4555; and Aussel, C. et al. (1988) J. Immunol. 140:215-220). The assay requires preloading neutrophils or T cells with a fluorescent dye such as FURA-2 or BCECF (Universal Imaging Corp, Westchester Pa.) whose emission characteristics are altered by Ca²⁺ binding. When the cells are exposed to one or more activating stimuli artificially (e.g., anti-CD3 antibody ligation of the T cell receptor) or physiologically (e.g., by allogeneic stimulation), Ca²⁺ flux takes place. This flux can be observed and quantified by assaying the cells in a fluorometer or fluorescent activated cell sorter. Measurements of Ca²⁺ flux are compared between cells in their normal state and those transfected with INTSIG. Increased Ca²⁺ mobilization attributable to increased INTSIG concentration is proportional to INTSIG activity.

[0393] Alternatively, GTP-binding activity of INTSIG is determined in an assay that measures the binding of INTSIG to [α-³²P]-labeled GTP. Purified INTSIG is first blotted onto filters and rinsed in a suitable buffer. The filters are then incubated in buffer containing radiolabeled [α-³²P]-GTP. The filters are washed in buffer to remove unbound GTP and counted in a radioisotope counter. Non-specific binding is determined in an assay that contains a 100-fold excess of unlabeled GTP. The amount of specific binding is proportional to the activity of INTSIG.

[0394] Alternatively, GTPase activity of INTSIG is determined in an assay that measures the conversion of [α-³²P]-GTP to [α-³²P]-GDP. INTSIG is incubated with [α³²]-GTP in buffer for an appropriate period of dme, and the reaction is terminated by heating or acid precipitation followed by centrifugation. An aliquot of the supernatant is subjected to polyacrylamide gel electrophoresis (PAGE to separate GDP and GTP together with unlabeled standards. The GDP spot is cut out and counted in a radioisotope counter. The amount of radioactivity recovered in GDP is proportional to the GTPase activity of INTSIG.

[0395] GTP-binding activity is assayed by incubating varying amounts of INTSIG for 10 minutes at 30° C. in 50 mM Tris buffer, pH 7.5, containing 1 mM dithiothreitol, 1 mM EDTA, 1 μM [α-³²P]GTP, in the absence or presence of 100 μM of the following compounds: GTP, GDP, GTPγS, ATP, CTP, UTP, and TTP. Samples are passed through nitrocellulose filters and washed twice with a buffer consisting of 50 mM Tris-HCl, pH 7.8, 1 mM NaN₃, 10 mM MgCl₂, 1 mM EDTA, 0.5 mM dithiothreitol, 0.01 mM PMSF, and 200 mM NaCl. The filter-bound counts are determined by liquid scintillation.

[0396] Alternatively, GTPase activity of INTSIG is determined by incubating INTSIG at 37° C. in 20 mM Pipes, 20 mM Hepes, 2 mM MgCl₂, 1 mM EGTA, 1 mM dithiothreitol buffer, pH 7.0, fixed in ionic strength at 42 mM, and containing 0.1% BSA and [α³²P]GTP at a final concentration of 25 mM in a final reaction volume of 20 μl. The reaction is initiated by the addition of 0.1 μCi of [α-³²P]GTP. At 1 minute intervals, 1.5 μl aliquots are removed from the reaction mixture, spotted onto cellulose polyethyleneimine TLC plates with fluorescent indicator, and resolved in 1M LiCl₂:2M formic acid (1:1). Quantitation of GTP and GDP at each time point is performed on a PhosphorImager (Molecular Dynamics: Inc., Sunnyvale, Calif.) and rates of GTP hydrolysis are calculated from a minimum of five time points and expressed as the percent of GDP per GTP plus GDP (Warnock, D. E. et al. supra).

[0397] Alternatively, INTSIG activity is measured by quantifying the amount of a non-hydrolyzable GTP analogue, GTPγS, bound over a 10 minute incubation period. Varying amounts of INTSIG are incubated at 30° C. in 50 mM Tris buffer, pH 7.5, containing 1 mM dithiothreitol, 1 mM EDTA and 1 μM [³⁵S]GTPγS. Samples are passed through nitrocellulose filters and washed twice with a buffer consisting of 50 mM Tris-HCl, pH 7.8, 1 mM NaN₃, 10 mM MgCl₂, 1 mM EDTA, 0.5 mM dithiothreitol, 0.01 mM PMSF, and 200 mM NaCl. The filter-bound counts are measured by liquid scintillation to quantify the amount of bound [³⁵S]GTPγS. INTSIG activity may also be measured as the amount of GTP hydrolysed over a 10 minute incubation period at 37° C. INTSIG is incubated in 50 mM Tris-HCl buffer, pH 7.8, containing 1 mM dithiothreitol, 2 mM EDTA, 10 μM [α-³²P]GTP, and 1 μM H-rabo protein. GTPase activity is initiated by adding MgCl₂ to a final concentration of 10 mM. Samples are removed at various time points, mixed with an equal volume of ice-cold 0.5 mM EDTA, and frozen. Aliquots are spotted onto polyethyleneimine-cellulose thin layer chromatography plates, which are developed in 1M LiCl, dried, and autoradiographed. The signal detected is proportional to INTSIG activity.

[0398] Alternatively, INTSIG activity may be demonstrated as the ability to interact with its associated LMW GTPase in an in vitro binding assay. The candidate LMW GTPases are expressed as fusion proteins with glutathione S-transferase (GST), and purified by affinity chromatography on glutathione-Sepharose. The LMW GTPases are loaded with GDP by incubating 20 mM Tris buffer, pH 8.0, containing 100 mM NaCl, 2 mM EDTA, 5 mM MgCl₂, 0.2 mM DTT, 100 μM AMP-PNP and 10 μM GDP at 30° C. for 20 minutes. INTSIG is expressed as a FLAG fusion protein in a baculovirus system. Extracts of these baculovirus cells containing INTSIG-FLAG fusion proteins are precleared with GST beads, then incubated with GST-GTPase fusion proteins. The complexes formed are precipitated by glutathione-Sepharose and separated by SDS-polyacrylamide gel electrophoresis. The separated proteins are blotted onto nitrocellulose membranes and probed with commercially available anti-FLAG antibodies. INTSIG activity is proportional to the amount of INTSIG-FLAG fusion protein detected in the complex.

[0399] Another alternative assay to detect INTSIG activity is the use of a yeast two-hybrid system (Zalcman, G. et al. (1996) J. Biol. Chem. 271:30366-30374). Specifically, a plasmid such as pGAD 1318 which may contain the coding region of INTSIG can be used to transform reporter L40 yeast cells which contain the reporter genes LacZ and HIS3 downstream from the binding sequences for LexA. These yeast cells have been previously transformed with a pLexA-Rab6-GDP (mouse) plasmid or with a plasmid which contains pLexA-lamin C. The pLEXA-lamin C cells serve as a negative control. The transformed cells are plated on a histidine-free medium and incubated at 30° C. for 3 days. His+colonies are subsequently patched on selective plates and assayed for P-galactosidase activity by a filter assay. INTSIG binding with Rab6-GDP is indicated by positive His⁺/lacZ⁺ activity for the cells transformed with the plasmid containing the mouse Rab6-GDP and negative His⁺/lacZ⁺ activity for those transformed with the plasmid containing lamin C.

[0400] Alternatively, INTSIG activity is measured by binding of INTSIG to a substrate which recognizes WD40 repeats, such as ElonginB, by coimmunoprecipitation (Kamura, T. et al. (1998) Genes Dev. 12:3872-3881). Briefly, epitope tagged substrate and INTSIG are mixed and immunoprecipitated with commercial antibody against the substrate tag. The reaction solution is run on SDS-PAGE and the presence of INTSIG visualized using an antibody to the INTSIG tag. Substrate binding is proportional to INTSIG activity.

[0401] Alternatively, INTSIG activity is measured by its inclusion in coated vesicles. INTSIG can be expressed by transforming a mammalian cell line such as COS7, HeLa, or CHO with a eukaryotic expression vector encoding INTSIG. Eukaryotic expression vectors are commercially available, and the techniques to introduce them into cells are well known to those skilled in the art. A small amount of a second plasmid, which expresses any one of a number of marker genes, such as β-galactosidase, is co-transformed into the cells in order to allow rapid identification of those cells which have taken up and expressed the foreign DNA. The cells are incubated for 48-72 hours after transformation under conditions appropriate for the cell line to allow expression and accumulation of INTSIG and β-galactosidase.

[0402] In the alternative, INTSIG activity is measured by its ability to alter vesicle trafficking pathways. Vesicle trafficking in cells transformed with INTSIG is examined using fluorescence microscopy. Antibodies specific for vesicle coat proteins or typical vesicle trafficking substrates such as transferrin or the mannose-6-phosphate receptor are commercially available. Various cellular components such as ER, Golgi bodies, peroxisomes, endosomes, lysosomes, and the plasmalemma are examined. Alterations in the numbers and locations of vesicles in cells transformed with INTSIG as compared to control cells are characteristic of INTSIG activity. Transformed cells are collected and cell lysates are assayed for vesicle formation. A non-hydrolyzable form of GTP, GTPγS, and an ATP regenerating system are added to the lysate and the mixture is incubated at 37° C. for 10 minutes. Under these conditions, over 90% of the vesicles remain coated (Orci, L. et al. (1989) Cell 56:357-368). Transport vesicles are salt-released from the Golgi membranes, loaded under a sucrose gradient, centriged, and fractions are collected and analyzed by SDS-PAGE. Co-localization of INTSIG with clathrin or COP coatamer is indicative of INTSIG activity in vesicle formation. The contribution of INTSIG in vesicle formation can be confirmed by incubating lysates with antibodies specific for INTSIG prior to GTPγS addition. The antibody will bind to INTSIG and interfere with its activity, thus preventing vesicle formation.

[0403] Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims. TABLE 1 Polynu- Incyte Incyte Polypeptide Incyte cleotide Polynucleotide Project ID SEQ ID NO: Polypeptide ID SEQ ID NO: ID 2372478 1 2372478CD1 19 2372478CB1 4586623 2 4586623CD1 20 4586623CB1 4825215 3 4825215CD1 21 4825215CB1 6892116 4 6892116CD1 22 6892116CB1 5990388 5 5990388CD1 23 5990388CB1  011293 6  011293CD1 24  011293CB1 4080676 7 4080676CD1 25 4080676CB1 4791825 8 4791825CD1 26 4791825CB1 7481996 9 7481996CD1 27 7481996CB1 7610864 10 7610864CD1 28 7610864CB1 6985813 11 6985813CD1 29 6985813CB1 4002434 12 4002434CD1 30 4002434CB1 2506117 13 2506117CD1 31 2506117CB1 7193277 14 7193277CD1 32 7193277CB1 2307889 15 2307889CD1 33 2307889CB1 5369710 16 5369710CD1 34 5369710CB1 5502841 17 5502841CD1 35 5502841CB1  361856 18  361856CD1 36  361856CB1

[0404] TABLE 2 Polypeptide GenBank ID NO: SEQ Incyte or PROTEOME Probability ID NO: Polypeptide ID ID NO: Score Annotation 1 2372478CD1 g7209811 6.1E−11 [Homo sapiens] F-box and WD-repeats protein beta-TRCP2 isoform B Koike, J., et al. (2000) Molecular cloning and genomic structure of the betaTRCP2 gene on chromosome 5q35.1. Biochem. Biophys. Res. Commun. 269, 103-109 g17225204 4.0E-14 beta transducin-like protein HET-E2C [Podospora anserina] Espagne, E. et al. (1997) Mol Gen Genet. 256, 620-627. 2 4586623CD1 g57732 2.5E−222 [Rattus rattus] potential ligand-binding protein Dear, T. N., et al. (1991) Novel genes for potential ligand-binding proteins in subregions of the olfactory mucosa. EMBO J. 10, 2813-2819 3 4825215CD1 g3170450 3.1E−55 [Homo sapiens] GTPase-activating protein Ebrahimi, S., et al. (1998) Genomic organization and cloning of the human homologue of murine Sipa-1. Gene 214, 215-221 4 6892116CD1 g4688902 5.5E−240 [Homo sapiens] centaurin beta2 5 5990388CD1 g183002 6.4E−274 [Homo sapiens] guanylate binding protein isoform I Cheng, Y. S. E., et al. (1991) Interferon-induced guanylate-binding proteins lack an N(T)KXD consensus motif and bind GMP in addition to GDP and GTP. Mol. Cell. Biol. 11, 4717-4725 6  011293CD1 g1174187 4.5E−234 [Mus musculus] purine nucleotide binding protein 7 4080676CD1 g4160304 1.2E−148 [Mus musculus] HS1 binding protein 3 Takemoto, Y., et al. (1999) Int. Immunol. 11: 1957-1964 8 4791825CD1 g409027 2.5E−25 [Homo sapiens] CDC42 GTPase-activating protein Barfod, E. T., et al. (1993) Cloning and expression of a human CDC42 GTPase-activating protein reveals a functional SH3-binding domain. J. Biol. Chem. 268, 26059-26062 g7547029 6.0E−43 GAP-like protein [Homo sapiens] Zhao, N. and Le Beau, M. M. (2000) Genomics 70, 123-130 9 7481996CD1 g7650388 6.0E−59 [Rattus norvegicus] Kalirin-9a Johnson, R. C., et al. (2000) Isoforms of kalirin, a neuronal dbl family member, generated through use of different 5′-and 3′-ends along with ar internal translational initiation site. J. Biol. Chem. 275, 19324-19333 10 7610864CD1 g1657835 0.0 Rho-guanine nucleotide exchange factor [Mus musculus] 11 6985813CD1 g6224676 0.0 T-cell lymphoma invasion and metastasis 2 [Homo sapiens] (Chiu, C. Y. et al. (1999) Cloning and characterization of T-cell lymphoma invasion and metastasis 2 (TIAM2), a novel guanine nucleotide exchange factor related to TIAM1. Genomics 61: 66-73.) 12 4002434CD1 g3875648 5.4E−77 [Caenorhabditis elegans] Similarity to Human rab13 protein (PIR Acc. No. A49647). Contains the ATP/GTP-binding site motif (PROSITE PS00017)˜cDNA EST EMBL: M89412 comes from this gene˜cDNA EST yk212g9.3 comes from this gene˜cDNA EST yk212g9.5 comes from this gene˜cDNA EST yk480d1.3 comes from this gene˜cDNA EST yk480d1.5 comes from this gene (The C. elegans Sequencing Consortium (1998) Science 282 (5396), 2012-2018) 13 2506117CD1 g840786 9.5E−118 [Homo sapiens] p115 (Tribioli, C. et al (1996) Proc. Natl. Acad. Sci. U.S.A. 93 (2), 695-699) g14028714 0.0 Rho GTPase-activating protein [Mus musculus] 14 7193277CD1 g1864091 0.0 [Rattus norvegicus] PSD-95/SAP90-associated protein-3 (Takeuchi, M. et al (1997) J. Biol. Chem. 272 (18), 11943-11951) 15 2307889CD1 g498257 1.8E−46 [Rattus norvegicus] Ras-related protein (Yamagata, K. et al (1994) J. Biol. Chem. 269 (23), 16333-16339) 16 5369710CD1 g10176983 8.4E−173 [Arabidopsis thaliana] GTP-binding membrane protein LepA homolog (Sato, S. et al (1998) DNA Res. 5(1), 41-54) 17 5502841CD1 g7650487 3.1E−149 [Drosophila melanogaster] Centaurin Gamma 1A g15625584 0.0 centaurin gamma2 [Homo sapiens] 18  361856CD1 g3924774 5.6E−43 [Caenorhabditis elegans] contains similarity to Pfam domain: PF00293 (Bacterial mutT protein), Score = 30.4, E-value = 1.1e−07, N = 1˜cDNA EST yk357h8.5 comes from this gene (The C. elegans Sequencing Consortium (1998) Science 282 (5396), 2012-2018)

[0405] TABLE 3 SEQ Incyte Amino Potential Potential Analytical ID Polypeptide Acid Phosphorylation Glycosylation Signature Sequences, Motifs, Methods and NO: ID Residues Sites Sites and Domains Databases 1 2372478CD1 458 S18 S22 S61 S92 N222 signal_cleavage: M1-S63 SPSCAN S223 S322 S353 F-box domain: S75-L125 HMMER_PFAM T13 T24 T119 T219 WD domain, G-beta repeat: HMMER_PFAM T247 T289 T405 G218-D252, Q259-D292, L299-D333, T407 T410 T425 V163-D201, I381-V415, P419-R455 Trp-Asp (WD-40) repeat BLIMPS_BLOCKS proteins signature BL00678: S241-W251 Trp-Asp (WD-40) repeats PROFILESCAN signature G_beta_repeats S178-A234 Trp-Asp (WD) repeats MOTIFS signature: C188-L202, V239-M253 2 4586623CD1 614 S114 S238 S402 N273 signal_cleavage: M1-G17 SPSCAN S599 T18 T275 Y85 signal Peptide: HMMER Y130 Y287 M1-T18, M1-T22, M1-T24 TMAP: A165-L190 L190-L218 TMAP S250-T275 N317-Q345 L346-S367 D560-S586 N-terminus is non-cytosolic POTENTIAL LIGAND BINDING BLAST_PRODOM PROTEIN RYA3 PD177882: S219-Y394 PROTEIN PRECURSOR SIGNAL BLAST_PRODOM GLYCOPROTEIN LIPID TRANSPORT ANTIBIOTIC TRANSMEMBRANE LIPOPOLYSACCHARIDE BINDING LBP PD006440: L227-D608 TENP BLAST_PRODOM PD140738: N317-L612 do LIGAND; RY2G5; RYA3; BLAST_DOMO DM05385|S17447|1-470: R146-S613 LIPOPOLYSACCHARIDE-BINDING BLAST_DOMO PROTEIN DM02253|P17213|11-486: I229-A614 3 4825215CD1 1036 S49 S62 S75 S93 N47 N91 N97 Rap/ran-GAP: HMMER_PFAM S185 S447 S455 N280 N705 M243-L430 S458 S596 S659 N743 PROTEIN GTPASE ACTIVATING BLAST_PRODOM S707 S764 S818 GTPASE ACTIVATION TUBERIN S838 S843 S862 TUBEROUS SCLEROSIS S921 S976 S978 ANTIONCOGENE ALTERNATIVE S990 S1003 S1028 SPLICING T104 T149 T171 PD004725: Y122-L434 T239 T265 T278 do ACTIVATING; GTPASE; BLAST_DOMO T422 T638 T680 DM04902|P46062|1-332: M243-L430 T932 4 6892116CD1 834 S12 S84 S102 S229 Putative GTP-ase activating HMMER_PFAM S253 S257 S280 protein for Arf domain: S319 S347 S375 E403-P525 S387 S391 S492 PH domain: V269-A363 HMMER_PFAM S499 S500 S544 Ank repeat: E702-S734, R735-Q767 HMMER_PFAM S580 S592 S629 Transmembrane domain: TMAP S633 S645 S813 T705-F721 T18 T53 T121 T160 N-terminus is non-cytosolic T496 T549 T635 HIV Rev interacting protein BLIMPS_PRINTS T653 Y374 signature PR00405: N415-G434, G434-H451, V455-N476 PROTEIN ZINCFINGER NUCLEAR BLAST_PRODOM DNABINDING PUTATIVE GTPASE ACTIVATING FACTOR CHROMOSOME REPEAT PD002425: V405-P495 HYPOTHETICAL PROTEIN KIAA0050 BLAST_PRODOM ZINC FINGER NUCLEAR DNA BINDING REPEAT ANK PD070169: E488-K553 GATA-TYPE ZINC FINGER DOMAIN BLAST_DOMO DM00122|P40529|16-71: G414-E466 5 5990388CD1 595 S156 S157 S203 N111 Guanylate-binding protein HMMER_PFAM S211 S303 S358 domain: S370 S402 S414 M7-D373 S468 S500 S521 Transmembrane domain: L28-R48 TMAP S590 T17 T49 T70 PROTEIN BINDING INTERFERON BLAST_PRODOM T149 T179 T195 INDUCED GUANYLATE BINDING T347 T481 T530 GUANINE NUCLEOTIDE INTERFERON T549 T580 T585 INDUCTION GTP BINDING MULTIGENE PD010106: M1-Y431 GTP NP_BIND BLAST_DOMO DM04725|P32455|1-591: M1-K584 ATP/GTP-binding site motif A MOTIFS (P-loop): G45-S52 6 011293CD1 640 S386 S417 S429 N105 N126 Guanylate-binding protein: HMMER_PFAM S492 S537 S599 M22-D389 T64 T194 T210 Transmembrane domain: E44-R72 TMAP T295 T303 T313 N126-S145 L607-Y635 T363 T497 T600 N-terminus is cytosolic Y260 Y461 PROTEIN-BINDING INTERFERON- BLAST_PRODOM INDUCED GUANYLATE-BINDING GUANINE NUCLEOTIDE INTERFERON INDUCTION GTP-BINDING MULTIGENE PD010106: S18-H447 MACROPHAGE ACTIVATION 2 GUANYLATE-BINDING PROTEIN PD184314: L449-G499 PROTEIN COILED COIL CHAIN MYOSIN REPEAT HEAVY ATP- BINDING FILAMENT HEPTAD PD000002: E452-E603 GTP NP_BIND BLAST_DOMO DM04725|P32455|1-591: S18-K601 DM04725|P32456|1-590: P25-S599 DM04725|Q01514|1-588: S18-K594 ATP/GTP-binding site motif A MOTIFS (P-loop) G60-S67 7 4080676CD1 392 S10 S54 S68 S72 PX domain: L22-R138 HMMER_PFAM S82 S151 S185 S194 S209 S225 S249 S258 S297 T9 T18 T146 T160 T229 8 4791825CD1 277 S44 S152 T229 signal_cleavage: SPSCAN T236 Y165 M1-A13 RhoGAP domain: HMMER_PFAM P59-M210 PROTEIN GTPASE DOMAIN AC BLIMPS_PRODOM PD00930: P59-G84, L160-C200 PROTEIN GTPASE DOMAIN SH2 BLAST_PRODOM ACTIVATION ZINC 3 KINASE SH3 PHOSPHATIDYLINOSITOL REGULATORY PD000780: I58-P204 PH DOMAIN BLAST_DOMO DM00470|P42331|74-343: L40-N199 9 7481996CD1 1605 S4 S48 S130 S223 N632 PH domain: HMMER_PFAM S244 S276 S284 L1331-W1438 S330 S331 S351 RhoGEF domain: HMMER_PFAM S364 S442 S584 I1143-D1317 S666 S690 S756 do DBL; ONCOGENE; BLAST_DOMO S787 S818 S858 TRANSFORMING; PROTO; S1137 S1383 S1412 DM08582|S51620|292-780: S1421 S1478 S1488 E1040-E1446 S1510 T149 T215 GUANINE-NUCLEOTIDE BLAST_DOMO T258 T393 T485 DISSOCIATION STIMULATORS CDC24 T724 T727 T730 FAMILY T1097 T1150 T1368 DM08581|P40995|20-518: T1524 T1113-K1367 Cell attachment sequence: MOTIFS R401-D403 10 7610864CD1 1736 S4 S155 S161 S297 N254 N457 Phorbol esters/diacylglycerol HMMER_PFAM S310 S313 S413 N529 N635 binding domain: S476 S477 S486 N718 N943 H653-C699 S506 S513 S531 N1063 N1378 PH (pleckstrin homology) HMMER_PFAM S561 S579 S580 N1554 N1621 domain: S588 S612 S614 N1679 L1087-E1188 S632 S720 S766 RhoGEF domain: HMMER_PFAM S776 S782 S787 V853-L1043 S888 S910 S922 Transmembrane domain: TMAP S1489 S1598 S1623 A170-A191 S1172 S1189 S1199 N-terminus is non-cytosolic. T762 T772 T1000 10 S1172 S1189 S1199 Phorbol esters/ BLIMPS_BLOCKS S1201 S1247 S1299 diacylglycerol binding domain. S1303 S1314 S1337 proteins: S1368 S1395 S1481 BL00479: H653-G675, E677-C692 S1172 S1189 S1199 RHO-GUANINE NUCLEOTIDE BLAST_PRODOM S1201 S1247 S1299 EXCHANGE FACTOR RHO-GEF S1303 S1314 S1337 GUANINE-NUCLEOTIDE RELEASING S1368 S1395 S1481 FACTOR COILED COIL: S1201 S1247 S1299 PD148158: M1-R652 S1303 S1314 S1337 PD143828: C1190-R1428 S1368 S1395 S1481 PD177931: R1520-R1699 T1099 T1223 T1391 FACTOR LYMPHOID PROTO-ONCOGENE BLAST_PRODOM T1662 T1686 NUCLEOTIDE EXCHANGE GUANINE- NUCLEOTIDE: PD017306: K1044-S1189 Phorbol esters/ MOTIFS diacylglycerol binding domain: H653-C699 11 6985813CD1 1725 S330 S337 S375 N15 N144 N291 PDZ domain (Also known as DHR HMMER_PFAM S384 S391 S411 N638 N805 or GLGF): S440 S485 S491 N808 N1027 D914-P999 S577 S593 S604 N1093 N1155 PH (pleckstrin homology) HMMER_PFAM S741 S767 S784 N1406 N1436 domain: S810 S821 S922 N1524 N1664 V507-A620, F1377-R1479 S974 S986 S1008 N1689 RhoGEF domain: HMMER_PFAM S1010 S1060 S1070 V1127-E1316 S29 S1091 S1119 Spectrin pleckstrin homology BLIMPS_PRINTS S158 S1170 S1263 domain signature: S225 S1288 S218 PR00683: R533-G554, G595-T613 T478 T1602 T1666 PROTEIN GUANINE-NUCLEOTIDE BLAST_PRODOM S1336 S1346 S1438 RELEASING FACTOR MYRISTYLATION S229 S1447 S1462 STILL LIFE DEVELOPMENTAL: S248 S1510 S237 PD006236: L496-K762 S1515 S1518 S1526 PD038093: M1317-E1493 S261 S1593 S1665 PD011829: V838-K1126 S1685 S298 S1696 PROTEIN FACTOR GUANINE- BLAST_PRODOM T541 T606 T632 NUCLEOTIDE RELEASING T751 T755 T1043 NUCLEOTIDE GUANINE EXCHANGE T1078 T1134 T82 PROTO-ONCOGENE BINDING SH3: T1160 T1184 T370 PD000777: V1127-E1316 T1244 T93 T1290 GUANINE-NUCLEOTIDE BLAST_DOMO T1326 T129 T1338 DISSOCIATION STIMULATORS CDC24 T1408 T1445 T1495 FAMILY: T471 T1534 T1538 DM08581|P40995|20-518: Y408 Y874 Y888 L1211-S1401 KINASE; ZINC; SH2: BLAST_DOMO DM08580|P15498|1-483: E1076-K1319 Guanine-nucleotide MOTIFS dissociation stimulators CDC24 family signature: L1265-T1290 12 4002434CD1 878 S86 S213 S389 N623 Transforming protein P21 RAS BLIMPS_PRINTS S402 S425 S427 signature S470 S471 S492 PR00449: M44-G65, P67-I83, S525 S535 S551 T167-M180 S553 S555 S640 do NEUROFILAMENT; TRIPLET; BLAST_DOMO S673 S769 S806 DM04498|P12036|434-1019: Q235-E708 S874 T54 T89 T253 BROMODOMAIN BLAST_DOMO T510 T528 T582 DM04744|P45481|480-1076: T599 T702 Y268-S678 ATP/GTP-binding site motif A MOTIFS (P-loop) G50-T57 13 2506117CD1 836 S80 S110 S135 N261 Fes/CIP4 homology domain: HMMER_PFAM S195 S224 S305 K22-Y120 S324 S421 S481 RhoGAP domain: HMMER_PFAM S493 S531 S650 P505-Q657 S681 S695 S709 SH3 domain: HMMER_PFAM S713 S724 S748 I731-Q785 S796 S799 T115 Transmembrane Domains: TMAP T203 T379 T397 K603-H625 T403 T425 T477 N-terminus is cytosolic T494 T708 T723 Src homology 3 (SH3) domain BLIMPS_BLOCKS T743 T813 Y63 BL50002: A735-A753, N771-V784 Y690 SH3 domain signature BLIMPS_PRINTS PR00452: I773-Q785, I731-G741, R745-R760, S762-N771 PROTEIN GTPASE DOMAIN AC BLIMPS_PRODOM PD00930: P505-G530, L608-L648 F12F6.5 RHOGAP HEMATOPOIETIC BLAST_PRODOM PROTEIN C1 P115 KIAA0131 GTPASE ACTIVATION SH3 PD042850: E133-T477, Q521-D559 PROTEIN GTPASE DOMAIN SH2 BLAST_PRODOM ACTIVATION ZINC 3 KINASE SH3 PHOSPHATIDYLINOSITOL REGULATORY PD000780: I504-E653 PH DOMAIN BLAST_DOMO DM00470|P98171|405-693: Q498-I678, F413-P505, E159-E199 DM00470|Q03070|63-292: S493-I678 DM00470|P52757|241-463: S493-I678 DM00470|P15882|109-331: P505-I678 14 7193277CD1 979 S64 S206 S262 N649 PSD95/SAP90 ASSOCIATED DAP1 BLAST_PRODOM S295 S300 S326 ALPHA PROTEIN1 PROTEIN 2 S412 S416 S430 PROTEIN 4 PROTEIN 3 S512 S528 S560 PD014607: M1-E309, P140-Q369, S564 S580 S605 S561-L585 S643 S645 S651 PROTEIN PSD95/SAP90 ASSOCIATED BLAST_PRODOM S773 S781 S785 DAP1 GUANYLATE KINASE S845 S882 S900 ASSOCIATED BETA ALPHA PSD95 S955 S960 T101 BINDING T120 T158 T425 PD006399: D772-S959 T426 T570 T641 PSD95/SAP90 ASSOCIATED PROTEIN BLAST_PRODOM T868 T887 DAP1 GUANYLATE KINASE ASSOCIATED BETA ALPHA PSD95 BINDING PD007821: M401-G574, S580-R711, V370-R505, V327-P493, C389-Q469, D491-A589, G574-P608, K910-K919, M320-P345 PSD95/SAP90 ASSOCIATED BLAST_PRODOM PROTEIN3 PD142278: V370-P417 15 2307889CD1 182 S149 T144 Ras family: HMMER_PFAM K8-M182 Transmembrane domain: TMAP P71-S86 N-terminus is non-cytosolic Transforming protein P21 RAS BLIMPS_PRINTS signature PR00449: R7-E28, E30-I46, V47-I69, T110-L123, F145-D167 RAS TRANSFORMING PROTEIN BLAST_DOMO DM00006|S41960|3-148: R7-S148 DM00006|I55401|3-148: R7-S148 DM00006|P34443|10-155: R7-E147 DM00006|P22280|6-151: V4-S148 ATP/GTP-binding site motif A MOTIFS (P-loop): G13-T20 16 5369710CD1 622 S50 S225 S261 N70 N335 N375 signal_cleavage: SPSCAN S281 S327 S393 M1-A44 S481 S620 T45 T83 Elongation factor Tu family: HMMER_PFAM T117 T230 T291 E66-V287, Y315-V390 T310 T333 T433 Transmembrane domain: TMAP T438 T515 T565 I171-V192, S346-M363 T583 N-terminus is cytosolic GTP-binding elongation factors BLIMPS_BLOCKS proteins BL00301: N70-K81, I139-G170, Q265-G278 16 Initiation factor 2 proteins BLIMPS_BLOCKS BL01176: I193-K247, A256-K293, L136-A173 GTP-binding elongation factor BLIMPS_PRINTS signature PR00315: N70-T83, E113-Q121, N137-F147, R153-V164, V189-L198 Transforming protein P21 RAS BLIMPS_PRINTS signature PR00449: Y127-Y149, A185-L198, C221-I243 GTP BINDING PROTEIN LEPA BLAST_PRODOM MEMBRANE GTPASE GUF1 PUTATIVE C1B3.04C ZK1236.1 CHROMOSOME PD004661: K403-N604 RAS TRANSFORMING PROTEIN BLAST_DOMO DM00006|P46943|43-209: V65-G229 DM00006|P34617|39-197: E66-G229 DM00006|P37949|11-176: I68-G229 DM00006|P07682|1-166: V65-I216 ATP/GTP-binding site motif A MOTIFS (P-loop): A75-S82 GTP-binding elongation factors MOTIFS signature: D106-Q121 17 5502841CD1 726 S16 S35 S70 S161 N38 N629 N711 Putative GTP-ase activating HMMER_PFAM S183 S187 S192 protein for Arf: S214 S229 S255 A477-D597 S294 S326 S351 PH domain: HMMER_PFAM S381 S392 S402 P219-L456 S413 S439 S464 Ank repeat: HMMER_PFAM S555 S624 T77 D636-A668, R669-L701 T191 T243 T274 Transmembrane domain: TMAP T403 T405 T440 Q3-L31, A640-G660 T485 T631 HIV Rev interacting protein BLIMPS_PRINTS signature PR00405: N489-G508, G508-H525, V529-N550 HYPOTHETICAL PROTEIN KIAA0167 BLAST_PRODOM REPEAT ANK PD041379: V101-P329, D385-L478 PROTEIN ZINC FINGER NUCLEAR BLAST_PRODOM DNA BINDING PUTATIVE GTPASE ACTIVATING FACTOR CHROMOSOME REPEAT PD002425: G488-P567 HYPOTHETICAL PROTEIN KIAA0167 BLAST_PRODOM REPEAT ANK PD030267: G563-H622 GATA-TYPE ZINC FINGER DOMAIN BLAST_DOMO DM00122|P40529|16-71: G488-E540 DM00122|P35197|18-72: V486-P539 18 361856CD1 420 S11 S240 S247 N303 N315 MutT-like domain: HMMER_PFAM S284 S317 S374 G96-G219 S375 S400 S406 T3 mutT domain proteins. BLIMPS_BLOCKS T149 T190 T213 BL00893: P127-F151 T336 Y93 MutT domain signature BLIMPS_PRINTS PR00502: W124-H138, H138-I153 MUTT DOMAIN BLAST_DOMO DM00443|P53550|73-165: C73-D161 mutT domain signature: MOTIFS G129-E148

[0406] TABLE 4 Polynucleotide SEQ ID NO:/ Incyte ID/Sequence Length Sequence Fragments 19/2372478CB1/ 1-161, 1-254, 3-658, 18-318, 19-721, 34-286, 36-344, 364-960, 379-682, 534-780, 1750 534-792, 534-794, 534-1018, 534-1026, 534-1071, 534-1088, 534-1120, 534-1121, 534-1173, 534-1194, 537-1071, 562-710, 608-1191, 664-1171, 683-1233, 702-1284, 714-1278, 716-983, 720-909, 726-940, 726-1009, 742-1082, 747-1159, 754-1287, 822-1282, 856-1318, 880-1423, 881-1381, 883-1111, 884-1185, 892-1563, 902-1383, 913-1129, 914-1179, 963-1423, 1011-1271, 1013-1181, 1058-1335, 1065-1188, 1098-1415, 1112-1718, 1129-1396, 1173-1430, 1180-1750, 1181-1701, 1189-1750, 1214-1445, 1214-1725, 1214-1742, 1253-1750, 1265-1729, 1279-1729, 1284-1734, 1285-1734, 1289-1712, 1292-1750, 1296-1750, 1309-1729, 1320-1586, 1320-1740, 1330-1573, 1337-1735, 1341-1721, 1349-1734, 1352-1734, 1352-1743, 1359-1734, 1364-1696, 1369-1740, 1376-1750, 1414-1729, 1423-1696, 1429-1670, 1452-1750, 1454-1734, 1478-1733, 1479-1729, 1501-1728, 1534-1734, 1580-1729, 1623-1734, 1662-1728, 1682-1734 20/4586623CB1/ 1-627, 136-398, 136-599, 193-789, 297-771, 353-852, 401-654, 401-663, 401-932, 2370 401-937, 473-1028, 531-889, 531-1235, 609-1174, 705-1316, 742-1378, 868-1171, 868-1538, 912-1538, 954-1088, 974-1545, 1008-1612, 1029-1414, 1084-1731, 1110-1633, 1138-1235, 1187-1605, 1214-1863, 1230-1831, 1230-1852, 1235-1688, 1244-1467, 1313-1913, 1408-1514, 1408-1910, 1409-1917, 1439-1919, 1455-1980, 1462-1911, 1484-2092, 1518-2100, 1522-2122, 1525-2034, 1548-2097, 1557-2032, 1569-2054, 1634-1805, 1663-2267, 1663-2350, 1664-1937, 1729-2289, 1765-1913, 1776-2353, 1861-2338, 1873-2022, 1891-2170, 1892-2334, 1933-2209, 1999-2258, 1999-2369, 1999-2370, 2003-2333, 2005-2361, 2042-2332, 2042-2360 21/4825215CB1/ 1-693, 6-577, 152-729, 152-835, 155-418, 359-628, 393-944, 630-1198, 633-1031, 3669 866-1380, 908-1357, 911-1072, 913-1498, 965-1525, 1024-1051, 1048-1575, 1078-1301, 1126-1388, 1355-1934, 1376-1666, 1467-1860, 1479-1977, 1637-2344, 1642-2344, 1670-1872, 1675-2344, 1691-2344, 1697-2344, 1703-2344, 1720-2344, 1740-2344, 1742-2344, 1754-2344, 1759-2334, 1772-2344, 1781-2344, 1806-2343, 1811-2344, 1844-2344, 1861-2113, 1861-2344, 1862-2344, 1869-2344, 1935-2344, 1959-2057, 1959-2344, 1961-2253, 1965-2344, 2008-2279, 2008-2329, 2040-2344, 2110-2340, 2133-2416, 2253-2344, 2253-2488, 2325-2548, 2325-2617, 2340-2834, 2340-2973, 2358-2587, 2359-2567, 2439-2688, 2454-2649, 2454-2992, 2499-2735, 2499-2778, 2549-3222, 2587-2706, 2587-3131, 2600-2893, 2706-3077, 2708-2979, 2715-3014, 2793-3095, 2845-3104, 2846-3135, 2890-3129, 2890-3414, 2970-3636, 2991-3124, 2991-3239, 2991-3513, 3012-3635, 3022-3641, 3036-3630, 3037-3650, 3047-3653, 3054-3205, 3061-3632, 3072-3313, 3078-3663, 3104-3610, 3145-3434, 3196-3647, 3227-3643, 3232-3669, 3235-3669, 3264-3497, 3264-3645, 3284-3644, 3315-3644, 3320-3641, 3332-3575, 3332-3579, 3332-3644, 3343-3663, 3351-3658, 3354-3664, 3357-3540, 3357-3639, 3360-3615, 3376-3644, 3439-3658, 3494-3669 22/6892116CB1/ 1-314, 1-380, 1-409, 1-431, 1-441, 1-448, 1-465, 1-468, 1-481, 1-509, 1-517, 1-522, 2505 1-531, 1-611, 1-615, 47-282, 48-608, 262-889, 273-666, 382-1021, 453-1083, 601-1290, 623-1202, 628-1154, 748-1119, 748-1329, 787-1528, 945-1602, 968-1560, 1036-1580, 1256-1602, 1288-1602, 1397-1602, 1424-1602, 1498-1562, 1569-2050, 1569-2060, 1569-2074, 1569-2111, 1591-2175, 1598-2166, 1694-2333, 1935-2424, 1960-2505, 2111-2505, 2133-2505, 2164-2505, 2309-2505, 2326-2505, 2337-2505 23/5990388CB1/ 1-172, 1-254, 1-337, 1-376, 1-550, 1-617, 1-646, 1-650, 1-655, 1-689, 34-392, 45-551, 3030 47-301, 47-430, 55-327, 55-451, 55-577, 55-650, 68-528, 97-788, 118-792, 125-404, 151-400, 159-610, 162-836, 280-869, 306-920, 373-528, 378-1074, 438-964, 480-998, 503-916, 513-670, 527-1246, 551-714, 552-1264, 583-1232, 592-1251, 631-1165, 654-996, 658-945, 658-1052, 695-1193, 712-1361, 716-1368, 734-1252, 739-1261, 767-1358, 783-1026, 807-981, 807-1052, 812-1512, 819-1408, 819-1460, 825-1516, 840-1342, 847-1471, 873-1050, 874-1451, 889-1565, 918-1495, 920-1524, 925-1463, 969-1515, 979-1252, 988-1627, 1002-1537, 1024-1627, 1036-1525, 1062-1574, 1089-1614, 1094-1411, 1096-1687, 1097-1756, 1104-1722, 1120-1590, 1125-1762, 1148-1722, 1155-1741, 1159-1678, 1182-1443, 1189-1757, 1214-1625, 1251-1920, 1270-1549, 1319-1612, 1332-1633, 1334-1849, 1378-1672, 1385-2121, 1388-2102, 1395-2112, 1396-2004, 1408-1698, 1471-1963, 1483-1941, 1496-2182, 1508-1738, 1528-2196, 1546-1699, 1571-2258, 1577-2257, 1579-2240, 1602-2176, 1604-2309, 1619-1843, 1637-1919, 1638-1893, 1645-1930, 1645-1954, 1647-1896, 1669-2232, 1672-1891, 1672-1898, 1712-1958, 1712-1973, 1714-2262, 1727-2276, 1728-2049, 1743-2044, 1750-1961, 1806-2044, 1841-2329, 1841-2336, 1841-2364, 1841-2428, 1852-2405, 1873-2152, 1886-2480, 1891-2187, 1894-2611, 1911-2422, 1932-2564, 1950-2588, 1951-2611, 1960-2507, 1960-2581, 1976-2214, 1988-2232, 2002-2311, 2005-2650, 2062-2594, 2068-2329, 2072-2316, 2082-2326, 2091-2334, 2092-2610, 2099-2729, 2133-2777, 2154-2437, 2173-2417, 2181-2589, 2185-2454, 2187-2401, 2187-2404, 2235-2484, 2235-2514, 2260-2570, 2263-2569, 2280-2531, 2295-2700, 2343-2595, 2358-2648, 2358-2956, 2358-2958, 2359-2894, 2360-2920, 2363-2646, 2363-2648, 2386-3011, 2399-2646, 2400-2711, 2404-2895, 2407-2917, 2410-2710, 2411-2698, 2411-2699, 2412-2706, 2412-2721, 2429-2896, 2434-3011, 2436-2997, 2438-2974, 2447-2841, 2447-2983, 2457-3020, 2469-3030, 2472-2922, 2472-2969, 2534-2838, 2535-2897, 2555-2896, 2573-3030, 2586-3011, 2591-3011, 2591-3017, 2592-3011, 2594-3013, 2597-2900, 2598-3030, 2600-2976, 2619-2897, 2630-2996, 2634-3011, 2635-2896, 2640-3011, 2659-2896, 2675-2962, 2677-3019, 2694-2970, 2694-3030, 2708-2974, 2738-3015, 2765-2992, 2765-3013, 2827-2996, 2831-2852, 2864-3030, 2900-3012, 2911-3005, 2911-3030, 2922-3003 24/011293CB1/ 1-249, 1-474, 1-536, 1-620, 12-294, 37-316, 92-685, 123-788, 131-671, 248-497, 2466 307-912, 349-832, 425-677, 442-578, 495-1121, 617-999, 669-1229, 673-947, 676-1183, 678-1160, 703-1253, 728-941, 765-1429, 772-1394, 775-1388, 782-1324, 793-1397, 796-1089, 852-1425, 911-1496, 921-1501, 975-1493, 1014-1388, 1038-1673, 1076-1376, 1106-1672, 1187-1415, 1232-1925, 1287-1556, 1311-1857, 1338-1901, 1432-1658, 1459-2116, 1578-2136, 1594-1827, 1594-1845, 1617-2021, 1864-2466 25/4080676CB1/ 1-71, 1-274, 1-659, 17-376, 24-222, 24-671, 26-555, 27-569, 28-238, 30-749, 32-367, 1680 34-278, 41-313, 41-503, 41-643, 41-652, 42-599, 43-257, 49-365, 85-294, 156-464, 222-461, 233-429, 266-536, 266-554, 266-573, 436-489, 444-959, 451-706, 451-750, 451-822, 451-969, 459-746, 460-747, 765-985, 765-1352, 771-1227, 781-958, 799-1453, 806-958, 859-1431, 895-1151, 907-1365, 908-1187, 969-1262, 969-1389, 975-1262, 998-1229, 1013-1270, 1017-1591, 1030-1285, 1034-1220, 1044-1436, 1146-1519, 1148-1519, 1209-1680 26/4791825CB1/ 1-221, 1-242, 1-380, 1-409, 1-499, 1-522, 1-554, 1-565, 1-573, 1-595, 1-615, 1-644, 1133 1-664, 1-668, 1-692, 1-748, 1-757, 1-792, 3-276, 3-426, 3-516, 3-525, 3-580, 3-660, 3-679, 3-700, 41-143, 41-444, 41-565, 41-683, 41-707, 41-738, 41-789, 74-641, 130-962, 191-830, 215-558, 225-794, 230-792, 245-895, 270-862, 284-739, 289-792, 296-758, 318-792, 352-976, 391-1132, 405-859, 409-792, 479-792, 494-792, 515-792, 534-1125, 547-792, 579-792, 581-792, 591-792, 688-1133, 793-1118, 793-1133, 824-1074, 824-1133 27/7481996CB1/ 1-515, 45-620, 49-333, 51-646, 51-752, 52-751, 141-1356, 372-963, 833-973, 964-1001, 5145 1016-1306, 1017-1305, 1102-1736, 1467-1726, 1467-2082, 1467-2146, 1467-2180, 1471-1878, 1471-2081, 1721-1894, 1771-2274, 1988-3505, 2079-2394, 2082-2383, 2082-2569, 2082-2570, 2187-2570, 2248-2570, 2289-2521, 2311-2570, 2354-2570, 2365-2570, 2406-2570, 2416-2570, 2449-2570, 2571-4250, 2976-3186, 2976-3483, 3110-3505, 3227-4045, 3525-3848, 3540-4353, 3547-4353, 3640-4353, 3849-4121, 4187-4431, 4187-4713, 4271-4759, 4273-4943, 4468-5145, 4528-4619, 4528-4627, 4531-5081, 4648-5133, 4651-5005, 4900-4936, 4900-4971, 4969-5040 28/7610864CB1/ 1-529, 324-744, 324-847, 677-1264, 794-1264, 1059-1348, 1059-2059, 1180-1497, 5434 1461-2059, 1824-2059, 1974-2397, 1974-2629, 2066-2777, 2167-2777, 2720-3422, 3250-3633, 3367-3619, 3391-3940, 3521-4211, 3578-4023, 3600-3962, 3637-4240, 3637-4307, 3693-4111, 3725-4123, 3789-3963, 3789-4008, 3798-4054, 3820-4441, 4194-4982, 4194-5132, 4342-5036, 4382-4966, 4481-4982, 4554-5109, 4557-5096, 4719-4982, 4751-5325, 4757-5047, 4759-4954, 4759-5253, 4759-5326, 4770-4982, 4776-4982, 4798-4982, 4800-4982, 4809-4982, 4816-5308, 4819-5300, 4829-5243, 4832-5307, 4852-5134, 4852-5434, 4872-4982, 4879-4982, 4885-5202, 4919-5190 29/6985813CB1/ 1-1631, 1-3240, 1384-1828, 1384-1966, 1494-1723, 1629-2246, 1629-2247, 1804-2028, 6480 1899-6480 30/4002434CB1/ 1-647, 6-664, 40-555, 41-465, 46-662, 49-535, 50-803, 74-882, 77-830, 78-831, 83-868, 3161 87-606, 118-629, 155-661, 203-598, 220-613, 228-612, 233-850, 287-912, 302-970, 358-977, 360-986, 388-890, 427-934, 435-606, 443-1228, 459-1129, 466-873, 471-1129, 496-999, 502-1177, 512-1009, 516-1242, 521-1016, 532-1008, 532-1040, 532-1091, 532-1109, 532-1119, 532-1151, 532-1202, 532-1292, 546-1115, 573-855, 574-1020, 577-851, 584-1214, 607-859, 612-1202, 617-958, 619-870, 625-862, 636-1258, 638-964, 642-1245, 652-1171, 678-983, 684-1248, 688-1252, 695-1256, 696-943, 704-1252, 721-949, 721-1225, 721-1249, 723-1162, 735-898, 742-1049, 775-1406, 916-1611, 934-1594, 951-1639, 967-1177, 986-1652, 1022-1687, 1051-1507, 1058-1707, 1106-1715, 1115-1861, 1119-1386, 1135-1799, 1146-1802, 1147-1802, 1180-1361, 1201-1717, 1237-1556, 1244-1541, 1253-1502, 1265-1594, 1266-1843, 1276-1560, 1308-1904, 1343-1899, 1366-1581, 1370-2040, 1378-1576, 1386-2070, 1392-2022, 1396-2107, 1437-1834, 1438-1753, 1444-1991, 1474-1751, 1503-2107, 1503-2154, 1504-2222, 1518-2208, 1527-2131, 1536-2191, 1537-2128, 1543-2126, 1544-1812, 1555-2221, 1557-2001, 1562-1858, 1570-1853, 1571-2037, 1573-1863, 1576-1848, 1579-2131, 1582-1753, 1584-1866, 1584-1896, 1592-1882, 1596-1858, 1596-1898, 1598-2224, 1617-2287, 1617-2326, 1648-2248, 1687-1774, 1687-2224, 1691-2244, 1699-2253, 1699-2277, 1705-2270, 1707-1926, 1718-2207, 1722-2241, 1723-1949, 1727-1958, 1739-2254, 1740-2271, 1754-2253, 1754-2254, 1761-2271, 1785-2286, 1796-2231, 1799-2268, 1813-2268, 1821-2257, 1821-2461, 1823-2455, 1827-2236, 1835-2243, 1835-2286, 1840-2265, 1848-2285, 1850-2062, 1850-2212, 1851-2266, 1852-2269, 1857-2308, 1881-2231, 1887-2267, 1887-2269, 1889-2257, 1890-2127, 1890-2257, 1905-2284, 1909-2144, 1931-2286, 1937-2217, 1938-2326, 1962-2204, 1984-2257, 1996-2245, 2005-2295, 2011-2223, 2013-2273, 2022-2278, 2043-2271, 2048-2257, 2068-2305, 2139-2862, 2266-2453, 2284-2452, 2395-2590, 2454-2930, 2454-2942, 2455-2915, 2456-2926, 2457-3091, 2462-2922, 2462-3110, 2463-2943, 2476-3118, 2481-2938, 2486-2946, 2486-2947, 2500-2920, 2502-2758, 2502-2939, 2502-2981, 2505-3137, 2506-3092, 2508-2945, 2525-3160, 2533-2984, 2534-2774, 2546-3062, 2553-2844, 2588-2820, 2610-2746, 2626-2890, 2626-3116, 2630-2881, 2641-2895, 2645-2944, 2645-2950, 2672-2937, 2688-2882, 2688-2905, 2689-2943, 2706-2994, 2708-2927, 2708-2997, 2731-2930, 2769-2958, 2791-3067, 2798-3066, 2798-3073, 2813-3101, 2813-3161, 2837-3023, 2837-3161, 2838-3061, 2875-3147, 2907-3161, 2919-3161, 2935-3155, 2936-3155, 2952-3155, 2954-3155, 2992-3161 31/2506117CB1/ 2907-3161, 2919-3161, 2935-3155, 2936-3155, 2952-3155, 2954-3155, 2992-3161 4479 32/7193277CB1/ 1-282, 239-2176, 356-590, 356-940, 440-896, 1194-1449, 1213-1476, 1215-1476, 3723 1835-2076, 2068-2655, 2175-2360, 2312-2374, 2596-2825, 2714-3383, 2968-3406, 3065-3723, 3091-3708, 3299-3578 33/2307889CB1/ 1-529, 1-600, 1-825, 38-197, 113-381, 204-277, 247-503, 268-567, 346-510, 346-705 825 34/5369710CB1/ 1-2564, 282-986, 325-1057, 386-677, 476-910, 508-902, 508-1189, 600-1233, 609-844, 2564 609-1097, 609-1189, 868-1452, 868-1505, 1038-1373, 1043-1520, 1043-1675, 1179-1637, 1187-1644, 1406-1652, 1406-1736, 1406-1995, 1410-1738, 1412-1999, 1491-1943, 1498-1945, 1498-1984, 1530-2148, 1536-2149, 1536-2165, 1552-2167, 1572-2017, 1572-2076, 1600-1934, 1601-2055, 1905-2258, 1927-2166, 2105-2564, 2116-2563, 2123-2528, 2137-2564, 2139-2564, 2162-2544, 2193-2461 35/5502841CB1/ 1-626, 4-624, 82-883, 100-896, 104-901, 167-652, 259-680, 408-909, 444-742, 3621 488-917, 571-909, 584-904, 595-909, 603-909, 607-903, 611-904, 622-909, 628-909, 634-909, 643-1255, 916-1730, 940-1567, 1027-1551, 1030-1739, 1051-1547, 1052-1546, 1065-1545, 1066-1545, 1112-1549, 1140-1509, 1152-1509, 1174-1445, 1175-1480, 1199-1795, 1210-1545, 1216-1507, 1372-1573, 1374-1480, 1389-2000, 1431-1480, 1434-1796, 1440-2111, 1481-1535, 1481-1573, 1481-1678, 1548-1828, 1548-1971, 1557-2147, 1557-2170, 1557-2211, 1558-2021, 1574-1678, 1585-2057, 1586-1981, 1599-2052, 1616-2243, 1624-2163, 1631-1886, 1679-1847, 1680-1927, 1825-2044, 1829-2104, 1854-2138, 1857-2695, 1972-2247, 1977-2277, 1982-2490, 2018-2165, 2019-2156, 2019-2311, 2029-2542, 2051-2615, 2060-2349, 2075-2659, 2087-2475, 2103-2648, 2105-2354, 2112-2376, 2112-2562, 2132-2758, 2154-2975, 2157-2311, 2157-2402, 2164-2460, 2190-2376, 2227-2484, 2227-2499, 2263-2500, 2263-2823, 2265-2609, 2270-2515, 2272-2557, 2273-2510, 2312-2402, 2322-2962, 2354-2792, 2354-2949, 2371-2855, 2403-2625, 2403-2743, 2403-2881, 2405-2716, 2410-2647, 2410-2892, 2426-2672, 2442-2728, 2465-3110, 2480-2767, 2519-3160, 2540-2726, 2540-2763, 2569-2867, 2569-3073, 2570-3113, 2585-2847, 2617-2826, 2617-3158, 2618-3095, 2626-2881, 2626-3085, 2650-2918, 2650-2919, 2674-2956, 2682-3229, 2734-3008, 2734-3018, 2752-3374, 2779-3128, 2785-3010, 2786-3291, 2789-3182, 2792-3040, 2792-3131, 2795-3148, 2804-3578, 2806-3392, 2806-3418, 2806-3461, 2809-3428, 2809-3488, 2810-3395, 2819-3085, 2819-3091, 2828-3124, 2830-3577, 2834-3114, 2848-3082, 2848-3085, 2848-3120, 2850-3578, 2851-3140, 2857-3529, 2858-3133, 2873-3533, 2882-3085, 2883-3071, 2887-3502, 2903-3206, 2911-3493, 2919-3510, 2938-3562, 2939-3571, 2954-3558, 2989-3565, 2990-3560, 2993-3556, 2993-3564, 2993-3581, 3012-3524, 3034-3315, 3057-3579, 3091-3593, 3096-3621, 3115-3393, 3116-3584, 3148-3487, 3151-3540, 3178-3539, 3186-3517, 3212-3593, 3213-3579, 3215-3589, 3217-3588, 3243-3518, 3254-3527, 3267-3579, 3268-3579, 3276-3579, 3277-3580, 3278-3579, 3282-3568, 3289-3578, 3295-3579 36/361856CB1/ 1-406, 4-250, 41-324, 41-654, 301-823, 697-991, 697-1190, 759-969, 868-1151, 1860 908-1330, 926-1199, 927-1198, 927-1311, 990-1567, 1063-1331, 1063-1613, 1196-1860

[0407] TABLE 5 Polynucleotide SEQ ID NO: Incyte Project ID: Representative Library 19 2372478CB1 ADRENOT07 20 4586623CB1 NOSEDIT02 21 4825215CB1 BRAHTDK01 22 6892116CB1 BRABDIE02 23 5990388CB1 BRAYDIN03 24  011293CB1 PANCTUT02 25 4080676CB1 CONFNOT02 26 4791825CB1 BRAFNON02 27 7481996CB1 BRAIFEE04 28 7610864CB1 STOMTDE01 29 6985813CB1 BRAIFER05 30 4002434CB1 THP1AZS08 31 2506117CB1 PLACFET04 32 7193277CB1 BRALNOT01 33 2307889CB1 NGANNOT01 34 5369710CB1 BMARTXE01 35 5502841CB1 OVARNOT07 36  361856CB1 COLAUCT01

[0408] TABLE 6 Library Vector Library Description ADRENOT07 pINCY Library was constructed using RNA isolated from adrenal tissue removed from a 61-year-old female during a bilateral adrenalectomy. Patient history included an unspecified disorder of the adrenal glands. BMARTXE01 pINCY This 5′ biased random primed library was constructed using RNA isolated from treated SH-SY5Y cells derived from a metastatic bone marrow neuroblastoma, removed from a 4-year-old Caucasian female (Schering AG). The medium was MEM/HAM'S F12 with 10% fetal calf serum. After reaching about 80% confluency cells were treated with 6- Hydroxydopamine (6-OHDA) at 100 microM for 8 hours. BRABDIE02 pINCY This 5′ biased random primed library was constructed using RNA isolated from diseased cerebellum tissue removed from the brain of a 57-year-old Caucasian male who died from a cerebrovascular accident. Serologies were negative. Patient history included Huntington's disease, emphysema, and tobacco abuse (3-4 packs per day, for 40 years). BRAFNON02 pINCY This normalized frontal cortex tissue library was constructed from 10.6 million independent clones from a frontal cortex tissue library. Starting RNA was made from superior frontal cortex tissue removed from a 35-year-old Caucasian male who died from cardiac failure. Pathology indicated moderate leptomeningeal fibrosis and multiple microinfarctions of the cerebral neocortex. Grossly, the brain regions examined and cranial nerves were unremarkable. No atherosclerosis of the major vessels was noted. Microscopically, the cerebral hemisphere revealed moderate fibrosis of the leptomeninges with focal calcifications. There was evidence of shrunken and slightly eosinophilic pyramidal neurons throughout the cerebral hemispheres. There were also multiple small microscopic areas of cavitation with surrounding gliosis scattered throughout the cerebral cortex. Patient history included dilated cardiomyopathy, congestive heart failure, cardiomegaly, and an enlarged spleen and liver. Patient medications included simethicone, Lasix, Digoxin, Colace, Zantac, captopril, and Vasotec. The library was normalized in two rounds using conditions adapted from Soares et al., PNAS (1994) 91: 9228 and Bonaldo et al., Genome Research (1996) 6: 791, except that a significantly longer (48 hours/round) reannealing hybridization was used. BRAHTDK01 PSPORT1 This amplified and normalized library was constructed using pooled RNA isolated from archaecortex, anterior and posterior hippocampus tissue removed from a 55-year-old Caucasian female who died from cholangiocarcinoma. Pathology indicated mild meningeal fibrosis predominately over the convexities, scattered axonal spheroids in the white matter of the cingulate cortex and the thalamus, and a few scattered neurofibrillary tangles in the entorhinal cortex and the periaqueductal gray region. Pathology for the associated tumor tissue indicated well-differentiated cholangiocarcinoma of the liver with residual or relapsed tumor. Patient history included cholangiocarcinoma, post-operative Budd-Chiari syndrome, biliary ascites, hydrothorax, dehydration, malnutrition, oliguria and acute renal failure. Previous surgeries included cholecystectomy and resection of 85% of the liver. 7.6 × 10e5 independent clones from this amplified library were normalized in 1 round using conditions adapted from Soares et al., PNAS (1994) 91: 9228-9232 and Bonaldo et al., Genome Research (1996) 6: 791, except that a significantly longer (48 hours/round) reannealing hybridization was used. BRAIFEE04 pINCY This 5′ biased random primed library was constructed using RNA isolated from brain tissue removed from a Caucasian male fetus who was stillborn with a hypoplastic left heart at 23 weeks' gestation. BRAIFER05 pINCY Library was constructed using RNA isolated from brain tissue removed from a Caucasian male fetus who was stillborn with a hypoplastic left heart at 23 weeks' gestation. BRALNOT01 pINCY Library was constructed using RNA isolated from thalamus tissue removed from a 35-year-old Caucasian male. No neuropathology was found. Patient history included dilated cardiomyopathy, congestive heart failure, and an enlarged spleen and liver. BRAYDIN03 pINCY This normalized library was constructed from 6.7 million independent clones from a brain tissue library. Starting RNA was made from RNA isolated from diseased hypothalamus tissue removed from a 57-year-old Caucasian male who died from a cerebrovascular accident. Patient history included Huntington's disease and emphysema. The library was normalized in 2 rounds using conditions adapted from Soares et al., PNAS (1994) 91:9228 and Bonaldo et al., Genome Research (1996) 6: 791, except that a significantly longer (48-hours/round) reannealing hybridization was used. The library was linearized and recircularized to select for insert containing clones. COLAUCT01 pINCY Library was constructed using RNA isolated from diseased ascending colon tissue removed from a 74-year-old Caucasian male during a multiple- segment large bowel excision with temporary ileostomy. Pathology indicated inflammatory bowel disease most consistent with chronic ulcerative colitis, characterized by severe acute and chronic mucosal inflammation with erythema, ulceration, and pseudopolyp formation involving the entire colon and rectum. The sigmoid colon had an area of mild stricture formation. One diverticulum with diverticulitis was identified near this zone. CONFNOT02 pINCY Library was constructed using RNA isolated from abdominal fat tissue removed from a 52-year-old Caucasian female during an ileum resection and incarcerated ventral hernia repair. Patient history included diverticulitis. Family history included hyperlipidemia. NGANNOT01 PSPORT1 Library was constructed using RNA isolated from tumorous neuroganglion tissue removed from a 9-year-old Caucasian male during a soft tissue excision of the chest wall. Pathology indicated a ganglioneuroma. Family history included asthma. NOSEDIT02 pINCY Library was constructed using RNA isolated from nasal polyp tissue. OVARNOT07 pINCY Library was constructed using RNA isolated from left ovarian tissue removed from a 28-year-old Caucasian female during a vaginal hysterectomy and removal of the fallopian tubes and ovaries. The tissue was associated with multiple follicular cysts, endometrium in a weakly proliferative phase, and chronic cervicitis of the cervix with squamous metaplasia. Family history included benign hypertension, hyperlipidemia, and atherosclerotic coronary artery disease. PANCTUT02 pINCY Library was constructed using RNA isolated from pancreatic tumor tissue removed from a 45-year-old Caucasian female during radical pancreaticoduodenectomy. Pathology indicated a grade 4 anaplastic carcinoma. Family history included benign hypertension, hyperlipidemia and atherosclerotic coronary artery disease. PLACFET04 pINCY Library was constructed using RNA isolated from placental tissue removed from a Caucasian male fetus who died after 18 weeks' gestation from fetal demise. STOMTDE01 PCDNA2.1 This 5′ biased random primed library was constructed using RNA isolated from stomach tissue removed from a 61-year-old Caucasian male during a partial esophagectomy, proximal gastrectomy, pyloromyotomy, and regional lymph node excision. Pathology for the associated tumor indicated an invasive grade 3 adenocarcinoma in the esophagus, extending distally to involve the gastroesophageal junction. The tumor extended through the muscularis to involve periesophageal and perigastric soft tissues. One perigastric and two periesophageal lymph nodes were positive for tumor. There were multiple perigastric and periesophageal tumor implants. The patient presented with deficiency anemia and myelodysplasia. Patient history included hyperlipidemia, and tobacco and alcohol abuse in remission. Previous surgeries included adenotonsillectomy, rhinoplasty, vasectomy, and hemorrhoidectomy. A previous bone marrow aspiration found the marrow to be hypercellular for age and had a cellularity-to-fat ratio of 95:5. The marrow was focally densely fibrotic. Granulocytic precursors were slightly increased with normal maturation. The estimate of blast cells was greater than 5%. Megakaryocytes were increased and appeared atypical in clusters. Storage cells and granulomata were absent. Patient medications included Epoetin, Danocrine, Berocca Plus tablets, Selenium, vitamin B6 phosphate, vitamins E & C, and beta carotene. Family history included alcohol abuse, atherosclerotic coronary artery disease, type II diabetes, chronic liver disease, and primary cardiomyopathy in the father; and benign hypertension and cerebrovascular disease in the mother. THP1AZS08 PSPORT1 This subtracted THP-1 promonocyte cell line library was constructed using 5.76 × 1e6 clones from a 5-aza-2′-deoxycytidine (AZ) treated THP-1 cell library. Starting RNA was made from THP-1 promonocyte cells treated for three days with 0.8 micromolar AZ. The donor had acute monocytic leukemia. The hybridization probe for subtraction was derived from a similarly constructed library, made from 1 microgram of polyA RNA isolated from untreated THP-1 cells. 5.76 million clones from the AZ-treated THP-1 cell library were then subjected to two rounds of subtractive hybridization with 5 million clones from the untreated THP-1 cell library. Subtractive hybridization conditions were based on the methodologies of Swaroop et al., NAR (1991) 19: 1954, and Bonaldo et al., Genome Research (1996) 6: 791.

[0409] TABLE 7 Program Description Reference Parameter Threshold ABI A program that removes vector sequences and Applied Biosystems, Foster City, CA. FACTURA masks ambiguous bases in nucleic acid sequences. ABI/ A Fast Data Finder useful in comparing and Applied Biosystems, Foster City, CA; Mismatch < 50% PARACEL annotating amino acid or nucleic acid sequences. Paracel Inc., Pasadena, CA. FDF ABI Auto- A program that assembles nucleic acid sequences. Applied Biosystems, Foster City, CA. Assembler BLAST A Basic Local Alignment Search Tool useful in Altschul, S. F. et al. (1990) J. Mol. Biol. ESTs: Probability value = 1.0E−8 sequence similarity search for amino acid and 215: 403-410; Altschul, S. F. et al. (1997) or less nucleic acid sequences. BLAST includes five Nucleic Acids Res. 25: 3389-3402. Full Length sequences: Probability functions: blastp, blastn, blastx, tblastn, and tblastx. value = 1.0E−10 or less FASTA A Pearson and Lipman algorithm that searches for Pearson, W. R. and D. J. Lipman (1988) Proc. ESTs: fasta E value = 1.06E−6 similarity between a query sequence and a group of Natl. Acad Sci. USA 85: 2444-2448; Pearson, Assembled ESTs: fasta Identity = sequences of the same type. FASTA comprises as W. R. (1990) Methods Enzymol. 183: 63-98; 95% or greater and least five functions: fasta, tfasta, fastx, tfastx, and and Smith, T. F. and M. S. Waterman (1981) Match length = 200 bases or great- ssearch. Adv. Appl. Math. 2: 482-489. er; fastx E value = 1.0E−8 or less Full Length sequences: fastx score = 100 or greater BLIMPS A BLocks IMProved Searcher that matches a Henikoff, S. and J. G. Henikoff (1991) Nucleic Probability value = 1.0E−3 or less sequence against those in BLOCKS, PRINTS, Acids Res. 19: 6565-6572; Henikoff, J. G. and DOMO, PRODOM, and PFAM databases to search S. Henikoff (1996) Methods Enzymol. for gene families, sequence homology, and 266: 88-105; and Attwood, T. K. et al. structural fingerprint regions. (1997) J. Chem. Inf. Comput. Sci. 37: 417-424. HMMER An algorithm for searching a query sequence against Krogh, A. et al. (1994) J. Mol. Biol. PFAM hits: Probability value = hidden Markov model (HMM)-based databases of 235: 1501-1531; Sonnhammer, E. L. L. et al. 1.0E−3 or less protein family consensus sequences, such as PFAM. (1988) Nucleic Acids Res. 26: 320-322; Signal peptide hits: Score = 0 or Durbin, R. et al. (1998) Our World View, in a greater Nutshell, Cambridge Univ. Press, pp. 1-350. ProfileScan An algorithm that searches for structural and Gribskov, M. et al. (1988) CABIOS 4: 61-66; Normalized quality score ≧ GCG- sequence motifs in protein sequences that match Gribskov, M. et al. (1989) Methods Enzymol. specified “HIGH” value for that defined in Prosite. 183: 146-159; Bairoch, A. et al. (1997) particular Prosite motif. Nucleic Acids Res. 25: 217-221. Generally, score = 1.4-2.1. Phred A base-calling algorithm that examines automated Ewing, B. et al. (1998) Genome Res. sequencer traces with high sensitivity and 8: 175-185; Ewing, B. and P. Green probability. (1998) Genome Res. 8: 186-194. Phrap A Phils Revised Assembly Program including Smith, T. F. and M. S. Waterman (1981) Adv. Score = 120 or greater; SWAT and CrossMatch, programs based on Appl. Math. 2: 482-489; Smith, T. F. and Match length = 56 or greater efficient implementationof the Smith-Waterman M. S. Waterman (1981) J. Mol. Biol. 147: algorithm, useful in searching sequence homology 195-197; and Green, P., University of and assembling DNA sequences. Washington, Seattle, WA. Consed A graphical tool for viewing and editing Phrap Gordon, D. et al. (1998) Genome Res. assemblies. 8: 195-202. SPScan A weight matrix analysis program that scans protein Nielson, H. et al. (1997) Protein Engineering Score = 3.5 or greater sequences for the presence of secretory 10: 1-6; Claverie, J. M. and S. Audic (1997) signal peptides. CABIOS 12: 431-439. TMAP A program that uses weight matrices to delineate Persson, B. and P. Argos (1994) J. Mol. Biol. transmembrane segments on protein sequences and 237: 182-192; Persson, B. and P. Argos (1996) determine orientation. Protein Sci. 5: 363-371. TMHMMER A program that uses a hidden Markov Sonnhammer, E. L. et al. (1998) Proc. Sixth model (HMM) to delineate transmembrane segments Intl. Conf. on Intelligent Systems for Mol. on protein sequences and determine orientation. Biol., Glasgow et al., eds., The Am. Assoc. for Artificial Intelligence Press, Menlo Park, CA, pp. 175-182. Motifs A program that searches amino acid sequences for Bairoch, A. et al. (1997) Nucleic Acids Res. patterns that matched those defined in Prosite. 25: 217-221; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.

[0410]

1 36 1 458 PRT Homo sapiens misc_feature Incyte ID No 2372478CD1 1 Met Glu Leu Pro Leu Gly Arg Cys Asp Asp Ser Arg Thr Trp Asp 1 5 10 15 Asp Asp Ser Asp Pro Glu Ser Glu Thr Asp Pro Asp Ala Gln Ala 20 25 30 Lys Ala Tyr Val Ala Arg Val Leu Ser Pro Pro Lys Ser Gly Leu 35 40 45 Ala Phe Ser Arg Pro Ser Gln Leu Ser Thr Pro Ala Ala Ser Pro 50 55 60 Ser Ala Ser Glu Pro Arg Ala Ala Ser Arg Val Ser Ala Val Ser 65 70 75 Glu Pro Gly Leu Leu Ser Leu Pro Pro Glu Leu Leu Leu Glu Ile 80 85 90 Cys Ser Tyr Leu Asp Ala Arg Leu Val Leu His Val Leu Ser Arg 95 100 105 Val Cys His Ala Leu Arg Asp Leu Val Ser Asp His Val Thr Trp 110 115 120 Arg Leu Arg Ala Leu Arg Arg Val Arg Ala Pro Tyr Pro Val Val 125 130 135 Glu Glu Lys Asn Phe Asp Trp Pro Ala Ala Cys Ile Ala Leu Glu 140 145 150 Gln His Leu Ser Arg Trp Ala Glu Asp Gly Arg Trp Val Glu Tyr 155 160 165 Phe Cys Leu Ala Glu Gly His Val Ala Ser Val Asp Ser Val Leu 170 175 180 Leu Leu Gln Gly Gly Ser Leu Cys Leu Ser Gly Ser Arg Asp Arg 185 190 195 Asn Val Asn Leu Trp Asp Leu Arg Gln Leu Gly Thr Glu Ser Asn 200 205 210 Gln Val Leu Ile Lys Thr Leu Gly Thr Lys Arg Asn Ser Thr His 215 220 225 Glu Gly Trp Val Trp Ser Leu Ala Ala Gln Asp His Arg Val Cys 230 235 240 Ser Gly Ser Trp Asp Ser Thr Val Lys Leu Trp Asp Met Ala Ala 245 250 255 Asp Gly Gln Gln Phe Gly Glu Ile Lys Ala Ser Ser Ala Val Leu 260 265 270 Cys Leu Ser Tyr Leu Pro Asp Ile Leu Val Thr Gly Thr Tyr Asp 275 280 285 Lys Lys Val Thr Ile Tyr Asp Pro Arg Ala Gly Pro Ala Leu Leu 290 295 300 Lys His Gln Gln Leu His Ser Arg Pro Val Leu Thr Leu Leu Ala 305 310 315 Asp Asp Arg His Ile Ile Ser Gly Ser Glu Asp His Thr Leu Val 320 325 330 Val Val Asp Arg Arg Ala Asn Ser Val Leu Gln Arg Leu Gln Leu 335 340 345 Asp Ser Tyr Leu Leu Cys Met Ser Tyr Gln Glu Pro Gln Leu Trp 350 355 360 Ala Gly Asp Asn Gln Gly Leu Leu His Val Phe Ala Asn Arg Asn 365 370 375 Gly Cys Phe Gln Leu Ile Arg Ser Phe Asp Val Gly His Ser Phe 380 385 390 Pro Ile Thr Gly Ile Gln Tyr Ser Val Gly Ala Leu Tyr Thr Thr 395 400 405 Ser Thr Asp Lys Thr Ile Arg Val His Val Pro Thr Asp Pro Pro 410 415 420 Arg Thr Ile Cys Thr Arg Arg His Asp Asn Gly Leu Asn Arg Val 425 430 435 Cys Ala Glu Gly Asn Leu Val Val Ala Gly Ser Gly Asp Leu Ser 440 445 450 Leu Glu Val Trp Arg Leu Gln Ala 455 2 614 PRT Homo sapiens misc_feature Incyte ID No 4586623CD1 2 Met Trp Met Ala Trp Cys Val Ala Ala Leu Ser Val Val Ala Val 1 5 10 15 Cys Gly Thr Ser His Glu Thr Asn Thr Val Leu Arg Val Thr Lys 20 25 30 Asp Val Leu Ser Asn Ala Ile Ser Gly Met Leu Gln Gln Ser Asp 35 40 45 Ala Leu His Ser Ala Leu Arg Glu Val Pro Leu Gly Val Gly Asp 50 55 60 Ile Pro Tyr Asn Asp Phe His Val Arg Gly Pro Pro Pro Val Tyr 65 70 75 Thr Asn Gly Lys Lys Leu Asp Gly Ile Tyr Gln Tyr Gly His Ile 80 85 90 Glu Thr Asn Asp Asn Thr Ala Gln Leu Gly Gly Lys Tyr Arg Tyr 95 100 105 Gly Glu Ile Leu Glu Ser Glu Gly Ser Ile Arg Asp Leu Arg Asn 110 115 120 Ser Gly Tyr Arg Ser Ala Glu Asn Ala Tyr Gly Gly His Arg Gly 125 130 135 Leu Gly Arg Tyr Arg Ala Ala Pro Val Gly Arg Leu His Arg Arg 140 145 150 Glu Leu Gln Pro Gly Glu Ile Pro Pro Gly Val Ala Thr Gly Ala 155 160 165 Val Gly Pro Gly Gly Leu Leu Gly Thr Gly Gly Met Leu Ala Ala 170 175 180 Asp Gly Ile Leu Ala Gly Gln Gly Gly Leu Leu Gly Gly Gly Gly 185 190 195 Leu Leu Gly Asp Gly Gly Leu Leu Gly Gly Gly Gly Val Leu Gly 200 205 210 Val Leu Gly Glu Gly Gly Ile Leu Ser Thr Val Gln Gly Ile Thr 215 220 225 Gly Leu Arg Ile Val Glu Leu Thr Leu Pro Arg Val Ser Val Arg 230 235 240 Leu Leu Pro Gly Val Gly Val Tyr Leu Ser Leu Tyr Thr Arg Val 245 250 255 Ala Ile Asn Gly Lys Ser Leu Ile Gly Phe Leu Asp Ile Ala Val 260 265 270 Glu Val Asn Ile Thr Ala Lys Val Arg Leu Thr Met Asp Arg Thr 275 280 285 Gly Tyr Pro Arg Leu Val Ile Glu Arg Cys Asp Thr Leu Leu Gly 290 295 300 Gly Ile Lys Val Lys Leu Leu Arg Gly Leu Leu Pro Asn Leu Val 305 310 315 Asp Asn Leu Val Asn Arg Val Leu Ala Asp Val Leu Pro Asp Leu 320 325 330 Leu Cys Pro Ile Val Asp Val Val Leu Gly Leu Val Asn Asp Gln 335 340 345 Leu Gly Leu Val Asp Ser Leu Ile Pro Leu Gly Ile Leu Gly Ser 350 355 360 Val Gln Tyr Thr Phe Ser Ser Leu Pro Leu Val Thr Gly Glu Phe 365 370 375 Leu Glu Leu Asp Leu Asn Thr Leu Val Gly Glu Ala Gly Gly Gly 380 385 390 Leu Ile Asp Tyr Pro Leu Gly Trp Pro Ala Val Ser Pro Lys Pro 395 400 405 Met Pro Glu Leu Pro Pro Met Gly Asp Asn Thr Lys Ser Gln Leu 410 415 420 Ala Met Ser Ala Asn Phe Leu Gly Ser Val Leu Thr Leu Leu Gln 425 430 435 Lys Gln His Ala Leu Asp Leu Asp Ile Thr Asn Gly Met Phe Glu 440 445 450 Glu Leu Pro Pro Leu Thr Thr Ala Thr Leu Gly Ala Leu Ile Pro 455 460 465 Lys Val Phe Gln Gln Tyr Pro Glu Ser Cys Pro Leu Ile Ile Arg 470 475 480 Ile Gln Val Leu Asn Pro Pro Ser Val Met Leu Gln Lys Asp Lys 485 490 495 Ala Leu Val Lys Val Leu Ala Thr Ala Glu Val Met Val Ser Gln 500 505 510 Pro Lys Asp Leu Glu Thr Thr Ile Cys Leu Ile Asp Val Asp Thr 515 520 525 Glu Leu Leu Ala Ser Phe Ser Ile Glu Gly Asp Lys Leu Met Ile 530 535 540 Asp Ala Lys Leu Glu Lys Thr Ser Leu Asn Leu Arg Thr Ser Asn 545 550 555 Val Gly Asn Phe Asp Ile Gly Leu Met Glu Val Leu Val Glu Lys 560 565 570 Ile Phe Asp Leu Ala Phe Met Pro Ala Met Asn Ala Val Leu Gly 575 580 585 Ser Gly Val Pro Leu Pro Lys Ile Leu Asn Ile Asp Phe Ser Asn 590 595 600 Ala Asp Ile Asp Val Leu Glu Asp Leu Leu Val Leu Ser Ala 605 610 3 1036 PRT Homo sapiens misc_feature Incyte ID No 4825215CD1 3 Met Asp Pro Leu Thr Lys Val Pro Cys Gly Ser Gln Ile Ala Gln 1 5 10 15 Thr Ile Leu Trp Lys Ala Lys Ser Ser Leu Ser Phe Gly Ile Gln 20 25 30 Pro Leu Gln Thr Trp Pro Thr Lys Asp Pro Glu Leu Glu Ser Gln 35 40 45 Val Asn Leu Ser Val Ser Glu Asp Leu Gly Cys Arg Arg Gly Asp 50 55 60 Phe Ser Arg Lys His Tyr Gly Ser Val Glu Leu Leu Ile Ser Ser 65 70 75 Asp Ala Asp Gly Ala Ile Gln Arg Ala Gly Arg Phe Arg Val Glu 80 85 90 Asn Gly Ser Ser Asp Glu Asn Ala Thr Ala Leu Pro Gly Thr Trp 95 100 105 Arg Arg Thr Asp Val His Leu Glu Asn Pro Glu Tyr His Thr Arg 110 115 120 Trp Tyr Phe Lys Tyr Phe Leu Gly Gln Val His Gln Asn Tyr Ile 125 130 135 Gly Asn Asp Ala Glu Lys Ser Pro Phe Phe Leu Ser Val Thr Leu 140 145 150 Ser Asp Gln Asn Asn Gln Arg Val Pro Gln Tyr Arg Ala Ile Leu 155 160 165 Trp Arg Lys Thr Gly Thr Gln Lys Ile Cys Leu Pro Tyr Ser Pro 170 175 180 Thr Lys Thr Leu Ser Val Lys Ser Ile Leu Ser Ala Met Asn Leu 185 190 195 Asp Lys Phe Glu Lys Gly Pro Arg Glu Ile Phe His Pro Glu Ile 200 205 210 Gln Lys Asp Leu Leu Val Leu Glu Glu Gln Glu Gly Ser Val Asn 215 220 225 Phe Lys Phe Gly Val Leu Phe Ala Lys Asp Gly Gln Leu Thr Asp 230 235 240 Asp Glu Met Phe Ser Asn Glu Ile Gly Ser Glu Pro Phe Gln Lys 245 250 255 Phe Leu Asn Leu Leu Gly Asp Thr Ile Thr Leu Lys Gly Trp Thr 260 265 270 Gly Tyr Arg Gly Gly Leu Asp Thr Lys Asn Asp Thr Thr Gly Ile 275 280 285 His Ser Val Tyr Thr Val Tyr Gln Gly His Glu Ile Met Phe His 290 295 300 Val Ser Thr Met Leu Pro Tyr Ser Lys Glu Asn Lys Gln Gln Val 305 310 315 Glu Arg Lys Arg His Ile Gly Asn Asp Ile Val Thr Ile Val Phe 320 325 330 Gln Glu Gly Glu Glu Ser Ser Pro Ala Phe Lys Pro Ser Met Ile 335 340 345 Arg Ser His Phe Thr His Ile Phe Ala Leu Val Arg Tyr Asn Gln 350 355 360 Gln Asn Asp Asn Tyr Arg Leu Lys Ile Phe Ser Glu Glu Ser Val 365 370 375 Pro Leu Phe Gly Pro Pro Leu Pro Thr Pro Pro Val Phe Thr Asp 380 385 390 His Gln Glu Phe Arg Asp Phe Leu Leu Val Lys Leu Ile Asn Gly 395 400 405 Glu Lys Ala Thr Leu Glu Thr Pro Thr Phe Ala Gln Lys Arg Arg 410 415 420 Arg Thr Leu Asp Met Leu Ile Arg Ser Leu His Gln Asp Leu Met 425 430 435 Pro Asp Leu His Lys Asn Met Leu Asn Arg Arg Ser Phe Ser Asp 440 445 450 Val Leu Pro Glu Ser Pro Lys Ser Ala Arg Lys Lys Glu Glu Ala 455 460 465 Arg Gln Ala Glu Phe Val Arg Ile Gly Gln Ala Leu Lys Leu Lys 470 475 480 Ser Ile Val Arg Gly Asp Ala Pro Ser Ser Leu Ala Ala Ser Gly 485 490 495 Ile Cys Lys Lys Glu Pro Trp Glu Pro Gln Cys Phe Cys Ser Asn 500 505 510 Phe Pro His Glu Ala Val Cys Ala Asp Pro Trp Gly Gln Ala Leu 515 520 525 Leu Val Ser Thr Asp Ala Gly Val Leu Leu Val Asp Asp Asp Leu 530 535 540 Pro Ser Val Pro Val Phe Asp Arg Thr Leu Pro Val Lys Gln Met 545 550 555 His Val Leu Glu Thr Leu Asp Leu Leu Val Leu Arg Ala Asp Lys 560 565 570 Gly Lys Asp Ala Arg Leu Phe Val Phe Arg Leu Ser Ala Leu Gln 575 580 585 Lys Gly Leu Glu Gly Lys Gln Ala Gly Lys Ser Arg Ser Asp Cys 590 595 600 Arg Glu Asn Lys Leu Glu Lys Thr Lys Gly Cys His Leu Tyr Ala 605 610 615 Ile Asn Thr His His Ser Arg Glu Leu Arg Ile Val Val Ala Ile 620 625 630 Arg Asn Lys Leu Leu Leu Ile Thr Arg Lys His Asn Lys Pro Ser 635 640 645 Gly Val Thr Ser Thr Ser Leu Leu Ser Pro Leu Ser Glu Ser Pro 650 655 660 Val Glu Glu Phe Gln Tyr Ile Arg Glu Ile Cys Leu Ser Asp Ser 665 670 675 Pro Met Val Met Thr Leu Val Asp Gly Pro Ala Glu Glu Ser Asp 680 685 690 Asn Leu Ile Cys Val Ala Tyr Arg His Gln Phe Asp Val Val Asn 695 700 705 Glu Ser Thr Gly Glu Ala Phe Arg Leu His His Val Glu Ala Asn 710 715 720 Arg Val Asn Phe Val Ala Ala Ile Asp Val Tyr Glu Asp Gly Glu 725 730 735 Ala Gly Leu Leu Leu Cys Tyr Asn Tyr Ser Cys Ile Tyr Lys Lys 740 745 750 Val Cys Pro Phe Asn Gly Gly Ser Phe Leu Val Gln Pro Ser Ala 755 760 765 Ser Asp Phe Gln Phe Cys Trp Asn Gln Ala Pro Tyr Ala Ile Val 770 775 780 Cys Ala Phe Pro Tyr Leu Leu Ala Phe Thr Thr Asp Ser Met Glu 785 790 795 Ile Arg Leu Val Val Asn Gly Asn Leu Val His Thr Ala Val Val 800 805 810 Pro Gln Leu Gln Leu Val Ala Ser Arg Ser Asp Ile Tyr Phe Thr 815 820 825 Ala Thr Ala Ala Val Asn Glu Val Ser Ser Gly Gly Ser Ser Lys 830 835 840 Gly Ala Ser Ala Arg Asn Ser Pro Gln Thr Pro Pro Gly Arg Asp 845 850 855 Thr Pro Val Phe Pro Ser Ser Leu Gly Glu Gly Glu Ile Gln Ser 860 865 870 Lys Asn Leu Tyr Lys Ile Pro Leu Arg Asn Leu Val Gly Arg Ser 875 880 885 Ile Glu Arg Pro Leu Lys Ser Pro Leu Val Ser Lys Val Ile Thr 890 895 900 Pro Pro Thr Pro Ile Ser Val Gly Leu Ala Ala Ile Pro Val Thr 905 910 915 His Ser Leu Ser Leu Ser Arg Met Glu Ile Lys Glu Ile Ala Ser 920 925 930 Arg Thr Arg Arg Glu Leu Leu Gly Leu Ser Asp Glu Gly Gly Pro 935 940 945 Lys Ser Glu Gly Ala Pro Lys Ala Lys Ser Lys Pro Arg Lys Arg 950 955 960 Leu Glu Glu Ser Gln Gly Gly Pro Lys Pro Gly Ala Val Arg Ser 965 970 975 Ser Ser Ser Asp Arg Ile Pro Ser Gly Ser Leu Glu Ser Ala Ser 980 985 990 Thr Ser Glu Ala Asn Pro Glu Gly His Ser Ala Ser Ser Asp Gln 995 1000 1005 Asp Pro Val Ala Asp Arg Glu Gly Ser Pro Val Ser Gly Ser Ser 1010 1015 1020 Pro Phe Gln Leu Thr Ala Phe Ser Asp Glu Asp Ile Ile Asp Leu 1025 1030 1035 Lys 4 834 PRT Homo sapiens misc_feature Incyte ID No 6892116CD1 4 Met Thr Val Glu Phe Glu Glu Cys Val Lys Asp Ser Pro Arg Phe 1 5 10 15 Arg Ala Thr Ile Asp Glu Val Glu Thr Asp Val Val Glu Ile Glu 20 25 30 Ala Lys Leu Asp Lys Leu Val Lys Leu Cys Ser Gly Met Val Glu 35 40 45 Ala Gly Lys Ala Tyr Val Ser Thr Ser Arg Leu Phe Val Ser Gly 50 55 60 Val Arg Asp Leu Ser Gln Gln Cys Gln Gly Asp Thr Val Ile Ser 65 70 75 Glu Cys Leu Gln Arg Phe Ala Asp Ser Leu Gln Glu Val Val Asn 80 85 90 Tyr His Met Ile Leu Phe Asp Gln Ala Gln Arg Ser Val Arg Gln 95 100 105 Gln Leu Gln Ser Phe Val Lys Glu Asp Val Arg Lys Phe Lys Glu 110 115 120 Thr Lys Lys Gln Phe Asp Lys Val Arg Glu Asp Leu Glu Leu Ser 125 130 135 Leu Val Arg Asn Ala Gln Ala Pro Arg His Arg Pro His Glu Val 140 145 150 Glu Glu Ala Thr Gly Ala Leu Thr Leu Thr Arg Lys Cys Phe Arg 155 160 165 His Leu Ala Leu Asp Tyr Val Leu Gln Ile Asn Val Leu Gln Ala 170 175 180 Lys Lys Lys Phe Glu Ile Leu Asp Ser Met Leu Ser Phe Met His 185 190 195 Ala Gln Ser Ser Phe Phe Gln Gln Gly Tyr Ser Leu Leu His Gln 200 205 210 Leu Asp Pro Tyr Met Lys Lys Leu Ala Ala Glu Leu Asp Gln Leu 215 220 225 Val Ile Asp Ser Ala Val Glu Lys Arg Glu Met Glu Arg Lys His 230 235 240 Ala Ala Ile Gln Gln Arg Thr Leu Leu Gln Asp Phe Ser Tyr Asp 245 250 255 Glu Ser Lys Val Glu Phe Asp Val Asp Ala Pro Ser Gly Val Val 260 265 270 Met Glu Gly Tyr Leu Phe Lys Arg Ala Ser Asn Ala Phe Lys Thr 275 280 285 Trp Asn Arg Arg Trp Phe Ser Ile Gln Asn Ser Gln Leu Val Tyr 290 295 300 Gln Lys Lys Leu Lys Asp Ala Leu Thr Val Val Val Asp Asp Leu 305 310 315 Arg Leu Cys Ser Val Lys Pro Cys Glu Asp Ile Glu Arg Arg Phe 320 325 330 Cys Phe Glu Val Leu Ser Pro Thr Lys Ser Cys Met Leu Gln Ala 335 340 345 Asp Ser Glu Lys Leu Arg Gln Ala Trp Val Gln Ala Val Gln Ala 350 355 360 Ser Ile Ala Ser Ala Tyr Arg Glu Ser Pro Asp Ser Cys Tyr Ser 365 370 375 Glu Arg Leu Asp Arg Thr Ala Ser Pro Ser Thr Ser Ser Ile Asp 380 385 390 Ser Ala Thr Asp Thr Arg Glu Arg Gly Val Lys Gly Glu Ser Val 395 400 405 Leu Gln Arg Val Gln Ser Val Ala Gly Asn Ser Gln Cys Gly Asp 410 415 420 Cys Gly Gln Pro Asp Pro Arg Trp Ala Ser Ile Asn Leu Gly Val 425 430 435 Leu Leu Cys Ile Glu Cys Ser Gly Ile His Arg Ser Leu Gly Val 440 445 450 His Cys Ser Lys Val Arg Ser Leu Thr Leu Asp Ser Trp Glu Pro 455 460 465 Glu Leu Leu Lys Leu Met Cys Glu Leu Gly Asn Ser Ala Val Asn 470 475 480 Gln Ile Tyr Glu Ala Gln Cys Glu Gly Ala Gly Ser Arg Lys Pro 485 490 495 Thr Ala Ser Ser Ser Arg Gln Asp Lys Glu Ala Trp Ile Lys Asp 500 505 510 Lys Tyr Val Glu Lys Lys Phe Leu Arg Lys Ala Pro Met Ala Pro 515 520 525 Ala Leu Glu Ala Pro Arg Arg Trp Arg Val Gln Lys Cys Leu Arg 530 535 540 Pro His Ser Ser Pro Arg Ala Pro Thr Ala Arg Arg Lys Val Arg 545 550 555 Leu Glu Pro Val Leu Pro Cys Val Ala Ala Leu Ser Ser Val Gly 560 565 570 Thr Leu Asp Arg Lys Phe Arg Arg Asp Ser Leu Phe Cys Pro Asp 575 580 585 Glu Leu Asp Ser Leu Phe Ser Tyr Phe Asp Ala Gly Ala Ala Gly 590 595 600 Ala Gly Pro Arg Ser Leu Ser Ser Asp Ser Gly Leu Gly Gly Ser 605 610 615 Ser Asp Gly Ser Ser Asp Val Leu Ala Phe Gly Ser Gly Ser Val 620 625 630 Val Asp Ser Val Thr Glu Glu Glu Gly Ala Glu Ser Glu Glu Ser 635 640 645 Ser Gly Glu Ala Asp Gly Asp Thr Glu Ala Glu Ala Trp Gly Leu 650 655 660 Ala Asp Val Arg Glu Leu His Pro Gly Leu Leu Ala His Arg Ala 665 670 675 Ala Arg Ala Arg Asp Leu Pro Ala Leu Ala Ala Ala Leu Ala His 680 685 690 Gly Ala Glu Val Asn Trp Ala Asp Ala Glu Asp Glu Gly Lys Thr 695 700 705 Pro Leu Val Gln Ala Val Leu Gly Gly Ser Leu Ile Val Cys Glu 710 715 720 Phe Leu Leu Gln Asn Gly Ala Asp Val Asn Gln Arg Asp Ser Arg 725 730 735 Gly Arg Ala Pro Leu His His Ala Thr Leu Leu Gly Arg Thr Gly 740 745 750 Gln Val Cys Leu Phe Leu Lys Arg Gly Ala Asp Gln His Ala Leu 755 760 765 Asp Gln Glu Gln Arg Asp Pro Leu Ala Ile Ala Val Gln Ala Ala 770 775 780 Asn Ala Asp Ile Val Thr Leu Leu Arg Leu Ala Arg Met Ala Glu 785 790 795 Glu Met Arg Glu Ala Glu Ala Ala Pro Gly Pro Pro Gly Ala Leu 800 805 810 Ala Gly Ser Pro Thr Glu Leu Gln Phe Arg Arg Cys Ile Gln Glu 815 820 825 Phe Ile Ser Leu His Leu Glu Glu Ser 830 5 595 PRT Homo sapiens misc_feature Incyte ID No 5990388CD1 5 Met Ala Pro Glu Ile His Met Thr Gly Pro Met Cys Leu Ile Glu 1 5 10 15 Asn Thr Asn Gly Glu Leu Val Ala Asn Pro Glu Ala Leu Lys Ile 20 25 30 Leu Ser Ala Ile Thr Gln Pro Val Val Val Val Ala Ile Val Gly 35 40 45 Leu Tyr Arg Thr Gly Lys Ser Tyr Leu Met Asn Lys Leu Ala Gly 50 55 60 Lys Asn Lys Gly Phe Ser Leu Gly Ser Thr Val Lys Ser His Thr 65 70 75 Lys Gly Ile Trp Met Trp Cys Val Pro His Pro Lys Lys Pro Glu 80 85 90 His Thr Leu Val Leu Leu Asp Thr Glu Gly Leu Gly Asp Val Lys 95 100 105 Lys Gly Asp Asn Gln Asn Asp Ser Trp Ile Phe Thr Leu Ala Val 110 115 120 Leu Leu Ser Ser Thr Leu Val Tyr Asn Ser Met Gly Thr Ile Asn 125 130 135 Gln Gln Ala Met Asp Gln Leu Tyr Tyr Val Thr Glu Leu Thr His 140 145 150 Arg Ile Arg Ser Lys Ser Ser Pro Asp Glu Asn Glu Asn Glu Asp 155 160 165 Ser Ala Asp Phe Val Ser Phe Phe Pro Asp Phe Val Trp Thr Leu 170 175 180 Arg Asp Phe Ser Leu Asp Leu Glu Ala Asp Gly Gln Pro Leu Thr 185 190 195 Pro Asp Glu Tyr Leu Glu Tyr Ser Leu Lys Leu Thr Gln Gly Thr 200 205 210 Ser Gln Lys Asp Lys Asn Phe Asn Leu Pro Arg Leu Cys Ile Arg 215 220 225 Lys Phe Phe Pro Lys Lys Lys Cys Phe Val Phe Asp Leu Pro Ile 230 235 240 His Arg Arg Lys Leu Ala Gln Leu Glu Lys Leu Gln Asp Glu Glu 245 250 255 Leu Asp Pro Glu Phe Val Gln Gln Val Ala Asp Phe Cys Ser Tyr 260 265 270 Ile Phe Ser Asn Ser Lys Thr Lys Thr Leu Ser Gly Gly Ile Lys 275 280 285 Val Asn Gly Pro Arg Leu Glu Ser Leu Val Leu Thr Tyr Ile Asn 290 295 300 Ala Ile Ser Arg Gly Asp Leu Pro Cys Met Glu Asn Ala Val Leu 305 310 315 Ala Leu Ala Gln Ile Glu Asn Ser Ala Ala Val Gln Lys Ala Ile 320 325 330 Ala His Tyr Asp Gln Gln Met Gly Gln Lys Val Gln Leu Pro Ala 335 340 345 Glu Thr Leu Gln Glu Leu Leu Asp Leu His Arg Val Ser Glu Arg 350 355 360 Glu Ala Thr Glu Val Tyr Met Lys Asn Ser Phe Lys Asp Val Asp 365 370 375 His Leu Phe Gln Lys Lys Leu Ala Ala Gln Leu Asp Lys Lys Arg 380 385 390 Asp Asp Phe Cys Lys Gln Asn Gln Glu Ala Ser Ser Asp Arg Cys 395 400 405 Ser Ala Leu Leu Gln Val Ile Phe Ser Pro Leu Glu Glu Glu Val 410 415 420 Lys Ala Gly Ile Tyr Ser Lys Pro Gly Gly Tyr Cys Leu Phe Ile 425 430 435 Gln Lys Leu Gln Asp Leu Glu Lys Lys Tyr Tyr Glu Glu Pro Arg 440 445 450 Lys Gly Ile Gln Ala Glu Glu Ile Leu Gln Thr Tyr Leu Lys Ser 455 460 465 Lys Glu Ser Val Thr Asp Ala Ile Leu Gln Thr Asp Gln Ile Leu 470 475 480 Thr Glu Lys Glu Lys Glu Ile Glu Val Glu Cys Val Lys Ala Glu 485 490 495 Ser Ala Gln Ala Ser Ala Lys Met Val Glu Glu Met Gln Ile Lys 500 505 510 Tyr Gln Gln Met Met Glu Glu Lys Glu Lys Ser Tyr Gln Glu His 515 520 525 Val Lys Gln Leu Thr Glu Lys Met Glu Arg Glu Arg Ala Gln Leu 530 535 540 Leu Glu Glu Gln Glu Lys Thr Leu Thr Ser Lys Leu Gln Glu Gln 545 550 555 Ala Arg Val Leu Lys Glu Arg Cys Gln Gly Glu Ser Thr Gln Leu 560 565 570 Gln Asn Glu Ile Gln Lys Leu Gln Lys Thr Leu Lys Lys Lys Thr 575 580 585 Lys Arg Tyr Met Ser His Lys Leu Lys Ile 590 595 6 640 PRT Homo sapiens misc_feature Incyte ID No 011293CD1 6 Met Gly Glu Arg Thr Leu His Ala Ala Val Pro Thr Pro Gly Tyr 1 5 10 15 Pro Glu Ser Glu Ser Ile Met Met Ala Pro Ile Cys Leu Val Glu 20 25 30 Asn Gln Glu Glu Gln Leu Thr Val Asn Ser Lys Ala Leu Glu Ile 35 40 45 Leu Asp Lys Ile Ser Gln Pro Val Val Val Val Ala Ile Val Gly 50 55 60 Leu Tyr Arg Thr Gly Lys Ser Tyr Leu Met Asn Arg Leu Ala Gly 65 70 75 Lys Arg Asn Gly Phe Pro Leu Gly Ser Thr Val Gln Ser Glu Thr 80 85 90 Lys Gly Ile Trp Met Trp Cys Val Pro His Leu Ser Lys Pro Asn 95 100 105 His Thr Leu Val Leu Leu Asp Thr Glu Gly Leu Gly Asp Val Glu 110 115 120 Lys Ser Asn Pro Lys Asn Asp Ser Trp Ile Phe Ala Leu Ala Val 125 130 135 Leu Leu Ser Ser Ser Phe Val Tyr Asn Ser Val Ser Thr Ile Asn 140 145 150 His Gln Ala Leu Glu Gln Leu His Tyr Val Thr Glu Leu Ala Glu 155 160 165 Leu Ile Arg Ala Lys Ser Cys Pro Arg Pro Asp Glu Ala Glu Asp 170 175 180 Ser Ser Glu Phe Ala Ser Phe Phe Pro Asp Phe Ile Trp Thr Val 185 190 195 Arg Asp Phe Thr Leu Glu Leu Lys Leu Asp Gly Asn Pro Ile Thr 200 205 210 Glu Asp Glu Tyr Leu Glu Asn Ala Leu Lys Leu Ile Pro Gly Lys 215 220 225 Asn Pro Lys Ile Gln Asn Ser Asn Met Pro Arg Glu Cys Ile Arg 230 235 240 His Phe Phe Arg Lys Arg Lys Cys Phe Val Phe Asp Arg Pro Thr 245 250 255 Asn Asp Lys Gln Tyr Leu Asn His Met Asp Glu Val Pro Glu Glu 260 265 270 Asn Leu Glu Arg His Phe Leu Met Gln Ser Asp Asn Phe Cys Ser 275 280 285 Tyr Ile Phe Thr His Ala Lys Thr Lys Thr Leu Arg Glu Gly Ile 290 295 300 Ile Val Thr Gly Lys Arg Leu Gly Thr Leu Val Val Thr Tyr Val 305 310 315 Asp Ala Ile Asn Ser Gly Ala Val Pro Cys Leu Glu Asn Ala Val 320 325 330 Thr Ala Leu Ala Gln Leu Glu Asn Pro Ala Ala Val Gln Arg Ala 335 340 345 Ala Asp His Tyr Ser Gln Gln Met Ala Gln Gln Leu Arg Leu Pro 350 355 360 Thr Asp Thr Leu Gln Glu Leu Leu Asp Val His Ala Ala Cys Glu 365 370 375 Arg Glu Ala Ile Ala Val Phe Met Glu His Ser Phe Lys Asp Glu 380 385 390 Asn His Glu Phe Gln Lys Lys Leu Val Asp Thr Ile Glu Lys Lys 395 400 405 Lys Gly Asp Phe Val Leu Gln Asn Glu Glu Ala Ser Ala Lys Tyr 410 415 420 Cys Gln Ala Glu Leu Lys Arg Leu Ser Glu His Leu Thr Glu Ser 425 430 435 Ile Leu Arg Gly Ile Phe Ser Val Pro Gly Gly His Asn Leu Tyr 440 445 450 Leu Glu Glu Lys Lys Gln Val Glu Trp Asp Tyr Lys Leu Val Pro 455 460 465 Arg Lys Gly Val Lys Ala Asn Glu Val Leu Gln Asn Phe Leu Gln 470 475 480 Ser Gln Val Val Val Glu Glu Ser Ile Leu Gln Ser Asp Lys Ala 485 490 495 Leu Thr Ala Gly Glu Lys Ala Ile Ala Ala Glu Arg Ala Met Lys 500 505 510 Glu Ala Ala Glu Lys Glu Gln Glu Leu Leu Arg Glu Lys Gln Lys 515 520 525 Glu Gln Gln Gln Met Met Glu Ala Gln Glu Arg Ser Phe Gln Glu 530 535 540 Tyr Met Ala Gln Met Glu Lys Lys Leu Glu Glu Glu Arg Glu Asn 545 550 555 Leu Leu Arg Glu His Glu Arg Leu Leu Lys His Lys Leu Lys Val 560 565 570 Gln Glu Glu Met Leu Lys Glu Glu Phe Gln Lys Lys Ser Glu Gln 575 580 585 Leu Asn Lys Glu Ile Asn Gln Leu Lys Glu Lys Ile Glu Ser Thr 590 595 600 Lys Asn Glu Gln Leu Arg Leu Leu Lys Ile Leu Asp Met Ala Ser 605 610 615 Asn Ile Met Ile Val Thr Leu Pro Gly Ala Ser Lys Leu Leu Gly 620 625 630 Val Gly Thr Lys Tyr Leu Gly Ser Arg Ile 635 640 7 392 PRT Homo sapiens misc_feature Incyte ID No 4080676CD1 7 Met Gln Ser Pro Ala Val Leu Val Thr Ser Arg Arg Leu Gln Asn 1 5 10 15 Ala His Thr Gly Leu Asp Leu Thr Val Pro Gln His Gln Glu Val 20 25 30 Arg Gly Lys Met Met Ser Gly His Val Glu Tyr Gln Ile Leu Val 35 40 45 Val Thr Arg Leu Ala Ala Phe Lys Ser Ala Lys His Arg Pro Glu 50 55 60 Asp Val Val Gln Phe Leu Val Ser Lys Lys Tyr Ser Glu Ile Glu 65 70 75 Glu Phe Tyr Gln Lys Leu Ser Ser Arg Tyr Ala Ala Ala Ser Leu 80 85 90 Pro Pro Leu Pro Arg Lys Val Leu Phe Val Gly Glu Ser Asp Ile 95 100 105 Arg Glu Arg Arg Ala Val Phe Asn Glu Ile Leu Arg Cys Val Ser 110 115 120 Lys Asp Ala Glu Leu Ala Gly Ser Pro Glu Leu Leu Glu Phe Leu 125 130 135 Gly Thr Arg Ser Pro Gly Ala Ala Gly Leu Thr Ser Arg Asp Ser 140 145 150 Ser Val Leu Asp Gly Thr Asp Ser Gln Thr Gly Asn Asp Glu Glu 155 160 165 Ala Phe Asp Phe Phe Glu Glu Gln Asp Gln Val Ala Glu Glu Gly 170 175 180 Pro Pro Val Gln Ser Leu Lys Gly Glu Asp Ala Glu Glu Ser Leu 185 190 195 Glu Glu Glu Glu Ala Leu Asp Pro Leu Gly Ile Met Arg Ser Lys 200 205 210 Lys Pro Lys Lys His Pro Lys Val Ala Val Lys Ala Lys Pro Ser 215 220 225 Pro Arg Leu Thr Ile Phe Asp Glu Glu Val Asp Pro Asp Glu Gly 230 235 240 Leu Phe Gly Pro Gly Arg Lys Leu Ser Pro Gln Asp Pro Ser Glu 245 250 255 Asp Val Ser Ser Met Asp Pro Leu Lys Leu Phe Asp Asp Pro Asp 260 265 270 Leu Gly Gly Ala Ile Pro Leu Gly Asp Ser Leu Leu Leu Pro Ala 275 280 285 Ala Cys Glu Ser Gly Gly Pro Thr Pro Ser Leu Ser His Arg Asp 290 295 300 Ala Ser Lys Glu Leu Phe Arg Val Glu Glu Asp Leu Asp Gln Ile 305 310 315 Leu Asn Leu Gly Ala Glu Pro Lys Pro Lys Pro Gln Leu Lys Pro 320 325 330 Lys Pro Pro Val Ala Ala Lys Pro Val Ile Pro Arg Lys Pro Ala 335 340 345 Val Pro Pro Lys Ala Gly Pro Ala Glu Ala Val Ala Gly Gln Gln 350 355 360 Lys Pro Gln Glu Gln Ile Gln Ala Met Asp Glu Met Asp Ile Leu 365 370 375 Gln Tyr Ile Gln Asp His Asp Thr Pro Ala Gln Ala Ala Pro Ser 380 385 390 Leu Phe 8 277 PRT Homo sapiens misc_feature Incyte ID No 4791825CD1 8 Met Gly Ala Gly Ala Leu Ala Ile Cys Gln Ser Lys Ala Ala Val 1 5 10 15 Arg Leu Lys Glu Asp Met Lys Lys Ile Val Ala Val Pro Leu Asn 20 25 30 Glu Gln Lys Asp Phe Thr Tyr Gln Lys Leu Phe Gly Val Ser Leu 35 40 45 Gln Glu Leu Glu Arg Gln Gly Leu Thr Glu Asn Gly Ile Pro Ala 50 55 60 Val Val Trp Asn Ile Val Glu Tyr Leu Thr Gln His Gly Leu Thr 65 70 75 Gln Glu Gly Leu Phe Arg Val Asn Gly Asn Val Lys Val Val Glu 80 85 90 Gln Leu Arg Leu Lys Phe Glu Ser Gly Val Pro Val Glu Leu Gly 95 100 105 Lys Asp Gly Asp Val Cys Ser Ala Ala Ser Leu Leu Lys Leu Phe 110 115 120 Leu Arg Glu Leu Pro Asp Ser Leu Ile Thr Ser Ala Leu Gln Pro 125 130 135 Arg Phe Ile Gln Leu Phe Gln Asp Gly Arg Asn Asp Val Gln Glu 140 145 150 Ser Ser Leu Arg Asp Leu Ile Lys Glu Leu Pro Asp Thr His Tyr 155 160 165 Cys Leu Leu Lys Tyr Leu Cys Gln Phe Leu Thr Lys Val Ala Lys 170 175 180 His His Val Gln Asn Arg Met Asn Val His Asn Leu Ala Thr Val 185 190 195 Phe Gly Pro Asn Cys Phe His Val Pro Pro Gly Leu Glu Gly Met 200 205 210 Lys Glu Gln Asp Leu Cys Asn Lys Ile Met Ala Lys Ile Leu Glu 215 220 225 Asn Tyr Asn Thr Leu Phe Glu Val Glu Tyr Thr Glu Asn Asp His 230 235 240 Leu Arg Cys Glu Asn Leu Ala Arg Leu Ile Ile Val Lys Val Ser 245 250 255 Asn Leu Val Phe Asn Phe Gln Tyr Cys Tyr Asn Phe Gly Gln Lys 260 265 270 Ile Leu Phe Asn Ser Phe Ser 275 9 1605 PRT Homo sapiens misc_feature Incyte ID No 7481996CD1 9 Met Gly Phe Ser Thr Ala Asp Gly Gly Gly Gly Pro Gly Ala Arg 1 5 10 15 Asp Leu Glu Ser Leu Asp Ala Cys Ile Gln Arg Thr Leu Ser Ala 20 25 30 Leu Tyr Pro Pro Phe Glu Ala Thr Ala Ala Thr Val Leu Trp Gln 35 40 45 Leu Phe Ser Val Ala Glu Arg Cys His Gly Gly Asp Gly Leu His 50 55 60 Cys Leu Thr Ser Phe Leu Leu Pro Ala Lys Arg Ala Leu Gln His 65 70 75 Leu Gln Gln Glu Ala Cys Ala Arg Tyr Arg Gly Leu Val Phe Leu 80 85 90 His Pro Gly Trp Pro Leu Cys Ala His Glu Lys Val Val Val Gln 95 100 105 Leu Ala Ser Leu His Gly Val Arg Leu Gln Pro Gly Asp Phe Tyr 110 115 120 Leu Gln Val Thr Ser Ala Gly Lys Gln Ser Ala Arg Leu Val Leu 125 130 135 Lys Cys Leu Ser Arg Leu Gly Arg Gly Thr Glu Glu Val Thr Val 140 145 150 Pro Glu Ala Met Tyr Gly Cys Val Phe Thr Gly Ala Phe Leu Glu 155 160 165 Trp Val Asn Arg Glu Arg Arg His Val Pro Leu Gln Thr Cys Leu 170 175 180 Leu Thr Ser Gly Leu Ala Val His Arg Ala Pro Trp Ser Asp Val 185 190 195 Thr Asp Pro Val Phe Val Pro Ser Pro Gly Ala Ile Leu Gln Thr 200 205 210 Tyr Ser Ser Cys Thr Gly Pro Glu Arg Leu Pro Ser Ser Pro Ser 215 220 225 Glu Ala Pro Val Pro Thr Gln Ala Thr Ala Gly Pro His Phe Gln 230 235 240 Gly Ser Ala Ser Cys Pro Asp Thr Leu Thr Ser Pro Cys Arg Arg 245 250 255 Gly Arg Thr Gly Ser Asp Gln Leu Arg His Leu Pro Tyr Pro Glu 260 265 270 Arg Ala Glu Leu Gly Ser Pro Arg Thr Leu Ser Gly Ser Ser Asp 275 280 285 Arg Asp Phe Glu Lys Ser Arg Ala His Gly Cys Pro Pro Glu Asn 290 295 300 Cys Gly Gly Ser Gly Glu Arg Pro Asp Pro Met Asp Gln Glu Asp 305 310 315 Arg Pro Lys Ala Leu Thr Phe His Thr Asp Leu Gly Ile Pro Ser 320 325 330 Ser Arg Arg Arg Pro Pro Gly Asp Pro Thr Cys Val Gln Pro Arg 335 340 345 Arg Trp Phe Arg Glu Ser Tyr Met Glu Ala Leu Arg Asn Pro Met 350 355 360 Pro Leu Gly Ser Ser Glu Glu Ala Leu Gly Asp Leu Ala Cys Ser 365 370 375 Ser Leu Thr Gly Ala Ser Arg Asp Leu Gly Thr Gly Ala Val Ala 380 385 390 Ser Gly Thr Gln Glu Glu Thr Ser Gly Pro Arg Gly Asp Pro Gln 395 400 405 Gln Thr Pro Ser Leu Glu Lys Glu Arg His Thr Pro Ser Arg Thr 410 415 420 Gly Pro Gly Ala Ala Gly Arg Thr Leu Pro Arg Arg Ser Arg Ser 425 430 435 Trp Glu Arg Ala Pro Arg Ser Ser Arg Gly Ala Gln Ala Ala Ala 440 445 450 Cys His Thr Ser His His Ser Ala Gly Ser Arg Pro Gly Gly His 455 460 465 Leu Gly Gly Gln Ala Val Gly Thr Pro Asn Cys Val Pro Val Glu 470 475 480 Gly Pro Gly Cys Thr Lys Glu Glu Asp Val Leu Ala Ser Ser Ala 485 490 495 Cys Val Ser Thr Asp Gly Gly Ser Leu His Cys His Asn Pro Ser 500 505 510 Gly Pro Ser Asp Val Pro Ala Arg Gln Pro His Pro Glu Gln Glu 515 520 525 Gly Trp Pro Pro Gly Thr Gly Asp Phe Pro Ser Gln Val Pro Lys 530 535 540 Gln Val Leu Asp Val Ser Gln Glu Leu Leu Gln Ser Gly Val Val 545 550 555 Thr Leu Pro Gly Thr Arg Asp Arg His Gly Arg Ala Val Val Gln 560 565 570 Val Arg Thr Arg Ser Leu Leu Trp Thr Arg Glu His Ser Ser Cys 575 580 585 Ala Glu Leu Thr Arg Leu Leu Leu Tyr Phe His Ser Ile Pro Arg 590 595 600 Lys Glu Val Arg Asp Leu Gly Leu Val Val Leu Val Asp Ala Arg 605 610 615 Arg Ser Pro Ala Ala Pro Ala Val Ser Gln Ala Leu Ser Gly Leu 620 625 630 Gln Asn Asn Thr Ser Pro Ile Ile His Ser Ile Leu Leu Leu Val 635 640 645 Asp Lys Glu Ser Ala Phe Arg Pro Asp Lys Asp Ala Ile Ile Gln 650 655 660 Cys Glu Val Val Ser Ser Leu Lys Ala Val His Lys Phe Val Asp 665 670 675 Ser Cys Gln Leu Thr Ala Asp Leu Asp Gly Ser Phe Pro Tyr Ser 680 685 690 His Gly Asp Trp Ile Cys Phe Arg Gln Arg Leu Glu His Phe Ala 695 700 705 Ala Asn Cys Glu Glu Ala Ile Ile Phe Leu Gln Asn Ser Phe Cys 710 715 720 Ser Leu Asn Thr His Arg Thr Pro Arg Thr Ala Gln Glu Val Ala 725 730 735 Glu Leu Ile Asp Gln His Glu Thr Met Met Lys Leu Val Leu Glu 740 745 750 Asp Pro Leu Leu Val Ser Leu Arg Leu Glu Gly Gly Thr Val Leu 755 760 765 Ala Arg Leu Arg Arg Glu Glu Leu Gly Thr Glu Asp Ser Arg Asp 770 775 780 Thr Leu Glu Ala Ala Thr Ser Leu Tyr Asp Arg Val Asp Glu Glu 785 790 795 Val His Arg Leu Val Leu Thr Ser Asn Asn Arg Leu Gln Gln Leu 800 805 810 Glu His Leu Arg Glu Leu Ala Ser Leu Leu Glu Gly Asn Asp Gln 815 820 825 Gln Ser Cys Gln Lys Gly Leu Gln Leu Ala Lys Glu Asn Pro Gln 830 835 840 Arg Thr Glu Glu Met Val Gln Asp Phe Arg Arg Gly Leu Ser Ala 845 850 855 Val Val Ser Gln Ala Glu Cys Arg Glu Gly Glu Leu Ala Arg Trp 860 865 870 Thr Arg Ser Ser Glu Leu Cys Glu Thr Val Ser Ser Trp Met Gly 875 880 885 Pro Leu Asp Pro Glu Ala Cys Pro Ser Ser Pro Val Ala Glu Cys 890 895 900 Leu Arg Ser Cys His Gln Glu Ala Thr Ser Val Ala Ala Glu Ala 905 910 915 Phe Pro Gly Ala Ala Arg Leu Trp Leu Gln Tyr Pro Arg Pro Ala 920 925 930 Arg Leu Glu Glu Ala Leu Ser Glu Ala Ala Pro Asp Pro Ser Leu 935 940 945 Pro Pro Leu Ala Gln Ser Pro Pro Lys His Glu Arg Ala Gln Glu 950 955 960 Ala Met Arg Arg His Gln Lys Pro Pro Ser Phe Pro Ser Thr Asp 965 970 975 Ser Gly Gly Gly Ala Trp Glu Pro Ala Gln Pro Leu Ser Gly Leu 980 985 990 Pro Gly Arg Ala Leu Leu Cys Gly Gln Asp Gly Glu Pro Leu Gly 995 1000 1005 Pro Gly Leu Cys Ala Leu Trp Asp Pro Leu Ser Leu Leu Arg Gly 1010 1015 1020 Leu Pro Gly Ala Gly Ala Thr Thr Ala His Leu Glu Asp Ser Ser 1025 1030 1035 Ala Cys Ser Ser Glu Pro Thr Gln Thr Leu Ala Ser Arg Pro Arg 1040 1045 1050 Lys His Pro Gln Lys Lys Met Ile Lys Lys Thr Gln Ser Phe Glu 1055 1060 1065 Ile Pro Gln Pro Asp Ser Gly Pro Arg Asp Ser Cys Gln Pro Asp 1070 1075 1080 His Thr Ser Val Phe Ser Lys Gly Leu Glu Val Thr Ser Thr Val 1085 1090 1095 Ala Thr Glu Lys Lys Leu Pro Leu Trp Gln His Ala Arg Ser Pro 1100 1105 1110 Pro Val Thr Gln Ser Arg Ser Leu Ser Ser Pro Ser Gly Leu His 1115 1120 1125 Pro Ala Glu Glu Asp Gly Arg Gln Gln Val Gly Ser Ser Arg Leu 1130 1135 1140 Arg His Ile Met Ala Glu Met Ile Ala Thr Glu Arg Glu Tyr Ile 1145 1150 1155 Arg Cys Leu Gly Tyr Val Ile Asp Asn Tyr Phe Pro Glu Met Glu 1160 1165 1170 Arg Met Asp Leu Pro Gln Gly Leu Arg Gly Lys His His Val Ile 1175 1180 1185 Phe Gly Asn Leu Glu Lys Leu His Asp Phe His Gln Gln His Phe 1190 1195 1200 Leu Arg Glu Leu Glu Arg Cys Gln His Cys Pro Leu Ala Val Gly 1205 1210 1215 Arg Ser Phe Leu Arg His Glu Glu Gln Phe Gly Met Tyr Val Ile 1220 1225 1230 Tyr Ser Lys Asn Lys Pro Gln Ser Asp Ala Leu Leu Ser Ser His 1235 1240 1245 Gly Asn Ala Phe Phe Lys Asp Lys Gln Arg Glu Leu Gly Asp Lys 1250 1255 1260 Met Asp Leu Ala Ser Tyr Leu Leu Arg Pro Val Gln Arg Val Ala 1265 1270 1275 Lys Tyr Ala Leu Leu Leu Gln Asp Leu Leu Lys Glu Ala Ser Cys 1280 1285 1290 Gly Leu Ala Gln Gly Gln Glu Leu Gly Glu Leu Arg Ala Ala Glu 1295 1300 1305 Val Val Val Cys Phe Gln Leu Arg His Gly Asn Asp Leu Leu Ala 1310 1315 1320 Met Asp Ala Ile Arg Gly Cys Asp Val Asn Leu Lys Glu Gln Gly 1325 1330 1335 Gln Leu Arg Cys Arg Asp Glu Phe Ile Val Cys Cys Gly Arg Lys 1340 1345 1350 Lys Tyr Leu Arg His Val Phe Leu Phe Glu Asp Leu Ile Leu Phe 1355 1360 1365 Ser Lys Thr Gln Lys Val Glu Gly Ser His Asp Val Tyr Leu Tyr 1370 1375 1380 Lys Gln Ser Phe Lys Thr Ala Glu Ile Gly Met Thr Glu Asn Val 1385 1390 1395 Gly Asp Ser Gly Leu Arg Phe Glu Ile Trp Phe Arg Arg Arg Arg 1400 1405 1410 Lys Ser Gln Asp Thr Tyr Ile Leu Gln Ala Ser Ser Ala Glu Val 1415 1420 1425 Lys Ser Ala Trp Thr Asp Val Ile Gly Arg Ile Leu Trp Arg Gln 1430 1435 1440 Ala Leu Lys Ser Arg Glu Leu Arg Ile Gln Glu Met Ala Ser Met 1445 1450 1455 Gly Ile Gly Asn Gln Pro Phe Met Asp Val Lys Pro Arg Asp Arg 1460 1465 1470 Thr Pro Asp Cys Ala Val Ile Ser Asp Arg Ala Pro Lys Cys Ala 1475 1480 1485 Val Met Ser Asp Arg Val Pro Asp Ser Ile Val Lys Gly Thr Glu 1490 1495 1500 Ser Gln Met Arg Gly Ser Thr Ala Val Ser Ser Ser Asp His Ala 1505 1510 1515 Ala Pro Phe Lys Arg Pro His Ser Thr Ile Ser Asp Ser Ser Thr 1520 1525 1530 Ser Ser Ser Ser Ser Gln Ser Ser Ser Ile Leu Gly Ser Leu Gly 1535 1540 1545 Leu Leu Val Ser Ser Ser Pro Ala His Pro Gly Leu Trp Ser Pro 1550 1555 1560 Ala His Ser Pro Trp Ser Ser Asp Ile Arg Ala Cys Val Glu Glu 1565 1570 1575 Asp Glu Pro Glu Pro Glu Leu Glu Thr Gly Thr Gln Ala Ala Val 1580 1585 1590 Cys Glu Gly Ala Pro Ala Val Leu Leu Ser Arg Thr Arg Gln Ala 1595 1600 1605 10 1736 PRT Homo sapiens misc_feature Incyte ID No 7610864CD1 10 Met Glu Leu Ser Cys Ser Glu Ala Pro Leu Tyr Gly Gln Met Met 1 5 10 15 Ile Tyr Ala Lys Phe Asp Lys Asn Val Tyr Leu Pro Glu Asp Ala 20 25 30 Glu Phe Tyr Phe Thr Tyr Asp Gly Ser His Gln Arg His Val Met 35 40 45 Ile Ala Glu Arg Ile Glu Asp Asn Val Leu Gln Ser Ser Val Pro 50 55 60 Gly His Gly Leu Gln Glu Thr Val Thr Val Ser Val Cys Leu Cys 65 70 75 Ser Glu Gly Tyr Ser Pro Val Thr Met Gly Ser Gly Ser Val Thr 80 85 90 Tyr Val Asp Asn Met Ala Cys Arg Leu Ala Arg Leu Leu Val Thr 95 100 105 Gln Ala Asn Arg Leu Thr Ala Cys Ser His Gln Thr Leu Leu Thr 110 115 120 Pro Phe Ala Leu Thr Ala Gly Ala Leu Pro Ala Leu Asp Glu Glu 125 130 135 Leu Val Leu Ala Leu Thr His Leu Glu Leu Pro Leu Glu Trp Thr 140 145 150 Val Leu Gly Ser Ser Ser Leu Glu Val Ser Ser His Arg Glu Ser 155 160 165 Leu Leu His Leu Ala Met Arg Trp Gly Leu Ala Lys Leu Ser Gln 170 175 180 Phe Phe Leu Cys Leu Pro Gly Gly Val Gln Ala Leu Ala Leu Pro 185 190 195 Asn Glu Glu Gly Ala Thr Pro Leu Asp Leu Ala Leu Arg Glu Gly 200 205 210 His Ser Lys Leu Val Glu Asp Val Thr Asn Phe Gln Gly Arg Arg 215 220 225 Ser Pro Ser Phe Ser Arg Val Gln Leu Ser Glu Glu Ala Ser Leu 230 235 240 His Tyr Ile His Ser Ser Glu Thr Leu Thr Leu Thr Leu Asn His 245 250 255 Thr Ala Glu His Leu Leu Glu Ala Asp Ile Lys Leu Phe Arg Lys 260 265 270 Tyr Phe Trp Asp Arg Ala Phe Leu Val Lys Ala Phe Glu Gln Glu 275 280 285 Ala Arg Pro Glu Glu Arg Thr Ala Met Pro Ser Ser Gly Ala Glu 290 295 300 Thr Glu Glu Glu Ile Lys Asn Ser Val Ser Ser Arg Ser Ala Ala 305 310 315 Glu Lys Glu Asp Ile Lys Arg Val Lys Ser Leu Val Val Gln His 320 325 330 Asn Glu His Glu Asp Gln His Ser Leu Asp Leu Asp Arg Ser Phe 335 340 345 Asp Ile Leu Lys Lys Ser Lys Pro Pro Ser Thr Leu Leu Ala Ala 350 355 360 Gly Arg Leu Ser Asp Met Leu Asn Gly Gly Asp Glu Val Tyr Ala 365 370 375 Asn Cys Met Val Ile Asp Gln Val Gly Asp Leu Asp Ile Ser Tyr 380 385 390 Ile Asn Ile Glu Gly Ile Thr Ala Thr Thr Ser Pro Glu Ser Arg 395 400 405 Gly Cys Thr Leu Trp Pro Gln Ser Ser Lys His Thr Leu Pro Thr 410 415 420 Glu Thr Ser Pro Ser Val Tyr Pro Leu Ser Glu Asn Val Glu Gly 425 430 435 Thr Ala His Thr Glu Ala Gln Gln Ser Phe Met Ser Pro Ser Ser 440 445 450 Ser Cys Ala Ser Asn Leu Asn Leu Ser Phe Gly Trp His Gly Phe 455 460 465 Glu Lys Glu Gln Ser His Leu Lys Lys Arg Ser Ser Ser Leu Asp 470 475 480 Ala Leu Asp Ala Asp Ser Glu Gly Glu Gly His Ser Glu Pro Ser 485 490 495 His Ile Cys Tyr Thr Pro Gly Ser Gln Ser Ser Ser Arg Thr Gly 500 505 510 Ile Pro Ser Gly Asp Glu Leu Asp Ser Phe Glu Thr Asn Thr Glu 515 520 525 Pro Asp Phe Asn Ile Ser Arg Ala Glu Ser Leu Pro Leu Ser Ser 530 535 540 Asn Leu Gln Leu Lys Glu Ser Leu Leu Ser Gly Val Arg Ser Arg 545 550 555 Ser Tyr Ser Cys Ser Ser Pro Lys Ile Ser Leu Gly Lys Thr Arg 560 565 570 Leu Val Arg Glu Leu Thr Val Cys Ser Ser Ser Glu Glu Gln Lys 575 580 585 Ala Tyr Ser Leu Ser Glu Pro Pro Arg Glu Asn Arg Ile Gln Glu 590 595 600 Glu Glu Trp Asp Lys Tyr Ile Ile Pro Ala Lys Ser Glu Ser Glu 605 610 615 Lys Tyr Lys Val Ser Arg Thr Phe Ser Phe Leu Met Asn Arg Met 620 625 630 Thr Ser Pro Arg Asn Lys Ser Lys Val Lys Ser Lys Asp Ala Lys 635 640 645 Asp Lys Glu Lys Leu Asn Arg His Gln Phe Ala Pro Gly Thr Phe 650 655 660 Ser Gly Val Leu Gln Cys Leu Val Cys Asp Lys Thr Leu Leu Gly 665 670 675 Lys Glu Ser Leu Gln Cys Ser Asn Cys Asn Ala Asn Val His Lys 680 685 690 Gly Cys Lys Asp Ala Ala Pro Ala Cys Thr Lys Lys Phe Gln Glu 695 700 705 Lys Tyr Asn Lys Asn Lys Pro Gln Thr Ile Leu Gly Asn Ser Ser 710 715 720 Phe Arg Asp Ile Pro Gln Pro Gly Leu Ser Leu His Pro Ser Ser 725 730 735 Ser Val Pro Val Gly Leu Pro Thr Gly Arg Arg Glu Thr Val Gly 740 745 750 Gln Val His Pro Leu Ser Arg Ser Val Pro Gly Thr Thr Leu Glu 755 760 765 Ser Phe Arg Arg Ser Ala Thr Ser Leu Glu Ser Glu Ser Asp His 770 775 780 Asn Ser Cys Arg Ser Arg Ser His Ser Asp Glu Leu Leu Gln Ser 785 790 795 Met Gly Ser Ser Pro Ser Thr Glu Ser Phe Ile Met Glu Asp Val 800 805 810 Val Asp Ser Ser Leu Trp Ser Asp Leu Ser Ser Asp Ala Gln Glu 815 820 825 Phe Glu Ala Glu Ser Trp Ser Leu Val Val Asp Pro Ser Phe Cys 830 835 840 Asn Arg Gln Glu Lys Asp Val Ile Lys Arg Gln Asp Val Ile Phe 845 850 855 Glu Leu Met Gln Thr Glu Met His His Ile Gln Thr Leu Phe Ile 860 865 870 Met Ser Glu Ile Phe Arg Lys Gly Met Lys Glu Glu Leu Gln Leu 875 880 885 Asp His Ser Thr Val Asp Lys Ile Phe Pro Cys Leu Asp Glu Leu 890 895 900 Leu Glu Ile His Arg His Phe Phe Tyr Ser Met Lys Glu Arg Arg 905 910 915 Gln Glu Ser Cys Ala Gly Ser Asp Arg Asn Phe Val Ile Asp Arg 920 925 930 Ile Gly Asp Ile Leu Val Gln Gln Phe Ser Glu Glu Asn Ala Ser 935 940 945 Lys Met Lys Lys Ile Tyr Gly Glu Phe Cys Cys His His Lys Glu 950 955 960 Ala Val Asn Leu Phe Lys Glu Leu Gln Gln Asn Lys Lys Phe Gln 965 970 975 Asn Phe Ile Lys Leu Arg Asn Ser Asn Leu Leu Ala Arg Arg Arg 980 985 990 Gly Ile Pro Glu Cys Ile Leu Leu Val Thr Gln Arg Ile Thr Lys 995 1000 1005 Tyr Pro Val Leu Val Glu Arg Ile Leu Gln Tyr Thr Lys Glu Arg 1010 1015 1020 Thr Glu Glu His Lys Asp Leu Thr Gln Ser Leu Cys Leu Ile Lys 1025 1030 1035 Asp Met Ile Ala Thr Val Asp Leu Lys Val Asn Glu Tyr Glu Lys 1040 1045 1050 Asn Gln Lys Trp Leu Glu Ile Leu Asn Lys Ile Glu Asn Lys Thr 1055 1060 1065 Tyr Thr Lys Leu Lys Asn Gly His Val Phe Arg Lys Gln Ala Leu 1070 1075 1080 Met Ser Glu Glu Arg Thr Leu Leu Tyr Asp Gly Leu Val Tyr Trp 1085 1090 1095 Lys Thr Ala Thr Gly Arg Phe Lys Asp Ile Leu Ala Leu Leu Leu 1100 1105 1110 Thr Asp Val Leu Leu Phe Leu Gln Glu Lys Asp Gln Lys Tyr Ile 1115 1120 1125 Phe Ala Ala Val Asp Gln Lys Pro Ser Val Ile Ser Leu Gln Lys 1130 1135 1140 Leu Ile Ala Arg Glu Val Ala Asn Glu Glu Arg Gly Met Phe Leu 1145 1150 1155 Ile Ser Ala Ser Ser Ala Gly Pro Glu Met Tyr Glu Ile His Thr 1160 1165 1170 Asn Ser Lys Glu Glu Arg Asn Asn Trp Met Arg Arg Ile Gln Gln 1175 1180 1185 Ala Val Glu Ser Cys Pro Glu Glu Lys Gly Gly Arg Thr Ser Glu 1190 1195 1200 Ser Asp Glu Asp Lys Arg Lys Ala Glu Ala Arg Val Ala Lys Ile 1205 1210 1215 Gln Gln Cys Gln Glu Ile Leu Thr Asn Gln Asp Gln Gln Ile Cys 1220 1225 1230 Ala Tyr Leu Glu Glu Lys Leu His Ile Tyr Ala Glu Leu Gly Glu 1235 1240 1245 Leu Ser Gly Phe Glu Asp Val His Leu Glu Pro His Leu Leu Ile 1250 1255 1260 Lys Pro Asp Pro Gly Glu Pro Pro Gln Ala Ala Ser Leu Leu Ala 1265 1270 1275 Ala Ala Leu Lys Glu Ala Glu Ser Leu Gln Val Ala Val Lys Ala 1280 1285 1290 Ser Gln Met Gly Ala Val Ser Gln Ser Cys Glu Asp Ser Cys Gly 1295 1300 1305 Asp Ser Val Leu Ala Asp Thr Leu Ser Ser His Asp Val Pro Gly 1310 1315 1320 Ser Pro Thr Ala Ser Leu Val Thr Gly Gly Arg Glu Gly Arg Gly 1325 1330 1335 Cys Ser Asp Val Asp Pro Gly Ile Gln Gly Val Val Thr Asp Leu 1340 1345 1350 Ala Val Ser Asp Ala Gly Glu Lys Val Glu Cys Arg Asn Phe Pro 1355 1360 1365 Gly Ser Ser Gln Ser Glu Ile Ile Gln Ala Ile Gln Asn Leu Thr 1370 1375 1380 Arg Leu Leu Tyr Ser Leu Gln Ala Ala Leu Thr Ile Gln Asp Ser 1385 1390 1395 His Ile Glu Ile His Arg Leu Val Leu Gln Gln Gln Glu Gly Leu 1400 1405 1410 Ser Leu Gly His Ser Ile Leu Arg Gly Gly Pro Leu Gln Asp Gln 1415 1420 1425 Lys Ser Arg Asp Ala Asp Arg Gln His Glu Glu Leu Ala Asn Val 1430 1435 1440 His Gln Leu Gln His Gln Leu Gln Gln Glu Gln Arg Arg Trp Leu 1445 1450 1455 Arg Arg Cys Glu Gln Gln Gln Arg Ala Gln Ala Thr Arg Glu Ser 1460 1465 1470 Trp Leu Gln Glu Arg Glu Arg Glu Cys Gln Ser Gln Glu Glu Leu 1475 1480 1485 Leu Leu Arg Ser Arg Gly Glu Leu Asp Leu Gln Leu Gln Glu Tyr 1490 1495 1500 Gln His Ser Leu Glu Arg Leu Arg Glu Gly Gln Arg Leu Val Glu 1505 1510 1515 Arg Glu Gln Ala Arg Met Arg Ala Gln Gln Ser Leu Leu Gly His 1520 1525 1530 Trp Lys His Gly Arg Gln Arg Ser Leu Pro Ala Val Leu Leu Pro 1535 1540 1545 Gly Gly Pro Glu Val Met Glu Leu Asn Arg Ser Glu Ser Leu Cys 1550 1555 1560 His Glu Asn Ser Phe Phe Ile Asn Glu Ala Leu Val Gln Met Ser 1565 1570 1575 Phe Asn Thr Phe Asn Lys Leu Asn Pro Ser Val Ile His Gln Asp 1580 1585 1590 Ala Thr Tyr Pro Thr Thr Gln Ser His Ser Asp Leu Val Arg Thr 1595 1600 1605 Ser Glu His Gln Val Asp Leu Lys Val Asp Pro Ser Gln Pro Ser 1610 1615 1620 Asn Val Ser His Lys Leu Trp Thr Ala Ala Gly Ser Gly His Gln 1625 1630 1635 Ile Leu Pro Phe Gln Glu Ser Ser Lys Asp Ser Cys Lys Asn Leu 1640 1645 1650 Ala Asp Leu Asp Thr Ser His Thr Glu Ser Pro Thr Pro His Asp 1655 1660 1665 Ser Asn Ser His Arg Pro Pro Ser Thr Ala Gly Val Tyr Asn Arg 1670 1675 1680 Ser Lys Ala Lys Ser Thr Asp Lys Asp Asn Asp Gln Thr Arg Trp 1685 1690 1695 Gly Asn Trp Arg Trp Ser Gln Arg Lys Tyr Cys Leu Pro Leu Ile 1700 1705 1710 Val Leu Ser Phe Phe Gln Thr Lys Gln Asn Thr Gly Thr Phe Gly 1715 1720 1725 Arg Asn Phe Leu Ser Pro Phe Leu Met Tyr Val 1730 1735 11 1725 PRT Homo sapiens misc_feature Incyte ID No 6985813CD1 11 Met Gly Asn Ser Asp Ser Gln Tyr Thr Leu Gln Gly Ser Lys Asn 1 5 10 15 His Ser Asn Thr Ile Thr Gly Ala Lys Gln Ile Pro Cys Ser Leu 20 25 30 Lys Ile Arg Gly Ile His Ala Lys Glu Glu Lys Ser Leu His Gly 35 40 45 Trp Gly His Gly Ser Asn Gly Ala Gly Tyr Lys Ser Arg Ser Leu 50 55 60 Ala Arg Ser Cys Leu Ser His Phe Lys Ser Asn Gln Pro Tyr Ala 65 70 75 Ser Arg Leu Gly Gly Pro Thr Cys Lys Val Ser Arg Gly Val Ala 80 85 90 Tyr Ser Thr His Arg Thr Asn Ala Pro Gly Lys Asp Phe Gln Gly 95 100 105 Ile Ser Ala Ala Phe Ser Thr Glu Asn Gly Phe His Ser Val Gly 110 115 120 His Glu Leu Ala Asp Asn His Ile Thr Ser Arg Asp Cys Asn Gly 125 130 135 His Leu Leu Asn Cys Tyr Gly Arg Asn Glu Ser Ile Ala Ser Thr 140 145 150 Pro Pro Gly Glu Asp Arg Lys Ser Pro Arg Val Leu Ile Lys Thr 155 160 165 Leu Gly Lys Leu Asp Gly Cys Leu Arg Val Glu Phe His Asn Gly 170 175 180 Gly Asn Pro Ser Lys Val Pro Ala Glu Asp Cys Ser Glu Pro Val 185 190 195 Gln Leu Leu Arg Tyr Ser Pro Thr Leu Ala Ser Glu Thr Ser Pro 200 205 210 Val Pro Glu Ala Arg Arg Gly Ser Ser Ala Asp Ser Leu Pro Ser 215 220 225 His Arg Pro Ser Pro Thr Asp Ser Arg Leu Arg Ser Ser Lys Gly 230 235 240 Ser Ser Leu Ser Ser Glu Ser Ser Trp Tyr Asp Ser Pro Trp Gly 245 250 255 Asn Ala Gly Glu Leu Ser Glu Ala Glu Gly Ser Phe Leu Ala Pro 260 265 270 Gly Met Pro Asp Pro Ser Leu His Ala Ser Phe Pro Pro Gly Asp 275 280 285 Ala Lys Lys Pro Phe Asn Gln Ser Ser Ser Leu Ser Ser Leu Arg 290 295 300 Glu Leu Tyr Lys Asp Ala Asn Leu Gly Ser Leu Ser Pro Ser Gly 305 310 315 Ile Arg Leu Ser Asp Glu Tyr Met Gly Thr His Ala Ser Leu Ser 320 325 330 Asn Arg Val Ser Phe Ala Ser Asp Ile Asp Val Pro Ser Arg Val 335 340 345 Ala His Gly Asp Pro Ile Gln Tyr Ser Ser Phe Thr Leu Pro Cys 350 355 360 Arg Lys Pro Lys Ala Phe Val Glu Asp Thr Ala Lys Lys Asp Ser 365 370 375 Leu Lys Ala Arg Met Arg Arg Ile Ser Asp Trp Thr Gly Ser Leu 380 385 390 Ser Arg Lys Lys Arg Lys Leu Gln Glu Pro Arg Ser Lys Glu Gly 395 400 405 Ser Asp Tyr Phe Asp Ser Arg Ser Asp Gly Leu Asn Thr Asp Val 410 415 420 Gln Gly Ser Ser Gln Ala Ser Ala Phe Leu Trp Ser Gly Gly Ser 425 430 435 Thr Gln Ile Leu Ser Gln Arg Ser Glu Ser Thr His Ala Ile Gly 440 445 450 Ser Asp Pro Leu Arg Gln Asn Ile Tyr Glu Asn Phe Met Arg Glu 455 460 465 Leu Glu Met Ser Arg Thr Asn Thr Glu Asn Ile Glu Thr Ser Thr 470 475 480 Glu Thr Ala Glu Ser Ser Ser Glu Ser Leu Ser Ser Leu Glu Gln 485 490 495 Leu Asp Leu Leu Phe Glu Lys Glu Gln Gly Val Val Arg Lys Ala 500 505 510 Gly Trp Leu Phe Phe Lys Pro Leu Val Thr Val Gln Lys Glu Arg 515 520 525 Lys Leu Glu Leu Val Ala Arg Arg Lys Trp Lys Gln Tyr Trp Val 530 535 540 Thr Leu Lys Gly Cys Thr Leu Leu Phe Tyr Glu Thr Tyr Gly Lys 545 550 555 Asn Ser Met Asp Gln Ser Ser Ala Pro Arg Cys Ala Leu Phe Ala 560 565 570 Glu Asp Ser Ile Val Gln Ser Val Pro Glu His Pro Lys Lys Glu 575 580 585 Asn Val Phe Cys Leu Ser Asn Ser Phe Gly Asp Val Tyr Leu Phe 590 595 600 Gln Ala Thr Ser Gln Thr Asp Leu Glu Asn Trp Val Thr Ala Val 605 610 615 His Ser Ala Cys Ala Ser Leu Phe Ala Lys Lys His Gly Lys Glu 620 625 630 Asp Thr Leu Arg Leu Leu Lys Asn Gln Thr Lys Asn Leu Leu Gln 635 640 645 Lys Ile Asp Met Asp Ser Lys Met Lys Lys Met Ala Glu Leu Gln 650 655 660 Leu Ser Val Val Ser Asp Pro Lys Asn Arg Lys Ala Ile Glu Asn 665 670 675 Gln Ile Gln Gln Trp Glu Gln Asn Leu Glu Lys Phe His Met Asp 680 685 690 Leu Phe Arg Met Arg Cys Tyr Leu Ala Ser Leu Gln Gly Gly Glu 695 700 705 Leu Pro Asn Pro Lys Ser Leu Leu Ala Ala Ala Ser Arg Pro Ser 710 715 720 Lys Leu Ala Leu Gly Arg Leu Gly Ile Leu Ser Val Ser Ser Phe 725 730 735 His Ala Leu Val Cys Ser Arg Asp Asp Ser Ala Leu Arg Lys Arg 740 745 750 Thr Leu Ser Leu Thr Gln Arg Gly Arg Asn Lys Lys Gly Ile Phe 755 760 765 Ser Ser Leu Lys Gly Leu Asp Thr Leu Ala Arg Lys Gly Lys Glu 770 775 780 Lys Arg Pro Ser Ile Thr Gln Ile Phe Asp Ser Ser Gly Ser His 785 790 795 Gly Phe Ser Gly Thr Gln Leu Pro Gln Asn Ser Ser Asn Ser Ser 800 805 810 Glu Val Asp Glu Leu Leu His Ile Tyr Gly Ser Thr Val Asp Gly 815 820 825 Val Pro Arg Asp Asn Thr Trp Glu Ile Gln Thr Tyr Val His Phe 830 835 840 Gln Asp Asn His Gly Val Thr Val Gly Ile Lys Pro Glu His Arg 845 850 855 Val Glu Asp Ile Leu Thr Leu Ala Cys Lys Met Arg Gln Leu Glu 860 865 870 Pro Ser His Tyr Gly Leu Gln Leu Arg Lys Leu Val Asp Asp Asn 875 880 885 Val Glu Tyr Cys Ile Pro Ala Pro Tyr Glu Tyr Met Gln Gln Gln 890 895 900 Val Tyr Asp Glu Ile Glu Val Phe Pro Leu Asn Val Tyr Asp Val 905 910 915 Gln Leu Thr Lys Thr Gly Ser Val Cys Asp Phe Gly Phe Ala Val 920 925 930 Thr Ala Gln Val Asp Glu Arg Gln His Leu Ser Arg Ile Phe Ile 935 940 945 Ser Asp Val Leu Pro Asp Gly Leu Ala Tyr Gly Glu Gly Leu Arg 950 955 960 Lys Gly Asn Glu Ile Met Thr Leu Asn Gly Glu Ala Val Ser Asp 965 970 975 Leu Asp Leu Lys Gln Met Glu Ala Leu Phe Ser Glu Lys Ser Val 980 985 990 Gly Leu Thr Leu Ile Ala Arg Pro Pro Asp Thr Lys Ala Thr Leu 995 1000 1005 Cys Thr Ser Trp Ser Asp Ser Asp Leu Phe Ser Arg Asp Gln Lys 1010 1015 1020 Ser Leu Leu Pro Pro Pro Asn Gln Ser Gln Leu Leu Glu Glu Phe 1025 1030 1035 Leu Asp Asn Phe Lys Lys Asn Thr Ala Asn Asp Phe Ser Asn Val 1040 1045 1050 Pro Asp Ile Thr Thr Gly Leu Lys Arg Ser Gln Thr Asp Gly Thr 1055 1060 1065 Leu Asp Gln Val Ser His Arg Glu Lys Met Glu Gln Thr Phe Arg 1070 1075 1080 Ser Ala Glu Gln Ile Thr Ala Leu Cys Arg Ser Phe Asn Asp Ser 1085 1090 1095 Gln Ala Asn Gly Met Glu Gly Pro Arg Glu Asn Gln Asp Pro Pro 1100 1105 1110 Pro Arg Pro Leu Ala Arg His Leu Ser Asp Ala Asp Arg Leu Arg 1115 1120 1125 Lys Val Ile Gln Glu Leu Val Asp Thr Glu Lys Ser Tyr Val Lys 1130 1135 1140 Asp Leu Ser Cys Leu Phe Glu Leu Tyr Leu Glu Pro Leu Gln Asn 1145 1150 1155 Glu Thr Phe Leu Thr Gln Asp Glu Met Glu Ser Leu Phe Gly Ser 1160 1165 1170 Leu Pro Glu Met Leu Glu Phe Gln Lys Val Phe Leu Glu Thr Leu 1175 1180 1185 Glu Asp Gly Ile Ser Ala Ser Ser Asp Phe Asn Thr Leu Glu Thr 1190 1195 1200 Pro Ser Gln Phe Arg Lys Leu Leu Phe Ser Leu Gly Gly Ser Phe 1205 1210 1215 Leu Tyr Tyr Ala Asp His Phe Lys Leu Tyr Ser Gly Phe Cys Ala 1220 1225 1230 Asn His Ile Lys Val Gln Lys Val Leu Glu Arg Ala Lys Thr Asp 1235 1240 1245 Lys Ala Phe Lys Ala Phe Leu Asp Ala Arg Asn Pro Thr Lys Gln 1250 1255 1260 His Ser Ser Thr Leu Glu Ser Tyr Leu Ile Lys Pro Val Gln Arg 1265 1270 1275 Val Leu Lys Tyr Pro Leu Leu Leu Lys Glu Leu Val Ser Leu Thr 1280 1285 1290 Asp Gln Glu Ser Glu Glu His Tyr His Leu Thr Glu Ala Leu Lys 1295 1300 1305 Ala Met Glu Lys Val Ala Ser His Ile Asn Glu Met Gln Lys Ile 1310 1315 1320 Tyr Glu Asp Tyr Gly Thr Val Phe Asp Gln Leu Val Ala Glu Gln 1325 1330 1335 Ser Gly Thr Glu Lys Glu Val Thr Glu Leu Ser Met Gly Glu Leu 1340 1345 1350 Leu Met His Ser Thr Val Ser Trp Leu Asn Pro Phe Leu Ser Leu 1355 1360 1365 Gly Lys Ala Arg Lys Asp Leu Glu Leu Thr Val Phe Val Phe Lys 1370 1375 1380 Arg Ala Val Ile Leu Val Tyr Lys Glu Asn Cys Lys Leu Lys Lys 1385 1390 1395 Lys Leu Pro Ser Asn Ser Arg Pro Ala His Asn Ser Thr Asp Leu 1400 1405 1410 Asp Pro Phe Lys Phe Arg Trp Leu Ile Pro Ile Ser Ala Leu Gln 1415 1420 1425 Val Arg Leu Gly Asn Pro Ala Gly Thr Glu Asn Asn Ser Ile Trp 1430 1435 1440 Glu Leu Ile His Thr Lys Ser Glu Ile Glu Gly Arg Pro Glu Thr 1445 1450 1455 Ile Phe Gln Leu Cys Cys Ser Asp Ser Glu Ser Lys Thr Asn Ile 1460 1465 1470 Val Lys Val Ile Arg Ser Ile Leu Arg Glu Asn Phe Arg Arg His 1475 1480 1485 Ile Lys Cys Glu Leu Pro Leu Glu Lys Thr Cys Lys Asp Arg Leu 1490 1495 1500 Val Pro Leu Lys Asn Arg Val Pro Val Ser Ala Lys Leu Ala Ser 1505 1510 1515 Ser Arg Ser Leu Lys Val Leu Lys Asn Ser Ser Ser Asn Glu Trp 1520 1525 1530 Thr Gly Glu Thr Gly Lys Gly Thr Leu Leu Asp Ser Asp Glu Gly 1535 1540 1545 Ser Leu Ser Ser Gly Thr Gln Ser Ser Gly Cys Pro Thr Ala Glu 1550 1555 1560 Gly Arg Gln Asp Ser Lys Ser Thr Ser Pro Gly Lys Tyr Pro His 1565 1570 1575 Pro Gly Leu Ala Asp Phe Ala Asp Asn Leu Ile Lys Glu Ser Asp 1580 1585 1590 Ile Leu Ser Asp Glu Asp Asp Asp His Arg Gln Thr Val Lys Gln 1595 1600 1605 Gly Ser Pro Thr Lys Asp Ile Glu Ile Gln Phe Gln Arg Leu Arg 1610 1615 1620 Ile Ser Glu Asp Pro Asp Val His Pro Glu Ala Glu Gln Gln Pro 1625 1630 1635 Gly Pro Glu Ser Gly Glu Gly Gln Lys Gly Gly Glu Gln Pro Lys 1640 1645 1650 Leu Val Arg Gly His Phe Cys Pro Ile Lys Arg Lys Ala Asn Ser 1655 1660 1665 Thr Lys Arg Asp Arg Gly Thr Leu Leu Lys Ala Gln Ile Arg His 1670 1675 1680 Gln Ser Leu Asp Ser Gln Ser Glu Asn Ala Thr Ile Asp Leu Asn 1685 1690 1695 Ser Val Leu Glu Arg Glu Phe Ser Val Gln Ser Leu Thr Ser Val 1700 1705 1710 Val Ser Glu Glu Cys Phe Tyr Glu Thr Glu Ser His Gly Lys Ser 1715 1720 1725 12 878 PRT Homo sapiens misc_feature Incyte ID No 4002434CD1 12 Met Phe Ser Ala Leu Lys Lys Leu Val Gly Ser Asp Gln Ala Pro 1 5 10 15 Gly Arg Asp Lys Asn Ile Pro Ala Gly Leu Gln Ser Met Asn Gln 20 25 30 Ala Leu Gln Arg Arg Phe Ala Lys Gly Val Gln Tyr Asn Met Lys 35 40 45 Ile Val Ile Arg Gly Asp Arg Asn Thr Gly Lys Thr Ala Leu Trp 50 55 60 His Arg Leu Gln Gly Arg Pro Phe Val Glu Glu Tyr Ile Pro Thr 65 70 75 Gln Glu Ile Gln Val Thr Ser Ile His Trp Ser Tyr Lys Thr Thr 80 85 90 Asp Asp Ile Val Lys Val Glu Val Trp Asp Val Val Asp Lys Gly 95 100 105 Lys Cys Lys Lys Arg Gly Asp Gly Leu Lys Met Glu Asn Asp Pro 110 115 120 Gln Glu Ala Glu Ser Glu Met Ala Leu Asp Ala Glu Phe Leu Asp 125 130 135 Val Tyr Lys Asn Cys Asn Gly Val Val Met Met Phe Asp Ile Thr 140 145 150 Lys Gln Trp Thr Phe Asn Tyr Ile Leu Arg Glu Leu Pro Lys Val 155 160 165 Pro Thr His Val Pro Val Cys Val Leu Gly Asn Tyr Arg Asp Met 170 175 180 Gly Glu His Arg Val Ile Leu Pro Asp Asp Val Arg Asp Phe Ile 185 190 195 Asp Asn Leu Asp Arg Pro Pro Gly Ser Ser Tyr Phe Arg Tyr Ala 200 205 210 Glu Ser Ser Met Lys Asn Ser Phe Gly Leu Lys Tyr Leu His Lys 215 220 225 Phe Phe Asn Ile Pro Phe Leu Gln Leu Gln Arg Glu Thr Leu Leu 230 235 240 Arg Gln Leu Glu Thr Asn Gln Leu Asp Met Asp Ala Thr Leu Glu 245 250 255 Glu Leu Ser Val Gln Gln Glu Thr Glu Asp Gln Asn Tyr Gly Ile 260 265 270 Phe Leu Glu Met Met Glu Ala Arg Ser Arg Gly His Ala Ser Pro 275 280 285 Leu Ala Ala Asn Gly Gln Ser Pro Ser Pro Gly Ser Gln Ser Pro 290 295 300 Val Val Pro Ala Gly Ala Val Ser Thr Gly Ser Ser Ser Pro Gly 305 310 315 Thr Pro Gln Pro Ala Pro Gln Leu Pro Leu Asn Ala Ala Pro Pro 320 325 330 Ser Ser Val Pro Pro Val Pro Pro Ser Glu Ala Leu Pro Pro Pro 335 340 345 Ala Cys Pro Ser Ala Pro Ala Pro Arg Arg Ser Ile Ile Ser Arg 350 355 360 Leu Phe Gly Thr Ser Pro Ala Thr Glu Ala Ala Pro Pro Pro Pro 365 370 375 Glu Pro Val Pro Ala Ala Gln Gly Pro Ala Thr Val Gln Ser Val 380 385 390 Glu Asp Phe Val Pro Asp Asp Arg Leu Asp Arg Ser Phe Leu Glu 395 400 405 Asp Thr Thr Pro Ala Arg Asp Glu Lys Lys Val Gly Ala Lys Ala 410 415 420 Ala Gln Gln Asp Ser Asp Ser Asp Gly Glu Ala Leu Gly Gly Asn 425 430 435 Pro Met Val Ala Gly Phe Gln Asp Asp Val Asp Leu Glu Asp Gln 440 445 450 Pro Arg Gly Ser Pro Pro Leu Pro Ala Gly Pro Val Pro Ser Gln 455 460 465 Asp Ile Thr Leu Ser Ser Glu Glu Glu Ala Glu Val Ala Ala Pro 470 475 480 Thr Lys Gly Pro Ala Pro Ala Pro Gln Gln Cys Ser Glu Pro Glu 485 490 495 Thr Lys Trp Ser Ser Ile Pro Ala Ser Lys Pro Arg Arg Gly Thr 500 505 510 Ala Pro Thr Arg Thr Ala Ala Pro Pro Trp Pro Gly Gly Val Ser 515 520 525 Val Arg Thr Gly Pro Glu Lys Arg Ser Ser Thr Arg Pro Pro Ala 530 535 540 Glu Met Glu Pro Gly Lys Gly Glu Gln Ala Ser Ser Ser Glu Ser 545 550 555 Asp Pro Glu Gly Pro Ile Ala Ala Gln Met Leu Ser Phe Val Met 560 565 570 Asp Asp Pro Asp Phe Glu Ser Glu Gly Ser Asp Thr Gln Arg Arg 575 580 585 Ala Asp Asp Phe Pro Val Arg Asp Asp Pro Ser Asp Val Thr Asp 590 595 600 Glu Asp Glu Gly Pro Ala Glu Pro Pro Pro Pro Pro Lys Leu Pro 605 610 615 Leu Pro Ala Phe Arg Leu Lys Asn Asp Ser Asp Leu Phe Gly Leu 620 625 630 Gly Leu Glu Glu Ala Gly Pro Lys Glu Ser Ser Glu Glu Gly Lys 635 640 645 Glu Gly Lys Thr Pro Ser Lys Glu Lys Lys Lys Lys Lys Lys Lys 650 655 660 Gly Lys Glu Glu Glu Glu Lys Ala Ala Lys Lys Lys Ser Lys His 665 670 675 Lys Lys Ser Lys Asp Lys Glu Glu Gly Lys Glu Glu Arg Arg Arg 680 685 690 Arg Gln Gln Arg Pro Pro Arg Ser Arg Glu Arg Thr Ala Ala Asp 695 700 705 Glu Leu Glu Ala Phe Leu Gly Gly Gly Ala Pro Gly Gly Arg His 710 715 720 Pro Gly Gly Trp Arg Leu Arg Gly Ala Leu Gly Arg Arg Gly Gln 725 730 735 Trp Pro Pro Trp Gly Gly Gly Arg Ala Cys His Cys Leu Gly Arg 740 745 750 His Leu Pro Leu Tyr His Arg Leu Cys Arg Cys Pro Val Ala Ala 755 760 765 Val Cys Ala Ser Glu Leu Glu Glu Ala Gly His Trp Trp Ser Pro 770 775 780 Gly Trp Ala Leu Gln Val Leu Gly Leu Gln Ala Gln Cys Glu Pro 785 790 795 Ala Leu Gln Glu Gly Arg Gly Gln Leu Ala Ser Ala Arg Leu Gly 800 805 810 Gly His Pro Gly Pro Leu Gly Ala Glu Pro Pro Val Phe Leu Arg 815 820 825 Asp Val Thr Glu Ala Gln Glu Gly Pro Val Arg Val Cys Leu Gln 830 835 840 Arg Leu Gly Arg Gly Arg Leu Ala Val Gly Cys Ala Leu Pro Arg 845 850 855 His Leu Leu Ala Leu Arg Ala His Leu Gly Pro Gln His Ala Tyr 860 865 870 Gly Ser Ala Ser Gly Arg Glu Pro 875 13 836 PRT Homo sapiens misc_feature Incyte ID No 2506117CD1 13 Met Thr Ser Pro Ala Lys Phe Lys Lys Asp Lys Glu Ile Ile Ala 1 5 10 15 Glu Tyr Asp Thr Gln Val Lys Glu Ile Arg Ala Gln Leu Thr Glu 20 25 30 Gln Met Lys Cys Leu Asp Gln Gln Cys Glu Leu Arg Val Gln Leu 35 40 45 Leu Gln Asp Leu Gln Asp Phe Phe Arg Lys Lys Ala Glu Ile Glu 50 55 60 Met Asp Tyr Ser Arg Asn Leu Glu Lys Leu Ala Glu Arg Phe Leu 65 70 75 Ala Lys Thr Arg Ser Thr Lys Asp Gln Gln Phe Lys Lys Asp Gln 80 85 90 Asn Val Leu Ser Pro Val Asn Cys Trp Asn Leu Leu Leu Asn Gln 95 100 105 Val Lys Arg Glu Ser Arg Asp His Thr Thr Leu Ser Asp Ile Tyr 110 115 120 Leu Asn Asn Ile Ile Pro Arg Phe Val Gln Val Ser Glu Asp Ser 125 130 135 Gly Arg Leu Phe Lys Lys Ser Lys Glu Val Gly Gln Gln Leu Gln 140 145 150 Asp Asp Leu Met Lys Val Leu Asn Glu Leu Tyr Ser Val Met Lys 155 160 165 Thr Tyr His Met Tyr Asn Ala Asp Ser Ile Ser Ala Gln Ser Lys 170 175 180 Leu Lys Glu Ala Glu Lys Gln Glu Glu Lys Gln Ile Gly Lys Ser 185 190 195 Val Lys Gln Glu Asp Arg Gln Thr Pro Arg Ser Pro Asp Ser Thr 200 205 210 Ala Asn Val Arg Ile Glu Glu Lys His Val Arg Arg Ser Ser Val 215 220 225 Lys Lys Ile Glu Lys Met Lys Glu Lys Arg Gln Ala Lys Tyr Thr 230 235 240 Glu Asn Lys Leu Lys Ala Ile Lys Ala Arg Asn Glu Tyr Leu Leu 245 250 255 Ala Leu Glu Ala Thr Asn Ala Ser Val Phe Lys Tyr Tyr Ile His 260 265 270 Asp Leu Ser Asp Leu Ile Asp Gln Cys Cys Asp Leu Gly Tyr His 275 280 285 Ala Ser Leu Asn Arg Ala Leu Arg Thr Phe Leu Ser Ala Glu Leu 290 295 300 Asn Leu Glu Gln Ser Lys His Glu Gly Leu Asp Ala Ile Glu Asn 305 310 315 Ala Val Glu Asn Leu Asp Ala Thr Ser Asp Lys Gln Arg Leu Met 320 325 330 Glu Met Tyr Asn Asn Val Phe Cys Pro Pro Met Lys Phe Glu Phe 335 340 345 Gln Pro His Met Gly Asp Met Ala Ser Gln Leu Cys Ala Gln Gln 350 355 360 Pro Val Gln Ser Glu Leu Val Gln Arg Cys Gln Gln Leu Gln Ser 365 370 375 Arg Leu Ser Thr Leu Lys Ile Glu Asn Glu Glu Val Lys Lys Thr 380 385 390 Met Glu Ala Thr Leu Gln Thr Ile Gln Asp Ile Val Thr Val Glu 395 400 405 Asp Phe Asp Val Ser Asp Cys Phe Gln Tyr Ser Asn Ser Met Glu 410 415 420 Ser Val Lys Ser Thr Val Ser Glu Thr Phe Met Ser Lys Pro Ser 425 430 435 Ile Ala Lys Arg Arg Ala Asn Gln Gln Glu Thr Glu Gln Phe Tyr 440 445 450 Phe Thr Lys Met Lys Glu Tyr Leu Glu Gly Arg Asn Leu Ile Thr 455 460 465 Lys Leu Gln Ala Lys His Asp Leu Leu Gln Lys Thr Leu Gly Glu 470 475 480 Ser Gln Arg Thr Asp Cys Ser Leu Ala Arg Arg Ser Ser Thr Val 485 490 495 Arg Lys Gln Asp Ser Ser Gln Ala Ile Pro Leu Val Val Glu Ser 500 505 510 Cys Ile Arg Phe Ile Ser Arg His Gly Leu Gln His Glu Gly Ile 515 520 525 Phe Arg Val Ser Gly Ser Gln Val Glu Val Asn Asp Ile Lys Asn 530 535 540 Ala Phe Glu Arg Gly Glu Asp Pro Leu Ala Gly Asp Gln Asn Asp 545 550 555 His Asp Met Asp Ser Ile Ala Gly Val Leu Lys Leu Tyr Phe Arg 560 565 570 Gly Leu Glu His Pro Leu Phe Pro Lys Asp Ile Phe His Asp Leu 575 580 585 Met Ala Cys Val Thr Met Asp Asn Leu Gln Glu Arg Ala Leu His 590 595 600 Ile Arg Lys Val Leu Leu Val Leu Pro Lys Thr Thr Leu Ile Ile 605 610 615 Met Arg Tyr Leu Phe Ala Phe Leu Asn His Leu Ser Gln Phe Ser 620 625 630 Glu Glu Asn Met Met Asp Pro Tyr Asn Leu Ala Ile Cys Phe Gly 635 640 645 Pro Ser Leu Met Ser Val Pro Glu Gly His Asp Gln Val Ser Cys 650 655 660 Gln Ala His Val Asn Glu Leu Ile Lys Thr Ile Ile Ile Gln His 665 670 675 Glu Asn Ile Phe Pro Ser Pro Arg Glu Leu Glu Gly Pro Val Tyr 680 685 690 Ser Arg Gly Gly Ser Met Glu Asp Tyr Cys Asp Ser Pro His Gly 695 700 705 Glu Thr Thr Ser Val Glu Asp Ser Thr Gln Asp Val Thr Ala Glu 710 715 720 His His Thr Ser Asp Asp Glu Cys Glu Pro Ile Glu Ala Ile Ala 725 730 735 Lys Phe Asp Tyr Val Gly Arg Thr Ala Arg Glu Leu Ser Phe Lys 740 745 750 Lys Gly Ala Ser Leu Leu Leu Tyr Gln Arg Ala Ser Asp Asp Trp 755 760 765 Trp Glu Gly Arg His Asn Gly Ile Asp Gly Leu Ile Pro His Gln 770 775 780 Tyr Ile Val Val Gln Asp Thr Glu Asp Gly Val Val Glu Arg Ser 785 790 795 Ser Pro Lys Ser Glu Ile Glu Val Ile Ser Glu Pro Pro Glu Glu 800 805 810 Lys Val Thr Ala Arg Ala Gly Ala Ser Cys Pro Ser Gly Gly His 815 820 825 Val Ala Asp Ile Tyr Leu Ala Asn Ile Asn Lys 830 835 14 979 PRT Homo sapiens misc_feature Incyte ID No 7193277CD1 14 Met Arg Gly Tyr His Gly Asp Arg Gly Ser His Pro Arg Pro Ala 1 5 10 15 Arg Phe Ala Asp Gln Gln His Met Asp Val Gly Pro Ala Ala Arg 20 25 30 Ala Pro Tyr Leu Leu Gly Ser Arg Glu Ala Phe Ser Thr Glu Pro 35 40 45 Arg Phe Cys Ala Pro Arg Ala Gly Leu Gly His Ile Ser Pro Glu 50 55 60 Gly Ala Leu Ser Leu Ser Glu Gly Pro Ser Val Gly Pro Glu Gly 65 70 75 Gly Pro Ala Gly Ala Gly Val Gly Gly Gly Ser Ser Thr Phe Pro 80 85 90 Arg Met Tyr Pro Gly Gln Gly Pro Phe Asp Thr Cys Glu Asp Cys 95 100 105 Val Gly His Pro Gln Gly Lys Gly Ala Pro Arg Leu Pro Pro Thr 110 115 120 Leu Leu Asp Gln Phe Glu Lys Gln Leu Pro Val Gln Gln Asp Gly 125 130 135 Phe His Thr Leu Pro Tyr Gln Arg Gly Pro Ala Gly Ala Gly Pro 140 145 150 Gly Pro Ala Pro Gly Thr Gly Thr Ala Pro Glu Pro Arg Ser Glu 155 160 165 Ser Pro Ser Arg Ile Arg His Leu Val His Ser Val Gln Lys Leu 170 175 180 Phe Ala Lys Ser His Ser Leu Glu Ala Pro Gly Lys Arg Asp Tyr 185 190 195 Asn Gly Pro Lys Ala Glu Gly Arg Gly Gly Ser Gly Gly Asp Ser 200 205 210 Tyr Pro Gly Pro Gly Ser Gly Gly Pro His Thr Ser His His His 215 220 225 His His His His His His His His His Gln Ser Arg His Gly Lys 230 235 240 Arg Ser Lys Ser Lys Asp Arg Lys Gly Asp Gly Arg His Gln Ala 245 250 255 Lys Ser Thr Gly Trp Trp Ser Ser Asp Asp Asn Leu Asp Ser Asp 260 265 270 Ser Gly Phe Leu Ala Gly Gly Arg Pro Pro Gly Glu Pro Gly Gly 275 280 285 Pro Phe Cys Leu Glu Gly Pro Asp Gly Ser Tyr Arg Asp Leu Ser 290 295 300 Phe Lys Gly Arg Ser Gly Gly Ser Glu Gly Arg Cys Leu Ala Cys 305 310 315 Thr Gly Met Ser Met Ser Leu Asp Gly Gln Ser Val Lys Arg Ser 320 325 330 Ala Trp His Thr Met Met Val Ser Gln Gly Arg Asp Gly Tyr Pro 335 340 345 Gly Ala Gly Pro Gly Lys Gly Leu Leu Gly Pro Glu Thr Lys Ala 350 355 360 Lys Ala Arg Thr Tyr His Tyr Leu Gln Val Pro Gln Asp Asp Trp 365 370 375 Gly Gly Tyr Pro Thr Gly Gly Lys Asp Gly Glu Ile Pro Cys Arg 380 385 390 Arg Met Arg Ser Gly Ser Tyr Ile Lys Ala Met Gly Asp Glu Glu 395 400 405 Ser Gly Asp Ser Asp Gly Ser Pro Lys Thr Ser Pro Lys Ala Val 410 415 420 Ala Arg Arg Phe Thr Thr Arg Arg Ser Ser Ser Val Asp Gln Ala 425 430 435 Arg Ile Asn Cys Cys Val Pro Pro Arg Ile His Pro Arg Ser Ser 440 445 450 Ile Pro Gly Tyr Ser Arg Ser Leu Thr Thr Gly Gln Leu Ser Asp 455 460 465 Glu Leu Asn Gln Gln Leu Glu Ala Val Cys Gly Ser Val Phe Gly 470 475 480 Glu Leu Glu Ser Gln Ala Val Asp Ala Leu Asp Leu Pro Gly Cys 485 490 495 Phe Arg Met Arg Ser His Ser Tyr Leu Arg Ala Ile Gln Ala Gly 500 505 510 Cys Ser Gln Asp Asp Asp Cys Leu Pro Leu Leu Ala Thr Pro Ala 515 520 525 Ala Val Ser Gly Arg Pro Gly Ser Ser Phe Asn Phe Arg Lys Ala 530 535 540 Pro Pro Pro Ile Pro Pro Gly Ser Gln Ala Pro Pro Arg Ile Ser 545 550 555 Ile Thr Ala Gln Ser Ser Thr Asp Ser Ala His Glu Ser Phe Thr 560 565 570 Ala Ala Glu Gly Pro Ala Arg Arg Cys Ser Ser Ala Asp Gly Leu 575 580 585 Asp Gly Pro Ala Met Gly Ala Arg Thr Leu Glu Leu Ala Pro Val 590 595 600 Pro Pro Arg Ala Ser Pro Lys Pro Pro Thr Leu Ile Ile Lys Thr 605 610 615 Ile Pro Gly Arg Glu Glu Leu Arg Ser Leu Ala Arg Gln Arg Lys 620 625 630 Trp Arg Pro Ser Ile Gly Val Gln Val Glu Thr Ile Ser Asp Ser 635 640 645 Asp Thr Glu Asn Arg Ser Arg Arg Glu Phe His Ser Ile Gly Val 650 655 660 Gln Val Glu Glu Asp Lys Arg Arg Ala Arg Phe Lys Arg Ser Asn 665 670 675 Ser Val Thr Ala Gly Val Gln Ala Asp Leu Glu Leu Glu Gly Leu 680 685 690 Ala Gly Leu Ala Thr Val Ala Thr Glu Asp Lys Ala Leu Gln Phe 695 700 705 Gly Arg Ser Phe Gln Arg His Ala Ser Glu Pro Gln Pro Gly Pro 710 715 720 Arg Ala Pro Thr Tyr Ser Val Phe Arg Thr Val His Thr Gln Gly 725 730 735 Gln Trp Ala Tyr Arg Glu Gly Tyr Pro Leu Pro Tyr Glu Pro Pro 740 745 750 Ala Thr Asp Gly Ser Pro Gly Pro Ala Pro Ala Pro Thr Pro Gly 755 760 765 Pro Gly Ala Gly Arg Arg Asp Ser Trp Ile Glu Arg Gly Ser Arg 770 775 780 Ser Leu Pro Asp Ser Gly Arg Ala Ser Pro Cys Pro Arg Asp Gly 785 790 795 Glu Trp Phe Ile Lys Met Leu Arg Ala Glu Val Glu Lys Leu Glu 800 805 810 His Trp Cys Gln Gln Met Glu Arg Glu Ala Glu Asp Tyr Glu Leu 815 820 825 Pro Glu Glu Ile Leu Glu Lys Ile Arg Ser Ala Val Gly Ser Thr 830 835 840 Gln Leu Leu Leu Ser Gln Lys Val Gln Gln Phe Phe Arg Leu Cys 845 850 855 Gln Gln Ser Met Asp Pro Thr Ala Phe Pro Val Pro Thr Phe Gln 860 865 870 Asp Leu Ala Gly Phe Trp Asp Leu Leu Gln Leu Ser Ile Glu Asp 875 880 885 Val Thr Leu Lys Phe Leu Glu Leu Gln Gln Leu Lys Ala Asn Ser 890 895 900 Trp Lys Leu Leu Glu Pro Lys Glu Glu Lys Lys Val Pro Pro Pro 905 910 915 Ile Pro Lys Lys Pro Leu Arg Ala Arg Gly Val Pro Val Lys Glu 920 925 930 Arg Ser Leu Asp Ser Val Asp Arg Gln Arg Gln Glu Ala Arg Lys 935 940 945 Arg Leu Leu Ala Ala Lys Arg Ala Ala Ser Phe Arg His Ser Ser 950 955 960 Ala Thr Glu Ser Ala Asp Ser Ile Glu Ile Tyr Ile Pro Glu Ala 965 970 975 Gln Thr Arg Leu 15 182 PRT Homo sapiens misc_feature Incyte ID No 2307889CD1 15 Met Pro Leu Val Arg Tyr Arg Lys Val Val Ile Leu Gly Tyr Arg 1 5 10 15 Cys Val Gly Lys Thr Ser Leu Ala His Gln Phe Val Glu Gly Glu 20 25 30 Phe Ser Glu Gly Tyr Asp Pro Thr Val Glu Asn Thr Tyr Ser Lys 35 40 45 Ile Val Thr Leu Gly Lys Asp Glu Phe His Leu His Leu Val Asp 50 55 60 Thr Ala Gly Gln Asp Glu Tyr Ser Ile Leu Pro Tyr Ser Phe Ile 65 70 75 Ile Gly Val His Gly Tyr Val Leu Val Tyr Ser Val Thr Ser Leu 80 85 90 His Ser Phe Gln Val Ile Glu Ser Leu Tyr Gln Lys Leu His Glu 95 100 105 Gly His Gly Lys Thr Arg Val Pro Val Val Leu Val Gly Asn Lys 110 115 120 Ala Asp Leu Ser Pro Glu Arg Glu Val Gln Ala Val Glu Gly Lys 125 130 135 Lys Leu Ala Glu Ser Trp Gly Ala Thr Phe Met Glu Ser Ser Ala 140 145 150 Arg Glu Asn Gln Leu Thr Gln Gly Ile Phe His Gln Ser His Pro 155 160 165 Gly Asp Ala Arg Val Glu Asn Leu Trp Ala Glu Arg Arg Cys His 170 175 180 Leu Met 16 622 PRT Homo sapiens misc_feature Incyte ID No 5369710CD1 16 Met Trp Thr Leu Val Gly Arg Gly Trp Gly Cys Ala Arg Ala Leu 1 5 10 15 Ala Pro Arg Ala Thr Gly Ala Ala Leu Leu Val Ala Pro Gly Pro 20 25 30 Arg Ser Ala Pro Thr Leu Gly Ala Ala Pro Glu Ser Trp Ala Thr 35 40 45 Asp Arg Leu Tyr Ser Ser Ala Glu Phe Lys Glu Lys Pro Asp Met 50 55 60 Ser Arg Phe Pro Val Glu Asn Ile Arg Asn Phe Ser Ile Val Ala 65 70 75 His Val Asp His Gly Lys Ser Thr Leu Ala Asp Arg Leu Leu Glu 80 85 90 Leu Thr Gly Thr Ile Asp Lys Thr Lys Asn Asn Lys Gln Val Leu 95 100 105 Asp Lys Leu Gln Val Glu Arg Glu Arg Gly Ile Thr Val Lys Ala 110 115 120 Gln Thr Ala Ser Leu Phe Tyr Asn Cys Glu Gly Lys Gln Tyr Leu 125 130 135 Leu Asn Leu Ile Asp Thr Pro Gly His Val Asp Phe Ser Tyr Glu 140 145 150 Val Ser Arg Ser Leu Ser Ala Cys Gln Gly Val Leu Leu Val Val 155 160 165 Asp Ala Asn Glu Gly Ile Gln Ala Gln Thr Val Ala Asn Phe Phe 170 175 180 Leu Ala Phe Glu Ala Gln Leu Ser Val Ile Pro Val Ile Asn Lys 185 190 195 Ile Asp Leu Lys Asn Ala Asp Pro Glu Arg Val Glu Asn Gln Ile 200 205 210 Glu Lys Val Phe Asp Ile Pro Ser Asp Glu Cys Ile Lys Ile Ser 215 220 225 Ala Lys Leu Gly Thr Asn Val Glu Ser Val Leu Gln Ala Ile Ile 230 235 240 Glu Arg Ile Pro Pro Pro Lys Val His Arg Lys Asn Pro Leu Arg 245 250 255 Ala Leu Val Phe Asp Ser Thr Phe Asp Gln Tyr Arg Gly Val Ile 260 265 270 Ala Asn Val Ala Leu Phe Asp Gly Val Val Ser Lys Gly Asp Lys 275 280 285 Ile Val Ser Ala His Thr Gln Lys Thr Tyr Glu Val Asn Glu Val 290 295 300 Gly Val Leu Asn Pro Asn Glu Gln Pro Thr His Lys Leu Met Tyr 305 310 315 Pro Leu Asp Gln Ser Glu Tyr Asn Asn Leu Lys Ser Ala Ile Glu 320 325 330 Lys Leu Thr Leu Asn Asp Ser Ser Val Thr Val His Arg Asp Ser 335 340 345 Ser Leu Ala Leu Gly Ala Gly Trp Arg Leu Gly Phe Leu Gly Leu 350 355 360 Leu His Met Glu Val Phe Asn Gln Arg Leu Glu Gln Glu Tyr Asn 365 370 375 Ala Ser Val Ile Leu Thr Thr Pro Thr Val Pro Tyr Lys Ala Val 380 385 390 Leu Ser Ser Ser Lys Leu Ile Lys Glu His Arg Glu Lys Glu Ile 395 400 405 Thr Ile Ile Asn Pro Ala Gln Phe Pro Asp Lys Ser Lys Val Thr 410 415 420 Glu Tyr Leu Glu Pro Val Val Leu Gly Thr Ile Ile Thr Pro Asp 425 430 435 Glu Tyr Thr Gly Lys Ile Met Met Leu Cys Glu Ala Arg Arg Ala 440 445 450 Val Gln Lys Asn Met Ile Phe Ile Asp Gln Asn Arg Val Met Leu 455 460 465 Lys Tyr Leu Phe Pro Leu Asn Glu Ile Val Val Asp Phe Tyr Asp 470 475 480 Ser Leu Lys Ser Leu Ser Ser Gly Tyr Ala Ser Phe Asp Tyr Glu 485 490 495 Asp Ala Gly Tyr Gln Thr Ala Glu Leu Val Lys Met Asp Ile Leu 500 505 510 Leu Asn Gly Asn Thr Val Glu Glu Leu Val Thr Val Val His Lys 515 520 525 Asp Lys Ala His Ser Ile Gly Lys Ala Ile Cys Glu Arg Leu Lys 530 535 540 Asp Ser Leu Pro Arg Gln Leu Phe Glu Ile Ala Ile Gln Ala Ala 545 550 555 Ile Gly Ser Lys Ile Ile Ala Arg Glu Thr Val Lys Ala Tyr Arg 560 565 570 Lys Asn Val Leu Ala Lys Cys Tyr Gly Gly Asp Ile Thr Arg Lys 575 580 585 Met Lys Leu Leu Lys Arg Gln Ala Glu Gly Lys Lys Lys Leu Arg 590 595 600 Lys Ile Gly Asn Val Glu Val Pro Lys Asp Ala Phe Ile Lys Val 605 610 615 Leu Lys Thr Gln Ser Ser Lys 620 17 726 PRT Homo sapiens misc_feature Incyte ID No 5502841CD1 17 Met Leu Gln Phe Ala Ala Trp Val Asp Ala Val Val Phe Val Phe 1 5 10 15 Ser Leu Glu Asp Glu Ile Ser Phe Gln Thr Val Tyr Asn Tyr Phe 20 25 30 Leu Arg Leu Cys Ser Phe Arg Asn Ala Ser Glu Val Pro Met Val 35 40 45 Leu Val Gly Thr Gln Asp Ala Ile Ser Ala Ala Asn Pro Arg Val 50 55 60 Ile Asp Asp Ser Arg Ala Arg Lys Leu Ser Thr Asp Leu Lys Arg 65 70 75 Cys Thr Tyr Tyr Glu Thr Cys Ala Thr Tyr Gly Leu Asn Val Glu 80 85 90 Arg Val Phe Gln Asp Val Ala Gln Lys Val Val Ala Leu Arg Lys 95 100 105 Lys Gln Gln Leu Ala Ile Gly Pro Cys Lys Ser Leu Pro Asn Ser 110 115 120 Pro Ser His Ser Ala Val Ser Ala Ala Ser Ile Pro Ala Val His 125 130 135 Ile Asn Gln Ala Thr Asn Gly Gly Gly Ser Ala Phe Ser Asp Tyr 140 145 150 Ser Ser Ser Val Pro Ser Thr Pro Ser Ile Ser Gln Arg Glu Leu 155 160 165 Arg Ile Glu Thr Ile Ala Ala Ser Ser Thr Pro Thr Pro Ile Arg 170 175 180 Lys Gln Ser Lys Arg Arg Ser Asn Ile Phe Thr Ser Arg Lys Gly 185 190 195 Ala Asp Leu Asp Arg Glu Lys Lys Ala Ala Glu Cys Lys Val Asp 200 205 210 Ser Ile Gly Ser Gly Arg Ala Ile Pro Ile Lys Gln Gly Ile Leu 215 220 225 Leu Lys Arg Ser Gly Lys Ser Leu Asn Lys Glu Trp Lys Lys Lys 230 235 240 Tyr Val Thr Leu Cys Asp Asn Gly Leu Leu Thr Tyr His Pro Ser 245 250 255 Leu His Asp Tyr Met Gln Asn Ile His Gly Lys Glu Ile Asp Leu 260 265 270 Leu Arg Thr Thr Val Lys Val Pro Gly Lys Arg Leu Pro Arg Ala 275 280 285 Thr Pro Ala Thr Ala Pro Gly Thr Ser Pro Arg Ala Asn Gly Leu 290 295 300 Ser Val Glu Arg Ser Asn Thr Gln Leu Gly Gly Gly Thr Gly Ala 305 310 315 Pro His Ser Ala Ser Ser Ala Ser Leu His Ser Glu Arg Pro Leu 320 325 330 Ser Ser Ser Ala Trp Ala Gly Pro Arg Pro Glu Gly Leu His Gln 335 340 345 Arg Ser Cys Ser Val Ser Ser Ala Asp Gln Trp Ser Glu Ala Thr 350 355 360 Thr Ser Leu Pro Pro Gly Met Gln His Pro Ala Ser Gly Pro Ala 365 370 375 Glu Val Leu Ser Ser Ser Pro Lys Leu Asp Pro Pro Pro Ser Pro 380 385 390 His Ser Asn Arg Lys Lys His Arg Arg Lys Lys Ser Thr Gly Thr 395 400 405 Pro Arg Pro Asp Gly Pro Ser Ser Ala Thr Glu Glu Ala Glu Glu 410 415 420 Ser Phe Glu Phe Val Val Val Ser Leu Thr Gly Gln Thr Trp His 425 430 435 Phe Glu Ala Ser Thr Ala Glu Glu Arg Glu Leu Trp Val Gln Ser 440 445 450 Val Gln Ala Gln Ile Leu Ala Ser Leu Gln Gly Cys Arg Ser Ala 455 460 465 Lys Asp Lys Thr Arg Leu Gly Asn Gln Asn Ala Ala Leu Ala Val 470 475 480 Gln Ala Val Arg Thr Val Arg Gly Asn Ser Phe Cys Ile Asp Cys 485 490 495 Asp Ala Pro Asn Pro Asp Trp Ala Ser Leu Asn Leu Gly Ala Leu 500 505 510 Met Cys Ile Glu Cys Ser Gly Ile His Arg His Leu Gly Ala His 515 520 525 Leu Ser Arg Val Arg Ser Leu Asp Leu Asp Asp Trp Pro Pro Glu 530 535 540 Leu Leu Ala Val Met Thr Ala Met Gly Asn Ala Leu Ala Asn Ser 545 550 555 Val Trp Glu Gly Ala Leu Gly Gly Tyr Ser Lys Pro Gly Pro Asp 560 565 570 Ala Cys Arg Glu Glu Lys Glu Arg Trp Ile Arg Ala Lys Tyr Glu 575 580 585 Gln Lys Leu Phe Leu Ala Pro Leu Pro Ser Ser Asp Val Pro Leu 590 595 600 Gly Gln Gln Leu Leu Arg Ala Val Val Glu Asp Asp Leu Arg Leu 605 610 615 Leu Val Met Leu Leu Ala His Gly Ser Lys Glu Glu Val Asn Glu 620 625 630 Thr Tyr Gly Asp Gly Asp Gly Arg Thr Ala Leu His Leu Ser Ser 635 640 645 Ala Met Ala Asn Val Val Phe Thr Gln Leu Leu Ile Trp Tyr Gly 650 655 660 Val Asp Val Arg Ser Arg Asp Ala Arg Gly Leu Thr Pro Leu Ala 665 670 675 Tyr Ala Arg Arg Ala Gly Ser Gln Glu Cys Ala Asp Ile Leu Ile 680 685 690 Gln His Gly Cys Pro Gly Glu Gly Cys Gly Leu Ala Pro Thr Pro 695 700 705 Asn Arg Glu Pro Ala Asn Gly Thr Asn Pro Ser Ala Glu Leu His 710 715 720 Arg Ser Pro Ser Leu Leu 725 18 420 PRT Homo sapiens misc_feature Incyte ID No 361856CD1 18 Met Glu Thr Lys Arg Val Glu Ile Pro Gly Ser Val Leu Asp Asp 1 5 10 15 Leu Cys Ser Arg Phe Ile Leu His Ile Pro Ser Glu Glu Arg Asp 20 25 30 Asn Ala Ile Arg Val Cys Phe Gln Ile Glu Leu Ala His Trp Phe 35 40 45 Tyr Leu Asp Phe Tyr Met Gln Asn Thr Pro Gly Leu Pro Gln Cys 50 55 60 Gly Ile Arg Asp Phe Ala Lys Ala Val Phe Ser His Cys Pro Phe 65 70 75 Leu Leu Pro Gln Gly Glu Asp Val Glu Lys Val Leu Asp Glu Trp 80 85 90 Lys Glu Tyr Lys Met Gly Val Pro Thr Tyr Gly Ala Ile Ile Leu 95 100 105 Asp Glu Thr Leu Glu Asn Val Leu Leu Val Gln Gly Tyr Leu Ala 110 115 120 Lys Ser Gly Trp Gly Phe Pro Lys Gly Lys Val Asn Lys Glu Glu 125 130 135 Ala Pro His Asp Cys Ala Ala Arg Glu Val Phe Glu Glu Thr Gly 140 145 150 Phe Asp Ile Lys Asp Tyr Ile Cys Lys Asp Asp Tyr Ile Glu Leu 155 160 165 Arg Ile Asn Asp Gln Leu Ala Arg Leu Tyr Ile Ile Pro Gly Ile 170 175 180 Pro Lys Asp Thr Lys Phe Asn Pro Lys Thr Arg Arg Glu Ile Arg 185 190 195 Asn Ile Glu Trp Phe Ser Ile Glu Lys Leu Pro Cys His Arg Asn 200 205 210 Asp Met Thr Pro Lys Ser Lys Leu Gly Leu Ala Pro Asn Lys Phe 215 220 225 Phe Met Ala Ile Pro Phe Ile Arg Pro Leu Arg Asp Trp Leu Ser 230 235 240 Arg Arg Phe Gly Asp Ser Ser Asp Ser Asp Asn Gly Phe Ser Ser 245 250 255 Thr Gly Ser Thr Pro Ala Lys Pro Thr Val Glu Lys Leu Ser Arg 260 265 270 Thr Lys Phe Arg His Ser Gln Gln Leu Phe Pro Asp Gly Ser Pro 275 280 285 Gly Asp Gln Trp Val Lys His Arg Gln Pro Leu Gln Gln Lys Pro 290 295 300 Tyr Asn Asn His Ser Glu Met Ser Asp Leu Leu Lys Gly Lys Asn 305 310 315 Gln Ser Met Arg Gly Asn Gly Arg Lys Gln Tyr Gln Asp Ser Pro 320 325 330 Asn Gln Lys Lys Arg Thr Asn Gly Leu Gln Pro Ala Lys Gln Gln 335 340 345 Asn Ser Leu Met Lys Cys Glu Lys Lys Leu His Pro Arg Lys Leu 350 355 360 Gln Asp Asn Phe Glu Thr Asp Ala Val Tyr Asp Leu Pro Ser Ser 365 370 375 Ser Glu Asp Gln Leu Leu Glu His Ala Glu Gly Gln Pro Val Ala 380 385 390 Cys Asn Gly His Cys Lys Phe Pro Phe Ser Ser Arg Ala Phe Leu 395 400 405 Ser Phe Lys Phe Asp His Asn Ala Ile Met Lys Ile Leu Asp Leu 410 415 420 19 1750 DNA Homo sapiens misc_feature Incyte ID No 2372478CB1 19 gtgccctcgt actgcctagg agacaagacg cgaggccggc agcgcccacc cggtcgcaat 60 ggagcttccc ctagggcggt gcgatgattc ccgcacctgg gacgatgact cggacccaga 120 gtcagagaca gacccagacg cgcaggccaa ggcctacgtg gcccgcgttc tcagtccgcc 180 aaaatccggg ctggcgttct cgcgcccctc gcagctatcc acacccgccg cgtccccgag 240 cgcttcggag cctcgggccg cgtccagggt ttcggccgta agtgagccgg gccttctgag 300 ccttcccccg gagctgctgc tcgagatctg ctcctacctg gacgcccgcc tcgtgctcca 360 cgtcctgtcg cgggtgtgcc acgcgctccg cgacctcgtg tctgaccatg tcacctggag 420 gctacgcgcg ctacgccgcg tacgcgcgcc ctacccagtg gtggaggaga agaactttga 480 ctggccggca gcctgcattg cgctggagca gcacctgtcc cgctgggcag aggatgggcg 540 ctgggtcgaa tacttctgcc tggccgaagg ccacgtggct tccgttgact cagtgctgct 600 gctccagggt gggtcactct gtctgtcggg ctcccgagat cgcaacgtca acttgtggga 660 cctgcggcag ctggggacgg agtccaacca ggttctgatc aagaccttag gcactaagcg 720 aaatagtacc catgagggct gggtgtggtc actggcagcg caggaccacc gcgtgtgctc 780 cggctcctgg gacagcacag tgaagctctg ggacatggca gcggatgggc agcagttcgg 840 cgagataaag gccagctcag ccgtgctgtg cctctcctac ctgcctgaca tcctggtgac 900 tggcacctat gacaagaagg tgaccatcta cgaccccaga gccggcccag ccctgttgaa 960 gcaccagcaa ctacactcca gacccgtgct gaccctgctg gcggatgacc ggcacatcat 1020 ctcaggcagc gaggaccaca ccctggtggt ggtggaccgc cgagccaaca gcgtcctgca 1080 gcgtctgcag ctggactcct acctgctctg catgtcctac caggaacccc agctctgggc 1140 tggtgacaac cagggcctgc tgcacgtctt cgccaaccgc aacggctgct tccagcttat 1200 ccggtccttt gatgtgggcc acagctttcc catcactggg atccagtact ccgtgggagc 1260 cttgtacacc acatccactg acaagaccat ccgggtgcac gtgcccacag acccaccaag 1320 gaccatttgc acccgaaggc atgacaatgg gctcaatagg gtctgtgctg agggcaacct 1380 ggtggtggcc ggctctggag acctgtcgct agaggtctgg aggctgcagg cctgagcagg 1440 tgggcgtgga tgtggatact gcctgccgga ggctgggctt cctcctctgt tcttggggga 1500 ccatccccaa tgttggtgct gcctccgccc cgtgggccta gggcacaagg agtcccagcc 1560 acattcgggt gagcgtcctg gcctgggccc tatgcccggg ggaagggtga aattggggtt 1620 caggcccacc cagggggccg cttcccactc ttgggccctg gttttgttat gatttggatg 1680 ccccgctctc agttgagagc gaaggagaaa taaacctgac atgttggtgc ttgggaaaaa 1740 aaaaaaaaaa 1750 20 2370 DNA Homo sapiens misc_feature Incyte ID No 4586623CB1 20 agagcaaatc tgaattccgg tctcttgtaa ttacacagtg tttccctctc tggggtctgg 60 gctcagcctc aggctgctat ataagactga tctgtgacca gactcagcca aaagcagagg 120 ggctggggaa caggacttct caagactcag cggcagggac ctcctagggg gaagcagtgc 180 cagcatgtgg atggcctggt gtgtggctgc gctgtctgtg gtggctgtgt gtggcaccag 240 ccacgagaca aacacggtcc tcagggtgac gaaagatgtg ttgagcaatg ccatttcagg 300 catgctgcag caaagtgatg ctctccactc ggccctgaga gaggtgccct tgggtgttgg 360 tgatattccc tacaatgact tccatgtccg aggacccccc ccagtatata ccaacggcaa 420 aaaacttgat ggtatttacc agtatggtca cattgagacc aacgacaaca ctgctcagct 480 ggggggcaaa taccgatatg gtgagatcct tgagtccgag ggaagcatca gggacctccg 540 aaacagtggc tatcgcagtg ccgagaatgc atatggaggc cacaggggcc tcgggcgata 600 cagggcagca cctgtgggca ggcttcaccg gcgagagctg cagcctggag aaatcccacc 660 tggagttgcc actggggcgg tgggcccagg tggtttgctg ggcactggag gcatgctggc 720 agctgatggc atcctcgcag gccaaggtgg cctgctcggc ggaggtggtc tccttggtga 780 tggaggactt cttggaggag ggggtgtcct gggcgtgctc ggcgagggtg gcatcctcag 840 cactgtgcaa ggcatcacgg ggctgcgtat cgtggagctg accctccctc gggtgtccgt 900 gcggctcctg cccggcgtgg gtgtctacct gagcttgtac acccgtgtgg ccatcaacgg 960 gaagagtctt attggcttcc tggacatcgc agtagaagtg aacatcacag ccaaggtccg 1020 gctgaccatg gaccgcacgg gttatcctcg gctggtcatt gagcgatgtg acaccctcct 1080 agggggcatc aaagtcaagc tgctgcgagg gcttctcccc aatctcgtgg acaatttagt 1140 gaaccgagtc ctggccgacg tcctccctga cttgctctgc cccatcgtgg atgtggtgct 1200 gggtcttgtc aatgaccagc tgggcctcgt ggattctctg attcctctgg ggatattggg 1260 aagtgtccag tacaccttct ccagcctccc gcttgtgacc ggggaattcc tggagctgga 1320 cctcaacacg ctggttgggg aggctggagg aggactcatc gactacccat tggggtggcc 1380 agctgtgtct cccaagccga tgccagagct gcctcccatg ggtgacaaca ccaagtccca 1440 gctggccatg tctgccaact tcctgggctc agtgctgact ctactgcaga agcagcatgc 1500 tctagacctg gatatcacca atggcatgtt tgaagagctt cctccactta ccacagccac 1560 actgggagcc ctgatcccca aggtgttcca gcagtacccc gagtcctgcc cacttatcat 1620 caggatccag gtgctgaacc caccatctgt gatgctgcag aaggacaaag cgctggtgaa 1680 ggtgttggcc actgccgagg tcatggtctc ccagcccaaa gacctggaga ctaccatctg 1740 cctcattgac gtggacacag aactcttggc ctcattttcc atagaaggag ataagctcat 1800 gattgatgcc aagctggaga agaccagcct caacctcaga acctcaaacg tgggcaactt 1860 tgatattggc ctcatggagg tgctggtgga gaagattttt gacctggcat tcatgcccgc 1920 aatgaacgct gtgctgggtt ctggcgtccc tctccccaaa atcctcaaca tcgactttag 1980 caatgcagac attgacgtgt tggaggacct tttggtgctg agcgcatgag tgacagaggc 2040 agagatgctg ctgcaactgg aagaagctgg aaccagtccc agagaggctc ggcctggaaa 2100 cagtcccctg cccagagtcc cctcagcctc catgacaggt ccctccctgg ccccccaacc 2160 ctcttcctcc cttgccccaa ccctgagaaa gggtccagcc actaccctgt tggcaaacat 2220 tcccttccat ggtcagcctg ccaggaggag gggagtcacc ttggggctgg aggcctctca 2280 gaccccatcc tgacagcagg ttgagtattc ccactttcaa taaaagactc cactttcccg 2340 gcaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2370 21 3669 DNA Homo sapiens misc_feature Incyte ID No 4825215CB1 21 agagcagaac tgagcaggcg gtggagctgg gtctggtccg ggcacggagt gggggcttcg 60 aagggaaaag gcggggctcc tgggggcgga gccatacctg tgggcgggac atgggaaagg 120 agggcccgag gggcggagct acaatagaaa gggccaggag gtgctgaggc gaggagaggc 180 cgaactccaa gggacgacgc tcgcggaagc agaggtttgg ggacagctgc ccagcctcca 240 ggcccactga tggacccgtt aacgaaggtg ccttgtggga gtcagatagc acaaaccatt 300 ctatggaaag caaagtcgtc tctctccttc ggcatccagc cccttcagac atggccaacg 360 aaagaccctg aactagagtc ccaggtcaac ctctctgtct cggaagacct aggctgtaga 420 cgtggggatt tcagtaggaa acattatgga tctgtggagc tgcttatttc cagtgatgct 480 gatggagcca tccaaagggc tggaagattc agagtggaaa atggctcttc agatgagaat 540 gcaactgccc tgcctggtac ttggcgaaga acagacgtgc acttagagaa cccagaatac 600 cacaccagat ggtatttcaa atatttttta ggacaagtcc atcagaacta cattggaaac 660 gatgccgaga agagcccttt cttcttgtcc gtgacccttt ctgaccaaaa caatcaacgt 720 gtccctcaat accgtgcaat tctttggaga aaaacaggta cccagaaaat atgccttccc 780 tacagtccca caaaaactct ttctgtgaag tccatcttaa gtgccatgaa tctggacaaa 840 tttgagaaag gccccaggga aatttttcat cctgaaatac aaaaggactt gctggttctt 900 gaagaacaag agggctctgt gaatttcaag tttggggttc tttttgccaa agatgggcag 960 ctcactgatg atgagatgtt cagcaatgaa attggaagcg agccttttca aaaattttta 1020 aatcttctgg gtgacacaat cactctaaag ggctggacgg gctaccgtgg cggtctggat 1080 accaaaaatg ataccacagg gatacattca gtttatactg tgtaccaagg gcatgagatc 1140 atgtttcatg tttccaccat gttgccatat tccaaagaga acaaacagca ggtggaaagg 1200 aaacgccaca ttggaaacga tatcgtcacc attgtgttcc aagaaggaga ggaatcttct 1260 cctgccttta agccttccat gatccgctcc cactttacac atatttttgc cttagtgaga 1320 tacaatcaac aaaatgacaa ttacaggctg aaaatatttt cagaagagag cgtaccactc 1380 tttggccctc ccttgccaac tccaccagtg tttacagacc accaggaatt cagggacttt 1440 ttgctagtga aattaattaa tggtgaaaaa gccactttgg aaaccccaac atttgcccag 1500 aaacgtcggc gtaccctgga tatgttgatt agatctttac accaggattt gatgccagat 1560 ttgcataaga acatgcttaa tagacgatct tttagtgatg tcttaccaga gtcacccaag 1620 tcagcgcgga agaaagagga ggcccgccag gcggagtttg ttagaatagg gcaggcacta 1680 aaactgaaat ccattgtgag aggggatgct ccatcaagct tggcagcttc agggatctgt 1740 aaaaaagagc cgtgggagcc ccagtgtttc tgcagtaatt tccctcatga agccgtgtgt 1800 gcagatccct ggggccaggc cttgctggtt tccactgatg ctggcgtctt gctagtggat 1860 gatgaccttc catcagtgcc cgtgtttgac agaactctgc cagtgaagca aatgcatgtg 1920 cttgagaccc tggaccttct ggttctcaga gcagacaaag gaaaagatgc tcgcctcttt 1980 gtcttcaggc taagtgctct gcaaaagggc cttgagggga agcaggctgg gaagagcagg 2040 tctgactgca gagaaaacaa gttggagaaa acaaaaggct gccacctgta tgctattaac 2100 actcaccaca gcagagagct gaggattgtg gttgcaattc ggaataaact gcttctgatc 2160 acaagaaaac acaacaagcc aagcggggtc accagcacct cattgttatc tcccctgtct 2220 gagtcacctg ttgaagaatt ccagtacatc agggagatct gtctgtctga ctctcccatg 2280 gtgatgacct tagtggatgg gccagctgaa gagagtgaca atctcatctg tgtggcttat 2340 cgacaccaat ttgatgtggt gaatgagagc acaggagaag ccttcaggct gcaccacgtg 2400 gaggccaaca gggttaattt tgttgcagct attgatgtgt acgaagatgg agaagctggt 2460 ttgctgttgt gttacaacta cagttgcatc tataaaaagg tttgcccctt taatggtggc 2520 tcttttttgg ttcaaccttc tgcgtcagat ttccagttct gttggaacca ggctccctat 2580 gcaattgtct gtgctttccc gtatctcctg gccttcacca ccgactccat ggagatccgc 2640 ctggtggtga acgggaacct ggtccacact gcagtcgtgc cgcagctgca gctggtggcc 2700 tccaggtcgg atatatactt cacagcaact gcagctgtga atgaggtctc atctggaggc 2760 agctccaagg gggccagtgc ccgaaattct cctcagacac ccccgggccg agatactcca 2820 gtatttcctt cttccctggg ggaaggtgaa attcaatcaa aaaatctgta caagattcca 2880 cttagaaacc tcgtgggcag aagcatcgaa cgacctctga agtcaccctt agtctccaag 2940 gtcatcaccc cacccactcc catcagtgtg ggccttgctg ccattccagt cacgcactcc 3000 ttgtccctgt ctcgcatgga gatcaaagaa atagcaagca ggacccgcag ggaactactg 3060 ggcctctcgg atgaaggtgg acccaagtca gaaggagcgc caaaggccaa atcaaaaccc 3120 cggaagcggt tagaagaaag ccaaggaggc cccaagccag gggcagtgag gtcatctagc 3180 agtgacagga tcccatcagg ctccttggaa agtgcttcta cttccgaagc caaccctgag 3240 gggcactcag ccagctctga ccaggaccct gtggcagaca gagagggcag cccggtctcc 3300 ggcagcagcc ccttccagct cacggctttc tccgatgaag acattataga cttgaagtaa 3360 cagagttgaa tctcatttgc catctttagt tttcttatgg aggtttatac tctttaaaca 3420 gttctgatgt aatttctcaa caaaatgtgg cttttagcct gtcagtgatc tattggacca 3480 aaccttctgc acactcggcc agttccctct ccaatgtccg gtgccatctt tcctgacctt 3540 tgtttctttc tgttcaggaa ccatcagtcc ccttgtaata aaggtggtag atttcattga 3600 ggttttagat tgaaactttg aataaatcaa aaatactcat tcttaaaaaa aaaaaaaaaa 3660 aaaaaaaaa 3669 22 2505 DNA Homo sapiens misc_feature Incyte ID No 6892116CB1 22 atgaccgtgg agttcgagga gtgcgtcaag gactccccgc gcttcagggc gaccattgac 60 gaggtggaga cggacgtggt ggagattgag gccaaactgg acaagctggt gaagctgtgc 120 agtggcatgg tggaagccgg taaggcctac gtcagcacca gcaggctttt cgtgagcggc 180 gtccgcgacc tgtcccagca gtgccagggc gacaccgtca tctcggaatg tctgcagagg 240 ttcgctgaca gcctacagga ggtggtgaac taccacatga tcctgtttga ccaggcccag 300 aggtccgtgc ggcagcagct ccagagcttt gtcaaagagg atgtgcggaa gttcaaggag 360 acaaagaagc agtttgacaa ggtgcgggag gacctggagc tgtccctggt gaggaacgcc 420 caggccccga ggcaccggcc ccacgaggtg gaggaagcca ccggggccct caccctcacc 480 aggaagtgct tccgccacct ggcactggac tatgtgctcc agatcaatgt tctgcaggcc 540 aagaagaagt ttgagatcct ggactctatg ctgtccttca tgcacgccca gtccagcttc 600 ttccagcagg gctacagcct cctgcaccag ctggacccct acatgaagaa gctggcagcc 660 gagctggacc agctggtgat cgactctgcg gtggaaaagc gtgagatgga gcgaaagcac 720 gccgccatcc agcagcggac gctgctgcag gacttctcct acgatgagtc caaagtggag 780 tttgacgtgg acgcgcccag tggggtggtg atggagggct acctcttcaa gagggccagc 840 aacgctttca agacatggaa ccggcgctgg ttctccattc agaacagcca gctggtctac 900 cagaagaagc tcaaggatgc cctcaccgtg gtggtggatg acctccgcct gtgctctgtg 960 aagccgtgtg aggacatcga gcggaggttc tgcttcgagg tgctgtcacc caccaagagc 1020 tgcatgctgc aggctgactc cgagaagctg cggcaagcct gggtccaggc tgtgcaggcc 1080 agcatcgcct ccgcctaccg cgagagccct gacagttgct atagcgagag gctggaccgc 1140 acagcatccc cgtccacgag cagcatcgac tccgccaccg acactcggga gcgtggcgtg 1200 aagggcgaga gtgtgctgca gcgtgtgcag agtgtggccg gcaacagcca gtgcggcgac 1260 tgcggccagc cggacccccg ctgggccagc atcaacctgg gcgtgctgct ctgcattgag 1320 tgctccggca tccacaggag cctgggtgtc cactgctcca aggtgcggtc cctgacgctg 1380 gactcgtggg agcctgagct gctaaagctg atgtgtgagc ttggaaacag cgctgtgaat 1440 cagatctatg aggcccagtg tgagggtgca ggcagcagga aacccacagc cagcagctcc 1500 cggcaggaca aggaggcctg gatcaaggac aaatacgtgg aaaagaagtt tctgcggaag 1560 gcgcccatgg caccagccct ggaggcccca agacgctgga gggtgcagaa gtgcctgcgg 1620 ccccacagct ctccccgcgc tcccactgcc cgccgcaagg tccggcttga gcccgttctg 1680 ccctgtgtgg ccgctctgtc ctcagtgggc accctggatc gtaagttccg ccgagactcc 1740 ctcttctgtc ccgacgagct ggactcgctc ttctcctact tcgacgcagg ggccgcaggg 1800 gctggccctc gcagtctgag tagcgacagt ggccttgggg gcagctcgga tggcagctcg 1860 gacgtcctgg ctttcggctc gggctctgtg gtggacagcg tcactgagga ggagggtgca 1920 gagtcggagg agtccagcgg tgaggcagac ggggacactg aggccgaggc ctggggcctg 1980 gcggacgtgc gcgagctgca cccggggctc ttggcgcacc gcgcagcgcg tgcccgcgac 2040 cttcctgcgc tggcggcggc gctggcccac ggggccgagg tcaactgggc ggacgcggag 2100 gatgagggca agacgccgct ggtgcaggcc gtgctagggg gctccttgat cgtctgtgag 2160 ttcctgctgc aaaacggagc ggacgtgaac caaagagaca gccggggccg ggcgcccctg 2220 caccacgcca cgctgctggg ccgcaccggc caggtttgcc tgttcctgaa gcggggcgcg 2280 gaccagcacg ccctggacca agagcagcgg gacccgttgg ccatcgcagt gcaggcggcc 2340 aacgctgaca tcgtgacact gctccgtctg gcgcgcatgg cggaggaaat gcgcgaggcc 2400 gaggctgccc ctggtccccc gggcgccctg gcgggcagcc ccacggagct ccagttccgc 2460 aggtgtatcc aggagttcat cagcctccac ctggaagaga gctag 2505 23 3030 DNA Homo sapiens misc_feature Incyte ID No 5990388CB1 23 gaagccatta caaaggttgc ttaacttcta attatttgat cactgaggaa aatccagaaa 60 gctacacaac actgaagggg tgaaataaaa gtccagcgat ccagcgaaag aaaagagaag 120 tgacagaaac aactttacct ggactgaaga taaaagcaca gacaagagaa caatgccctg 180 gacatggctc cagagatcca catgacaggc ccaatgtgcc tcattgagaa cactaatggg 240 gaactggtgg cgaatccaga agctctgaaa atcctgtctg ccattacaca gcctgtggtg 300 gtggtggcaa ttgtgggcct ctaccgcaca ggaaaatcct acctgatgaa caagctagct 360 gggaagaata agggcttctc tctgggctcc acagtgaaat ctcacaccaa aggaatctgg 420 atgtggtgtg tgcctcaccc caaaaagcca gaacacacct tagtcctgct tgacactgag 480 ggcctgggag atgtaaagaa gggtgacaac cagaatgact cctggatctt caccctggcc 540 gtcctcctga gcagcactct cgtgtacaat agcatgggaa ccatcaacca gcaggctatg 600 gaccaactgt actatgtgac agagctgaca catcgaatcc gatcaaaatc ctcacctgat 660 gagaatgaga atgaggattc agctgacttt gtgagcttct tcccagattt tgtgtggaca 720 ctgagagatt tctccctgga cttggaagca gatggacaac ccctcacacc agatgagtac 780 ctggagtatt ccctgaagct aacgcaaggt accagtcaaa aagataaaaa ttttaatctg 840 ccccgactct gtatccggaa gttcttccca aagaaaaaat gttttgtctt cgatctgccc 900 attcaccgca ggaagcttgc ccagcttgag aaactacaag atgaagagct ggaccctgaa 960 tttgtgcaac aagtagcaga cttctgttcc tacatcttta gcaattccaa aactaaaact 1020 ctttcaggag gcatcaaggt caatgggcct cgtctagaga gcctagtgct gacctatatc 1080 aatgctatca gcagagggga tctgccctgc atggagaacg cagtcctggc cttggcccag 1140 atagagaact cagccgcagt gcaaaaggct attgcccact atgaccagca gatgggccag 1200 aaggtgcagc tgcccgcaga aaccctccag gagctgctgg acctgcacag ggttagtgag 1260 agggaggcca ctgaagtcta tatgaagaac tctttcaagg atgtggacca tctgtttcaa 1320 aagaaattag cggcccagct agacaaaaag cgggatgact tttgtaaaca gaatcaagaa 1380 gcatcatcag atcgttgctc agctttactt caggtcattt tcagtcctct agaagaagaa 1440 gtgaaggcgg gaatttattc gaaaccaggg ggctattgtc tctttattca gaagctacaa 1500 gacctggaga aaaagtacta tgaggaacca aggaagggga tacaggctga agagattctg 1560 cagacatact tgaaatccaa ggagtctgtg accgatgcaa ttctacagac agaccagatt 1620 ctcacagaaa aggaaaagga gattgaagtg gaatgtgtaa aagctgaatc tgcacaggct 1680 tcagcaaaaa tggtggagga aatgcaaata aagtatcagc agatgatgga agagaaagag 1740 aagagttatc aagaacatgt gaaacaattg actgagaaga tggagaggga gagggcccag 1800 ttgctggaag agcaagagaa gaccctcact agtaaacttc aggaacaggc ccgagtacta 1860 aaggagagat gccaaggtga aagtacccaa cttcaaaatg agatacaaaa gctacagaag 1920 accctgaaaa aaaaaaccaa gagatatatg tcgcataagc taaagatcta aacaacagag 1980 cttttctgtc atcctaaccc aaggcataac tgaaacaatt ttagaatttg gaacaagtgt 2040 cactatattt gataataatt agatcttgca tcataacact aaaagtttac aagaacatgc 2100 agttcaatga tcaaaatcat gttttttcct taaaaagatt gtaaattgtg caacaaagat 2160 gcatttacct ctgtaccaac agaggaggga tcatgagttg ccaccactca gaagtttatt 2220 cttccagacg accagtggat actgaggaaa gtcttaggta aaaatcttgg gacatatttg 2280 ggcactggtt tggccaagtg tacaatgggt cccaatatca gaaacaacca tcctagcttc 2340 ctagggaaga cagtgtacag ttctccatta tatcaaggct acaaggtcta tgagcaataa 2400 tgtgatttct ggacattgcc catggataat tctcactgat ggatctcaag ctaaagcaaa 2460 ccatcttata cagagatcta gaatcttata ttttccatag gaaggtaaag aaatcattag 2520 caagagtagg aattgaatca taaacaaatt ggctaatgaa gaaatctttt ctttcttgtt 2580 caattcatct agattataac cttaatgtga cacctgagac ctttagacag ttgaccctga 2640 attaaatagt cacatggtaa caattatgca ctgtgtaatt ttagtaatgt ataacatgca 2700 atgatgcact ttaactgaag atagagacta tgttagaaaa ttgaactaat ttaattattt 2760 gattgtttta atcctaaagc ataagttagt cttttcctga ttcttaaagg tcatacttga 2820 aatcctgcca attttcccca aagggaatat ggaatttttt tgactttctt ttgagcaata 2880 aaataattgt cttgccatta cttagtatat gtagacttca tcccaattgt caaacatcct 2940 aggtaagtgg ttgacatttc ttacagcaat tacagattat ttttgaacta gaaataaact 3000 aaactagaaa taaaaaaaaa aaaaaaaaaa 3030 24 2466 DNA Homo sapiens misc_feature Incyte ID No 011293CB1 24 cttacttgga tgtctgtaaa tccggctgga ctttcagctt ctaagaacag tccgtttctc 60 gaggatccag gcgcaggagg acagagcaat gggtgagaga actcttcacg ctgcagtgcc 120 cacaccaggt tatccagaat ctgaatccat catgatggcc cccatttgtc tagtggaaaa 180 ccaggaagag cagctgacag tgaattcaaa ggcattagag attcttgaca agatttctca 240 gcccgtggtg gtggtggcca ttgtagggct ataccgcaca ggaaaatcct atctcatgaa 300 tcgtcttgca ggaaagcgca atggcttccc tctgggctcc acggtgcagt ctgaaactaa 360 gggcatctgg atgtggtgtg tgccccacct ctctaagcca aaccacaccc tggtccttct 420 ggacaccgag ggcctgggcg atgtagaaaa gagtaaccct aagaatgact cgtggatctt 480 tgccctggct gtgcttctaa gcagcagctt tgtctataac agcgtgagca ccatcaacca 540 ccaggccctg gagcagctgc actatgtgac tgagctagca gagctaatca gggcaaaatc 600 ctgccccaga cctgatgaag ctgaggactc cagcgagttt gcgagtttct ttccagactt 660 tatttggact gttcgggatt ttaccctgga gctaaagtta gatggaaacc ccatcacaga 720 agatgagtac ctggagaatg ccttgaagct gattccaggc aagaatccca aaattcaaaa 780 ttcaaacatg cctagagagt gtatcaggca tttcttccga aaacggaagt gctttgtctt 840 tgaccggcct acaaatgaca agcaatattt aaatcatatg gacgaagtgc cagaagaaaa 900 tctggaaagg catttcctta tgcaatcaga caacttctgt tcttatatct tcacccatgc 960 aaagaccaag accctgagag agggaatcat tgtcactgga aagcggctgg ggactctggt 1020 ggtgacttat gtagatgcca tcaacagtgg agcagtacct tgtctggaga atgcagtgac 1080 agcactggcc cagcttgaga acccagcggc tgtgcagagg gcagccgacc actatagcca 1140 gcagatggcc cagcaactga ggctccccac agacacgctc caggagctgc tggacgtgca 1200 tgcagcctgt gagagggaag ccattgcagt cttcatggag cactccttca aggatgaaaa 1260 ccatgaattc cagaagaagc ttgtggacac catagagaaa aagaagggag actttgtgct 1320 gcagaatgaa gaggcatctg ccaaatattg ccaggctgag cttaagcggc tttcagagca 1380 cctgacagaa agcattttga gaggaatttt ctctgttcct ggaggacaca atctctactt 1440 agaagaaaag aaacaggttg agtgggacta taagctagtg cccagaaaag gagttaaggc 1500 aaacgaggtc ctccagaact tcctgcagtc acaggtggtt gtagaggaat ccatcctgca 1560 gtcagacaaa gccctcactg ctggagagaa ggccatagca gcggagcggg ccatgaagga 1620 agcagctgag aaggaacagg agctgctaag agaaaaacag aaggagcagc agcaaatgat 1680 ggaggctcaa gagagaagct tccaggaata catggcccaa atggagaaga agttggagga 1740 ggaaagggaa aaccttctca gagagcatga aaggctgcta aaacacaagc tgaaggtaca 1800 agaagaaatg cttaaggaag aatttcaaaa gaaatctgag cagttaaata aagagattaa 1860 tcaactgaaa gaaaaaattg aaagcactaa aaatgaacag ttaaggctct taaagatcct 1920 tgacatggct agcaacataa tgattgtcac tctacctggg gcttccaagc tacttggagt 1980 agggacaaaa tatcttggct cacgtattta agagcctgaa tattccagat ggcctgaagc 2040 aagtgaagaa tcacaaaaga agtgaaaatg gcctgttcct gccttaactg atgacattac 2100 cttgtgaaat tccttctcct ggctcatcct ggctcaaaag ctcccccact aagcaacttg 2160 tgacacccac ctctgcccgc cagagaacaa ccccctttga ctgtaatttt cctttaccaa 2220 cccaaatcct gtaaaatggt cccaacccta tctcccttca ctgactgtct tttcggactc 2280 agccagcctg cacccaggtg attaaaaagc tttatggctc acaaaaaaaa aaaaaagggg 2340 cgggccgcga caagggagct cgtcaacccg ggagaattta aattccgcag agacccgggg 2400 aaccctgtga cagggcaggg ggccttggca ggagaattcc gaattatccc aagggctaac 2460 ggatac 2466 25 1680 DNA Homo sapiens misc_feature Incyte ID No 4080676CB1 25 cgtgactgcg cgccccgccc ggagtccccg ccgccgtcat gcagtccccg gcggtgctcg 60 tcacctccag gcgacttcag aatgcccaca ctggcctcga cctgactgtg ccccagcacc 120 aggaggtacg gggcaagatg atgtctggac acgtggagta ccagatcctg gtggtgaccc 180 gtctggctgc gttcaagtcg gccaagcaca ggcccgagga tgtcgtccag ttcttggtct 240 ccaaaaagta cagcgagatt gaggagtttt accagaaact gagcagtcgt tatgcagcag 300 ccagcctccc cccactaccc aggaaggtcc tgtttgttgg ggagtctgac atccgggaga 360 ggagagccgt gttcaatgag atcctgcgct gtgtctccaa ggatgccgag ttggcaggca 420 gcccagagct gctagagttc ttaggtacca gatccccagg ggctgcaggg ctcaccagca 480 gagattcctc tgtcctggat ggcacagaca gtcagacagg gaatgatgaa gaggctttcg 540 acttttttga ggagcaagac caagtggcag aagagggtcc gcccgtccag agcctgaagg 600 gcgaggatgc tgaggaatcc ttggaggagg aggaagcgct ggaccctctg ggcattatgc 660 gctccaagaa gcccaagaaa catcccaaag tggccgtgaa agccaagccc tcgccccggc 720 tcaccatctt tgacgaggag gtggaccctg atgaggggct ctttggcccg ggcaggaagc 780 tgtctccaca ggacccctcg gaggacgtgt catccatgga ccccctgaag ctatttgatg 840 atcctgacct cggcggggcc atccccctgg gtgactccct cctgctgccg gccgcctgtg 900 agagtggagg gcccacaccc agcctcagcc acagggacgc ctccaaggaa ctgttcagag 960 ttgaagagga cttggaccag attctgaacc tgggagctga gcccaaaccc aagccccagc 1020 ttaagcccaa gccaccagtg gcagctaagc cggtgatacc cagaaaacca gctgttcccc 1080 ccaaagcggg cccggctgaa gctgtggctg ggcagcagaa gccgcaggag cagatccaag 1140 ccatggacga gatggacatc ttgcagtaca tccaggacca cgatacacca gcccaggccg 1200 cccccagcct cttctgaccc ttccatgctg gcccctggcc cagcaggcct gtctgtgggg 1260 acatcggtgt gaagggaagg gactgggccc tgcagggtca gaacctcccc acccccaggg 1320 gaggccaggc agaagcctgg gtcacagcac ccagaactgc atggttccat tttctccggg 1380 gctgtggggc caaagtagaa gcctgcgggc tgcgggagcg gctctcaccc taggagccag 1440 agcccaatgt gtcttattcc ccgtggacat gaaggggagg gagggtgtgg ggatgccttg 1500 ccaaccagat gcccagcccc aaggatgaag caagacatgt ggggccgtag cgaggtgtca 1560 catggggcag ggaagcttca tgcccacggg ttctgccagc cccagcacag acccaaactg 1620 gggctgggcc tctatccctc ctctgcctct gttcgcatag taagaaggag tgaccgggat 1680 26 1133 DNA Homo sapiens misc_feature Incyte ID No 4791825CB1 26 gcggaaagag aagcaaaacc actcttccta aaatgttaga agctgctctt cgcttacctt 60 ggggcctttg cattgggagc tgtttttcac atcaaagaat atgtgctgaa tggaatttta 120 gtattttgct gtcgttttaa tattttcgtc tggtcttcct cagttcttcc agacgctttc 180 tgagagaatg ggggcaggag ctctagccat ctgtcaaagt aaagcagcgg ttcggctgaa 240 agaagacatg aaaaagatag tggcagtgcc attaaatgaa cagaaggatt ttacctatca 300 gaagttattt ggagtcagtc tccaagaact tgaacggcag gggctcaccg agaatggcat 360 tccagcagta gtgtggaata tagtggaata tttgacgcag catggactta cccaagaagg 420 tctttttagg gtgaatggta acgtgaaggt ggtggaacaa cttcgactga agttcgagag 480 tggagtgccc gtggagctcg ggaaggacgg tgatgtctgc tcagcagcca gtctgttgaa 540 gctgtttctg agggagctgc ctgacagtct gatcacctca gcgttgcagc ctcgattcat 600 tcaactcttt caggatggca gaaatgatgt tcaggagagt agcttaagag acttaataaa 660 agagctgcca gacacccact actgcctcct caagtacctt tgccagttct tgacaaaagt 720 agccaagcat catgtgcaga atcgcatgaa tgttcacaat ctcgccactg tatttgggcc 780 aaattgcttt catgtgccac ctgggcttga aggcatgaag gaacaggacc tgtgcaacaa 840 gataatggct aaaattctag aaaattacaa taccctgttt gaagtagagt atacagaaaa 900 tgatcatctg agatgtgaaa acctggctag gcttatcata gtaaaagtaa gcaacttggt 960 ttttaatttt cagtattgct ataattttgg acagaagatt ttatttaatt ctttctcata 1020 aaaattccat atggatataa ccctcagatt attattcctg tgtatagtga atccttctta 1080 tgaaatctat tattccaaat gcttattaaa ttgaaatata gccttctaaa att 1133 27 5145 DNA Homo sapiens misc_feature Incyte ID No 7481996CB1 27 gggaacgcgc gcggcgaagg cggcctcggc ccagtgcaca gcgggaccag gcagagttcg 60 gggaaagcgt cggagttcgg gagaccaggg ccagcatggg tttcagcaca gcagacggcg 120 ggggcggccc aggcgcccgg gatctggaat ctcttgatgc ctgtatccag aggacgctct 180 ctgccttgta cccaccgttt gaagccacgg cagccacggt gctctggcag ctgttcagcg 240 tggccgagag gtgccacggt ggggacgggc tgcactgcct caccagcttc ctcctcccag 300 ccaagagggc cctgcagcac ctgcagcagg aagcctgtgc caggtacagg ggtctggtct 360 tcctgcaccc aggctggccg ctgtgcgccc atgagaaggt ggtggtgcag ctggcgtccc 420 tgcacggagt caggctccag cctggggact tctacctgca ggtcacgtcg gcggggaagc 480 agtcagctag actggtcttg aaatgcctgt cccggctggg aagaggcaca gaggaagtca 540 ccgtccctga ggccatgtat ggctgtgtct tcacgggggc gttcctggag tgggtaaacc 600 gggagcggcg ccatgtcccc ctgcaaacct gcttgctgac ctcaggcttg gccgtccacc 660 gagccccgtg gagcgacgtc actgaccctg tctttgtccc cagccctgga gccatcctgc 720 agacctactc cagctgcaca ggtcctgagc ggctgcccag cagcccctca gaggccccag 780 tccccaccca agccacagca ggcccccatt tccagggaag cgcctcttgc cccgacaccc 840 tgacctcacc ctgccgccga gggcgtacgg gcagcgacca gctcaggcac cttccttatc 900 cagaaagagc cgagctggga agccccagga ccctgtctgg aagctcagac agggacttcg 960 aaaagagcag ggcccacgga tgcccccctg agaactgtgg ggggtcgggg gagaggccgg 1020 accccatgga ccaggaggac agacccaagg ccctcacctt ccacacagac ctgggcatcc 1080 cgagcagcag gaggcggccg ccgggggacc ccacttgtgt gcagcctaga cgctggttca 1140 gggagtcgta catggaagcc ttgcggaacc ccatgcccct gggcagctct gaggaggccc 1200 tcggggacct ggcctgcagc tccctgactg gagccagcag ggacctgggg actggggcag 1260 tagccagtgg gacccaggag gaaacctctg gcccccgggg agacccccaa cagaccccaa 1320 gtctagagaa ggagaggcac acacccagcc ggacaggtcc aggagctgca gggcggactc 1380 ttcccaggag atctcggtcc tgggaaaggg cacccagaag ctccagaggg gcccaggctg 1440 cagcctgcca cacctcccac cactcagcag gctccaggcc tgggggccac ctaggaggac 1500 aagctgtggg gaccccaaac tgtgtcccag tagagggtcc cggctgcacc aaagaggaag 1560 acgttcttgc atcctcagcc tgtgtcagca cagacggcgg cagcctccat tgccacaacc 1620 ccagcgggcc ttccgatgtg cctgcccggc agccacaccc cgagcaagaa gggtggccac 1680 ccggcacagg agacttcccc agccaggtgc ccaagcaggt gctggacgtc agtcaggagc 1740 tgctgcagtc cggggtcgtc accctcccag ggacccgaga ccgtcatggc agagcagtgg 1800 tgcaggtccg caccaggagc ctgctctgga ccagggaaca ctcgtcctgt gctgagctga 1860 cccgcctgct gctgtacttc catagcatcc ccaggaaaga ggtccgggac ctggggctgg 1920 ttgtcctggt ggatgcacgc aggagtccag ctgcccctgc cgtctcccag gccctctcag 1980 gattgcagaa caacacatct cctataattc atagtatctt gctgttggta gataaagaat 2040 ctgcatttag gcctgacaag gatgcaataa ttcagtgtga ggtcgtgagc tccctgaagg 2100 ccgtgcacaa atttgttgac agctgccagc tgaccgcaga cctcgacggc tcctttccct 2160 acagccatgg tgactggatc tgcttccgtc agaggctgga acacttcgct gcaaactgtg 2220 aagaagccat cattttccta cagaattcat tctgctccct gaacacccac agaaccccaa 2280 gaacagccca ggaagtcgcc gagttaattg accagcatga gacgatgatg aagcttgtcc 2340 tggaagaccc actgcttgtg tctctcaggc tggagggggg caccgtcctg gcgcggctga 2400 ggagagaaga gcttggcaca gaagacagcc gggacaccct ggaggccgcc acaagcctgt 2460 acgaccgagt ggatgaggag gtgcacaggc tggtcctcac ctcgaacaat cgtctccagc 2520 agctggagca cctccgggag ctggcgtcac tcctggaagg gaatgaccag caatcctgcc 2580 agaaaggact acagctggcg aaggagaacc cgcaacgtac agaggaaatg gtccaggatt 2640 tcagaagggg cctgagcgcc gtggtcagcc aggctgagtg cagggaggga gagctggcca 2700 ggtggacccg ctcgtccgag ttgtgcgaga cggtgagcag ctggatgggg cccctggacc 2760 cggaggcttg tccctcctca cccgtggctg agtgtttgag gagctgtcac caggaggcta 2820 cctcggtggc tgcagaggcc ttccccgggg cagcaagact gtggctgcag taccccagac 2880 cggctcgtct ggaagaggcc ctttctgagg ctgccccaga ccccagctta ccgccccttg 2940 cccagagccc cccaaagcat gagcgtgccc aggaggccat gaggaggcac cagaagccac 3000 cctcattccc cagcacggac agtgggggtg gtgcctggga acctgcccaa ccactgtccg 3060 gcctccctgg acgagcgctt ctgtgtggac aggacgggga gcccctgggc ccagggctgt 3120 gtgctctgtg ggacccactg tccctcctca ggggccttcc aggggcaggg gccaccacgg 3180 cccacctgga ggacagctct gcctgttcct ctgagcccac ccagaccctg gccagccgcc 3240 ccaggaaaca tccccagaag aaaatgataa agaaaacgca aagtttcgag atacctcagc 3300 ccgacagtgg ccccagggac tcctgccagc cagaccatac tagtgtcttc agcaagggcc 3360 tggaggtaac cagcactgta gccacagaga agaagctccc gctgtggcag catgccagga 3420 gccccccggt cactcagagc cggagtctgt cctccccctc ggggctccac cctgctgagg 3480 aggatgggag gcagcaggtg ggcagcagcc gactgaggca catcatggcc gagatgatcg 3540 ccacagagag ggagtacatt cggtgcttag gatacgtcat tgacaactat tttccagaaa 3600 tggaaagaat ggacttgccc cagggccttc gagggaagca ccacgttatt ttcggcaact 3660 tggagaagct ccacgacttc caccagcagc acttcctccg ggagctggag cgctgccagc 3720 actgcccctt ggccgtgggc cgcagtttcc tgagacacga agagcagttt gggatgtacg 3780 tgatctacag caaaaacaag ccgcagtcgg atgccctgct cagcagccat ggcaacgcct 3840 tcttcaagga caagcagcgg gagctaggtg acaaaatgga cctggcctcc tacctgctgc 3900 ggcccgtgca gcgtgtggcc aagtacgcgc tgctactcca ggacctgctc aaggaggcca 3960 gctgtggcct ggcccagggg caggagctgg gcgagctccg agccgccgag gtcgtggtct 4020 gcttccagct gcgtcacggc aatgacctgc tggccatgga cgccatccgc ggctgtgacg 4080 tgaatttgaa ggaacagggg cagctgagat gccgggatga gtttatcgtt tgctgcggga 4140 ggaagaagta tctgaggcat gtgttcctct ttgaagacct catcctgttt agcaagaccc 4200 agaaggtgga gggcagccac gacgtctacc tgtacaagca gtccttcaag acggccgaga 4260 tcgggatgac agagaacgtc ggggacagtg gcttgaggtt tgagatttgg tttcgcaggc 4320 ggcggaaatc tcaggacacc tacattctcc aagcaagctc ggcagaggtc aagagtgcat 4380 ggaccgatgt catagggagg atcctgtggc ggcaggcact aaagagcaga gaactcagaa 4440 tccaagaaat ggcatccatg ggtataggca accagccatt catggatgtc aagcccagag 4500 accggacccc tgactgtgca gtgataagcg accgggctcc caaatgtgca gtgatgagcg 4560 accgagtccc cgacagcatc gtcaagggca cagagtcaca aatgagaggg tccacagcgg 4620 tgtcctcctc tgaccacgcc gcccccttca agcgaccaca ctccaccatc tcagacagca 4680 gcacctcctc ttctagcagc cagtcctcct ccatcctggg gtcgctgggc ctgcttgtgt 4740 cctccagccc agcccacccg ggcctatgga gccctgccca cagcccctgg tcatctgata 4800 tcagagcctg cgtcgaggaa gatgagccag agccagaact agagacgggc acccaggctg 4860 cagtgtgtga gggggctcct gctgtgctgc tgagccgcac acgccaggcc tgatgactgt 4920 cagggtggca gtgcccatca tgtggctaga acaatacaga gggagcagca cgccaggcct 4980 gatgactctg ggggtggcgg tgcccatcgc gtggctggaa cgatccagag ggaatagcac 5040 agcaggtgtc caggtatttc ccaggatttt agacattccc taacattttc aaacaaattt 5100 ataattttgt cttatttaaa aaacaacctt ccacttccac ccaag 5145 28 5434 DNA Homo sapiens misc_feature Incyte ID No 7610864CB1 28 ggaggtgcgg ggccatcgct ccagatgcga aagccatgga gttgagctgc agcgaagcac 60 ctctttacgg gcagatgatg atctatgcga agtttgacaa aaatgtgtat cttcctgaag 120 atgctgagtt ttactttact tatgacggat ctcatcagcg acatgtcatg attgcagagc 180 gcatcgagga taacgttctc cagtccagcg tcccaggcca tgggcttcag gagacggtga 240 cggtatctgt gtgcctctgc tcggaaggtt actctccggt gaccatgggc tctggctcag 300 tgacctacgt ggacaacatg gcttgcaggc tggctcgtct gctggtgacg caggccaatc 360 gcctcacagc ctgcagccac cagaccctgc tgaccccatt tgccttgacg gcaggagcac 420 tgcctgcctt ggatgaggag ctcgtgctgg ctctgaccca tctggaattg cctctagagt 480 ggactgtgtt gggaagttct tcacttgaag tatcttctca cagagaatct cttctacacc 540 tggctatgag atggggcctg gctaaacttt cccagttctt cttgtgtctc ccggggggag 600 tccaggcctt ggctttaccc aacgaagagg gtgccacacc attagactta gctttacgtg 660 aaggacactc caagctggtg gaagacgtca caaattttca gggcagacgg tccccaagct 720 tctcccgagt gcagctcagt gaagaagcct ccttgcatta cattcactca tcggaaacgc 780 tgaccctgac cctgaaccac acagccgagc atttgttgga ggcagatatt aaactcttcc 840 ggaaatactt ttgggataga gcctttcttg tcaaggcctt tgagcaagaa gccaggccag 900 aggaaagaac agctatgccc tccagcggtg cagaaactga agaagagatt aagaattcag 960 tgtccagcag atcagcagcc gaaaaggaag atataaagcg tgtcaaaagc ctggtggttc 1020 aacacaatga acatgaagac cagcacagcc tagatttgga tcgctccttc gatatcctaa 1080 aaaaatccaa gccgccctcg acattgcttg ctgcaggccg gctttcagac atgctgaatg 1140 gaggtgatga agtctacgct aactgtatgg tgattgatca ggttggtgat ttggatatca 1200 gctatattaa tatagaggga atcactgcca ctaccagccc tgaatccaga ggttgcactc 1260 tgtggcctca gagcagcaaa cacacccttc ctacagaaac cagtcccagt gtgtacccac 1320 ttagtgaaaa tgtcgaaggg acagcacaca ctgaagccca gcagtccttc atgtcaccat 1380 caagttcgtg tgcttccaac ttgaatcttt cttttggttg gcatggattt gaaaaggaac 1440 aaagtcatct aaagaaaaga agttctagcc ttgatgcctt ggacgccgac agtgaagggg 1500 aagggcattc tgagccatcc cacatctgtt acactccagg gtctcagagc tcctcaagaa 1560 ctgggattcc tagtggggat gaattggact cttttgagac taacactgaa ccggatttta 1620 atatctccag ggctgaatcc cttcctctat caagtaatct acagttgaag gaatcactgc 1680 tttctggagt tcgctcacgt tcttattctt gctcgtcacc caaaatttct ttaggaaaaa 1740 ctcgtttggt gcgtgaatta acagtatgca gttcaagtga agagcaaaaa gcttacagct 1800 tatcggagcc accaagagaa aacagaattc aggaagaaga atgggataaa tacatcatac 1860 ctgccaaatc agagtctgaa aaatataaag tgagtcgaac tttcagtttc ctcatgaata 1920 ggatgactag ccctcggaat aaatcaaagg taaaaagcaa ggatgccaaa gataaagaga 1980 agctgaatcg acatcagttt gccccaggaa cattctctgg ggttctgcag tgtttggttt 2040 gtgataaaac actcctgggg aaagagtcac tgcagtgttc taactgtaat gcaaatgtgc 2100 acaaaggttg taaagatgct gcgcctgcat gcaccaagaa attccaagag aaatataaca 2160 agaacaaacc acagaccatc cttggaaatt cttcatttag agacatccca cagcctggtc 2220 tctccttgca cccttcttcc tccgtgcctg ttggattgcc gactggaagg agggagactg 2280 tgggacaggt ccatccattg tccagaagtg ttccaggcac caccttggaa agcttcagga 2340 ggtcagccac atccttggag tctgagagtg accataacag ctgcagaagc aggtctcatt 2400 ctgatgagct gctacagtcc atgggctctt ctccctctac agagtctttc ataatggaag 2460 atgttgtgga ttcttctctg tggagtgacc tcagcagtga tgcccaggag tttgaagcag 2520 aatcttggag tcttgtggtg gatccctcat tttgtaatag gcaggagaag gatgtcatca 2580 aaagacagga tgtcattttt gagctaatgc aaacagagat gcatcacatc cagaccctgt 2640 tcatcatgtc tgagatcttc aggaaaggca tgaaagagga gctgcagctg gaccacagca 2700 ccgtggataa aattttcccc tgtttagatg agttgcttga aatccacagg catttcttct 2760 acagtatgaa ggaacgaagg caggaatcct gtgctggcag cgacaggaat tttgtgatcg 2820 accgaattgg agatattttg gtacaacagt tttcagaaga aaatgcaagt aaaatgaaga 2880 aaatatatgg agaattctgt tgccatcata aagaagctgt taacctcttt aaagaactcc 2940 agcagaataa aaagtttcag aattttatta agctccgaaa tagtaatctt ttggctcgac 3000 gccgaggaat tccagaatgc attctgttgg tcactcagcg tattacaaaa taccctgtct 3060 tggtggaaag gatattgcag tacacaaagg aaagaactga ggaacataaa gacttaacgc 3120 aaagcctttg cttaattaaa gacatgattg caacagtgga tttaaaagtc aatgaatatg 3180 agaaaaacca aaaatggctt gagatcctaa ataagattga aaacaaaaca tacacgaagc 3240 tcaaaaatgg acatgtgttt aggaagcagg cactgatgag tgaagaaagg actctgttat 3300 atgatggcct tgtttactgg aaaactgcta caggtcgttt caaagatatc ctagctctac 3360 ttctaactga tgtgctgctc tttttacaag aaaaagacca gaaatacatc tttgcagccg 3420 ttgatcagaa gccatcagtt atttcccttc aaaagcttat tgctagagaa gttgctaatg 3480 aggagagagg aatgtttctg atcagtgctt catctgctgg tcctgagatg tatgaaattc 3540 acaccaattc caaggaggaa cgcaataact ggatgagacg gatccagcag gctgtagaaa 3600 gttgtcctga agaaaaaggg ggaaggacaa gtgaatctga tgaagacaag aggaaagctg 3660 aagccagagt ggccaaaatt cagcaatgtc aagaaatact cactaaccaa gaccaacaaa 3720 tttgtgcgta tttggaggag aagctgcata tctatgctga acttggagaa ctgagcggat 3780 ttgaggacgt ccatctagag ccccacctcc ttattaaacc tgacccaggc gagcctcccc 3840 aggcagcctc attactggca gcagcactga aagaagctga gagcctacaa gttgcagtga 3900 aggcctcaca gatgggcgcc gtgagtcaat catgtgagga cagttgtgga gactctgtct 3960 tggcggacac actcagttct catgatgtac caggatcacc gactgcctca ttagtcacag 4020 gagggagaga aggaagaggc tgttcggatg tggatcccgg gatccagggt gtggtaaccg 4080 acttggccgt ctctgatgca ggggagaagg tggaatgtag aaattttcca ggttcttcac 4140 aatcagagat tatacaagcc atacagaatt taacccgtct cttatacagc cttcaggccg 4200 ccttgaccat tcaggacagc cacattgaga tccacaggct ggttctccag cagcaggagg 4260 gcctgtctct cggccactct atcctccgag gcggcccctt gcaggaccag aagtctcgcg 4320 acgcggacag gcagcatgag gagctggcca atgtgcacca gcttcagcac cagctccagc 4380 aggagcagcg gcgctggctg cgcaggtgtg agcagcagca gcgggcgcag gcgaccaggg 4440 agagctggct gcaggagcgg gagcgggagt gccagtcgca ggaggagctg ctgctgcgga 4500 gccggggcga gctggacctc cagctccagg agtaccagca cagcctggag cggctgaggg 4560 agggccagcg cctggtggag agggagcagg cgaggatgcg ggcccagcag agcctgctgg 4620 gccactggaa gcacggccgg cagaggagcc tgcccgcggt gctccttccg ggtggccccg 4680 aggtaatgga acttaatcga tctgagagtt tatgtcatga aaactcattc ttcatcaatg 4740 aagctttagt acaaatgtca tttaacactt tcaacaaact gaatccatca gttatccatc 4800 aggatgccac ttaccctaca actcaatctc attctgactt ggtgaggact agtgaacatc 4860 aagtagacct caaggtggac ccttctcagc cttcgaatgt cagtcacaaa ctgtggacag 4920 ccgctggttc cggccatcag atacttcctt tccaagaaag cagcaaggat tcttgtaaaa 4980 atcttgcaga tttggacacc tcccacactg agtccccaac cccccatgac tcaaattcac 5040 accgcccgcc ctcaactgca ggcgtttata acagaagcaa agctaaatct accgacaagg 5100 acaatgacca gacaagatgg ggaaactgga gatggagcca aagaaaatat tgtttacctc 5160 taattgtgtt gtcatttttc caaacaaaac aaaacactgg cacttttggg agaaactttt 5220 tgtctccatt ccttatgtat gtgtgattgt ctgtgtccaa attgctttaa gaataatatt 5280 taatatttcc tggaagctca tttttttggc atgagtctaa ttaaattatt gaaagccacc 5340 ctgtttgtat aatctttaac ttatcaaatc taatttcaga tttctggagg agaaactaac 5400 ttgaataagc aggactattt taaaaagtgg tttg 5434 29 6480 DNA Homo sapiens misc_feature Incyte ID No 6985813CB1 29 atgggcaact ccgacagtca gtacaccctt caaggatcta aaaatcatag caatactatt 60 actggtgcta agcaaattcc ttgctccctg aaaatacgtg gcattcatgc aaaagaggaa 120 aagtcattgc atggatgggg tcacggaagc aacggagcag gttacaagtc caggtccctg 180 gcccgaagct gcctttctca ctttaagagt aaccagcctt acgcatcgag actcggtggc 240 cccacatgca aggtctccag aggtgttgcc tactccacgc acaggacaaa tgccccaggg 300 aaggatttcc agggcatcag tgctgctttc tcaactgaga atggcttcca ctctgttggc 360 cacgagctgg cagataacca catcacctcc agagactgca acggacacct tctcaactgc 420 tacgggagga atgagagcat tgcctccacc ccaccgggcg aagaccgcaa gagcccccga 480 gtgctcatca aaacgctggg gaagctggat gggtgtttaa gggtcgagtt ccacaatggt 540 ggcaacccca gcaaagtgcc tgcagaggac tgcagtgagc cggtgcagct gctgaggtac 600 tcacctacct tagcatcgga aacctcccct gtgcctgaag ccaggagggg gtccagcgcc 660 gattccctgc ccagccatcg cccctctccc acggactctc gcctgcggtc cagcaaaggc 720 agctccctga gttctgagtc atcctggtac gactcccctt ggggcaatgc tggagagctg 780 agcgaggctg agggctcctt cctggccccc ggcatgcctg accccagtct ccatgccagc 840 ttcccacctg gcgatgccaa aaagcctttc aaccaaagct cttccctctc ctccctccgg 900 gaactgtaca aagatgccaa cctggggagc ctctccccct caggtatccg cctttctgat 960 gaatacatgg gcacgcatgc cagcctgagc aaccgtgtct cttttgcttc cgacattgat 1020 gtgccctcca gagtggcaca cggggacccc atccagtaca gttccttcac tctcccctgt 1080 cggaagccca aagcctttgt tgaggatact gcgaagaagg actccctcaa agccaggatg 1140 cgacggatca gtgactggac gggaagcctc tcaaggaaga aaaggaaact ccaggagccg 1200 aggtccaagg agggcagtga ctactttgac agtcgctctg atggactgaa tacagatgtg 1260 cagggatcct cccaggcatc tgcttttctg tggtcagggg gctctactca gatcctgtct 1320 cagagaagtg aatccacaca tgcgattggc agcgatcccc tccggcagaa catttatgag 1380 aatttcatgc gagagttgga aatgagcagg accaacactg agaacataga aacatctaca 1440 gaaaccgccg agtccagcag cgagtcactc agctctctgg aacagctgga tctgctcttt 1500 gagaaggaac agggggtggt ccggaaggcc gggtggctct tcttcaagcc cctggtcact 1560 gtgcagaagg aaaggaagct tgagctggtg gcacgaagga aatggaaaca gtactgggta 1620 acgctgaaag gatgcacgct gctgttttat gagacctatg ggaagaattc catggatcag 1680 agcagtgccc ctcggtgtgc tctgtttgca gaagacagca tagtgcagtc tgttccagag 1740 catcccaaga aagaaaatgt gttctgcctc agcaactcct ttggagatgt ctaccttttc 1800 caggccacca gccagacaga tctagaaaac tgggtcactg ctgtacactc tgcttgtgca 1860 tccctttttg caaagaagca tgggaaagag gacacgctgc ggctgctgaa gaaccagacc 1920 aaaaacctgc ttcagaagat agacatggac agcaagatga agaagatggc agagctgcag 1980 ctgtccgtgg tgagcgaccc aaagaacagg aaagccatag agaaccagat ccagcaatgg 2040 gagcagaatc ttgagaaatt tcacatggat ctgttcagga tgcgctgcta tctggccagc 2100 ctacaaggtg gggagttacc gaacccaaag agtctccttg cagccgccag ccgcccctcc 2160 aagctggccc tcggcaggct gggcatcttg tctgtttcct ctttccatgc tctggtatgt 2220 tctagagatg actctgctct ccggaaaagg acactgtcac tgacccagcg agggagaaac 2280 aagaagggaa tattttcttc gttaaaaggg ctggacacac tggccagaaa aggcaaggag 2340 aagagacctt ctataactca gatatttgat tcaagtggca gccatggatt ttctggaact 2400 cagctacctc aaaactccag taactccagt gaggtcgatg aacttctgca tatatatggt 2460 tcaacagtag acggtgttcc ccgagacaat acatgggaaa tccagactta tgtccacttt 2520 caggacaatc acggagttac tgtagggatc aagccagagc acagagtaga agatattttg 2580 actttggcat gcaagatgag gcagttggaa cccagccatt atggcctaca gcttcgaaaa 2640 ttagtagatg acaatgttga gtattgcatc cctgcaccat atgaatatat gcaacaacag 2700 gtttatgatg aaatagaagt ctttccacta aatgtttatg acgtgcagct cacgaagact 2760 gggagtgtgt gtgactttgg gtttgcagtt acagcgcagg tggatgagcg tcagcatctc 2820 agccggatat ttataagcga cgttcttccc gatggcctgg cgtatgggga agggctgaga 2880 aagggcaatg agatcatgac cttaaatggg gaagctgtgt ctgatcttga ccttaagcag 2940 atggaggccc tgttttctga gaagagcgtc ggactcactc tgattgcccg gcctccggac 3000 acaaaagcaa ccctgtgtac atcctggtca gacagtgacc tgttctccag ggaccagaag 3060 agtctgctgc cccctcctaa ccagtcccaa ctgctggagg aattcctgga taactttaaa 3120 aagaatacag ccaatgattt cagcaacgtc cctgatatca caacaggtct gaaaaggagt 3180 cagacagatg gcactctgga tcaggtttcc cacagggaga aaatggagca gacattcagg 3240 agtgctgagc agatcactgc actgtgcagg agttttaacg acagtcaggc caacggcatg 3300 gaaggaccgc gggagaatca ggatcctcct ccgaggcctc tggcccgcca cctgtctgat 3360 gcagaccgcc tccgcaaagt catccaggag cttgtggaca cagagaagtc ctacgtgaag 3420 gatttgagct gcctctttga attatacttg gagccacttc agaatgagac ctttcttacc 3480 caagatgaga tggagtcact ttttggaagt ttgccagaga tgcttgagtt tcagaaggtg 3540 tttctggaga ccctggagga tgggatttca gcatcatctg actttaacac cctagaaacc 3600 ccctcacagt ttagaaaatt actgttttcc cttggaggct ctttccttta ttacgcggac 3660 cactttaaac tgtacagtgg attctgtgct aaccatatca aagtacagaa ggttctggag 3720 cgagctaaaa ctgacaaagc cttcaaggct tttctggacg cccggaaccc caccaagcag 3780 cattcctcca cgctggagtc ctacctcatc aagccggttc agagagtgct caagtacccg 3840 ctgctgctca aggagctggt gtccctgacg gaccaggaga gcgaggagca ctaccacctg 3900 acggaagcac taaaggcaat ggagaaagta gcgagccaca tcaatgagat gcagaagatc 3960 tatgaggatt atgggaccgt gtttgaccag ctagtagctg agcagagcgg aacagagaag 4020 gaggtaacag aactttcgat gggagagctt ctgatgcact ctacggtttc ctggttgaat 4080 ccatttctgt ctctaggaaa agctagaaag gaccttgagc tcacagtatt tgtttttaag 4140 agagccgtca tactggttta taaagaaaac tgcaaactga aaaagaaatt gccctcgaat 4200 tcccggcctg cacacaactc tactgacttg gacccattta aattccgctg gttgatcccc 4260 atctccgcgc ttcaagtcag actggggaat ccagcaggga cagaaaataa ttccatatgg 4320 gaactgatcc atacgaagtc agaaatagaa ggacggccag aaaccatctt tcagttgtgt 4380 tgcagtgaca gtgaaagcaa aaccaacatt gttaaggtga ttcgttctat tctgagggag 4440 aacttcaggc gtcacataaa gtgtgaatta ccactggaga aaacgtgtaa ggatcgcctg 4500 gtacctctta agaaccgagt tcctgtttcg gccaaattag cttcatccag gtctttaaaa 4560 gtcctgaaga attcctccag caacgagtgg accggtgaga ctggcaaggg aaccttgctg 4620 gactctgacg agggcagctt gagcagcggc acccagagca gcggctgccc cacggctgag 4680 ggcaggcagg actccaagag cacttctccc gggaaatacc cacaccccgg cttggcagat 4740 tttgctgaca atctcatcaa agagagtgac atcctgagcg atgaagatga tgaccaccgt 4800 cagactgtga agcagggcag ccctactaaa gacatcgaaa ttcagttcca gagactgagg 4860 atttccgagg acccagacgt tcaccccgag gctgagcagc agcctggccc ggagtcgggt 4920 gagggtcaga aaggaggaga gcagcccaaa ctggtccggg ggcacttctg ccccattaaa 4980 cgaaaagcca acagcaccaa gagggacaga ggaactttgc tcaaggcgca gatccgtcac 5040 cagtcccttg acagtcagtc tgaaaatgcc accatcgacc taaattctgt tctagagcga 5100 gaattcagtg tccagagttt aacatctgtt gtcagtgagg agtgttttta tgaaacagag 5160 agccacggaa aatcatagta tgattcaatc cagatatggg ttaaattcct cattttactt 5220 ttaaactggt ggtaaagtgg aaattgcaaa aaaaaaaaaa aaaaaactgt tcattcctgg 5280 gttttgtgca gtatacattt tcccacaaaa tggttgtaaa gatttaagtt attttaattt 5340 attgtggatc agaaacctag atgaaactgg tcagaatctg taaattactt agtttatatc 5400 cactttgagc aggtatcaaa tgatttagga tccttaaaat tacattctaa taattaagtt 5460 atgtggaaaa agtaaggctg ggaagtcgtg attaatagtt ttcaaaggcc attttttaaa 5520 atcctctggg cattttcttt cagctgtttg ttagtttttg ctttatttaa agcatattta 5580 agttatttta atgtggttta ggggcaaaat gtgcagatac ttcatttttg taagatagat 5640 tgtaatagat gctgtttata ctaaacatgt cataactatc tatacagtat atattaaaag 5700 aaagcttgta ctgtatctta tttgatgata tttattttct ctgccaagct gtatagtaaa 5760 aggaaaataa gtcacatctg gtcattggca tttgtatcgt cattctgtaa agacaaaaga 5820 gtacctatat aagaagctcc acgtagtgca aatcgacatc tggtaggctg ctcgccccca 5880 ggcagcagct agagtctgta attctctgcg tcatcctctt ctttttcttc atttttgctt 5940 tttcttcgct tgagttcttc tctgaaatta tatgcaaaga gttgtgggtc ttcatcacac 6000 atttttctgt atacatcaca gaggctctta aagtgtgaga tggagagctg gtggggccga 6060 agagtagggt ctatgtctgc caactctaac agcctgcccg tgctttccaa gcgctgcgct 6120 tcagggaata acattctgag ccctcgatgg cagtatttcc ttcggaactg aaatacattc 6180 tgaaccactt tttccaccag cttgaatggc tgctctatct tgggctgtat caagggagtg 6240 aagtgcacca cgcccacgtc caccttcgtt gtaagcaaac atattatcat tctgtggcat 6300 gatatgtggc atagtgtgat caatcaactc atccttgtaa aacaggaaga tgggctgtca 6360 acagcctgtt ttcataaaca gacctttcca cgtacttcgg tttcatctct aggcatggaa 6420 gatggtacat tctggattcg caaatgacat ggagaaatca gccggctgca cctgttctct 6480 30 3161 DNA Homo sapiens misc_feature Incyte ID No 4002434CB1 30 gccctcgcgg cgccccgtag ccgcgcaccc ctcccgtccc gccgagccgg cgccaagatg 60 gcggcgctga ctcctggaga gcggtcgcgc cggaggccgc gggggccgga gcggagcagc 120 cgcggctgag gttcccgagt cgccgctcgg ggctgcgctc cgccgccggg accccggcct 180 ctggccgcgc cggctccggc ctccgggggg gccggggccg ccgggacatg gtgccagtcg 240 caccccttcc ccgccgccgc tgagctcgcc ggccgcgccc gggctgggac gtccgagcgg 300 gaagatgttt tccgccctga agaagctggt ggggtcggac caggccccgg gccgggacaa 360 gaacatcccc gccgggctgc agtccatgaa ccaggcgttg cagaggcgct tcgccaaggg 420 ggtgcagtac aacatgaaga tagtgatccg gggagacagg aacacgggca agacagcgct 480 gtggcaccgc ctgcagggcc ggccgttcgt ggaggagtac atccccacac aggagatcca 540 ggtcaccagc atccactgga gctacaagac cacggatgac atcgtgaagg ttgaagtctg 600 ggatgtagta gacaaaggaa aatgcaaaaa gcgaggcgac ggcttaaaga tggagaacga 660 cccccaggag gcggagtctg aaatggccct ggatgctgag ttcctggacg tgtacaagaa 720 ctgcaacggg gtggtcatga tgttcgacat taccaagcag tggaccttca attacattct 780 ccgggagctt ccaaaagtgc ccacccacgt gccagtgtgc gtgctgggga actaccggga 840 catgggcgag caccgagtca tcctgccgga cgacgtgcgt gacttcatcg acaacctgga 900 cagacctcca ggttcctcct acttccgcta tgctgagtct tccatgaaga acagcttcgg 960 cctaaagtac cttcataagt tcttcaatat cccatttttg cagcttcaga gggagacgct 1020 gttgcggcag ctggagacga accagctgga catggacgcc acgctggagg agctgtcggt 1080 gcagcaggag acggaggacc agaactacgg catcttcctg gagatgatgg aggctcgcag 1140 ccgtggccat gcgtccccac tggcggccaa cgggcagagc ccatccccgg gctcccagtc 1200 accagtggtg cctgcaggcg ctgtgtccac ggggagctcc agccccggca caccccagcc 1260 cgccccacag ctgcccctca atgctgcccc accatcctct gtgccccctg taccaccctc 1320 agaggccctg cccccacctg cgtgcccctc agcccccgcc ccacggcgca gcatcatctc 1380 taggctgttt gggacgtcac ctgccaccga ggcagcccct ccacctccag agccagtccc 1440 ggccgcacag ggcccagcaa cggtccagag tgtggaggac tttgttcctg acgaccgcct 1500 ggaccgcagc ttcctggaag acacaacccc cgccagggac gagaagaagg tgggggccaa 1560 ggctgcccag caggacagcg acagtgatgg ggaggccctg ggcggcaacc cgatggtggc 1620 agggttccag gacgatgtgg acctcgaaga ccagccacgt gggagtcccc cgctgcctgc 1680 aggccccgtc cccagtcaag acatcactct ttcgagtgag gaggaagcag aagtggcagc 1740 tcccacaaaa ggccctgccc cagctcccca gcagtgctca gagccagaga ccaagtggtc 1800 ctccatacca gcttcgaagc cacggagggg gacagctccc acgaggaccg cagcaccccc 1860 ctggccaggc ggtgtctctg ttcgcacagg tccggagaag cgcagcagca ccaggccccc 1920 tgctgagatg gagccgggga agggtgagca ggcctcctcg tcggagagtg accccgaggg 1980 acccattgct gcacaaatgc tgtccttcgt catggatgac cccgactttg agagcgaggg 2040 atcagacaca cagcgcaggg cggatgactt tcccgtgcga gatgacccct ccgatgtgac 2100 tgacgaggat gagggccctg ccgagccgcc cccacccccc aagctccctc tccccgcctt 2160 cagactgaag aatgactcgg acctcttcgg gctggggctg gaggaggccg gacccaagga 2220 gagcagtgag gaaggtaagg agggcaaaac cccctctaag gagaagaaga agaagaagaa 2280 aaaaggcaaa gaggaagaag aaaaagctgc caagaagaag agcaaacaca agaagagcaa 2340 ggacaaggag gagggcaagg aggagcggcg acggcggcag cagcggcccc cgcgcagcag 2400 ggagaggacg gctgccgatg agctggaggc tttcctgggg ggcggggccc cgggcggccg 2460 ccaccctggg gggtggcgac tacgaggagc tctaggccgg cgtgggcagt ggccgccctg 2520 gggcgggggg cgtgcctgtc actgcctggg gaggcatttg cctctgtacc atcgcctttg 2580 ccgctgcccc gtggctgccg tgtgcgcttc tgagctggaa gaggccgggc attggtggtc 2640 cccaggctgg gccctgcagg tgctgggcct tcaggcccag tgtgagcctg ctctgcaaga 2700 agggagggga cagctggctt cagccaggct cggtggacac cctggccctc tcggggcaga 2760 gccgccagtg tttctcaggg atgtgactga ggcccaggag ggacctgtga gggtctgttt 2820 acagaggctg ggcaggggcc gcttggctgt ggggtgtgcg ctgccccggc acctgcttgc 2880 cctccgcgct catctggggc cgcagcatgc ctatggttcc gcttccggcc gggagccctg 2940 aacacgggtg tgcagactca ccctaaaggg cggcccaggc cccacgctag aaggctggcg 3000 agaccgaagg cagcatgtga ggcctctcct gggagtgggg gttgtgtttc ccacagtggc 3060 ctcagctgcg cccccgctca ggtgagcccg aaggcaggag ccgggaggca ctcctcccaa 3120 acactccact cagaccataa agcactcctg tttcaaaaaa a 3161 31 4479 DNA Homo sapiens misc_feature Incyte ID No 2506117CB1 31 ttggcggagg ctcctccagg gactggggca cagatctgcg tagaaacggg tggcggggaa 60 gagaggggag gagagctctg agtgggaagc ggagccgggg gcctgggacc cgtcgcgtca 120 gagccaggca agtgaaccgg agcaaacgac ttccgatcca gtctgcgctg ttgcggctcc 180 cgtttgggat ttgatttgca gcatctttga gcctctacga caaaaaaccg cgaagcacgc 240 ccagccctcc cccggcaccc cgaaaagcac ccactccctc ccggggacac agctgggcgc 300 gtccacaccc ccgcagcccc acaccatgtt gtgcggaagg acttccactc cccgcctgtg 360 tcgttgatgt cagaccccag gccagcctcc gggcgctgca gttctcccgg ctaatgctga 420 ggctgcggct ccggctctag cacaggcacc agccgccgcc gcacccggcc ccagcgccca 480 ccgtctgcat gtgcccgccg tagccgtctg cccagcccgc agcccgcgct ccacggagcg 540 ctggagacca ccgtgggggg ccccttctgc cctcgagaga agcggtcttg gaggtattga 600 tttaggtggt tggatttttt ccgtggatct atcaattcac aattcgaatt tggaagaaag 660 aaggaaaaca tgacgtctcc agccaaattc aaaaaggata aggagatcat agcagagtac 720 gatactcagg tcaaagagat ccgtgctcag ctcacagagc agatgaaatg cctggaccag 780 cagtgtgagc ttcgggtgca actgttgcag gacctccagg acttcttccg aaagaaggca 840 gagattgaga tggactactc ccgcaacctg gagaagctgg cagaacgctt cctggccaag 900 acacgcagca ccaaggacca gcaattcaag aaggatcaga atgttctctc tccagtcaac 960 tgctggaatc tcctcttaaa ccaggtgaag cgggaaagca gggaccatac caccctgagt 1020 gacatctacc tgaataatat cattcctcga tttgtacaag tcagcgagga ctcaggaaga 1080 ctctttaaaa agagtaaaga agtcggccag cagctccaag atgatttgat gaaggtcctg 1140 aacgagctct actcggtgat gaagacatat cacatgtaca atgccgacag catcagtgct 1200 cagagcaaac taaaggaggc ggagaagcag gaggagaagc aaattggtaa atcggtaaag 1260 caggaggacc ggcagacccc acgctcccct gactccacgg ccaacgttcg cattgaggag 1320 aaacatgtcc ggaggagctc agtgaagaag attgagaaga tgaaggagaa gcgtcaagcc 1380 aagtacacgg agaataagct gaaggccatc aaagcccgga atgagtactt gctggctttg 1440 gaggcaacca atgcatctgt cttcaagtac tacatccatg acctatctga ccttattgat 1500 cagtgttgtg acttaggcta ccatgcaagt ctgaaccggg ctctacgcac cttcctctct 1560 gctgagttaa acctggaaca gtcgaagcat gagggtctgg atgccatcga gaatgcagta 1620 gaaaacctgg atgccaccag tgacaagcag cgcctcatgg agatgtacaa caacgtcttc 1680 tgccccccta tgaagtttga gtttcagccc cacatggggg atatggcttc ccagctctgt 1740 gcccagcagc ctgtccagag tgagctggta cagagatgcc aacaactgca gtctcgctta 1800 tccactctaa agattgaaaa cgaagaggta aagaagacaa tggaggccac cctgcaaacc 1860 atccaggaca ttgtgactgt cgaggacttt gatgtgtctg actgcttcca gtacagcaac 1920 tccatggagt ccgtcaagtc cacggtctct gaaaccttca tgagcaagcc cagcattgct 1980 aagaggagag ccaaccagca agagacagag cagttttatt tcacaaaaat gaaagagtac 2040 ctggagggca ggaacctcat caccaagtta caagccaagc atgaccttct gcagaaaacc 2100 ctgggagaaa gtcagcggac agattgcagt ctagccaggc gcagctcaac tgtgaggaaa 2160 caggactcca gccaggcaat tcctctggtg gtggaaagct gtatccggtt tatcagcaga 2220 cacggactac agcatgaagg aattttccgg gtgtcaggat cccaggtgga agtgaatgac 2280 atcaaaaatg cctttgagag aggagaggac cccctggctg gggaccagaa cgaccatgac 2340 atggattcca tagctggtgt cctgaagctt tacttccggg ggctggaaca ccctctcttc 2400 cccaaggaca tctttcatga cctgatggcc tgcgtcacaa tggacaacct gcaggagaga 2460 gctctgcaca tccggaaagt cctcctagtc ctgcccaaaa ccactctgat tatcatgaga 2520 tacctctttg ccttcctcaa tcatttatca cagttcagtg aagagaacat gatggacccc 2580 tacaacctcg ccatctgctt cgggccctcg ctaatgtcag tgccagaggg ccacgaccag 2640 gtgtcctgcc aagcccacgt gaatgagctg atcaaaacca tcatcatcca gcatgagaac 2700 atcttcccaa gccccaggga gctggagggc cctgtctaca gcagaggagg aagcatggag 2760 gattactgtg atagccctca tggagagact acctcggttg aagactcaac ccaggatgtg 2820 accgcagagc accacacgag cgatgacgaa tgtgagccca tcgaggccat tgccaagttt 2880 gactacgtgg gccggacagc ccgagagctg tcctttaaga agggagcatc cctgctgctt 2940 taccagcggg cttccgacga ctggtgggaa ggccggcaca atggcatcga cggactcatc 3000 ccccatcagt acatcgtggt ccaagacacc gaggacggtg tcgtggagag gtccagcccc 3060 aagtctgaga ttgaggtcat ttctgagcca cctgaagaaa aggtgacagc cagagcgggg 3120 gccagctgtc ccagtggggg tcatgtagcc gatatttatc ttgcaaacat caacaagtaa 3180 gctctgcttt tcattttctg ctcccctgaa tgacttgcaa cacccagcct caccctctgg 3240 cctaaccccc atctccattc ctgtgctgca cgtagggctc ccagctcccc cagcctaaca 3300 gtttgcatgt ggtcattgct gctgcaaggc ggacagggct gaggatgctg ctacaagcct 3360 cggggcaggt ccaggtctcc agctagctgc cctcgtgctg tggaagggtg ctttactgtg 3420 tgttcccgca gtgtctgtcc acccagacct ttgtggcagt cttacagcta aaactttgac 3480 caaagctttg gtcactttat gcaacctggt tttgtactgt ttctcagagg tgccttcttt 3540 tttccaatcc atactcaaat aatagtcttt gatgtctgtc ttccttgacc cgtgttcgtg 3600 caaagattca gagtctgtgt gtggcttcta ctaggctgat gttacaccag gtgggtttat 3660 tgagatatca tgtgtctgtt cctccccctg tcctgcattc actcctgtgg aggaaaggag 3720 gccacgatgt ccctaaggaa agctttgtcc tgagctcttc attcattggc taacccctag 3780 ctcccttttc ttctgccctt tcacaccagg agaaataatt ttccattttg ttcctattgc 3840 tttggccttt tgtattattc taccccctta gtccctttgc agatccccac tcctgctcag 3900 caggctctta cctctgaccc ccagctttca ttgtggctgt tagcaacatc ctggggttta 3960 aactccaccc acgcccgatc tggctgtcta gagggattct acgcctgcgt gctgccgcct 4020 ccccaagagg cattcaggtt attggagaac taatctcatc tcaaggggcc agacaccaag 4080 tcccaaagcc tacagacctc tttccgccag gccctgaaac ctggccccgt gccagcagga 4140 tgacaagccc cagggcgctc ctgatgaata tggattggag atgatgtaca gtttttattc 4200 ccctctggct tttgaggaat gaaatgattt gcactttgaa aacctgttaa ccgtagcctc 4260 tggacactga gactggaagg agaataaagg atgcttgttg tttttaaact ataccaggtt 4320 tcccagatct cttggctttt ttccacccag acggtagcag ggggagtggt cggggcacgt 4380 ggctcttttc catctctttc aacctcaagt tagtaaagtc gcgtattcag atcacttact 4440 cagcgtgagt ataatttaat tccgagcagt tttaacaac 4479 32 3723 DNA Homo sapiens misc_feature Incyte ID No 7193277CB1 32 aggcgcgcct ggaggaagaa tggggaccag cacaggcggc aggattcagt ggtcctgagc 60 cttctgaagt taggcttctg cctggtggtg gggatcctga catcacggat gggacaccct 120 ggatggaggt tcctggggcc tggcccccaa gactatgaag agcctttgct gaggccatga 180 ggggttacca tggcgaccga ggcagccatc cccgcccagc ccgctttgct gaccaacagc 240 atatggacgt gggccctgct gccagggccc catacctgct gggctccagg gaggccttct 300 ccaccgagcc ccgcttctgt gccccgagag ctggcctggg acacatttct cctgaagggg 360 ccctgagcct gagtgagggg ccgtcggtag gccctgaggg agggccagcg ggggccgggg 420 ttgggggggg tagcagcacc ttccccagga tgtaccctgg ccagggcccc ttcgacacct 480 gtgaagactg tgtgggccac ccacagggca agggtgcccc ccgcctgcct cctacactcc 540 tggatcagtt tgaaaagcag ttgccagttc aacaagatgg cttccacaca ctaccatacc 600 agcgagggcc agcaggggca gggcccgggc cagcgccagg gacgggcact gccccagagc 660 cccgcagtga gagccctagc cgcatccggc acctggttca ttctgtgcag aagctctttg 720 ccaagtccca ctctctggag gcgccgggga agcgggacta taatgggccc aaggctgagg 780 gaagaggtgg ctctggagga gacagctacc ccggcccggg ctctggaggc ccccacacct 840 cccatcacca ccatcaccac caccatcacc accaccacca gtcccggcac ggcaagagga 900 gcaagagcaa ggaccgcaag ggggatgggc ggcaccaggc caagtccaca ggctggtgga 960 gttccgatga caacttggac agtgatagcg gcttcctggc gggtgggagg ccccctgggg 1020 agcctggtgg tcccttctgc ctggagggtc cagatgggtc ctaccgggac ttgagcttca 1080 aggggcgctc gggcgggtcg gaaggccgct gccttgcctg cactggcatg tccatgtcac 1140 tggatggaca gtcggtcaag cgaagtgcct ggcataccat gatggtcagc cagggccggg 1200 atggataccc gggggccggg ccaggcaagg ggctcctggg tccggagacc aaggccaaag 1260 ccaggactta tcactatctg caggtgccgc aagatgactg ggggggttac cccaccggtg 1320 gcaaggatgg ggagatcccc tgccgcagga tgcggagcgg cagctacatc aaagccatgg 1380 gggatgagga gagcggagac tcagacggca gccccaagac atctcccaaa gcagtcgccc 1440 gacgcttcac cacccgtcgc tcctccagcg tggaccaggc caggatcaac tgctgtgtcc 1500 caccccggat ccacccccgg agctccatcc ctggctacag ccgttccctc accactggac 1560 agctcagcga tgagttgaac cagcagctgg aggccgtgtg cgggtcggtg tttggggagc 1620 tggagtccca ggccgtggac gccctggacc tgcccggctg tttccgcatg cggagccaca 1680 gctacctccg ggccatccag gccggctgct ctcaagacga cgactgcctg cccctcctcg 1740 ctacccctgc cgctgtctca gggaggcccg gctcctcctt caacttcaga aaggccccgc 1800 cccccatccc gccgggaagc caggccccgc cccgcatctc catcaccgcc cagagcagca 1860 ccgactccgc gcacgagagc ttcacggcgg ccgagggccc cgcccggcgc tgcagctccg 1920 ccgacgggct ggacggcccc gccatgggtg cgcgcacact ggagttggcg ccggtgccgc 1980 cccgggccag ccccaagccc cccacactca tcatcaagac catccctggc agggaggagc 2040 tgcggagcct ggcgcggcag cggaagtggc ggccgtccat tggggtgcag gtggagacga 2100 tctcagattc ggacaccgag aacaggagcc ggagggagtt ccactctatt ggcgtgcagg 2160 tggaagagga caagaggcga gcaaggttca agcgctccaa tagtgtgacg gctggcgtgc 2220 aggcagacct ggagctggag ggcctggcag gcctggccac ggtggccaca gaagacaagg 2280 ccctgcagtt tggacgctcg ttccagaggc acgcctctga gccccagcct gggccccggg 2340 cccccaccta ctcagtcttc cgcacggtcc acacgcaggg ccagtgggcc taccgcgagg 2400 gctacccact gccgtacgag ccgccggcca ccgatgggtc gcccggccct gcccccgccc 2460 ccacccccgg ccctggggcc ggccgccgtg actcctggat agagcgcggt tcacgtagcc 2520 tccccgactc aggccgcgca tccccctgcc cacgcgacgg cgagtggttc atcaagatgc 2580 tgcgggcaga ggtggagaag ctggagcact ggtgccagca gatggagcgt gaggcggagg 2640 actatgagct acccgaggag atcctggaga agatccgcag tgctgtgggc agcacacaac 2700 ttctcctgtc ccagaaggtt cagcagttct tccggctgtg tcagcaaagc atggatccca 2760 ctgcgttccc tgtgcccacc ttccaggacc tggcgggttt ctgggacctc ctacagctct 2820 ccatcgagga tgtgaccctc aagttcctgg agctacagca actcaaggcc aacagctgga 2880 aactcctgga gcctaaggag gagaagaagg tccctccgcc gattcccaag aagcccctgc 2940 gggcccgggg cgtccccgtg aaggagcgct ccctggactc cgtggaccgg cagcggcagg 3000 aagcgcgcaa gcggctcctg gcggccaagc gcgccgcttc cttccgccac agctcggcca 3060 ccgagagcgc cgacagcatc gagatctaca tccccgaggc ccagaccagg ctgtgaccgg 3120 tccggcccgc ccagcccggc ccgggcccgc ggttctccac ccgtactgta cacccagcgt 3180 cgaggtcact gtgaacgcgg gccgccccgt gcgcccgccc caccggcacc ggacgccccg 3240 gcccccgggc ccgtcacact ctcgtgggtt ttttaccttc ctgatcccac gcgaaggcgc 3300 ccgggctggg cagggggccg tgcctctccg ccctgcgccc ctcacctgga tcccctgccc 3360 acctggtccg acgctttgtc cccacctcct ccccatgggc accatctctg ccattctttc 3420 ccccacgggc caggccgggc cgggtccctc atctgggctc tgcgtccccc cctcccccac 3480 cccgcggggc tgggcttcgt ggggatcaag cttcgtggct ttttatgaag aatcccgaac 3540 cctgcctagg agcccgcccc accctcccag gggctccatc ctcagccctc tgcccactgg 3600 gcccagggac cacagtggct ggaccaaccc aggaccaggg cgcctgggcc tctccccttt 3660 cccagcggct ggggagggga gatgggggct tcccactcac cacacctgtg gctgttccca 3720 cat 3723 33 825 DNA Homo sapiens misc_feature Incyte ID No 2307889CB1 33 gcggcgcttg ttttggtttc cttctaactt gcccacggca gcttcggggt gagcgacttt 60 cctgcaccag ctgccgcgcc tgctcacacc ctgacctcgt tttcgggctc tctgagcccg 120 cagttccgca agcccctggg gcgggctcct gccatgccgc tagtccgcta caggaaggtg 180 gtcatcctcg gataccgctg tgtagggaag acatctttgg cacatcaatt tgtggaaggc 240 gagttctcgg aaggctacga tcctacagtg gagaatactt acagcaagat agtgactctt 300 ggcaaagatg agtttcacct acatctggtg gacacagcag ggcaggatga gtacagcatt 360 ctgccctatt cattcatcat tggggtccat ggttatgtgc ttgtgtattc tgtcacctct 420 ctgcatagct tccaagtcat tgagagtctg taccaaaagc tacatgaagg ccatgggaaa 480 acccgggtgc cagtggttct agtggggaac aaggcagatc tctctccaga gagagaggta 540 caggcagttg aaggaaagaa gctggcagag tcctggggtg cgacatttat ggagtcatct 600 gctcgagaga atcagctgac tcaaggcatc tttcaccaaa gtcatccagg agatgcccgt 660 gtggagaatc tatgggcaga gcgtcgctgc catctcatgt gagcctgggt gtgggggtac 720 tgcttggttc tggcccggct tgcatgttcc ctggggggcc atccccggct cccggtttgg 780 tgccggtgtt ccggccctgg cccggtggac tccgttgggc tttcg 825 34 2564 DNA Homo sapiens misc_feature Incyte ID No 5369710CB1 34 ggtccggatt tccagaggta gtttggggga actgacagta cacacaccac agggcagtag 60 taagaaagag acaatgcaaa ggaattggca cagcactcag cagacaatat aagctaatat 120 gtactctgtc tacaccctgc gttttaggga gtcaatcgaa agcctccact cacgtgacca 180 ctccactacc cggcgccaag acgcgctgat gtcacgacag cgtgcggcgt gcagacgtcg 240 gcaagctgcg ccgccgcttc gggttgcttc cggatctggt acttgggcag agctccccgg 300 ggttcattgt cttcgcttca caggatctgt ttgagtcctg tccaccggat cctacggggg 360 gtaccttcga aaaaaaacgg gctatgctgc tgttgcgtgt gggtaccctc tcctgacgcc 420 tccgccgccc gggtcatgtg gaccctcgtg ggtcggggct gggggtgcgc acgcgctctc 480 gcgccacgag ccactggggc cgcgcttctg gtggccccgg ggccccggtc cgcgccgacc 540 cttggggctg ctccagagtc ctgggctacc gacaggctct acagctccgc agaattcaag 600 gaaaaacctg acatgtctag gtttcctgtt gaaaatatta gaaatttcag tattgttgca 660 cacgtggatc atggcaaaag tactttagct gacaggctcc tagaacttac agggacaatt 720 gataaaacaa agaataataa gcaggttctt gataaattgc aagtggaacg agaaagagga 780 atcactgtta aagcacagac agcatctctc ttttacaatt gtgaaggaaa gcagtacctt 840 ttaaatctca ttgatacacc gggccatgtt gattttagtt atgaagtatc caggtcactt 900 tctgcttgcc agggtgtttt acttgtggtt gatgcaaatg agggaattca agcccaaact 960 gtagcaaact tctttcttgc cttcgaagca cagctatcgg taattccagt tataaataag 1020 atagatctga agaatgctga tcctgaaagg gttgaaaacc aaattgagaa agtgtttgat 1080 attccaagtg atgaatgtat taagatttct gctaaacttg gaacaaatgt tgagagtgtt 1140 cttcaggcaa ttattgaaag aatcccccct cctaaagtgc atcgcaaaaa tcctctgaga 1200 gctttggtat ttgactccac ctttgaccag tatagaggtg tgatagccaa tgtagcatta 1260 tttgacggag tggtttccaa aggagataaa attgtatctg cacatactca aaagacatac 1320 gaagttaatg aagtaggagt cttgaatcct aatgagcagc caactcataa attgatgtat 1380 cctctagacc aatctgaata taacaatctg aagagtgcta tagaaaaact gactttaaat 1440 gattccagtg tgaccgttca tcgggatagt agccttgctc tgggtgctgg ctggaggcta 1500 ggatttcttg gacttttgca catggaagtt ttcaaccagc gactggagca agaatataat 1560 gcttctgtta ttttaacaac ccctactgtt ccatataaag ctgtactgtc atcatcaaaa 1620 ttgataaagg aacatagaga aaaagaaatt acaattatca atcctgcaca attccccgat 1680 aaatcaaaag taacagaata tttggagcca gttgttttgg gcactattat cacaccagat 1740 gaatacactg gaaaaataat gatgctttgc gaggctcgaa gagcagttca gaagaatatg 1800 atatttattg atcaaaatag agttatgctt aaatatctct ttcctttgaa tgaaattgtg 1860 gtagattttt atgactcttt gaaatcccta tcttctggat atgctagttt tgattacgaa 1920 gatgcaggct accagactgc agaacttgta aaaatggata ttctactgaa tggaaatact 1980 gtagaggagc tagtaactgt tgtacacaaa gacaaagctc attcaattgg caaagccata 2040 tgtgaacggc tgaaggattc tcttcctagg caactgtttg agatagcaat tcaagctgct 2100 attggaagta aaatcattgc aagagaaact gtgaaagcct ataggaaaaa cgttttggca 2160 aaatgttatg gtggtgatat tacccgaaaa atgaagcttt tgaagagaca agcagaaggg 2220 aaaaaaaagc tgaggaaaat tggcaacgtt gaagttccaa aagatgcttt tataaaagtt 2280 ctgaaaacac aatcttctaa ataattggtg ggaaaacaaa gaattttcat tgcaatttgt 2340 aatatgctga caacagaaag aaaattataa aatttgcttg ttactttcag ggtattcagg 2400 ttcaaataac ctactagtct ttcgttgaaa gggagtagtt agtgggtagg caagagctta 2460 gattttgaag ccatgttgcc tgttctcaaa tatctgttcc aaccactcac tagtaaggtg 2520 accgtggcca gattaacctt tgtttcctct tcagtaaaat cgag 2564 35 3621 DNA Homo sapiens misc_feature Incyte ID No 5502841CB1 35 cctttgggat tatataccaa ctgacttcat ttttactcca taagccttct cattgctact 60 tgcatttttc ttcactaacc tatctgtttg ttagtaagtt tttcagttcc ttcttcatct 120 tttctttccc ttgtagctgt gagcactcca gtagattgca tcactaggtt gggtcctgtg 180 agctgttttg ttcttttcca agtgtctgat tcagcgggcc atagaccgct tgccagaaaa 240 tcgccattgc ttctaggctg acgcttgcct acttgttttg atcgtctgag agaagagact 300 ttgtttgcca aaaccacagt tgatagaaat agaaaggtac agataagaaa aagcactgca 360 attataatta agcaaattag catagccatg ttgttgttgt tttccgcaca gacatccttt 420 ttgaaaattt caccatgact tttgcttgtg ttttcaatgc tctgtactgt tgaaggactg 480 ttgctgacga cagaaggtat ataaagctcc tgttcagatt tagaagttaa agctacgatg 540 tgagatgttt caggcatgtt tgtagaatta cctttataat ctacttcagg agttataggg 600 tttgtgttaa tgttttcatt ttggtttctg cctgtcttgt tttgaataac tgaatcccag 660 gaagaagtac tgttagccca cagacgggta tagtttgctt ttgttccagg agacaaagaa 720 aaaactgttg tcatcagaaa ggcaagatgt aggtaatgtc ctgtgtgttc catgtccgtg 780 ggcatacttg gcaatcttac aaaatgcttg gtcaaaatct gattataacg tgattttgat 840 aaaccacttc ttttcttgtc ttctttttaa agcagaatag acttggagaa tatgagcctt 900 aaagtaaatg ctccagtttg ctgcctgggt ggatgcagtg gtgtttgtgt tcagcctgga 960 ggatgaaatc agtttccaga cggtgtacaa ctacttcctg cgtctctgca gcttccgcaa 1020 cgccagcgag gtgcccatgg tgcttgtggg cacgcaggat gccatcagcg ctgcgaatcc 1080 ccgggttatc gacgacagca gagcccgcaa gctctccaca gatctgaagc ggtgcaccta 1140 ctatgagacg tgcgcgacct acgggctcaa tgtggagcgt gtcttccagg acgtggccca 1200 gaaggtagtg gccttgcgaa agaagcagca actggccatc gggccctgca agtcactgcc 1260 caactcgccc agccactcgg ccgtgtccgc cgcctccatc ccggccgtgc acatcaacca 1320 ggccacgaat ggcggcggca gcgccttcag cgactactcg tcctcagtcc cctccacccc 1380 cagcatcagc cagcgggagc tgcgcatcga gaccatcgct gcctcctcca cccccacacc 1440 catccgaaag cagtccaagc ggcgctccaa catcttcacg tctcggaagg gtgctgacct 1500 ggaccgggag aagaaggctg ccgagtgcaa ggtggacagc atcgggagcg gccgcgccat 1560 ccccatcaag caggggatcc tgctaaagcg gagcggcaag tccctgaaca aggagtggaa 1620 gaagaagtat gtgacgctct gtgacaacgg gctgctcacc tatcacccca gcctgcatga 1680 ttacatgcag aacatccacg gcaaggagat tgacctgctg cggacaacgg tgaaagtgcc 1740 agggaagcgc ctgccccgag ccacacctgc cacagccccg ggcaccagcc cccgtgccaa 1800 cgggctgtcc gtggagcgga gtaacacaca gctgggtggg ggcacaggtg ccccccactc 1860 ggccagcagc gcatccctgc actctgagcg ccccctcagc agctcggcct gggctggccc 1920 gcgccctgag gggctgcacc agcgctcctg ctccgtttcc agcgccgacc agtggagtga 1980 ggccaccact tccctgcccc caggcatgca gcaccctgcc agtggcccag ctgaggtact 2040 cagttccagc cccaagctgg atcctccccc atctccccac tccaaccgga agaagcaccg 2100 gaggaaaaag agcaccggga ccccccgacc agacggcccc agcagtgcta ctgaagaggc 2160 agaggagtcg tttgaatttg tggtggtgtc cctcactggg cagacgtggc acttcgaggc 2220 ttcaacggcg gaggagcggg agctgtgggt tcagagtgtg caggcccaga tccttgccag 2280 cctgcaaggc tgccgcagtg ccaaggacaa gactcgactg gggaaccaga acgcagctct 2340 ggctgtgcag gccgtccgca ccgtccgcgg caacagcttt tgtatcgact gcgatgcacc 2400 caatccagac tgggccagcc tgaacctggg tgccctgatg tgcattgagt gctcaggcat 2460 ccaccgacac ctgggggctc acctgtcccg ggtgcgctcc cttgacctcg atgactggcc 2520 gcctgagctg ctggctgtca tgactgccat gggcaatgcc ctcgccaaca gcgtctggga 2580 gggggccttg ggtggctact ccaagccagg gcctgatgcc tgcagagagg agaaggaacg 2640 ctggatacgg gccaagtatg aacagaagct cttcctggcc ccactgccaa gctcagatgt 2700 gccactgggg cagcagctgc tccgggccgt ggtggaagat gacctgcggc tgttggtgat 2760 gctcctggca catggctcca aagaggaggt gaatgagacc tatggggacg gggacgggcg 2820 gacggctcta catctctcca gtgccatggc caacgttgtc ttcacgcagc tgctcatctg 2880 gtacggggtg gacgtgagga gccgggacgc ccggggcctg actccactgg catatgctcg 2940 ccgggccggc agccaggagt gtgcagacat cttgatccag catggctgcc ctggggaggg 3000 ctgtggctta gcgcctaccc ccaacagaga gcctgccaat ggcaccaacc cctctgctga 3060 gctgcaccgt agtcctagcc tcctataagg cccaggaaga gggcagaggg gccagaagga 3120 ctccatggcc caaagaccct cctccctgca ggcactgtgg gaacagacac agagatggag 3180 aagcagggac atgctgagag gacgaagcca aggaaattag ggaggagagt caaagggatc 3240 aaggagagtt ggggatttga gctgcagcag agagggatga gggatttagc cctctgccct 3300 aaggtgccat tgaaaaggga caggaccctt cggaggtgcc tgtgaggaga ggggagcagg 3360 acctctccct cctccagatc cctgcctcct agtgccagcc cctcacacgc cttcatcctg 3420 aaacaggaag aggacggcac caagttgggg gtgctggatg aaagagacga ggggtgatct 3480 gtgagtccca tgtaaacttt gtacattgga atatttatgt ttgtgtacat atttgatgtg 3540 tgtgtgtatg atgagccaat aaaccagact gtgtgcgtga aaaaaaaaaa aaaaaaaaaa 3600 aaaaaaaaaa aaaaaaaaaa a 3621 36 1860 DNA Homo sapiens misc_feature Incyte ID No 361856CB1 36 acggcccctt ccccttctcg tctccgttgg agtcgtctct gccgcggctt cctcggctgc 60 cagctctccg gcgagccgga gtcctagtgc cgtaccgtca gtccccggcc gcgcggagcc 120 gggatgcact gttcctgctg tgggtcctca tcatggagac caaacgggtg gagattcccg 180 gcagcgtcct ggacgatctc tgcagccgat ttattttgca tattcccagc gaggaaagag 240 acaatgcaat ccgagtgtgt tttcagattg aacttgccca ttggttttac ttggatttct 300 acatgcagaa cacaccagga ttacctcagt gtgggataag agactttgct aaagctgtct 360 tcagtcattg tccgtttttg ctgcctcaag gtgaagatgt ggaaaaagtt ttggatgaat 420 ggaaggaata taaaatggga gtaccaacat atggtgcaat tattcttgat gagacacttg 480 aaaatgtact actggttcag gggtacctag caaaatcagg ctggggattt ccaaaaggaa 540 aagtaaataa agaagaagct cctcatgatt gtgctgctag agaggtcttt gaagaaactg 600 gttttgatat caaagactat atttgtaagg atgattacat tgaacttcga atcaatgacc 660 aacttgctcg tttgtacatc attccaggaa ttccaaaaga cacaaaattt aacccaaaaa 720 ctagaagaga aattcggaac attgagtggt tctctattga gaaattgcct tgtcatagaa 780 atgatatgac ccccaaatcc aaacttggtt tggcacctaa caaatttttt atggccattc 840 cctttatcag accattaagg gactggcttt ctcgaagatt tggcgattcc tcagacagtg 900 acaatggatt ttcctcaact ggtagcacgc cggctaaacc cactgtggaa aaattgagtc 960 gaaccaaatt ccgccacagt cagcagttat ttcctgacgg ttctcctggt gaccagtggg 1020 taaagcacag gcaaccactg cagcaaaagc catataataa tcattctgaa atgtctgacc 1080 ttttaaaagg aaagaatcaa agtatgaggg gaaatggcag aaaacagtat caagattcac 1140 ctaatcaaaa gaaaagaaca aatgggcttc agccagcaaa gcagcagaat tctttgatga 1200 agtgtgaaaa gaaacttcat ccacggaaac ttcaggataa ttttgaaaca gatgctgtat 1260 atgacttgcc tagctccagt gaagaccagt tgctagaaca tgccgaggga cagcccgtgg 1320 catgtaatgg acattgcaag ttcccctttt catccagagc ctttttgagt ttcaagtttg 1380 accataatgc tataatgaaa atcttggacc tttgatagca gcacatgtat tgtaaatgtc 1440 ccaggatcag agacctgttg aatttgagtg ggtgtctcct caagccttac ctttctcagg 1500 tgttttaaag aaatgcaggg aggcaatgtt tctgaagaca ttttctgttt ataagagagt 1560 agaaagaaac acgagtttgc actgtaaatg cagttataac cttttataca gatttacctt 1620 ttcagtgttc agtacaagtt taagttgctt tctttgaggg catttattct gtgtgactgt 1680 gggttttatt ttgtattctg gttaagaaaa taatgtattg agttactgtc aagtagccaa 1740 gttaatggga atgctccatc tacctgttac agtgattgca ataatagtat attggagttt 1800 ttcaaagaaa cttaaagtaa tgaccaatta ttaaatgatt aggatagaat attagttgac 1860 

What is claimed is:
 1. An isolated polypeptide selected from the group consisting of: a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-12, SEQ ID NO:15, and SEQ ID NO:17, c) a polypeptide comprising a naturally occurring amino acid sequence at least 96% identical to an amino acid sequence of SEQ ID NO:14, d) a polypeptide comprising a naturally occurring amino acid sequence at least 94% identical to an amino acid sequence of SEQ ID NO:16, e) a polypeptide comprising a naturally occurring amino acid sequence at least 93% identical to an amino acid sequence of SEQ ID NO:18, f) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, and g) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-18.
 2. An isolated polypeptide of claim 1 comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-18.
 3. An isolated polynucleotide encoding a polypeptide of claim
 1. 4. An isolated polynucleotide encoding a polypeptide of claim
 2. 5. An isolated polynucleotide of claim 4 comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:19-36.
 6. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim
 3. 7. A cell transformed with a recombinant polynucleotide of claim
 6. 8. A transgenic organism comprising a recombinant polynucleotide of claim
 6. 9. A method of producing a polypeptide of claim 1, the method comprising: a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and b) recovering the polypeptide so expressed.
 10. A method of claim 9, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-18.
 11. An isolated antibody which specifically binds to a polypeptide of claim
 1. 12. An isolated polynucleotide selected from the group consisting of: a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:19-36, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:19-30, SEQ ID NO:32, SEQ ID NO:33, and SEQ ID NO:35, c) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 94% identical to a polynucleotide sequence of SEQ ID NO:34, d) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 93% identical to a polynucleotide sequence of SEQ ID NO:36, e) a polynucleotide complementary to a polynucleotide of a), f) a polynucleotide complementary to a polynucleotide of b), g) a polynucleotide complementary to a polynucleotide of c), h) a polynucleotide complementary to a polynucleotide of d), and i) an RNA equivalent of a)-h).
 13. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim
 12. 14. A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 12, the method comprising: a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.
 15. A method of claim 14, wherein the probe comprises at least 60 contiguous nucleotides.
 16. A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 12, the method comprising: a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.
 17. A composition comprising a polypeptide of claim 1 and a pharmaceutically acceptable excipient.
 18. A composition of claim 17, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-18.
 19. A method for treating a disease or condition associated with decreased expression of functional INTSIG, comprising administering to a patient in need of such treatment the composition of claim
 17. 20. A method of screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising: a) exposing a sample comprising a polypeptide of claim 1 to a compound, and b) detecting agonist activity in the sample.
 21. A composition comprising an agonist compound identified by a method of claim 20 and a pharmaceutically acceptable excipient.
 22. A method for treating a disease or condition associated with decreased expression of functional INTSIG, comprising administering to a patient in need of such treatment a composition of claim
 21. 23. A method of screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising: a) exposing a sample comprising a polypeptide of claim 1 to a compound, and b) detecting antagonist activity in the sample.
 24. A composition comprising an antagonist compound identified by a method of claim 23 and a pharmaceutically acceptable excipient.
 25. A method for treating a disease or condition associated with overexpression of functional INTSIG, comprising administering to a patient in need of such treatment a composition of claim
 24. 26. A method of screening for a compound that specifically binds to the polypeptide of claim 1, the method comprising: a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim
 1. 27. A method of screening for a compound that modulates the activity of the polypeptide of claim 1, the method comprising: a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1, b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim
 1. 28. A method of screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the method comprising: a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide, b) detecting altered expression of the target polynucleotide, and c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.
 29. A method of assessing toxicity of a test compound, the method comprising: a) treating a biological sample containing nucleic acids with the test compound, b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 12 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 12 or fragment thereof, c) quantifying the amount of hybridization complex, and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.
 30. A diagnostic test for a condition or disease associated with the expression of INTSIG in a biological sample, the method comprising: a) combining the biological sample with an antibody of claim 11, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex, and b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.
 31. The antibody of claim 11, wherein the antibody is: a) a chimeric antibody, b) a single chain antibody, c) a Fab fragment, d) a F(ab′)₂ fragment, or e) a humanized antibody.
 32. A composition comprising an antibody of claim 11 and an acceptable excipient.
 33. A method of diagnosing a condition or disease associated with the expression of INTSIG in a subject, comprising administering to said subject an effective amount of the composition of claim
 32. 34. A composition of claim 32, wherein the antibody is labeled.
 35. A method of diagnosing a condition or disease associated with the expression of INTSIG in a subject, comprising administering to said subject an effective amount of the composition of claim
 34. 36. A method of preparing a polyclonal antibody with the specificity of the antibody of claim 11, the method comprising: a) immunizing an animal with a polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, or an immunogenic fragment thereof, under conditions to elicit an antibody response, b) isolating antibodies from said animal, and c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-18.
 37. A polyclonal antibody produced by a method of claim
 36. 38. A composition comprising the polyclonal antibody of claim 37 and a suitable carrier.
 39. A method of making a monoclonal antibody with the specificity of the antibody of claim 11, the method comprising: a) immunizing an animal with a polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:1-18, or an immunogenic fragment thereof, under conditions to elicit an antibody response, b) isolating antibody producing cells from the animal, c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells, d) culturing the hybridoma cells, and e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-18.
 40. A monoclonal antibody produced by a method of claim
 39. 41. A composition comprising the monoclonal antibody of claim 40 and a suitable carrier.
 42. The antibody of claim 11, wherein the antibody is produced by screening a Fab expression library.
 43. The antibody of claim 11, wherein the antibody is produced by screening a recombinant immunoglobulin library.
 44. A method of detecting a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-18 in a sample, the method comprising: a) incubating the antibody of claim 11 with a sample under conditions to allow specific binding of the antibody and the polypeptide, and b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-18 in the sample.
 45. A method of purifying a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-18 from a sample, the method comprising: a) incubating the antibody of claim 11 with a sample under conditions to allow specific binding of the antibody and the polypeptide, and b) separating the antibody from the sample and obtaining the purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-18.
 46. A microarray wherein at least one element of the microarray is a polynucleotide of claim
 13. 47. A method of generating an expression profile of a sample which contains polynucleotides, the method comprising: a) labeling the polynucleotides of the sample, b) contacting the elements of the microarray of claim 46 with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex, and c) quantifying the expression of the polynucleotides in the sample.
 48. An array comprising different nucleotide molecules affixed in distinct physical locations on a solid substrate, wherein at least one of said nucleotide molecules comprises a first oligonucleotide or polynucleotide sequence specifically hybridizable with at least 30 contiguous nucleotides of a target polynucleotide, and wherein said target polynucleotide is a polynucleotide of claim
 12. 49. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 30 contiguous nucleotides of said target polynucleotide.
 50. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 60 contiguous nucleotides of said target polynucleotide.
 51. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to said target polynucleotide.
 52. An array of claim 48, which is a microarray.
 53. An array of claim 48, further comprising said target polynucleotide hybridized to a nucleotide molecule comprising said first oligonucleotide or polynucleotide sequence.
 54. An array of claim 48, wherein a linker joins at least one of said nucleotide molecules to said solid substrate.
 55. An array of claim 48, wherein each distinct physical location on the substrate contains multiple nucleotide molecules, and the multiple nucleotide molecules at any single distinct physical location have the same sequence, and each distinct physical location on the substrate contains nucleotide molecules having a sequence which differs from the sequence of nucleotide molecules at another distinct physical location on the substrate.
 56. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:1.
 57. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:2.
 58. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:3.
 59. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:4.
 60. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:5.
 61. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:6.
 62. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:7.
 63. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:8.
 64. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:9.
 65. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:10.
 66. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:11.
 67. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:12.
 68. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:13.
 69. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:14.
 70. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:15.
 71. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:16.
 72. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:17.
 73. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:18.
 74. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:19.
 75. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:20.
 76. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:21.
 77. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:22.
 78. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:23.
 79. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:24.
 80. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:25.
 81. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:26.
 82. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:27.
 83. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:28.
 84. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:29.
 85. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:30.
 86. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:31.
 87. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:32.
 88. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:33.
 89. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:34.
 90. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:35.
 91. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:36. 